**CIRRICULUM VITAE**

**Name:** Robert A. Kloner, MD, PhD

Chief Science Officer, Vice President of Translation and Scientific Director of Cardiovascular Research Institute, Huntington Medical Research Institute, Pasadena, CA

Professor of Medicine (Clinical Scholar), Department of Medicine, Keck School of Medicine of University of Southern California, Los Angeles, CA

**Address:** Huntington Medical Research Institutes

 686 S Fair Oakes Avenue

 Pasadena, Ca 91105

**Email:** robert.kloner@hmri.org

**Date of Birth:** October 8, 1949

**Place of Birth:** Buffalo, NY

**Education:**

1971 BS, Northwestern University (Honors Program in Medical Education), Evanston, IL

1974 PhD, Northwestern University, Chicago, IL (Mentor: Robert B. Jennings, MD)

1975 MD, Northwestern University Medical School, Chicago, IL

**Postdoctoral Training:**

1975-76 Medical House Officer, Peter Bent Brigham Hospital, Boston MA

1975-78 Clinical Fellow in Medicine, Harvard Medical School, Boston MA

1976-77 Assistant Resident Physician, Peter Bent Brigham Hospital, Boston, MA

1977-78 Senior Resident Physician, Peter Bent Brigham Hospital, Boston, MA

1978 Chief Resident, West Roxburt VA Hospital, West Roxbury, MA (Winter 1978)

**Research Fellowships:**

1978-1979 Research Fellow in Medicine, Harvard Medical School, Boston, MA

1978-1979 Research/Clinical Fellow in Medicine, Peter Bent Brigham Hospital – Cardiology, Boston, MA

**Certifications:**

7/1/76 Diplomate of National Board of Medical Examiners, Certificate # 132467

9/13/78 Diplomate of American Board of Internal Medicine, Certificate # 67780

11/11/81 Board Certified – Cardiovascular Diseases, Certificate # 67780

**Medical Licensure:**

Commonwealth of Massachusettes, # 43799

State of Michigan, # 048030

State of Califormia, #G64623

**Academic Appointments:**

1979-84 Assistant Professor of Medicine; Harvard Medical School, Boston, MA.

1984 Associate Professor of Medicine; Harvard Medical School, Boston, MA.

1985-88 Professor of Internal Medicine; Wayne State University School of Medicine, Detroit, MI.

1988-2014 Professor of Medicine; Keck School of Medicine at the University of Southern California, Los Angeles, CA.

2010 Associate Member of the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at USC.

2015 Professor of Clinical Medicine; Keck School of Medicine at the University of Southern California, Los Angeles, CA.

2016 Professor of Medicine ( Clinical Scholar); Keck School of Medicine at the University of Southern California, Los Angeles, CA.

**Hospital, Laboratory, and Institute Appointments:**

1979-82 Junior Associate in Medicine; Brigham and Women’s Hospital, Boston, MA.

1979-84 Director of Cardiac Research Laboratory (Experimental Myocardial Ischemia and Infarction); Harvard Medical School, Boston, MA.

1982-84 Associate Physician; Brigham and Women's Hospital, Boston, MA.

1985-88 Director of Myocardial Ischemia Laboratory; Wayne State University School of Medicine, Detroit, MI.

1987-88 Acting Co-Director - Noninvasive Cardiology Laboratory; Harper Hospital, Detroit, MI.

1988-2014 Director of Research - Board of Directors; The Heart Institute of the Hospital of the Good Samaritan, Los Angeles, CA.

1988-2019 Attending Cardiologist - Los Angeles County/University of Southern California Medical Center, Los Angeles, CA.

2015-2018 Vice President of Translation and Director of Cardiovascular Research Institute, Huntington Medical Research Institutes, Pasadena, CA.

2017 Interim, Chief Science Officer, Huntington Medical Research Institutes, Pasadena, CA.

2018- Chief Science Officer, Huntington Medical Research Institutes, Pasadena, CA.

**Awards and Honors:**

1973 Alpha Omega Alpha

1975 Merck Manual Award for Outstanding Achievement in the Study of Medicine

1976 Sheard-Sanford Award for Meritorius Original Student Research in Pathology during Medical School (presented by the American Society of Clinical Pathologists)

1981-86 Recipient of the Established Investigatorship Award of the American Heart Association

1988, March Research Prize, Poster Competition for Associates, American College of Physicians, 69th Scientific Sessions, New York, NY

"Delayed treatment with nifedipine abolishes postischemic myocardial stunning." (with Dr. GB Ghafari & Dr. Karin Przyklenk)

1988, November Scientific Exhibit Achievement Award, 82nd Annual Scientific Assembly of the Southern Medical Association, New Orleans, LA.

"The stunned myocardium: heart muscle weakness and recovery following ischemia." (with Dr. Karin Przyklenk).

1990, May Elected to American Society for Clinical Investigation; emeritus 2019.

1990, June Master Teacher Award from Cardiovascular Reviews and Reports for the manuscript "Recent advances in stunned myocardium," published October 1987. (with Dr. Karin Przyklenk).

1991 Continuing Service Award. American Heart Association, Greater Los Angeles Affiliate.

1995-98. ‘02 NIH, Cardiovascular Study Section A.

1996 The Henry N. Neufeld Memorial Award for "Cardiomyocytes Transplant to Repair Myocardial Infarction," by United States Israel Binational Science Foundation.

1999 Listed in Who’s Who in America.

2000 Elected to “The Best Doctors in America,” Woodward, White, Inc. Aiken, S.C.

2001 Appointed "Inaugural Fellow" of the Council on Basic Cardiovascular Sciences of the American Heart Association.

2002 Identified by the Institute for Scientific Information (ISI) as ISI Highly cited.com (one of world's most highly cited authors - comprising less than one half of one percent of all published researchers).

2003 Physician Leadership Award, Good Samaritan Hospital, Los Angeles.

2007 Listed in Guide to America’s Top Cardiologists by Consumer’s Research Council of America.

2024 H Index = 136; Citations: 86,979

**Editorial Activities:**

1979- Reviewer:

 American Heart Journal

 American Journal of Cardiology

 American Journal of Pathology

 American Journal of Physiology

 Annals of Internal Medicine

 The Annals of Thoracic Surgery

 Archives of Internal Medicine

 Basic Research in Cardiology

 Cardiology

 Cardiovascular Research

 The Canadian Journal of Cardiology

 Catheterization and Cardiovascular Diagnosis

 Chest

 Circulation

 Circulation Research

 Coronary Artery Disease

 Free Radicals in Biology and Medicine

 Journal of the American College of Cardiology

 Journal of Cardiovascular Pharmacology

 Journal of Cardiovascular Pharmacology and Therapeutics

 Journal of Clinical Investigation

 Journal of Electrocardiography

 The Journal of Thoracic and Cardiovascular Surgery

 John Hopkins Medical Journal

 Journal of Molecular and Cellular Cardiology

 Journal of Vascular Medicine and Biology

 Lancet

 Life Sciences

 New England Journal of Medicine

 Proceedings of the National Academy of Science

 Society for Experimental Biology and Medicine

 The American Journal of the Medical Sciences

 Toxicologic Pathology

1981-84 Editor: The Guide to Cardiology; John Wiley and Sons, Inc., New York; 1984

1989-1990 Editor: The Guide to Cardiology, Second Edition; LeJacq Communications Inc., Greenwich, Connecticut, 1990

1990 Editor: Cardiology Reference Book III. CoMedica Inc. New York, New York

1993 Co-Editor: Stunned Myocardium: Properties Mechanisms, and Clinical Manifestations. Marcel Dekker Inc. N.Y. (with Karin Przyklenk, Ph.D.)

1994 Co-Editor: "Ischemic Preconditioning:" The Concept of Endogenous Cardioprotection, with Karin Przyklenk Ph.D., Derek Yellon, Ph.D. Kluwer Academic Publishers, Norwell, Mass.

1995 Editor: The Guide to Cardiology, Third Edition; LeJacq Communications, Inc., Greenwich, Conn., 1995

1996 Co-Editor: Cardiovascular Trials Review with Dr. Yochai Birnbaum MD. LeJacq Communications Inc. - Greenwich, Conn., 1996.

1996- Medical Reviewer: Healthwise Inc. Boise, Idaho

1997 Co-Editor: Cardiovascular Trials Review, 2nd Edition with Yochai Birnbaum, MD. LeJacq Communications Inc. Greenwich, Conn, 1997.

1998 Co-Editor: Cardiovascular Trials Review 3rd Edition with Yochai Birnbaum, MD LeJacq Communications, Inc. Greenwich, Conn; 1998.

1999 Co-Editor: Cardiovascular Trials Review 4th Edition with Yochai Birnbaum, MD LeJacq Communications, Inc. Greenwich, Conn; 1999. LeJacq

2000 Co-Editor: Cardiovascular Trials Review 5th Edition with Yochai Birnbaum, MD LeJacq Communications, Inc. Greenwich, Conn; 2000.

2000-01 Physician Advisor: Weekly Briefings from the New England J. of Medicine ([www.healthgate.com)](http://www.healthgate.com)).

2001 Co-Editor: Cardiovascular Trials Review 6th Edition with Yochai Birnbaum, MD LeJacq Communications, Inc. Greenwich, Conn; 2001.

2001 Advisor Medical Breakthroughs 2001; The Readers Digest Assoc., Inc. Pleasantville, N.Y.

2002 Co-Editor: Cardiovascular Trials Review 7th Edition with Yochai Birnbaum, MD LeJacq Communications, Inc. Darien, Conn; 2002.

2003 Co-Editor: Cardiovascular Trials Review 8th Edition with Yochai Birnbaum, MD LeJacq Communications, Inc. Darien, Conn; 2003.

2004 Editor: Heart Disease and Erectile Dysfunction Humana Press. Totowa, New Jersey

2004 Co-Editor: Cardiovascular Trials Review 9th Edition with Yochai Birnbaum, MD. LeJacq Communications, Inc. Darien, Conn; 2004.

2005 Co-Editor: Cardiovascular Trials Review 10th Edition with Yochai Birnbaum, MD. LeJacq Communications, Inc. Darien, Conn; 2005.

**Editorial Boards:**

1982- Editorial Board: American Journal of Cardiology

1986-90 Editorial Board: Cardiac Chronicle

1987-94 Editorial Board: CARDIO

1988-2004 Editorial Board: Cardiovascular Reviews and Reports

1989-92 Editorial Board: Journal of the American College of Cardiology

1989-94 Editorial Board: Circulation Research

1990-93; 94-05 Editorial Board: Circulation

1991-96 Editorial Board: American Heart Journal

1992-2007 Editorial Board: American Journal of Geriatric Cardiology

1992- Editorial Board: Basic Research in Cardiology

1995-2009 Editorial Board: Congestive Heart Failure

1995 Editorial Board: Current Concepts in Hypertension (American Society of Hypertension)

1999-2004 Editorial Board: Heart Disease

2000 Editorial Board: Cardiac and Vascular Regeneration

2000-2013 Editorial Board: HEART (Official Journal of the British Cardiac Society)

2001-2005 Editorial Board: Journal of the American College of Cardiology

2001-2007 Editorial Board: Journal of Molecular and Cellular Cardiology

2005-2016 Guest Editor: Circulation

2005- Editorial Board: Regenerative Medicine

2008-2020 Editorial Board: International Journal of Impotence Research

2013- Editorial Board: Life Sciences

2017- Editorial Board: Journal of Men’s Health

**Associate Editor:**

1995-2009 Journal of Cardiovascular Pharmacology and Therapeutics

2004- International Journal of Impotence Research (Nature Publishing)

**Editor-in-Chief:**

2009-2019 Journal of Cardiovascular Pharmacology and Therapeutics

**Guest Editor:**

1990- A symposium: The ischemic myocardium: New directions in evaluation and Management. Am. J. Cardiol. Nov. 20, 1990 (Suppl H).

1992 Assessment of myocardial stunning, hibernating, and viability. Am. J. Cardiac Imaging, (Saunders) Vol. 6, No. 3, Sept. 1992.

1999- A Symposium: Heart disease and sexual health: What do cardiologists need to know? Am. J. Cardiol (Sept. 9, 1999) Vol. 84 (5B) Supplement.

2003­ A symposium: Erectile dysfunction and cardiovascular risk factors. Am. J. Cardiology November 6, 2003 (Supplement M).

**Abstract Reviews:**

1982-84, '93,'94, '97, '98, ’99, '00, '03, '04, '05, '06, '07, '09, '10, '11, '12, '13

Abstract Grader; American Heart Association Scientific Meeting

1984-95, '97, '98, '00, '01, '07, '08

Abstract Grader; American College of Cardiology Annual Meetings

1986 Abstract Grader; World Congress of Cardiology

1993 Abstract Grader; American Society Clinical Investigation/American Federation of Clinical Research National Meeting

2018 Abstract Grader: A-CURE Symposium; Satellite symposium at 2018 American Heart Association Meeting

**Grant Reviews:**

1985- Research Peer Review Committee; American Heart Association of Michigan

Research Committee-Department of Medicine; Wayne State University School of Medicine

 American Heart Association-Greater Los Angeles Affiliate

1988-91 Research Committee, American Heart Association, Greater Los Angeles Affiliate

1990 Academic Advisory Committee. Pfizer Visiting Professorship Program in Cardiovascular Medicine

1991-93 Chairman, External Advisory Committee to the U. of California at San Diego Coronary Heart Disease NIH - SCOR

1992-93 Vice Chair, Fellowship Study Section. American Heart Association. Greater Los Angeles Affiliate

1995 Clinical Sciences Special Emphasis Panel, NIH

1995-98 NIH Cardiovascular Study Section A

2001 NIH, National Center for Research Resources. Centers of Biomedical Research Excellence (COBRE) Applications, Special Emphasis Panel

2002 NIH Cardiovascular Study Section A, Nov ’02.

2006 National Heart, Lung, and Blood Institute Special Emphasis Panel ZHL1 CSR-H (F1) “Heart Failure Network Meeting.”

2006-2012 Protocol Review Committee for NHLBI Specialized Centers for Cell ­ Based Therapy

2007 CV Therapeutics Award Program

2012 National Heart, Lung, and Blood Institute Progenitor Cell Biology Consortium Ancillary Projects, Grant Reviewer.

2017-2020 American Heart Associtaion Collaborative Sciences Award Review Committee

**Professional Societies:**

1973- Alpha Omega Alpha

1979- American Heart Association

1979- American Association of Pathologists

1979-84 Brigham Medical Group

1980- American Federation for Clinical Research

1981- American Physiological Society

1981- New York Academy of Science

1981- Basic Science Council of the American Heart Association

1983- Fellow of the American College of Cardiology

1985-88 Detroit Heart Club

1985-88 Michigan State Medical Society

1985-88 Wayne County Medical Society

1986-88 Central Society for Clinical Research

1990- American Society for Clinical Investigation

1990-2016 International Society of Heart Research (Council Member 1994 - 1997)

1991- California Biomedical Research Association (Governing Board 1991-1996).

1991- Fellow, Council on Clinical Cardiology, American Heart Association

1992- Council on Geriatric Cardiology

1992 American College of Cardiology, California Chapter (council alternate 1992; 1993 – 1996 Council).

1996-00 Chairman, Publications Committee. American College of Cardiology, California Chapter.

2001 Inaugural Fellow of the Council on Basic Cardiovascular Sciences of the American Heart Association.

2004 Fellow of the International Academy of Cardiovascular Sciences.

**Major Research Interests:**

1. Protection of Ischemic Myocardium
2. Cardiac Function Following Coronary Artery Occlusion
3. Myocardial Biochemistry and Ultrastructure
4. Healing Phase of Myocardial Infarction
5. Clinical Studies with an Ultrashort-Acting Beta Blocker, and Nifedipine
6. Protecting Ischemic Myocardium During Angioplasty
7. Stunned and Hibernating Myocardium
8. Experimental Angioplasty Devices, Coronary Stents
9. Viral Myocarditis
10. Oxygen Free Radicals in Myocardial Ischemia/Reperfusion
11. Effect of toxins on the heart
12. Injection of DNA into in vivo myocardium (In collaboration with Dr. Laurence Kedes, Howard Prentice, USC; 1991-)
13. Amlodipine Cardiovascular Community Trial (ACCT)- A multicenter hypertension and LVH regression clinical trial; Steering Committee 1991-
14. Ancillary Studies of Preinfarct Angina and ECG - TIMI 4 and TIMI 9.
15. Analysis of Safety of Calcium Channel Blockers in Large Hypertensive Database.
16. Epidemiologic studies on the effects of natural disasters (earthquake and seasons) on cardiovascular events.
17. P.I. on CASTLE Trial - Study of Candesartan Cilexetil in hypertensive patients.
18. Investigator - Effects of non-steroidal anti-inflammatory drug on anti-hypertensive response to losartan vs captopril.
19. Investigator -A multicenter double-blinded parallel trial comparing amlodipine vs losartan in patients with mild to moderately severe hypertension.
20. Data Monitoring Committee - Halt MI trial
21. Ancillary Study Committee and investigator TNT (Treating to New Targets) – Study of high vs. low dose atorvastatin.
22. Steering Committee – AMISTAD II Trial (Adenosine in Myocardial Infarction).
23. Consultant to Los Angeles Cardiology Associates (1997-)
24. Investigator – CLAIM Trial (candesartan vs losartan)
25. National PI ­ ADHT Trial (ACEI or ARB ± CCB in diabetic hypertensive patient).
26. Cellular transplant therapy for the injured heart.
27. Steering Committee ­ INTENSIVE Study (Insulin in acute myocardial infarction multicenter study 2006­).
28. Steering Committee – EMRACE – STEMI Trial (Bendavia in acute ST elevation MI; 2011-).

**Clinical Responsibilities:**

1. Attending in Coronary Care Unit (Brigham and Women's Hospital)
2. Attending in Cardiology Consult Service (Brigham and Women's Hospital, Harper Hospital)
3. Attending in General Internal Medicine Service (West Roxbury Veterans Administration Hospital, Harper Hospital)
4. Attending in ECG Laboratory (Brigham and Women's Hospital; Harper Hospital)
5. Attending in Thoracic Consult Service (Brigham and Women's Hospital, Harper Hospital)
6. Attending in Outpatient Cardiology Clinic (Brigham and Women's, Harper Hospital, LAC/USC)
7. Attending in Noninvasive Cardiology Laboratory (Harper Hospital, LAC/USC)
8. Acting Co-Director Noninvasive Cardiology - Harper Hospital at Wayne State University (1987-1988).
9. Attending in LAC/USC Cardiology Clinic (1988-2019)
10. Echocardiography reader LAC/USC (1993-1996)
11. Outpatient Clinical trials – Los Angeles Cardiology Associates (1997-2014)

**Medical Advisory Board**

1992 SCIMED, Maple Grove, Minnesota

**Teaching Experience:**

**Harvard Medical School**

1. Instructor in Cardiovascular Pathophysiology Course; Harvard Medical School; 1979
2. Teaching Harvard medical students, housestaff, and fellows on coronary care unit rotation, cardiology consult service, electrocardiography service, thoracic consult service, and general medical service. This includes one-to-one teaching involving diagnosis and patient management as well as didactic teaching seminars dealing with clinical topics (1979-84)
3. Teaching Harvard medical students, cardiology fellows, and post-graduate fellows who rotate through the cardiology research laboratory the basics of research design, data analysis and interpretation. Includes didactic seminars on experimental myocardial ischemia and infarction (1979-84)
4. Lecturer in Physiology (Course #340) "The Heart Structure and Function"; Harvard Medical School; 1984
5. Cardiology Board Review Course; Brigham and Women's Hospital

**Wayne State University**

1. Teaching Wayne State University medical students, housestaff, fellows on coronary care unit and step-down unit, echocardiography laboratory, and cardiology consult service. One-to-one teaching involving diagnosis and patient management and some didactic teaching seminars dealing with clinical topics (1985-88)
2. Teaching Wayne State University medical students, residents and fellows who rotate through cardiology research laboratory (1985-88)
3. Lecturer in Internal Medicine Board Review Course; Wayne State University and Harper-Grace Hospitals (1985-88)
4. Lecturer in ECG minicourse for students and housestaff; Harper-Grace Hospitals (1985-88)
5. Student teaching seminars (years 2 and 3), Case Reports (1985-88)
6. Physical diagnosis (1987-1988)

**University of Southern California**

1. Teaching residents, cardiology fellows in Cardiology Clinic (1989-)
2. Teaching residents, cardiology fellows in monthly Cardiology Journal Club (1989-)
3. Teaching cardiology fellows laboratory skills in experimental cardiology laboratory (1989-)
4. Student preceptor (Internal Medicine Clerkship) (1993).
5. Teaching Cardiology Fellows echocardiography (1993 -1996).
6. Faculty Member ­ USC Refresher Courses in Medicine (2005­2007)
7. Faculty Member ­ “Stem Cell Biology and Medicine” Course at USC/Cal Tech/Children’s Hospital of Los Angeles (2007-2010)
8. Faculty ­ USC NEUR-490 Course (Mentor) (2007).
9. Lecturer –AME 599 Cardiovascular Biofluid Mechanics (2019).

**Caltech**

1. Faculty Member ­ “Stem Cell Biology and Medicine” Course at USC/Cal Tech/Children’s Hospital of Los Angeles (2007-2010)
2. Caltech Med E101. Introduction to ECG and Arrhythmias (2014).
3. Caltech Med E101. Primer on Cardiac Physiology; and Introduction to ECG and Arrhythmias (2015).

**Teaching Audio Tape:**

1. Kloner RA, Russel RV. Reperfusion Injury: Does it exist in man? ACCEL Tape. Am Coll Cardiology Sept. 1992.
2. Clinical Evidence for Preconditioning Kloner RA, Russel RO. ACCEL Tape. Am Coll Card. Apr. 1995 Vol 27, No.4
3. Mechanisms of Ischemic Preconditioning. Kloner RA, DeMaria AN. ACCEL Tape. Am Coll Card. Dec. 1997, Vol. 29, No.12.
4. Kloner RA, Hutter AM. Erectile dysfunction and Cardiac Risk Factors. ACCEL Tape. Am Coll. Card. July 2000, Vol 32; No. 7.
5. Kloner RA, Conti CR. Disasters ­ Natural and Man Made: Impact on CV Risk. ACCEL Am Coll. Cardiology. July 2003 Vol. 35, No. 7.
6. Roundtable discussion. Unique properties of PDE5 inhibitors in the management of erectile dysfunction. CIEF initiative. Doctor on Call Program. Volume 2, Number 7, 2004.
7. Kloner RA. The potential use of stem cells for cardiac repair. Practical Reviews Cardiology; Oakstone Medical Publishing and Johns Hopkins University School of Medicine. January 30, 2009; Volume 33; Number 11.

**Teaching Video Tapes:**

1. Lee T, Kloner RA. Critical Decisions in Medicine: “Sudden Onset Back Pain” New York: Park Row Publishers, 1984. Red Ribbon Award in category of Medical Sciences, 27th Annual American Film Festival, 1985.
2. Kloner RA, Aldajani O. “Critical Decisions in Medicine: Cardiac Complications in a Woman with Transient Ischemia Attack.” New York: Park Row Publishers, 1986.
3. O’Neill WW, Kloner RA. Cardiogenic Shock, Emergency Angioplasty, and Stunned Myocardium in a young Myocardial Infarction Patient. NCM Publisher, NYC, 1990.
4. Kloner RA. The Stunned Myocardium. Cardiology Update. Lifetime Medical Television. April 11, 1993.

**CD-ROM Teaching System**:

1. Downey JM, Kloner RA, Nobel D, Pfeffer MA, Yellon DM. The Cardiovascular System: Cardiac Muscle Action and Blood Flow. (Module 3). Andromeda Interactive Medical Science Division, 1996.
2. Anderson R, Downey J, Kloner RA, Noble D, Pfeffer M, Yellon D. Electrophysiology of the Heart. Andromeda Medical Science, 1996.
3. Anderson R, Downey J, Kloner RA, Noble D, Pfeffer M, Yellon D. The Cardiac Cycle. Andromeda Medical Science, 1996.
4. Anderson R, Downey JM, Kloner RA, Silverman NH. Introduction to Physical Signs in Cardiology. Andromeda Medical Science, 1997.
5. Grimm RH, Flack JM, Victor RG, Kloner RA. Frontiers in Hypertension. Systolic blood pressure and the new treatment paradigm. Proceedings from August 1, 2003 meeting at The George Washington University Medical DVD, CD ROM CME Program.

**Externship:**

1970-71 Summer Student Externship; Georgetown University Medical School, Washington, DC (with Proctor Harvey, MD)

1972 Summer Student Research Fellow; National Institute of Health, Bethesda, MD (with William Roberts, MD)

**Grants (Dr. Kloner is PI on these grants unless otherwise stated):**

1981-86 American Heart Association; Established investigatorship: Prolonged Myocardial Dysfunction Following Brief Ischemia; $150,000.

1982-85 NIH R01 HL-28048: Determinants of Healing Phase of Myocardial Infarction. Harvard Medical School and Brigham and Women’s Hospital; $190,282.

1984-89 NIH Ischemia SCOR HL-26215 Project II-E: Mechanisms of Myocardial Stunning. Subcontract through Harvard Medical School; $210,000.

1985 Sterling-Winthrop: Effect of Milrinone on Myocardial Infarct Size; $24,000.

1986-87 USCI: Passive Perfusion Catheter. (Co-PI with Zolan Turi, MD); $32,000.

1987-88 American Heart Association of Michigan: Nonradioactive Microspheres for Flow Measurement; $21,240.

1987-88 Du Pont: Proposal to Study Du Pont’s Fluorocarbon in Acute Myocardial Ischemia; $97,180.

1987-88 Pfizer Laboratories: Effect of Nifedipine on Systolic and Diastolic Function of Postischemic Stunned Myo­cardium. (Co-PI with Karin Przyklenk, Ph.D.); $36,960.

1987-88 E.R. Squibb and Sons: Proposal to Study Oxygen Free Radicals Scavenging Properties and Recovery of Stunned Myocardium on Zofenopril. (Co-PI with Karin Przyklenk, Ph.D. and Peter Whittaker, Ph.D.); $83,969.

1988-13 Rains’ Endowment (Support for the Heart Institute Research Facility) of Good Samaritan; ~$500,000/year.

1989-91 Advanced Cardiovascular Systems: Grant to test new systems in interventional cardiology (Co-PI with Stephen N. Oesterle, MD); $70,882

1989 Pfizer: Reversal of the Myocardial Functional Abnormalities Associated with “Stunned” Myocardium by Intracoronary Nifedipine; $15,000

1990-91 Pfizer: Effects of Amlodipine on myocardial infarct expansion $106,000

1990-91 Target Therapeutics – Testing device - $7330

1990 - Laser Technology Project Fund - $11,052

1991 - Medtronic - $15,849

1991-94 Alliance Pharmaceuticals: Influence of Perfluoro-octylbromide on Development of Necrosis after Coronary Artery Occlusion and Reperfusion in the Rabbit - $45,310

1992 Trimedyne Research Fund (Co-PI with Dr. Peter Whittaker) - $2625

1992-93 Cardiac Pathways (Co-PI with Dr. Peter Whittaker) - $8037

1993 ACS Laser Research (Co-PI with Dr. Andrew Eisenhauer) - $21,781

1994 Scimed – Device Testing - $20,000

1995 An Evaluation of Long-Term Amlodipine Therapy on Left Ventricular Remodeling in Post Myocardial Infarct Rat Model. CoPI – Peter Whittaker; Pfizer, $81,670.

1995 CORDIS – Testing of radiofrequency ablation device -$14,000

1996 per Q Surge – Device development - $11,250

1996 GLAXO – A-1 Agonist study in myocardial infarct model - $16,000

1997 Pfizer – The effects of amlodipine therapy in chronic experimental rat model of dilated cardiomyopathy-doxorubicin (adriamycin) induced - $84,000

1998 Pasarow Foundation – Support for research fellow $14,851.

1998 - Drown Foundation – Cardiovascular research $80,000.

1998 LXR Corporation – Study of anti-apoptotic agent $13,830.

1998 - Norris Foundation – Cardiovascular research $80,000.

1999 Hoffman LaRoche – Testing anti-white cell adhesion molecule $16,000

1999-01 NIH R03 AA12258 – Effect of moderate alcohol on cardiac ischemia ($100,000 direct costs)

1999-04 NIH R01-HL61488 – Collaborative R01 – Cardiac Grafts – Functional Analysis ($1,000,000 direct costs).

1999-08 Elizabeth Rose Silverforb Trust for Cardiology Research ($770,102).

2000 CARDION Collaborative Study with Loren Field, University of Indiana on Cell Transplantation $30,000.

2000-01 Advanced Cardiovascular Systems: Perfusion Balloon Angioplasty Catheter. (Co-PI

 with Zolan Turi, MD); $22,000.

2001-02 Radiant Medical. Can cooling protect myocardial microvasculature and improve reflow after ischemia/reperfusion in the rabbit? ($23,313).

2000-04 NIH R01HL52771 Subcontract with Dr. Laurence Kedes’s Laboratory at USC. Doxorubicin Cardiomyopathy. Molecular Genetics and Rescue ($252,438 direct costs).

2002 Viagra Research Grant, Pfizer. The effect of sildenafil on myocardial infarct size, ventricular function, and no reflow ($49,188).

2002-04 McNeil Pharmaceuticals­ Effects of acetaminophen on myocardial infarct size. ($120,000)

2002-05 NIH R21-HL71965 Biologic Ventricular Assist Device ($450,000 direct costs).

2003-08 NIH R01 HL073709 - Mesenchymal Stem Cells for Myocardial Infarction ($800,000 direct costs).

2004-05 Lilly ICOS Effects of Tadalafil on Myocardial ischemia/infarction ($94,993).

2004-09 NIH R01 HL052771 ­ Subcontract with Dr. Laurence Kedes’s laboratory at USC. Doxorubicin­ Cardiomyopathy: Molecular Genetics and Rescue ($108,326 direct costs).

2004-09 EPA (Environmental Protection Agency) USEPA Grant #RD-83195201. Air Pollution in Hypertension and Heart Attacks ­ With Dr. Michael Kleinman at UCI. ($768,343).

2005-06 Cardiovascular Therapeutics (CVT). Effects of ranolazine on infarct size, regional myocardial blood flow and recovery of left ventricular function in a rabbit model of ischemia/reperfusion. ($196,512).

2005-07 Marshall and Margherite McComb Foundation. Study to Limit Heart Attack Damage in Adult and Elderly Patients. ($230,000).

2005-11 Los Angeles Thoracic and Cardiovascular Foundation ($900,000).

2006 ES Cell International ($23,664). Direct Injection of hESC into athymic nude rats without myocardial infarction.

2006-07 Cardiovascular Therapeutics (CVT). ($39,432). Does ranolazine increase regional perfusion and decrease no-reflow in the ischemic/reperfused heart?

2007-08 Cardiovascular Therapeutics (CVT). ($55,925). Ranolazine as an adjunct to cardioplegia.

2008-09 Daiichi Sankyo ($68,153). The effect of olmesartan on myocardial infarct size and no reflow.

2008-09 Biorest ($96,088). The effect of liposomal alendronate on myocardial infarct size and remodeling.

2008-09 Cardiovascular Therapeutics (CVT) ($87,500). Study of ranolazine enantiomers as adjuncts to cardioplegia.

2008-09 PeriCor Therapeutics. Effect of Two Doses of GP531 on the anatomic zone of no-reflow and infarct size and regional blood flow following ischemia/reperfusion in the rabbit heart. With Sharon Hale ($86,625).

2008-10 Sub award Agreement Under NIH-NHLBI Prime Award #1K18HL092288 with Children’s Hospital of Los Angeles ­ Stem cell transplantation following myocardial infarcts in rats. GSH-H1 PI: Dr. Robert A. Kloner; CHLA PI: Dr. Mary Kearns-Jonker ($70,992).

2008-10 Cardiovascular Therapeutics (CVT) ($124,300). The study of ranolazine as an antiarrhythmic in models of myocardial/ischemia reperfusion.

2008-14 The Gwladys and John Zurlo Charitable Foundation ($180,000).

2009-10 Alavita Pharmaceuticals Inc. ($88,138). Effect of Diannexin on anatomic zone of no-reflow, infarct size, regional myocardial blood flow and left ventricular function following ischemia/reperfusion in the rabbit heart.

2009-10 AMIT ­ (Alfred Mann Institute at the Technion) Technion Research and Development Foundation ($107,025), Haifa, Israel. Study design for TVP1022 evaluation in the setting of a rat model of acute coronary syndrome.

2010 Boston Scientific. Analysis of rotational atherectomy in drug-eluting stent era. (With Drs Bryan Schwartz and David Shavelle; $12,000).

2010-11 Celavet ($119,490). Human fetal heart and brain derived stem cells (OK-99) for rebuilding a broken heart.

2010-11 Stealth Peptides. Effects of MTP-131 on the anatomic zone of no-reflow, zone of hemorrhage and infarct size following ischemia/reperfusion insult in the rabbit heart. ($114,125).

2010-11 Gilead. Study of the effect of ASK-1 on myocardial infarction. ($97,716).

2011 USC Bioengineering funds for studying sheer stress catheter ($10,000).

2011-12 Stealth Peptide. Effects of MTP-131 (Bendavia) on sub-acute no-reflow and on left ventricular function and healing in the chronic rat model of myocardial ischemia and reperfusion ($195,406).

2011-12 Stealth Peptide. Effects of Bendavia on the anatomic zone of no-reflow and infarct size following ischemia/reperfusion insult in the rabbit heart: Bendavia administered after reperfusion ($63,125)

2011-13 Gift from H. Rossbacher ($300,000).

2012 Heliox/Donald Vanderipe. Effect of Heliox breathing on infarct size and anatomic zone of no-reflow following ischemia/reperfusion in the rabbit heart, ($25,000).

2012-13 Gilead Sciences, Inc. To study the effect of an ASK-1 inhibitor upon cardiac function and left ventricular remodeling in the setting of a reperfused myocardial infarction. ($151,719.00).

2012-13 Boehringer-Ingelheim. The effect of dabigatran on no reflow in a myocardial infarct model model ($62,500).

2012-14 Stealth Peptides. Does chronic Bendavia administered post-myocardial infarction, reduce long-term parameters of heart failure and left ventricular remodeling? ($504,010.00).

2015-17 Stealth Peptides. Study of Bendavia and other mitochondrial protective peptides ($507,791; to Huntington Medical Research Institutes).

2016 Faraday Inc. The effect of FDY-5301 on myocardial infarct size and no-reflow in an experimental model of coronary artery occlusion/reperfusion.($47,736).

2016 Faraday. Does chronic administration of NaI post myocardial infarction limit adverse LV remodling and preserve LV function in an experiemental rat model? ($130,543).

2016-17 Servier (Institut De Recherches Servier). Effect of GTP-CH activators on the no-reflow phenomenon in rats. ($150,283).

2016-20 Dept of Defense (US Army, Medical Research Acquisitions Activity). W81XWH-16-1-0606, #PR150104. Application of combined cardioprotective agents to preserve organ function and improve survival during experimental hemorrhagic shock. Sep 2016-2020. ($1,911,650).

2017-19 Los Angeles Thoracic and Cardiovascular Foundation. Does myocardial hypothermia induced after reperfusion ( too late to reduce infarct size but not too late to reduce no-reflow) improve the healing phase of myocardial infarction, prevent adverse left ventricular remodeling and improve cardiac function? Nov 2017- Dec 2019. ($100,000).

2018-19 Subaward with EVAS Therapeutics, PI Dr. Tze-Chein Wun SBIR/NHLBI. Cardioprotection by inhibition of coagulation and inflammation in myocardial infarction. 1R43HL142325-01A1. ($51,838).

2018-20 ARENA Pharmaceuticals. The effects of Temanogrel on no-reflow and infarct size in an experimental model of acute myocardial infarction.( $232,634).

2018-23 NHLBI. R01HL144258. The effect of electronic cigarettes on young versus old normal hearts and pathologic hearts. ($1,839,340).

2018-22 Tobacco-Related Disease Research Program (TRDRP; University of California). Effects of Cigarette Smoking and Vaping on Heart Attack. Proposal Number (pC ID): 587712; Award Number; 28IR-0057. ($1,066,980.)

2019-20 OP2. Effects of OP2113 on myocardial infarct size and no reflow in a rat model. ($110,218).

2019-20 USC Training grant for PhD candidate, Rashid Alavi; $4,500.

2019-23 Pfeiffer Foundation Grant to Huntington Medical Research Institutes, Pasadena, CA “ Research Program in Brain Heart Connection: Training the Next Generation of Biomedical Researchers” ($3,200,000); Dr. Kloner’s role: coauthor with Dr. Julia Bradsher (CEO)  and senior staff of HMRI, Role in project:  Key Staff and CSO, Contributor to Implementation plan for developing a postdoctoral fellowship program and recruiting a new scientist.

2020-21 Ingram Cardio. Fund. The effect of nicotine on blood vessels and vascular function $71,097.

2020-21 NHLBI. 3R01HL144258-02S1. Supplement to “The effect of electronic cigarettes on young versus old normal hearts and pathologic hearts”. (To determine the cause of EVALI in a standardized experimental model). $468,326.

2020-21 Ingram Cardio. Fund. The effect of COVID 19 on the heart (with LA County, USC, UCLA) $40,000.

2021 Ingram Cardio Fund. Cardiovascular Research. $60,000.

2021 Francis Bacon/Crum Cardiovascular. Effects of COVID 19 on the heart $24,000

2021 USC, Dr. Niema Pahlevan’s laboratory grant to help generate preliminary data on acute Myocardial infarction survival rat model and ischemia rat model. $4580.

2021 Young Therapeutics, The effect of YT-007 on myocardial infarct size. $32,923.

2021-22 Sanofi US Services. The effect of PDE-5 inhibitors on major adverse cardiovascular events and mortality in a large cohort of men with erectile dysfunction from a nationwide insurance data base: A retrospective study. $701,824.26

2021-22 TRDRP. Effects of Cigarette Smoking and Vaping on Heart Attack. Award Number: 281R-0057C. Supplemental 4th year award for $115,367.

2021-22 Stealth Biotherapeutics. Study a new compound as well as elamipretide in HMRI’s heart attack model. $179,363.

2021-23 Mentor on Niema Pahlevan’s AHA Career Award “A system fluid dynamics approach for Development of noninvasive diagnostics of acute and chronic cardiovascular diseases.” ~ $30,000.

2022-23 Pulse Therpeutics, Inc. Pilot study for Pulse Therapeutics to treat no-reflow with iron nanoparticles in an experimental myocardial infarction model. $70,000.

2021-23 W. Keck Foundation. Fluctuating sodium in the nervous system as the root cause of fluctuating brain function. (Dr. Kloner assumed PI duties starting June 2021). $1,000,000.

2021-25 LK Whittier Foundation. Alzheimer's disease brain aging study. $8,000,000.

2021-26 NIA R01AG063857. Cognitive challenge to reveal systemic neurophysiology biomarkers in pre-symptomatic Alzheimer's disease. (Dr. Kloner as MPI with Dr. Xianghong Arakaki as primary PI). $3,685,799.

2021-24 National Institute of Neurologic Diosrders and Stroke (NIH). Dysfunction of homeostasis in migraine. (Xianghong Arakai, PI; RA Kloner Co-investigator (5%). $1,927,958.

2022-24 Sanofi. The effect of tadalafil (Cialis) on major adverse cardiovascular events and mortality in a large cohort of men with ED from a nationwide database: A retrospective study. $587,980.

2023-25 The James B. Boswell Foundation. Support of HMRI Cardiovascular Research Program. $1,000,000.

2022-23 Sanofi. Grant to support the Princeton 4 Guidelines meeting on PDE-5 inhibitors and cardiac health. Scheduled for March 10, 11th, 2022. Huntington Medical Research Insitutes, Pasadena, CA. $188,000.

2023-2024 Gordon Ross Foundation. Cardiovascular/diabetes research. $18,750.

2024 The James B. Bowell Foundation. Support for Postdoctoral Boswell Fellow. $100,000

2024-2025 Allysta Pharmaceuticals Inc. ALY688 effect on myocardial infarction. $86,670.

**Committees:**

1985-88 Coronary Care Unit Committee; Harper Hospital

1985-88 Research Committee, Department of Internal Medicine; Wayne State University

1986 Pharmacology Search Committee; Wayne State University

1986-87 Chairman, Internal Medicine Internal Review Committee; Wayne State University School of Medicine

1986-88 Promotion and Tenure Committee, Department of Medicine; Wayne State University School of Medicine

1986-88 Chairman, Cardiology Research Committee; Wayne State University School of Medicine/Harper Hospital

1988-14 Steering Committee - Heart Institute of the Hospital of the Good Samaritan

1988-14 Chairman, Research Committee of the Heart Institute of the Hospital of the Good Samaritan

1989-03 Research Advisory Committee-Hospital of the Good Samaritan

1989-14 Institutional Animal Care and Use Committee- Hospital of the Good Samaritan.

1988-91 Research Committee, American Heart Association, Greater Los Angeles Affiliate

1990 Academic Advisory Committee. Pfizer Visiting Professorship Program in Cardiovascular Medicine

1992 Steering Committee. Amlodipine Cardiovascular Community Trial [a large multicenter hypertension, LVH regression trial; sponsored by -Pfizer].

1994-97 Council Member - International Society for Heart Research, North American Section

1995 Annual Scientific Session Program Committee - American College of Cardiology

1995-98 NIH, NHLBI, Cardiovascular Study Section A

1996 Scientific Organizing Committee XVIII Annual Meeting of International Society for Heart Research, North American Section.

1996-00 Chair, Publications Committee. California Chapter of the American College of Cardiology.

1996-03 Chairman of Good Samaritan Hospital IRB

1999-03 Medical Executive Committee Good Samaritan Hospital.

2004-06 USC Stem Cell Steering Committee

2007, 2008 American College of Cardiology Annual Scientific Session Planning Committee

2019- USC, Division of CV Medicine, Research and Scholarly Task Force

**Patents:**

1. Patent # W01995/012979 May 1995

Inventors: Kedes LH; Sartorelli V, Prentice HM, Kloner RA. Compositons and methods

for transductions of cells. The University of Southern California

1. Patent # 6,206,004 March 27, 2001

Inventor: Robert A. Kloner

Treatment Method Via the Pericardial Space

1. Patent #9,877,997 Jan 30, 2018

Inventors: Travis Wilson, Robert A. Kloner

Methods and compositions for regulating SRCA2A expression levels in myocardial infarction.

1. Patent # 9,884,085 Feb 6, 2018

Inventors: Travis Wilson, Robert A. Kloner

Methods for the regulation of matrix metalloproteinase expression

1. Patent # 10322159 June 18, 2019

Inventors: Travis Wilson, Kenneth Borow, Robert A. Kloner, Sharon Hale

Methods for the prevention of treatment of no-reflow following ischemia/reperfusion injury.

**PUBLICATIONS**

**Original Reports**

1. Kloner RA, Ganote CE, Whalen D, Jennings RB. Effect of a transient period of ischemia on myocardial cells. II. Fine structure during the first few minutes of reflow. Am J Pathol 1974;74:399-422.
2. Kloner RA, Ganote CE, Reimer KA, Jennings RB. Distribution of coronary arterial flow in acute myocardial ischemia. Arch Pathol 1975;99:86-94.
3. Kloner RA, Ganote CE, Jennings RB. The "no-reflow" phenomenon fol­lowing temporary coronary occlusion in the dog. J Clin Invest 1974;54:1496­-1508.
4. Jennings RB, Ganote CE, Kloner RA, Whalen DA Jr, Hamilton DG. Explo­sive swelling of myocardial cells irreversibly injured by transient ischemia. In: Fleckenstein A, Rona G, eds, Recent Advances in Studies on Cardiac Structure and Metabolism. Baltimore: University Park Press, 1975;405-413.
5. Kloner RA, Ganote CE, Jennings RB, Reimer KA. Demonstration of the "no-reflow" phenomenon on the dog heart after temporary ischemia. In: Roy PE, Rona G, eds, Recent Advances in Studies on Cardiac Structure and Metabolism. Baltimore: University Park Press, 1975;463-474.
6. Kloner RA, Reimer KA, Jennings RB. Distribution of coronary collateral flow in acute myocardial ischaemic injury: Effect of propranolol. Cardiovasc Res 1976;10(1):81-90.
7. Kloner RA, Reimer KA, Willerson JT, Jennings RB. Reduction of myocardial infarct size with hyperosmolar mannitol. Proc Soc Exp Med Biol 1976;151:677-683.
8. Schatz M, Patterson R, Kloner RA, Falk J. The prevalence of tubercu­losis and positive tuberculin skin tests in a steroid-treated asthmatic population. Ann Intern Med 1976;84:261-265.
9. Kloner RA, Fishbein MC, Cotran RA, Braunwald E, Maroko PR. The effect of propranolol on microvascular injury in acute myocardial ischemia. Circulation 1977;55:872-880.
10. Kloner RA, Fishbein MC, Maclean D, Braunwald E, Maroko PR. Effect of hyaluronidase during the early phase of acute myocardial ischemia: An ultrastructural and morphometric analysis. Am J Cardiol 1977;40:43-49.
11. Rasmussen MM, Reimer KA, Kloner RA, Jennings RB. Infarct size reduc­tion by propranolol before and after coronary ligation in dogs. Circula­tion 1977;56:794-798.
12. Kloner RA, Fishbein MC, Lew H, Maroko PR, Braunwald E. Mummification of the infarcted myocardium by high dose corticosteroids. Circulation 1978; 57:56-63.
13. Kloner RA, Fishbein MC, Braunwald E, Maroko PR. Effect of propranolol on mitochondrial morphology during acute myocardial ischemia. Am J Cardiol 1978;41:880-886.
14. Kloner RA, Braunwald E, Maroko PR. Long-term preservation of ischemic myocardium in the dog by hyaluronidase. Circulation 1978;58:220-226.
15. McGee J, Singer D, Teneich RE, Kloner RA, Belig N, Reimer K, Elson J. Cellular electrophysiologic marker of irreversible ischemic myocardial injury. Am J Physiol 1978;235(5):H559-H568.
16. Hillis LD, Khuri S, Braunwald E, Kloner RA, Tow D, Barsamian E, Maroko PR. The mass spectrometric measurement of intramural carbon dioxide tension to assess the efficacy of interventions to limit ischemic injury. Trans Assoc Am Phys 1978;91:259-267.
17. Hillis LD, Khuri SF, Braunwald E, Kloner RA, Tow D, Barsamian E, Maroko PR. Assessment of the efficacy of interventions to limit ischemic injury by direct measurement of intramural carbon dioxide tension after coronary artery occlusion of the dog. J Clin Invest 1979;63:99-107.
18. Pfeffer MA, Pfeffer JM, Fishbein MC, Fletcher PF, Spadaro J, Kloner RA, Braunwald E. Myocardial infarct size and ventricular function in rats. Circ Res 1979;44:503-512.
19. Kloner RA, Fishbein MC, Hare CS, Maroko PR. Early ischemic ultrastructural and histochemical alterations in the myocardium of the rat following coronary artery occlusion. Exp Mol Path 1979;30:129-143.
20. Khuri SF, Kloner RA, Hillis LD, Tow DE, Baramian EM, Maroko PR, Braunwald E. Intramural PCO2: A reliable index of the severity of myocar­dial ischemic injury. Am J Physiol 1979;237(2):H253-H259.
21. Khuri SF, Karaffa S, Kloner RA, Barsamian EM, Yasuda T, Tow D. Deter­mination of intramural blood flow with xenon 127. New radionuclide with potential intraoperative application. J Thorac Cardiovasc Surg 1980;80:262­-270.
22. Kloner RA, Ingwall JS. The cultured fetal mouse heart as a model for studying myocardial ischemic necrosis. Exp Mol Path 1980;32:317-335.
23. Kloner RA, Rude RE, Carlson N, Maroko PR, DeBoer LWV, Braunwald E. Ultrastructural evidence of microvascular damage and myocardial cell injury following coronary artery occlusion: Which comes first? Circulation 1980; 62:178-184.
24. Rude RE, Kloner RA, Maroko PR, Khuri S, Karaffa S, DeBoer LWV, Braunwald E. Effects of amrinone on experimental acute myocardial ischemic injury. Cardiovasc Res 1980;14:419-427.
25. Kloner RA, Maroko PR, Braunwald E. Analysis of the geometry of myocar­dial infarct size reduction with hyaluronidase. Proc Soc Exp Biol Med 1980;165:141-146.
26. DeBoer LWV, Strauss HW, Kloner RA, Rude RE, Davis RF, Maroko PR, Braunwald E. Autoradiographic method for measuring the ischemic myocardium at risk: The effects of verapamil on infarct size following experimental coronary artery occlusion. Proc Natl Acad Sci USA 1980;77:6119-6123.
27. DeBoer LWV, Ingwall JS, Kloner RA, Braunwald E. Prolonged derangements of canine myocardial purine metabolism following a brief coronary artery occlusion not associated with anatomic evidence of necrosis. Proc Natl Acad Sci USA 1980;77:5471-5475.
28. Wolf RA, Chuang LY, Muller JE, Kloner RA, Braunwald E. Intravenous bovine testicular hyaluronidase depolymerizes myocardial hyaluronic acid in dogs with coronary artery occlusion. Circ. Res., 1980;47:88-95
29. Franco WP, Bracey AW, Franco KL, Hufnagel CA, Glogar DH, Kloner RA. Fibroblastic growth factor, an angiogenesis factor, for limitation of infarct size. (Letter presenting original data.) Ann Intern Med 1980;93:637-638.
30. Santini D, Fox D, Kloner RA, Konstam M, Rude RE, Lorell B. Pulmonary hypertension in systemic lupus erythematosus: Hemodynamics and effects of vasodilator therapy. Clin Cardiol 1980;3:406-411.
31. Carabello BA, Mee R, Collins JJ Jr, Kloner RA, Levin D, Grossman W. Contractile function in chronic gradually developing subcoronary aortic stenosis. Am J Physiol 1981;240:H80-H86.
32. Glogar D, Kloner RA, Muller JE, DeBoer LWV, Braunwald E, Clark LC Jr. Fluorocarbons reduce myocardial ischemic damage after coronary occlusion. Science 1981;211:1439-1441.
33. Ertl G, Kloner RA, Alexander RW, Braunwald E. Limitation of experi­mental infarct size by angiotensin converting enzyme inhibitor. Circula­tion 1982; 65:40-48.
34. DeBoer LWV, Nosta J, Kloner RA, Braunwald E. Studies of amiodarone during experimental myocardial infarction: Beneficial effects of hemody­namics and infarct size. Circulation 1982;65:508-512.
35. Rude RE, Glogar D, Khuri SF, Kloner RA, Karaffa S, Muller JE, Clark LC Jr, Braunwald E. Effects of intravenous fluorocarbons during and without oxygen enhancement on acute myocardial ischemic injury assessed by measure­ment of intramyocardial gas tensions. Am Heart J 1982;103:986-995.
36. Kloner RA, DeBoer LWV, Carlson N, Braunwald E. The effect of verapamil on myocardial ultrastructure during and following release of coronary artery occlusion. Exp Mol Path 1982;36:277-286.
37. Nieminen MS, Parisi AF, O'Boyle J, Folland ED, Khuri S, Kloner RA. Serial evaluation of myocardial thickening and thinning in acute myocardial infarction: Identification and quantification using two-dimensional echo­cardiography. Circulation 1982;66:174-180.
38. Wood D, Roberts C, Kloner RA, Cohn LH. Limitation of myocardial infarct size after surgical reperfusion of acute coronary occlusion. J Thorac Cardiovasc Surg 1982;84:353-358.
39. Parisi AF, Nieminen MS, O'Boyle JE, Moynihan PF, Khuri SF, Kloner RA, Folland ED, Schoen FJ. Enhanced detection of the evolution of tissue changes after acute myocardial infarction using color-encoded two­-dimensional echocardiography. Circulation 1982;66:764-770.
40. Goldhaber SZ, Pohost GM, Kloner RA, Newell JB, Ingwall JS. Inosine: a protective agent in an organ culture model of myocardial ischemia. Circ Res 1982;51:181-188.
41. Braunwald E, Kloner RA. The stunned myocardium - prolonged, post­-ischemic ventricular dysfunction. Circulation 1982;66:1146-1149.
42. Lange R, Zierler M, Kloner RA, Carlson N, Seiler M, Khuri SF. Intramyocardial pH measurement: A useful tool for the on-line assessment of ischemic damage and the adequacy of myocardial preservation during open heart surgery? Surg Forum 1983;33:290-292.
43. Braunwald E, Muller JE, Kloner RA, Maroko PR. The role of beta­-adrenergic blockade in the therapy of patients with myocardial infarction. Am J Med 1983;74:113-123.
44. Hammerman H, Kloner RA, Schoen FJ, Brown EJ Jr, Hale S, Braunwald E. The effects of early indomethacin administration on late scar formation following myocardial infarction. Trans Assoc Am Phys 1983;95:104-109.
45. Kloner RA, Kloner JA. The effect of early exercise on myocardial infarct scar formation. Am Heart J 1983;106:1009-1013.
46. Brown EJ Jr, Kloner RA, Schoen FJ, Hammerman H, Hale S, Braunwald E. Scar thinning due to ibuprofen administration following experimental myo­cardial infarction. Am J Cardiol 1983;51:877-883.
47. Roberts CS, Maclean D, Braunwald E, Maroko PR, Kloner RA. Topographic changes in the left ventricle after experimentally induced myocardial infarction in the rat. Am J Cardiol 1983;51:872-876.
48. Ellis SG, Henschke CI, Sandor T, Wynne J, Braunwald E, Kloner RA. Time course of functional and biochemical recovery of myocardium salvaged by reperfusion. J Am Coll Cardiol 1983;1:1047-1055.
49. Kloner RA, Ellis SG, Lange R, Braunwald E. Studies of experimental coronary artery reperfusion: Effects on infarct size, myocardial function, biochemistry, ultrastructure and microvascular damage. Circulation 1983; 68:I8-I15.
50. Ertl G, Alexander RW, Kloner RA. Interactions between coronary occlu­sion and the renin-angiotensin system in the dog. Basic Res Cardiol 1983;78:518-533.
51. Rude RE, Tumas J, Gunst M, Kloner RA, DeBoer LWV, Maroko PR. Effects of ortho-iodo sodium benzoate on acute myocardial ischemia, hemodynamics and infarct size following coronary artery occlusion in dogs. Am J Cardiol 1983;51:1422-1427.
52. Hammerman H, Kloner RA, Schoen FJ, Brown EJ Jr, Hale S, Braunwald E. Indomethacin induced scar thinning following experimental myocardial infarction. Circulation 1983;67:1290-1295.
53. O'Boyle JE, Parisi AF, Nieminen M, Kloner RA, Khuri S. Quantitative detection of regional left ventricular contraction abnormalities by two dimensional echocardiography: Comparison of myocardial thickening/thinning and endocardial motion in a canine model. Am J Cardiol 1983;51:1732-1738.
54. Lange R, Kloner RA, Zierler M, Carlson N, Seiler M, Khuri SF. Time course of ischemic alterations during normo- and hypothermic arrest and its reflection by on-line monitoring of tissue pH. J Thorac Cardiovasc Surg 1983; 86:418-434.
55. Lange R, Kloner RA, Braunwald E. First ultra short acting beta blocker: Its effects on size and segmental wall dynamics of reperfused myocardial infarcts in dogs. Am J Cardiol 1983;51:1759-1767.
56. Hammerman H, Kloner RA, Hale S, Schoen FJ, Braunwald E. Dose-dependent effects of short-term methylprednisolone on myocardial infarct extent, scar formation and ventricular function. Circulation 1983;68:446-452.
57. Kemper AJ, O'Boyle JE, Sharma S, Cohen CA, Kloner RA, Khuri SF, Parisi AF. Hydrogen peroxide contrast enhanced two-dimensional echocardiography: I. Real-time, in vivo delineation of regional myocardial perfusion. Circu­lation 1983;68:603-611.
58. Ellis SG, Wynne J, Braunwald E, Henschke CI, Sandor T, Kloner RA. Response of reperfusion-salvaged, stunned myocardium to inotropic stimula­tion. Am Heart J 1984;107:13-19.
59. Hammerman H, Schoen FJ, Kloner RA. Short-term exercise has a prolonged effect on scar formation after experimental acute myocardial infarction. J Am Coll Cardiol 1983;2:979-982.
60. Roberts CS, Schoen FJ, Kloner RA. Effect of coronary reperfusion on myocardial infarct healing and hemorrhage. Am J Cardiol 1983;52:610-614.
61. Lange R, Nieminen M, Kloner RA. Failure of pindolol and metoprolol to reduce the size of non-reperfused infarcts in dogs using area at risk techniques. Cardiovasc Res 1984;18:37-43.
62. Kloner RA, Ellis SG, Carlson NV, Braunwald E. Coronary reperfusion for the treatment of acute myocardial infarction: Post ischemic ventricular dysfunction. Cardiology 1983;70:233-246.
63. DeBoer LVW, Rude RE, Kloner RA, Ingwall JS, Maroko PR, Davis MA, Braunwald E. A flow and time-dependent index of ischemic injury after experimental coronary occlusion and reperfusion. Proc Natl Acad Sci (USA) 1983;80:5784-5788.
64. Hammerman H, Alker KJ, Schoen FJ, Kloner RA. Morphologic and func­tional effects of piroxicam on myocardial scar formation after coronary occlusion in dogs. Am J Cardiol 1984;53:604-607.
65. Lange R, Ware J, Kloner RA. Absence of a cumulative deterioration of regional function during three repeated 5 or 15-minute coronary occlusions. Circulation 1984;69:400-408.
66. Hammerman H, Schoen FJ, Braunwald E, Kloner RA. Drug induced expansion of infarct: Morphologic and functional correlations. Circulation 1984;69:611-617.
67. Wolf RA, Glogar D, Chuang LY, Garrett PE, Ertl G, Tumas J, Braunwald E, Kloner RA, Fishbein ML, Muller JE. Heparin inhibits bovine testicular hyaluronidase activity in myocardium of dogs with coronary artery occlusion. Am J Cardiol 1984;53:941-944.
68. Lange R, Ingwall J, Hale SL, Alker KJ, Kloner RA. Effects of recurrent ischemia on myocardial high energy phosphate content in canine hearts. Basic Res Cardiol 1984;79:469-478.
69. Hammerman H, Kloner RA, Briggs L, Braunwald E. Enhancement of salvage of reperfused myocardium by early beta adrenergic blockade. J Am Coll Cardiol 1984;36:1438-1443.
70. Henschke CI, Ellis SG, Risser TA, Wynne J, Kloner RA, Sandor T. Quantitative two-dimensional echocardiography analysis of pre- and post­-ischemic canine left ventricular function. Am J Roentgenol 1984;143:537­-542.
71. Hale SL, Lange R, Alker KJ, Kloner RA. Correlates of reperfusion ventricular fibrillation in dogs. Am J Cardiol 1984;53:1397-1400.
72. Roberts CS, Maclean D, Maroko P, Kloner RA. Early and late remodeling of the left ventricle after acute myocardial infarction. Am J Cardiol 1984; 54:407-410.
73. Lange R, Cavanaugh AC, Zierler M, Marston W, Kloner RA, Khuri SF. The relative importance of alkalinity, temperature and the washout effect of bicarbonate buffered multidose cardioplegia. Circulation 1984; 70:I75-I83.
74. Kloner RA, Alker KJ. Effect of streptokinase on intramyocardial hemorrhage, infarct size, and the no-reflow phenomenon during coronary reperfusion. Circulation 1984;70:513-521.
75. Lange R, Ingwall J, Hale SL, Alker KJ, Braunwald E, Kloner RA. Pre­servation of high energy phosphates by verapamil in reperfused myocardium. Circulation 1984;70:734-741.
76. Hammerman H, O'Boyle JE, Cohen C, Kloner RA, Parisi AF. Dissociation between two-dimensional echocardiographic left ventricular wall motion and myocardial salvage in early experimental acute myocardial infarction in dogs. Am J Cardiol 1984;54:875-879.
77. Roberts CS, Maclean D, Maroko PR, Kloner RA. Relation of early mono- nuclear and polymorphonuclear cell infiltration to late scar thickness after experimentally-induced myocardial infarction in the rat. Basic Res Cardiol 1985;80:202-209.
78. Hammerman H, Kloner RA, Alker KJ, Schoen FJ, Braunwald E. Effect of transient increased afterload during experimentally-induced acute myocardial infarction in dogs. Am J Cardiol 1985;55:566-570.
79. Przyklenk K, Vivaldi MT, Arnold JMO, Schoen FJ, Kloner RA. Capillary anastomoses between the left anterior descending and circumflex circulations in the canine heart: Possible importance during coronary artery occlusion. Microvasc Res 1986;31:54-65.
80. Khuri SF, Kloner RA, Karaffa SA, Taylor A, Lai NEJ, Marston W, Tow DE, Barsamian EM. The significance of the late fall in myocardial PCO2 and its relationship to myocardial pH following coronary occlusion in the dog. Circ Res 1985;56:537-547.
81. Tumas J, Deth R, Kloner RA. The effects of nisoldipine, a new calcium antagonist on myocardial infarction size and cardiac dynamics following acute myocardial infarction. J Cardiovasc Pharmacol 1985;7:361-367.
82. Kloner RA. Book review: Therapeutic Approaches to Myocardial Infarct Size Limitation, ed. by DJ Hearse and DM Yellon, New York Raven Press, 1984. N Engl J Med 1985;312:594-595.
83. Hale SL, Alker KJ, Lo H-M, Ingwall JS, Kloner RA. Alterations in the distribution of high energy phosphates during ischemia in a canine model of reperfusion-induced ventricular fibrillation. Am Heart J 1985; 110:590­-594.
84. Lo H-M, Kloner RA, Braunwald E. Effect of intracoronary verapamil on infarct size in ischemic, reperfused canine heart: The critical importance of the timing of treatment. Am J Cardiol 1985;56:672-677
85. Ellis SG, Henschke CI, Sandor T, Wynne T, Kloner RA. Relation between the transmural extent of acute myocardial infarction and associated myocardial contractility two weeks after infarction. Am J Cardiol 1985;55:1412-1416.
86. Kloner RA, Kirshenbaum J, Lange R, Antman EM, Braunwald E. Experi­mental and clinical observations on the efficacy of esmolol in myocardial ischemia. Am J Cardiol 1985; 56:40F-48F.
87. Warner KG, Josa M, Kloner RA, Lee SS, Seiler M, Khuri S. Metabolic and microscopic evidence of ischemia in valvular heart surgery: Are we really protecting the hypertrophied ventricle? Surgical Forum 1985;36:216-218.
88. Arnold JMO, Braunwald E, Sandor T, Kloner RA. Inotropic stimulation of reperfused myocardium: Effects on infarct size and myocardial function. J Am Coll Cardiol 1985;6:1026-1034.
89. Braunwald E, Kloner RA. Perspective. Myocardial Reperfusion: A double-edged sword? J Clin Invest 1985;76:1713-1719.
90. Connelley CM, Vogel WM, Wiegner AW, Osmers EL, Bing OHL, Kloner RA, Dunn-Lanchentin D, Franzblau C, Apstein CS. Effects of reperfusion after coronary artery occlusion on post-infarction scar tissue. Circ Res 1985;57:562-577.
91. Vivaldi MT, Kloner RA, Schoen FJ. Triphenyltetrazolium staining of irreversible ischemic injury following coronary artery occlusion in rats. Am J Pathol 1985;121:522-530.
92. Kirshenbaum JM, Kloner RA, Antman E, Braunwald E. Use of an ultrashort acting beta blocker in patients with acute myocardial ischemia. Circula­tion 1985;72:873-880.
93. Kemper AJ, Force T, Kloner RA, Gilfoil M, Perkins L, Hale SL, Alker KJ, Parisi AF. Contrast echocardiographic estimation of regional myocardial blood flow after acute coronary occlusion. Circulation 1985;72:1115-1124.
94. Kloner RA. Book review: Unstable Angina: A Clinical Approach, GD Plotnick, ed, Futura, Mt. Kisco, New York, 1985. N Engl J Med 1985;313:1301.
95. Przyklenk K, Vivaldi MT, Schoen FJ, Arnold JMO, Kloner RA. Salvage of ischemic myocardium by reperfusion: Importance of collateral blood flow and myocardial oxygen demand during occlusion. Cardiovasc Res 1986;20:403­-414.
96. Przyklenk K, Kloner RA. Superoxide dismutase plus catalase improves contractile function in the canine model of the "stunned myocardium." Circ Res 1986;73:148-156.
97. Campbell CA, Przyklenk K, Kloner RA. Infarct size reduction: a review of the clinical trials. J Clin Pharmacol 1986;26:317-329.
98. Roberts CS, Anderson HV, Carboni HA, Justicz AGS, Leimgruber PP, Kloner RA, Gruentzig AR. Usefulness of intracoronary infusion of fluorocarbon distal to prolonged coronary occlusion by angioplasty balloon in dogs. Am J Cardiol 1986;57:1202-1205
99. Campbell CA, Kloner RA, Alker KJ, Braunwald E. The effect of verapamil on infarct size in dogs subjected to coronary artery occlusion with tran­sient reperfusion. J Am Coll Cardiol 1986;8:1169-1174.
100. Holman BL, Campbell CA, Lister-James J, Jones AG, Davison A, Kloner RA. Effect of reperfusion and hyperemia on the myocardial distribution of technetium -99m T-butylisonitrile. J Nucl Med 1986;27:1172-1177.
101. Campbell CA, Mehta PM, Wynne J, Kloner RA. The cardiotonic agent amrinone does not increase anatomic infarct size. J Cardiovasc Pharmacol 1987;9:225-229.
102. Hale SL, Vivaldi MT, Kloner RA. Fluorescent microspheres: a new tool for visualization of ischemic myocardium in rats. Am J Physiol 1986;251:H863-H868.
103. Brown EJ, Erburu L, Kloner RA. Inability of Fructose 1, 6, diphosphate to reduce myocardial infarct size. Journal of Medicine 1987;18:43-53.
104. Warner KG, Khuri SF, Kloner RA, Josa M, Dalecki-Chipperfield KM, Butler MD, Assousa SN, Lee SS, Barsamian EM, Seiler M. Structural and metabolic correlates of cell injury in the hypertrophied myocardium during valve replacement. J Thorac Cardiovasc Surg 1987;93:741-754.
105. Patel B, Kloner RA. Analysis of reported randomized trials of streptokinase therapy for acute myocardial infarction in the 1980s. Am J Cardiol 1987;59:501-504.
106. Kloner RA, Braunwald E. Effects of calcium channel antagonists on infarcting myocardium. Am J Cardiol 1987;59:84B-94B.
107. Arnold JMO, Antman EM, Przyklenk K, Braunwald E, Sandor T, Vivaldi MT, Schoen FJ, Kloner RA. Differential effects of reperfusion on incidence of ventricular arrhythmias and recovery of ventricular function at 4 days following coronary occlusion. Am Heart J 1987;113:1055-1065.
108. Alker KJ, Kloner RA. The effect of digitalis on experimental myocardial infarct size and hemodynamics. Am Heart J 1987;113:1353-1355.
109. Kloner RA, Parisi AF. Acute myocardial infarction: diagnostic and prognostic applications of two-dimensional echocardiography. Circulation 1987;75:521-524.
110. Kloner RA, Przyklenk K, Campbell CA. Coronary reperfusion following experimental myocardial infarction. J Cardiac Surgery 1987;2:291-297.
111. Przyklenk K, Kloner RA. Effect of oxygen-derived free radical scavengers on infarct size following six hours of permanent coronary artery occlusion: salvage or delay of myocyte necrosis? Basic Res Cardiol 1987;32:146-158.
112. Hale SL, Kloner RA. Effect of early coronary artery reperfusion on infarct development in a model of low collateral flow. Cardiovasc Res 1987;21:668-673.
113. Patel B, Kloner RA, Ensley J, Al-Sarraf M, Kish J, Wynne J. 5-Fluorouracil cardiotoxicity: left ventricular dysfunction and effect of coronary vasodilators. Am J Med Sci 1987;294:238-243.
114. Turi ZG, Campbell CA, Gottimukkala M, Kloner RA. Preservation of distal coronary perfusion during prolonged balloon inflation using an autoperfusion angioplasty catheter. Circulation 1987;75:1273-1280.
115. Kloner RA. Book review: Cardiovascular Emergencies, ed. by J Ornato, Churchill, Livingston, New York 1986; N Engl J Med 1987;316:758.
116. Campbell C, Reddy R, Alker KJ, Wynne J, Kloner RA. Effect of milrinone on myocardial infarct size. Am J Cardiol 1987;60:422-423.
117. Vivaldi MT, Eyre DR, Kloner RA, Schoen FJ. Effects of methylprednisolone on collagen biosynthesis in healing acute myocardial infarction. Am J Cardiol 1987;60:424-425.
118. Ensley JF, Patel B, Kloner RA, Kish JA, Wynne J, Al-Sarraf M. The clinical syndrome of 5-fluorouracil cardiotoxicity. Investigational New Drugs, 1989;7:101-109.
119. Kloner RA. Introduction to the role of oxygen radicals in myocardial ischemia and infarction. Free Radical Biology and Medicine, 1988;4:5-7.
120. Przyklenk K, Connelly CM, McLaughlin RJ, Kloner RA, Apstein CS. Effect of myocyte necrosis on strength, strain and stiffness of isolated myocardial strips. Am Heart J 1987;114:1349-1359.
121. Przyklenk K, Kloner RA. Effect of hydralazine and enalapril on con­tractile function of postischemic `stunned' myocardium. Am J Cardiol 1987;60:934-936.
122. Mehta P, Kloner RA. Effects of acid base disturbance, septic shock, and calcium and phosphorous abnormalities on cardiovascular function. Critical Care Clinics 1987;5:747-758.
123. Przyklenk K, Patel B, Kloner RA. Diastolic abnormalities of post­ischemic `stunned' myocardium. Am J Cardiol 1987;60:1211-1213.
124. Przyklenk K, Kloner RA. Effect of verapamil on postischemic `stunned' myocardium: importance of timing of treatment. J Am Coll Cardiol 1988; 11:614-623.
125. Campbell CA, Clavenna CF, Wynne J, Kloner RA. Pentoxifylline does not reduce infarct size in a canine model of acute myocardial infarction. Br J Pharmacol 1988;93:587-590.
126. Mehta PM, Alker KJ, Kloner RA. Functional infarct expansion, left ventricular dilation and iso-volumic relaxation time following coronary occlusion: a two-dimensional echocardiographic study. J Am Coll Cardiol 1988;11:630-636.
127. Kloner RA. Editorial Comment: Calcium channel blockade during ischemia reperfusion sequences. J Mol Cell Cardiol 1988;20:457-458.
128. Rezkalla S, Kloner RA, Sowers J, Khatib R. Atrial natriuretic peptide in acute coxsackievirus murine myocarditis. Am J Cardiol 1988; 61:1361-1362.
129. Patel B, Kloner RA, Przyklenk K, Braunwald E. Postischemic myocardial "stunning": a clinically relevant phenomenon. Ann Intern Med 1988; 108:626-629.
130. Rezkalla S, Khatib R, Khatib G, Smith F, Walsh M, Sowers J, Kloner RA. Effect of indomethacin in the late phase of coxsackievirus myocarditis in a murine model. J Lab Clin Med 1988;112:118-121.
131. Hale SL, Alker KJ, Kloner RA. An evaluation of nonradioactive colored microspheres for measurement of regional myocardial blood flow in dogs. Circulation 1988;78:428-434.
132. Rezkalla S, Kloner RA, Khatib G, Smith FE, Khatib R. Effect of metoprolol in acute coxsackievirus B3 murine myocarditis. J Am Coll Cardiol 1988; 12:412-414.
133. Pazdur R, Chabot GG, Campbell CA, Lehmann MH, Kloner RA, Baker LH. Acodazole hydrochloride: Phase I Trial, Pharmacokinetics, and Evaluation of Cardiotoxicity in Dogs. Cancer Research 1988;48:4423-4426.
134. Turi ZG, Rezkalla S, Campbell CA, Kloner RA. Amelioration of ischemia during angioplasty of the left anterior descending coronary artery with an autoperfusion catheter. Am J Cardiol 1988;62:513-517.
135. Lavine SJ, Campbell CA, Kloner RA, Gunther SJ. Diastolic filling in acute left ventricular dysfunction: role of the pericardium. J Am Coll Cardiol 1988;12:1326-1333.
136. Kloner RA, Przyklenk K, Patel B. Altered myocardial states: The stunned and hibernating myocardium. Am J Med, 1989;86(Suppl 1A):14-22.
137. Kirshenbaum JM, Kloner RA, McGowan N, Antman E. Use of an ultrashort acting beta blocker in patients with acute myocardial ischemia and relative contraindications to beta blockade. J Am Coll Cardiol 1988;12;773-780.
138. Przyklenk K, Kloner RA. Reperfusion injury by oxygen-free radicals? Effect of superoxide dismutase plus catalase, given at the time of reperfusion, on myocardial infarct size, contractile function, coronary microvasculature, and regional myocardial blood flow. Circ Res 1989;64:86-96.
139. Przyklenk K, Kloner RA. What factors predict recovery of contractile function in the canine model of the "stunned" myocardium? Am J Cardiol Supplement 1989;64:18F-26F.
140. Hale SL, Kloner RA. Left ventricular topographic alterations in the completely healed rat infarct caused by early and late coronary reperfusion. Am Heart J 1988;116:1508-1513.
141. Rezkalla SH, Kloner RA. Management strategies in viral myocarditis. Am Heart J 1989;117:706-708.
142. Rezkalla SH, Kloner, RA, Khaw BA, Haber E, Fallon JT, Smith FE, Khatib R. Detection of experimental myocarditis by monoclonal antimyosin antibody, FAB Fragment. Am Heart J 1989;117:391-395.
143. Przyklenk K, Ghafari GB, Eitzman DT, Kloner RA. Nifedipine administered post reperfusion ablates systolic contractile dysfunction of postischemic "stunned" myocardium. J Am Coll Cardiol 1989;13:1176-1183.
144. Rezkalla S, Kloner RA, Ensley J, Al-Sarraf M, Revels S, Olivenstein A, Bhasin S, Kerpel-Fronious F, Turi ZG. Continuous ambulatory electrocardiographic monitoring during 5-fluorouracil therapy. A prospective study. J Clin Oncology 1989;7:509-514.
145. Kloner RA. Do neutrophils mediate the phenomenon of stunned myocardium? J Am Coll Cardiol 1989;13:1164-1166.
146. Whittaker P, Boughner DR, Kloner RA. Analysis of healing following myocardial infarction using polarized light microscopy. Am J Pathol 1989;134:879-893.
147. Kloner RA, Alker K, Campbell C, Figures G, Eisenhauer A, Hale S. Does tissue plasminogen activator have direct beneficial effects on the myocardium independent of its ability to lyse intracoronary thrombi? Circulation 1989;79:1125-1136.
148. Reddy RR, Kloner RA, Przyklenk K. Early treatment with deferoxamine limits ischemic/reperfusion injury. Free Radical Biology and Medicine 1989;7:45-52.
149. Alker KJ, Kloner RA. Differences in blood flow to the vasa vasorum of the coronary arteries. J Vasc Med and Biol 1989;1:55-58.
150. Hale SL, Lehmann MH, Kloner RA. Electrocardiographic abnormalities after acute administration of cocaine in the rat. Am J Cardiol 1989;63:1529-1530.
151. Przyklenk K, Kloner RA. Is "stunned myocardium" a protective mechanism? Effect of acute recruitment and acute beta blockade on recovery of contractile function and high energy phosphate stores at 1 day post reperfusion. Am Heart J 1989;118:480-489.
152. Campbell CA, Rezkalla S, Kloner RA, Turi Z. The autoperfusion balloon angioplasty catheter limits myocardial ischemia and necrosis during prolonged balloon inflation. J Am Coll Cardiol 1989;14:1045-1050.
153. Hale SL, Alker KJ, Rezkalla S, Figures G, Kloner RA. Adverse effects of cocaine on cardiovascular dynamics, myocardial blood flow and coronary artery diameter in an experimental model. Am Heart J 1989;118:927-933.
154. Kloner RA, Przyklenk K, Whittaker P. Deleterious effects of oxygen radicals in ischemia/reperfusion: Resolved and unresolved issues. Circulation 1989;80:1115-1127.
155. Kloner RA. No-Reflow Revisited. J Am Coll Cardiol 1989;14:1814-1815.
156. Przyklenk K, Kloner RA. Relationships between structure and effects of ACE inhibitors. Comparative effects in myocardial ischemic/reperfusion injury. Br J Pharmacol 1989;28:167S-175S.
157. Mehta PM, Przyklenk K, Kloner RA. Cardioprotective effects of Captopril in myocardial ischemia, ischemia/reperfusion and infarction. European Heart J (Supplement B) 1990;II:94-99.
158. Rezkalla S, Turi Z, Keedy D, Precevski P, Kloner RA. Left main coronary angioplasty in a sheep model using a new left main autoperfusion balloon catheter. J of Invasive Cardiology 1989;1:199-205.
159. Przyklenk K, Whittaker P, Kloner RA. In vivo infusion of oxygen free radical substrates causes myocardial systolic, but not diastolic dysfunction. Am Heart J 1990;119:807-815.
160. Rezkalla S, Kloner RA, Khatib G, Khatib R. Beneficial effects of captopril in acute coxsackievirus B3 murine myocarditis. Circulation 1990;81:1039-1046.
161. Kloner RA. Inverted T waves: An electrocardiographic marker of stunned or hibernating myocardium in man? Circulation 1990;82:1060-1061.
162. Rezkalla S, Kloner RA, Khatib G, Khatib R. Effect of delayed captopril therapy on left ventricular mass and myonecrosis during acute coxsackievirus murine myocarditis. Am Heart J 1990;120:1377- 1381.
163. Rezkalla S, Hale S. Kloner RA. Cocaine-induced heart disease. Am Heart J 1990;120:1403-1408.
164. Eisenhauer A, Alker K, Kloner RA, Matthews RV. The effect of balloon angioplasty on vasa vasorum blood flow in canine coronary arteries. Am Heart J 1990; 120:1285-1291.
165. Turi ZG, Rezkalla S, Campbell CA, Kloner RA. Left main percutaneous transluminal coronary angioplasty with the autoperfusion catheter in an animal model. Catheterization and Cardiovascular Diagnosis. 1990;21:45-50.
166. Whittaker P, Boughner DR, Kloner RA, Przyklenk K. Stunned myocardium and myocardial collagen damage: Differential effects of single and repeated occlusions. Am Heart J 1991;121:434-441.
167. Parmley WW, Chatterjee K, Frances GS, Firth BG, Kloner RA. Congestive Heart Failure: New Frontiers. Western J. Medicine 1991;154:427-441.
168. Kloner RA, Przyklenk K. Progress in Cardioprotection: The role of calcium antagonists. Am J Cardiol 1990;66:2H-9H.
169. Hagar JM, Hale SL, Kloner RA. Effect of preconditioning ischemia on reperfusion arrhythmias after coronary artery occlusion and reperfusion in the rat. Circ Res 1991;68:61-68.
170. Przyklenk K, Kloner RA. Angiotensin converting enzyme inhibitors improve contractile function of "stunned" myocardium by different mechanisms of action. American Heart J 1991;121:1319-1330.
171. Przyklenk K, Kloner RA. Calcium antagonists and the stunned myocardium. J. Cardiovasc. Pharmacol. 1991;18(Suppl. 10) S93-S101.
172. Kloner RA. Adjuvant pharmacologic therapy for acute myocardial infarction. Hospital Formulary 1991;26:108-117.
173. Hale SL, Alker KJ, Rezkalla SH, Eisenhauer AC, Kloner RA. Nifedipine protects the heart from the acute deleterious effects of cocaine if administered before but not after cocaine. Circulation 1991;83:1437-1443.
174. Hale SL, Kloner RA. Time course of infiltration and distribution of neutrophils following coronary artery reperfusion in the rat. Coronary Artery Disease 1991;2:373-378.
175. Hagar JM, Hale SL, Ilvento P, Kloner RA. Lack of significant effects of superoxide dismutase and catalase in development of reperfusion arrhythmias. Basic Res in Cardiol 1991;86:127-135.
176. Dzau V, Braunwald E, and participants. Resolved and unresolved issues in the prevention and treatment of coronary artery disease. A workshop consensus statement. Am Heart J 1991;121:1244-1263.
177. Przyklenk K, Kloner RA. Calcium antagonists and the stunned myocardium: Importance for Clinicians? Cardiovasc Drugs and Therapy, 1991; 5:947-952. Also; in Stunning, Hibernation, and Calcium in Myocardial Ischemia and Reperfusion ed. L.H. Opie. Kluwer Academic Publishers, Norwell, Mass. 1992; pages 180-189.
178. Kloner RA, Allen J, Cox TA, Zheng Y, Ruiz CE. Stunned left ventricular myocardium following exercise treadmill testing in coronary artery disease. Am J Cardiol, 1991; 68:329-334.
179. Reddy BR, Wynne J, Kloner RA, Przyklenk K. Pretreatment with the iron chelator deferoxamine fails to provide sustained protection against myocardial ischemia/reperfusion injury. Cardiovasc Res, 1991; 25:711-718.
180. Kloner RA, Przyklenk K. Experimental infarct size reduction with calcium channel blockers. J Am Coll Cardiol, 1991; 18:876-878.
181. Clugston R, Oesterle SN, Matthews R, Garrison M, Alker KJ, Reeves T, Virmani R, Kloner RA. A flow support catheter for prolonged maintenance of coronary blood flow. Catheterization and Cardiovascular Diagnosis, 1991; 24:308-314.
182. Kloner RA, Giacomelli F, Alker KJ, Hale SL, Matthews R, Bellows S. Influx of neutrophils into the walls of large epicardial coronary arteries in response to ischemia/reperfusion. Circulation, 1991; 84:1758-1772.
183. Li Y, Whittaker P, Kloner RA. The transient nature of the effects of ischemic preconditioning on myocardial infarct size and ventricular arrhythmia. Am Heart J. 1992; 123:346-353.
184. Whittaker P, Boughner D, Kloner RA. The role of collagen in acute myocardial infarct expansion. Circulation. 1991; 84:2123-2134.
185. Khatib R, Reyes M., Khatib G, Smith F, Rezkalla S., Kloner RA. Focal Ventricular Thinning Caused by Indomethacin in the Late Phase of Coxsackievirus B4 Murine Myocarditis. Am J Med Sci. 1992; 303:95-98.
186. Przyklenk K, Bauer B, Kloner RA. Reperfusion of 'hibernating' myocardium: Contractile Function, High Energy Phosphate Content and Myocyte Injury Following 3 Hours of Sublethal Ischemia and 3 Hours of Reperfusion in the Canine Model. Am Heart J. 1992; 123:575-588.
187. Kloner RA, Hale S, Alker K. Rezkalla S. The effects of acute and chronic cocaine on the heart. Circulation., 1992;85:407-419.
188. Ovize M, Kloner RA, Hale SL, Przyklenk K. Coronary cyclic flow variations "precondition" the ischemic myocardium. Circulation. 1992; 85:779-789.
189. Li Y, Kloner RA. The cardioprotective effects of ischemic "preconditioning" are not mediated by prostanoids. Cardiovasc. Res. 1992; 26:226-231.
190. Kloner RA, Przyklenk K. Hibernation and stunning of the myocardium. N. Engl. J. Med., 1991; 325:1877-1879.
191. Kloner RA, Eisenhauer A. Rt-PA: An infarct sparing effect beyond thrombolysis? J. Am. Coll. Cardiol. 1992; 20:226-227.
192. Przyklenk K, Kloner RA. Calcium antagonists and the stunned myocardium: A role during ischemia? A role during reperfusion? Letter to the editor. Cardiovas. Res. 1992; 26:82-84.
193. Hale SL, Kloner RA. Ischemic preconditioning in the rabbit: Effect on regional myocardial blood flow. Coronary Artery Disease 1992; 3:133-140.
194. Simkhovich BZ, Hale SL, Kloner RA. Effect of ischemic preconditioning on carnitine-linked metabolism in the rabbit heart. Coronary Artery Disease 1992; 3:141-147.
195. Kloner RA, Przyklenk K. Editorial: Dysfunctional myocardium: "Dead or alive?" Am. J. Cardiac. Imaging (Saunders) 1992; 6:197-199.
196. Cox TA, Kloner RA, Ruiz CE, Allen J. Quantitative echocardiographic demonstration of myocardial stunning in man following exercise testing. Am. J. Cardiac Imaging (Saunders) 1992; 6:208-213.
197. Przyklenk K, Ovize M, Kloner RA. Early but transient postischemic contraction: A reliable indicator of viable myocardium? Am. J. Cardiac Imaging, (Saunders) 1992; 6:259-266.
198. Ovize M, Przyklenk K, Hale SL, Kloner RA. Preconditioning does not attenuate myocardial stunning. Circulation 1992; 85:2247-2254.
199. Hagar JM, Newman LG, Kloner RA. Effects of amlodipine on myocardial infarction, infarct expansion and ventricular geometry in the rat. Am. Heart J. 1992; 124:571-580.
200. Kloner RA. Coronary angioplasty: A treatment option for left ventricular remodeling after myocardial infarction? J. Am Coll. Card. 1992; 20:314-316.
201. Kloner RA, Hale SL, Alker KJ. Absence of hemodynamic deterioration in the presence of amlodipine following experimental myocardial infarction. J. Cardiovasc. Pharmacol. 1992; 20:837-845.
202. Kloner RA, Przyklenk K. Cardioprotection with angiotensin converting enzyme inhibitors: Redefined for the 1990's. Clin. Card. 1993; 15:95-103.
203. Przyklenk K, Kloner RA. "Cardioprotection" by ACE inhibitors in acute myocardial ischemia and infarction? Basic Res in Card. 1993; 88 (Suppl I) 139-154.
204. Ovize M, Przyklenk K, Kloner RA. Partial coronary stenosis is sufficient and complete reperfusion mandatory, to induce preconditioning. Circ. Res. 1992; 71:1165-1173.
205. Kloner RA. Does reperfusion injury exist in man? J. Am Coll. Card. 1993;21:537-545.
206. Zheng S-M, Kloner RA, Whittaker P. Comparative examination of fiber tips in myocardium using a holmium: YAG laser. In Progress in Biomedical Optics. Proceedings of Laser-Tissue Interaction III. SPIE Vol.1646; 1992:358-365.
207. Kloner RA, Przyklenk K. Understanding the jargon: a glossary of terms used (and misused) in the study of ischaemia and reperfusion. Cardiovasc. Res. 1993;27:162-166.
208. Przyklenk K, Kloner RA. Oxygen radical scavenging agents as adjuvant therapy with tissue plasminogen activator in a canine model of coronary thrombolysis. Cardiovasc. Res. 1993; 27: 925-934.
209. Przyklenk K, Bauer B, Ovize M, Kloner RA, Whittaker P. Regional ischemic 'preconditioning' protects remote virgin myocardium from subsequent sustained coronary occlusion. Circulation 1993;87:893-899.
210. Rezkalla S, Hale S, Alker K, Kloner RA. Flow function dissociation following an acute dose of cocaine: effect of captopril on coronary flow. Coronary Artery Disease 1993;4:271-276.
211. Kloner RA, Hale S. Unraveling the complex effects of cocaine on the heart. Circulation 1993;87:1046-1047.
212. Bellows SD, Clugston RA, Kloner RA, Kirkman E, Oesterle SN, Matthews RV, Prcevski P, Eisenhauer AC. A porcine model of post angioplasty "restenosis" effects of cholesterol. The Journal of Vascular Medicine and Biology 1993;4:64-69.
213. Whittaker P, Kloner RA, Przyklenk K. Laser-mediated transmural myocardial channels do not salvage acutely ischemic myocardium. J. Am Coll. Cardiol. 1993; 22:302-309.
214. Simkhovich BZ, Hale SL, Ovize M, Przyklenk K, Kloner RA. Ischemic preconditioning and long-chain acyl carnitine in the canine heart. Coronary Artery Disease, 1993; 4:387-392.
215. Rezkalla SH, Mazza JJ, Kloner RA, Tillema V, Chang SH. Effects of cocaine on human platelets in healthy subjects. Am J. Cardiol. 1993; 72:243-246.
216. Bauer B, Simkhovich BZ, Kloner RA, Przyklenk K. Does preconditioning protect the coronary vasculature from subsequent ischemia/reperfusion injury? Circulation 1993; 88:659-672.
217. Yellon DM, Walker JM, Kloner RA, Downey JM, Pugsley WB. Unstable Angina. Lancet, 1993; 341:1323-1327.
218. Li Y, Kloner RA. The cardioprotective effects of ischemic 'preconditioning' are not mediated by adenosine receptors in rat hearts. Circulation, 1993; 87:1642-1648.
219. Kloner RA, Hale S. Cardiovascular applications of fluorocarbons in regional ischemia/reperfusion in Biomaterials, Artificial Cells, and Immobilization. Biotechnology Vol 22, 1994; 22:1069-1081.
220. Whittaker P, Zheng S, Kloner RA. Chronic response to direct myocardial revascularization: a preliminary study. Progress in Biomedical Optics: Proceedings of Diagnostic and Therapeutic Cardiovascular Interventions III 1993; 1878:160-166.
221. Zheng SM, Kloner RA, Whittaker P. Ablation and coagulation of myocardial tissue using a pulsed holmium - YAG laser. Am Heart J. 1993, 126:1474-1477.
222. Li Y, Kloner RA. Adenosine deaminase inhibitors is not cardioprotective in the rat. Am Heart J. 1993;126:1293-1298.
223. Ovize M, Kloner RA, Przyklenk K. Stretch preconditions the canine myocardium. Am J. Physiol. 1994; 35:H137-H146.
224. Allen JW, Cox TA, Kloner RA, Stunning and angina (readers' comments). Am. J. Cardiol. 1993; 72:1456.
225. Hale SL, Bellows SD, Hammerman H, Kloner RA. An adenosine A1 receptor agonist, R (-)-N-E2-Phenylisopropyl - Adenosine (PIA), but not adenosine itself, acts as a therapeutic preconditioning-mimetic agent in rabbits. Cardiovasc. Res. 1993; 27:2140-2145.
226. Kedes L, Kloner RA, Starnes VA. Can a few good cells now mend an injured heart? (editorial). J. Clin. Invest. 1993; 92:1115-1116.
227. Leor J, Nesto RW, Kloner RA. Acute myocardial infarction and diabetes mellitus. [Commentary] Cardiovasc. Res. 1993; 27:1913-1915.
228. Li Y, Kloner RA. The cardioprotective effects of ischemic preconditioning can be recaptured after they are lost. J. Am Coll Card. 1994; 23:470-474.
229. Simkhovich BZ, Kloner RA, Alker KJ, Giaconi J. The time course of direct cardiotoxic effects of high cocaine concentration in isolated rabbit hearts. J. Cardiovasc. Pharmacology 1994; 23:509-516.
230. Gardin JM, Wong N, Alker K, Hale SL, Paynter J, Knoll M, Jamison B, Patterson M, Kloner RA. Acute cocaine administration induces ventricular regional wall motion and ultrastructural abnormalities in an anesthetized rabbit model. Am Heart J. 1994; 128:1117-1129.
231. Przyklenk K, Simkhovich BZ, Bauer B, Kloner RA. Deterioration in myocardial blood flow following relief of sustained ischemia is not explained by release of endothelin. Basic Research in Cardiology 1994; 89:260-269.
232. Whittaker P, Kloner RA, Boughner D, Pickering JG. Quantitative assessment of myocardial collagen with pricosirius red staining and circularly polarized light. Basic Research in Cardiology 1994; 89:397-410.
233. Przyklenk K, Aoki A, Bellows S, Klinedinst D, Zubiate P, Hale SL, Simkhovich BZ, Kloner RA, Kay GL. Stunned myocardium following prolonged cardiopulmonary bypass: effect of warm versus cold cardioplegia in the canine model. J. Card. Surg 1994; 9 [Suppl]; 506-516.
234. Kloner RA, Przyklenk K, Kay GL. Clinical evidence for stunned myocardium after coronary artery bypass surgery. J. Card. Surg 1994; 9 [Suppl]; 397-402.
235. Kloner RA, Yellon D. Does ischemic preconditioning occur in patients? J. Am. Coll. Cardiol 1994; 24:1133-1142.
236. Bankwala Z, Hale S, Kloner RA. Alpha-adrenoceptor stimulation with exogenous norepinephrine, or release of endogenous catecholamines, mimics ischemic preconditioning. Circulation 1994; 90:1023-1028.
237. Prentice H, Kloner RA., Prigozy T, Christensen T, Newman L, Li Y, Kedes L. Tissue restricted gene expression assayed by direct DNA injection into cardiac and skeletal muscle. J. Mol. Cell Card. 1994; 26:1393-1401.
238. Hale SL, Kloner RA. Protection of myocardium by transient, preischemic phenylephrine administration in the rabbit. Coronary Artery Disease 1994; 5:605-610.
239. Hagar JM, Matthews R, Kloner RA. Quantitative 2-D echocardiographic assessment of regional wall motion during transient ischemia and reperfusion in the rat. J. Am. Soc. Echocardiography 1995; 8:162-174.
240. Kloner RA, Tubau JF. Application of nuclear cardiology to the diagnosis of stunned and hibernating myocardium. J. Nuclear Cardiology 1994; 1:490-491.
241. Bellows SD, Hale SL, Simkhovich BZ, Kay GL, Kloner RA. Do antioxidant vitamins reduce infarct size following acute myocardial ischemia/reperfusion? Cardiovascular Drugs and Therapy 1995; 9:117-123.
242. Gottlieb RA, Burleson KO, Kloner RA, Babior BM, Engler RL. Reperfusion injury induces apoptosis in rabbit cardiomyoctyes. J. Clin Invest. 1994; 94:1621-1628.
243. Kloner RA, Shook T, Przyklenk K, Davis VG, Junio L, Matthews RV, Burstein S. Gibson M, Poole WK, Cannon CP, McCabe C, Braunwald E for TIMI 4 Investigators. Previous angina alters in-hospital outcome in TIMI 4: A clinical correlate to preconditioning? Circulation 1995; 91:37-45.
244. Cannon CP, McCabe CH, Diver DJ et al. (and TIMI 4 Investigators). A Comparison of front-loaded tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: Results of the thrombolysis in Myocardial Infarction (TIMI) 4 Trial. J. Am Coll Card. 1994; 24:1602-1610.
245. Li Y, Kloner RA. Does protein kinase C play a role in ischemic preconditioning in rat hearts? Am J. Phys. 1995; 268:H426-H431.
246. Przyklenk K, Ovize M, Bauer B, Kloner RA. Gender does not influence the pathophysiology of acute myocardial infarction in adult dogs. Am Heart J 1995; 129:1108-1113.
247. Pollick C, Hale SL, Kloner RA. Echocardiographic and Cardiac Doppler Assessment of Mice. J. Am Soc. of Echocardiography 1995; 8:602-610.
248. Kloner RA, Przyklenk K, Whittaker P, Hale S. Preconditioning stimuli and inadvertent preconditioning (An editorial). J. Mol. Cell Card. 1995; 27:743-747.
249. Kloner RA, Muller J, Davis V. Effects of previous angina pectoris in patients with first acute myocardial infarction not receiving thrombolytics. Am. J. Cardiology 1995; 75:615-617.
250. Przyklenk K, Sussman MA, Simkhovich BZ, Kloner RA. Does ischemic preconditioning trigger translocation of protein kinase C in the canine model? Circulation 1995; 92:1546-1557.
251. Kloner RA, Przyklenk K, Cannon C, Davis V. Response to letter to the editor. Circulation 1995; 92:1064-1065.
252. Leor J, Kloner RA. Does magnesium have a place in the therapy of acute myocardial infarction? Lessons from an experimental model. Am J. Cardiology 1995; 75:1292-1293.
253. Simkhovich BZ, Whittaker P, Przyklenk K, Kloner RA. Transient pre-ischemic acidosis protects the isolated rabbit heart subjected to 30 minutes, but not 60 minutes, of global ischemia. Basic Research in Cardiology 1995; 90:397-403.
254. Hale SL, Hammerman H, Kloner RA. Effect of two perfluorocarbon emulsions on reperfusion injury after coronary artery occlusion in rabbits. Basic Research in Cardiology 1995; 90:404-409.
255. Leor J, Kloner RA. Basic view on the pathobiology of myocardial ischemia during coronary angioplasty: Implications for cardiac protection. Journal of Interventional Cardiology, 1995; 8:291-299.
256. Kloner RA, Przyklenk K, Shook T, Matthews RV, Burstein S, Cannom DS, Isber N, Kay G. Clinical aspects of preconditioning and implication for the cardiac surgeon. J. Card. Surg. 1995; 10:369-375.
257. Przyklenk K, Kloner RA. Low dose IV acetylcholine acts as a "preconditioning mimetic" in the canine model. J. Card. Surg. 1995; 10:389-395.
258. Kloner RA, Sowers JR, DiBona G, Gaffney M, Wein M. for the ACCT Study Group. Effects of amlodipine on left ventricular mass in the Amlodipine Cardiovascular Community Trial. J. Cardiovasc. Pharmacology, 1995; 26:471-476.
259. Li Y, Kloner RA. Is there a gender difference in infarct size and arrhythmias following experimental coronary occlusion and reperfusion? Journal of Thrombosis and Thrombolysis 1995; 2:221-225.
260. Birnbaum Y, Leor J, Kloner RA. The pathology and clinical impact of reperfusion injury. J. Thrombosis and Thrombolysis 1995; 2:177-186. Also reprinted in J. Thrombosis and Thrombolysis 1997; 4:185-195.
261. Birnbaum Y, Kloner RA. Clinical aspects of myocardial stunning. Coronary Artery Disease 1995; 6:606-612.
262. Przyklenk K, Kloner RA. Preconditioning: A balanced perspective. British Heart J 1995; 74:575-577.
263. Birnbaum Y, Kloner RA. Therapy for myocardial stunning. Basic Res Cardiol. 1995; 90:291-293.
264. Whittaker P, Rakusan K, Kloner RA. Transmural channels can protect ischemic tissue: Assessment of long-term myocardial response to laser-and needle-made channels. Circulation 1996; 93:143-152.
265. Kloner RA. Nifedipine in ischemic heart disease. Circulation 1995; 92:1074-1078.
266. Marber MS, Brown DL, Kloner RA. The open artery hypothesis. To open or not to open? That is the question. European Heart J. 1996; 17:505-509.
267. Prentice, H, Kloner RA, Li Y, Newman L, Kedes L. Ischemic/reperfused myocardium can express recombinant protein following direct DNA or retroviral injection. J. Mol. Cell Card. 1996; 28 133-140.
268. Alhaddad IA, Kloner RA, Hakin I, Garno JL, Brown EJ. Benefits of late coronary artery reperfusion on infarct expansion progressively diminish over time: relationship to viable islets of myocytes within the scar. Am. Heart J. 1996; 131:451-457.
269. Przyklenk K, Kloner RA. Role of protein Kinase C in ischemic preconditioning: In search of the "pure and simple truth." Basic Res Card. 1996; 91:41-43 and in New Paradigms of Coronary Artery Disease: Stunning, Hibernating, and Ischemic Preconditioning. (G. Heusch and R. Schulz, Eds) Steinkopff, Darnstadt, 1996, p. 159-161.
270. Rezkalla SH, Raikar S, Kloner RA. Treatment of viral myocarditis: lessons from experimental studies. Am J. Card 1996; 77:634-637.
271. Kloner RA, Sowers JR, DiBona G, Gaffney M, Wein M for the Amlodipine Cardiovascular Community Trial Study Group. Sex- and Age-Related Antihypertensive Effects of Amlodipine. Am J. Card. 1996; 77:713-722.
272. Hale SL, Birnbaum Y, Kloner RA. Beta-Estradiol, but not alpha-estradiol, reduces myocardial necrosis in rabbits after ischemia and reperfusion. Am Heart J. 1996; 132:258-262.
273. Whittaker P, Kloner RA, Przyklenk K. Intramyocardial injections and protection against myocardial ischemia: An attempt to examine the cardioprotective actions of adenosine. Circulation 1996; 93:2043-2051.
274. Birnbaum Y, Hale SL, Kloner RA. Is preconditioning by nicotine responsible for the better prognosis in smokers with acute myocardial infarction? Basic Res in Cardiology, 1996; 91:240-247.
275. Leor J, Poole WK, Kloner RA. Sudden cardiac death triggered by an earthquake. N. Engl. J. Med. 1996; 334:413-419.
276. Leor J, Kloner RA. The Northridge Earthquake as a trigger for acute myocardial infarction. Am. J. Card. 1996; 77:1230-1232.
277. Przyklenk K, Zhao L, Kloner RA, Elliott GT. Cardioprotection with ischemic preconditioning and MLA: role of adenosine regulating enzymes? Am. J. Physiology, 1996; 271:H1004-H1014.
278. Bellows S, Hale S, Kloner RA. Acute ethanol does not protect against ischemia/reperfusion injury in rabbit myocardium. Journal Thrombosis and Thrombolysis. 1996; 3:181-184.
279. Alker K, Bellows S, Kloner RA. Stuttering reperfusion of ischemic myocardium does not exacerbate ischemic myocardium; evidence against lethal cell reperfusion injury in the rabbit. Journal Thrombosis and Thrombolysis. 1996; 3:185-188.
280. Leor J, Quinones MJ, Patterson M, Kedes L, Kloner RA. Adenovirus mediated gene transfer into infarcted myocardium: Feasibility, timing, and location of expression. Journal Molecular Cellular Cardiology. 1996; 28:2057-2067.
281. Birnbaum Y, Hale SL, Kloner RA. Progressive decrease in the ST segment elevation during ischemic preconditioning: Is it related to recruitment of collateral vessels? Journal Molecular Cellular Cardiology. 1996; 28:1493-1499.
282. Quinones MJ, Leor J, Kloner RA, Masamichi I, Patterson M, Witke WF, Kedes L. Avoidance of immune response prolongs expression of genes delivered to the adult rat myocardium by replication-defective adenovirus. Circulation 1996; 94:1394-1401.
283. Kloner RA, Gibson M, Cannon C, Braunwald E. Preinfarction angina (letter to the editor). N. Engl J. Med. 1996; 335:59-60.
284. Birnbaum Y, Kloner RA, Sclarovsky S, Cannon CP, McCabe CH, Davis VG, Zaret BL, Wackers J.Th, Braunwald E for the TIMI 4 Investigators. Distortion of the terminal portion of the QRS on the admission electrocardiogram in acute myocardial infarction: Correlation with infarct size and long term prognosis in TIMI 4 trial. Am. J. Card. 1996; 78:396-403.
285. Kloner RA, Leor J, Poole K. Response to letter. N. Engl. J. Med. 1996; 334:1673.
286. Birnbaum Y, Hale SL, Kloner RA. The effect of coenzyme Q10 on infarct size in a rabbit model of ischemia/reperfusion. Cardiovasc. Res. 1996; 32:861-868.
287. Kloner RA. Lethal "reperfusion injury" - Is it a real entity? An editorial. J. Thrombosis and Thrombolysis 1997; 4:127-128.
288. Kloner RA. The issue of cardiovascular safety of dihydropyridines. Am. J. Hypertension 1996; 9:182S-186S.
289. Leor J, Patterson M, Quinones MJ, Kedes LH, Kloner RA. Transplantation of fetal myocardial tissue into infarcted myocardium of rat: A potential method for repair of infarcted myocardium? Circulation 1996; 94 [Suppl II]: II-332-II-336.
290. Simkhovich BZ, Przyklenk K, Hale SL, Patterson M, Kloner RA. Direct evidence that ischemic preconditioning does not cause protein kinase C translocation in rabbit heart. Cardiovas. Res. 1996; 32:1064-1070.
291. Bellows S, Kloner RA. Glucose-insulin-potassium does not reduce myocardial infarct size in an ischemic/reperfusion rabbit model. J. Thrombosis and Thrombolysis 1998; 5:25-27.
292. Chandraratna PA, Whittaker P, Chandraratna PM, Hutchison S, Kloner RA, Hla A. Characterization of collagen by high frequency ultrasound:Evidence for different acoustic properties based on collagen fiber morphology. Am. Heart J. 1997; 133:364-368.
293. Birnbaum Y, Przyklenk K, Kloner RA. The time frame of ischemic preconditioning-is it clinically relevant? J. Cardiovasc. Pharmacology & Therapeutics 1996; 1:339-346.
294. Birnbaum Y, Hale S, Kloner RA. Differences in reperfusion length following 30 minutes of ischemia in the rabbit influences infarct size, as measured by triphenyltetrazolium chloride staining. J. Mol. Cell Card. 1997; 29:657-666.
295. Kloner RA, Przyklenk K. Clinical evidence that nisoldipine attenuates stunning in patients post infarction. Cardiovascular Drugs and Therapy 1997; 11:17-18.
296. Kamlot A, Bellows SD, Simkhovich BZ, Hale S, Atsushi A, Kloner RA, Kay GL. Is warm retrograde blood cardioplegia better than cold for myocardial protection? The Annals of Thoracic Surgery 1997; 63:98-104.
297. Birnbaum Y, Kloner RA. Myocardial Viability. The Western J. of Medicine, 1996;165:364-371.
298. Hale SL, Birnbaum Y, Kloner RA. Estradiol, administered acutely, protects ischemic myocardium in both female and male rabbits. J. Cardiovascular Pharmacology and Therapeutics, 1997; 2:47-52.
299. Przyklenk K, Hata K, Kloner RA. Is calcium a mediator of infarct size reduction with preconditioning in canine myocardium? Circulation 1997; 96:1305-1312.
300. Birnbaum Y, Kloner RA, Perritt R, Poole K. Atherosclerotic cardiovascular mortality during the 1992 riots in Los Angeles. Am J. Card. 1997; 79: 1155-1158.
301. Whittaker P, Kloner RA. Transmural channels as a source of blood flow to ischemic myocardium? Insights from the reptile heart. Circulation 1997; 95:1357-1359.
302. Birnbaum Y, Patterson M, Kloner RA. The effect of CY-1503, a sialyl Lewis X analog blocker of the selectin adhesion molecules, on infarct size and "no-reflow" in the rabbit model of acute myocardial infarction/reperfusion. J. Mol. Cell Card. 1997; 29:2013-2025.
303. Deedwania PC, Amsterdam EA, Vagelos RH for the California Cardiology Working Group on Post-MI Management (Kloner RA - Member of The California Cardiology Working Group). Evidence-based, cost-effective risk stratification and management after myocardial infarction. Arch. Intern. Med 1997; 157:273-280.
304. Birnbaum Y, Hale SL, Kloner RA. "Ischemic preconditioning at a distance." Reduction of myocardial infarct size by partial reduction of blood supply combined with rapid stimulation of the gastrocnemius muscle in the rabbit. Circulation 1997; 96:1641-1646.
305. Birnbaum Y, Hale SL, Kloner RA. Changes in the R wave amplitude: Electrocardiographic differentiation between episodes of reocclusion and reperfusion associated with ST segment elevation. Journal of Electrocardiography 1997; 30:211-216.
306. Hale SL, Kloner RA. Myocardial temperature in acute myocardial infarction: Protecting ischemic myocardium with mild regional hypothermia. Am. J. Physiology 1997; 42:H220-H227.
307. Przyklenk K, Hata H, Zhao L, Kloner RA, Elliott GT. Disparate effects of preconditioning and MLA on 5' ­NT and adenosine levels during coronary occlusion. Am. J. Phys. 1997; 273: H945-H951.
308. Kloner RA, Kay G. Editorial: Intravenous co-infusion of adenosine and norepinephrine. J. Thorac. Cardiovasc. Surg. 1997; 114:234-235.
309. Leor J, Prentice H, Sartorelli V, Quinones MJ, Patterson M, Kedes LH, Kloner RA. Gene transfer and cell transplant: An experimental approach to repair a "Broken Heart." Cardiovasc Res. 1997; 35:431-441.
310. Schwarz ER, Whyte WS, Kloner RA. Ischemic Preconditioning. Current Opinion in Cardiology 1997; 12:475-481.
311. Kloner RA, Leor J, Poole WK, Perritt R. A population based analysis of the effect of the Northridge Earthquake on Cardiac death in Los Angeles County, California. J. Am. Coll. Cardiol 1997; 30:1174-1180.
312. Kloner RA, Schwarz ER, Prejean C, Kay G. Editorial Comment on "The Natural History of Fetal Rat Cardiomyocytes Transplanted into Adult Rat Myocardial Tissue," by Li et al. Circulation 1997 (Suppl II) 96:II-186-II-187.
313. Hale SL, Dave RH, Kloner RA. Regional hypothermia reduces myocardial necrosis even when instituted after the onset of ischemia. Basic Res. Card. 1997; 92:351-357.
314. Reyes MP, Khatib R, Khatib G, Ho KL, Smith F, Kloner RA. Prolonged captopril therapy in murine viral myocarditis. J. Cardiovasc. Pharmacology and Therapeutics 1998; 3:43-50.
315. Kloner RA. What is the evidence that preconditioning occurs in man? Dialogues in Cardiovascular Medicine 1997; 2:199-204.
316. Hata K, Whittaker P, Kloner RA, Przyklenk K. Brief antecedent ischemia attenuates platelet-mediated thrombus in damaged and stenotic canine coronary arteries: Role of adenosine. Circulation, 1998, 97:692-702.
317. Kloner RA, Vetrovec GW, Matterson BJ, Levenstein ML. Safety of long-acting dihydropyridine calcium channel blockers in hypertensive patients. Am J. Card. 1998, 81:163-169.
318. Kloner RA, Shook T, Antman EM, Cannon CP, Przyklenk K, Yoo K, McCabe CH, Braunwald E, and TIMI 9B Investigators. A prospective temporal analysis of the onset of preinfarct angina versus outcome: A prospective ancillary study in TIMI 9B. Circulation 1998; 97:1042-1045.
319. Simkhovich BZ, Kloner RA, Przyklenk K. Temporal changes in the subcellular distribution of protein kinase C in rabbit heart during global ischemia. Basic Res Cardiology 1998; 93:122-126.
320. Kloner RA, Bolli R, Marban E, Reinlib L, Braunwald E. Medical and cellular implications of stunning, hibernation, and preconditioning. An NHLBI Workshop. Circulation, 1998; 97:1848-1867.
321. Dave RH, Hale SH, Kloner RA. The effect of melatonin on hemodynamics, blood flow and myocardial infarct size in a rabbit model of ischemia-reperfusion. J. Cardiovasc Pharmacology and Therapeutics 1998; 3:153-160.
322. Schwarz E, Pollick C, Dow J, Patterson M, Birnbaum Y, Kloner RA. A small animal model of non-ischemic cardiomyopathy and its evaluation by transthoracic echocardiography. Cardiovasc Res 1998; 39:216-223.
323. Kloner RA. Ischemic preconditioning: the issues of refractoriness and tolerance. J. Am. Coll Cardiol 1998; 31:1150-1151.
324. Schwarz ER, Patterson M, Kloner RA. Kardiomyozytentransplantation - eine "Frischzellenkur" zur Gewebsreparatur in infarzierten Herzen? [Myocyte engraftment to replace jeopardized and dead myocardial tissue fad or future?] Z Kardiol 1998; 87:1-7.
325. Dave RH, Hale SL, Kloner RA. Hypothermic, closed circuit, pericardioperfusion. A potential cardioprotective technique in acute regional ischemia. J. Am Coll Cardiol. 1998; 31:1667-1671.
326. Kloner RA, Przyklenk K, Shook T, Cannon CP. Protection conferred by preinfarct angina is manifest in the aged heart: Evidence from the TIMI 4 Trial. J. Thrombosis and Thrombolysis 1998; 6:89-92.
327. Simkhovich BS, Przyklenk K, Kloner RA. Role of protein kinase C as a cellular mediator of ischemic preconditioning: a critical review. Cardiovasc. Res 1998; 40:9-22.
328. Kloner RA, Kay GL, Cannom D, Matta JM, Shook T, Fugelso P, Jamidar P, Jacques DB, Leeka A, Munger C. Carve-out concept: A review and its importance to cardiovascular medicine. Cardiovasc. Reviews and Reports. 1998; Vol 19, 34-43.
329. Hale SL, Kloner RA. Myocardial temperature reduction attenuates necrosis after prolonged ischemia in rabbits. Cardiovasc. Res 1998; 40:502-507.
330. Przyklenk K, Kloner RA. Ischemic preconditioning: Exploring the paradox. Progress in Cardiovascular Disease 1998; 40:517-547.
331. Schwarz ER, Pollick C, Meehan WP, Kloner RA. Evaluation of cardiac structures and function in small experimental animals: Transthoracic, transesophageal, and intraventricular echocardiography to assess contractile function in rat heart. Basic Res. in Card. 1998; 93:477-486.
332. Kloner RA. Viagra: What every physician should know. Ear, Nose, and Throat Journal 1998; 77:783-786.
333. Bauer, B, Simkhovich BZ, Kloner RA, Przyklenk K. Preconditioning-induced cardioprotection and release of the second messenger inositol (1, 4, 5) - triphosphate are both abolished by neomycin in rabbit heart. Basic Res in Card. 1999; 94:31-40.
334. Kloner RA, Jarow JP. Erectile dysfunction and sildenafil citrate and cardiologists. Am J Card. 1999; 83:576-582.
335. Kloner RA, Leor J. Natural disaster plus the wake-up time: A deadly combination of triggers. Am Heart J. 1999; 137:779-781.
336. Hale SL, Kloner RA. Myocardial hypothermia: A potential therapeutic technique for acute regional myocardial ischemia. J. of Cardiovascular Electrophysiology, March 1999; 10:405-413.
337. Kloner RA. Cardiovascular risk factors and erectile dysfunction. Am. J. Managed Care 1999; Vol 5; Number 1, Supplement – January pages S31-S39.
338. Birnbaum Y, Kloner RA. Percutaneous transluminal coronary angioplasty as a model of ischemic preconditioning and preconditioning-mimetic drugs. J. Am. Coll. Cardio 1999; 33:1036-1039.
339. Przyklenk K, Simkhovich BZ, Bauer B, Hata K, Zhao L, Elliott GT, Kloner RA. Cellular mechanisms of infarct size reduction with ischemic preconditioning: Role of calcium? Annals of the New York Academy of Sciences, 1999; 874:192-210.
340. Hale SL, Kloner RA. Ischemic preconditioning and myocardial hypothermia in rabbits with prolonged coronary artery occlusion. Am J. Physiology, 1999; 276:H2029-H2034.
341. Kloner RA, Zusman RM. Cardiovascular effects of sildenafil citrate and recommendations for its use. Am. J. Cardiology 1999; 84:11N-17N.
342. Hata K, Whittaker P, Kloner RA, Przyklenk K. Brief myocardial ischemia attenuates platelet thrombosis in remote, damaged and stenotic carotid arteries. Circulation, 1999; 100:843-848.
343. Schwarz ER, Reffelmann T, Kloner RA. Clinical effects of ischemic preconditioning. Current Opinion in Cardiology 1999; 14:340 - 348.
344. Schwarz ER, Speakman MT, von Dahl J, Kloner RA. Hibernating myocardium – Is there evidence for chronic flow reduction? Heart Disease: A Journal of Cardiovascular Medicine 1999; 1:155-162.
345. Kloner RA, Poole W Kenneth, Perritt RL. When throughout the year is coronary death most likely to occur? A twelve year population based analysis of over 220,000 cases. Circulation 1999; 100:1630-1634.
346. Speakman MT, Kloner RA. Viagra and Cardiovascular Disease. J. Cardiovascular Pharmacology and Therapeutics 1999; 4:259-267.
347. Gysembergh A, Lemairre S, Piot C, Sportouch C, Richard S, Kloner RA, Przyklenk K. Pharmacologic manipulation of Ins (1,4,5)P3 signaling mimics preconditioning in rabbit heart. Am J. Physiology 1999; 277:H2458-H2469.
348. Kloner RA. Hypertension as a risk factor for erectile dysfunction: Implications for sildenafil use. J. Clinical Hypertension 2000; 2:33-36.
349. Schwarz ER, Speakman MT, Kloner RA. A new model of ventricular plication: A suturing technique to decrease left ventricular dimensions, improve contractility, and attenuate ventricular remodeling after myocardial infarction in the rat heart. J Cardiovascular Pharmacology and Therapeutics 2000; 5:41-49.
350. Whittaker P, Zhang HP, Kloner RA. Biphasic survival response to amlodipine treatment after myocardial infarction in rats: Association with vascular remodeling. Cardiovascular Pathology, 2000; 9:85-93.
351. Friedewald VE, Kloner RA. Case 1: Isolated systolic hypertension. Interactive Grand Rounds. Am. J. Cardiology 1999; 84:1452. Linked to [www.CardiovascularEd](http://www.CardiovascularEd).com).
352. Schwarz ER, Speakman MT, Patterson M, Hale SL, Isner JM, Kedes LK, Kloner RA. Evaluation of the effects of intramyocardial injection of DNA expressing vascular endothelial growth factor (VEGF) in a myocardial infarction in the rat – angiogenesis and angioma formation. J. Am. Coll Cardiology, 2000; 35:1323-1330.
353. Hale SL, Kloner RA. Location as a determinant of myocardial infarction in rabbits. J. Mol Cell. Card. 2000; 32:505-510.
354. Schwarz ER, Somoano Y, Hale SL, Kloner RA. What is the required reperfusion period for assessment of myocardial infarct size using triphenyltetrazolium chloride staining in the rat? J. Thrombosis and Thrombolysis, 2000; 10:181-187.
355. Friedewald VE, Kloner RA. Case 2. A patient with systemic hypertension and diabetes mellitus. Am. J. Cardiology 2000; 85:273.
356. Kloner RA, Friedewald VE. Case 3. A patient with systemic hypertension and left ventricular hypertrophy. Am. J. Cardiology 2000; 85:522.
357. Kloner RA. Cardiovascular risk and sildenafil. Am. J. Cardiology, 2000; Jul 20; 86 (2 Suppl 1):57F-61F.
358. Kloner RA, Brown M, Prisant LM, Collins M for the Sildenafil Study Group. Effect of Sildenafil in Patients with Erectile Dysfunction Taking Antihypertensive Therapy. Am. J. Hypertension 2001; 14:70-73.
359. Kloner RA, Friedewald VE. Case 4: A patient with systemic hypertension and congestive heart failure. Am. J. Cardiology 2000; 85:917-918.
360. Whittaker P, Zheng S-M, Patterson MJ, Kloner RA, Daly KE, Hartman RA. Histologic signatures of thermal injury: Applications in transmyocardial laser revascularization and radiofrequency ablation. Lasers in Surgery and Medicine 2000; 27:305-318.
361. Kloner RA, Friedewald VE. Case 5: Hypertension and coronary artery disease. Am. J. Card. 2000; 85:1039-1040.
362. Baxter GF, Hale SL, Miki T, Kloner RA, Cohen MV, Downey JM, Yellon DM. Adenosine A1 Agonist at Reperfusion Trial (AART): Results of a Three-Center, blinded randomised, controlled experimental infarct study. Cardiovascular Drugs and Therapy, 2000; 14:607-614.
363. Schwarz ER, Patterson M, Kloner RA. Transplantation of fragments of fetal left ventricles in myocardial infarct tissue: a new pouch technique, its detection, survival, and impact on cardiac function in the rat heart. Cardiac and Vascular Regeneration 2000; 1:97-105.
364. Patterson MJ, Kloner RA. Flow cytometric analysis of S-phase DNA content in human, fetal myocardium. Cardiac and Vascular Regeneration 2000; 1:92-96.
365. Hale SL, Kloner RA. Effect of combined KATP channel activation and Na+/H+ exchange inhibition on infarct size in rabbits. Am. J Physiol., 2000; 279:H2673-H2677.
366. Levine LA, Kloner RA. Importance of asking questions about erectile dysfunction. Am. J. Cardiology 2000; 86:1210-1213.
367. Kloner RA, Dow J, Chung G, Kedes LH. Intramyocardial injection of DNA Encoding Vascular Endothelial Growth Factor (VEGF) in a Myocardial Infarction Model. J. Thrombosis and Thrombolysis 2000; 10:285-289.
368. DeBusk R, Drory Y, Goldstein I, Jackson G, Kaul S, Kimmel SE, Kostis JB, Kloner RA, Lakin M, Meston CM, Mittleman M, Muller JE, Padma-Nathan H, Rosen RC, Stein RA, Zusman R. Management of sexual dysfunction in patients with cardiovascular disease: recommendations of the Princeton Consensus Panel. Am. J. Cardiol. 2000; 86:175-181.
369. Kavanagh GJ, Whittaker P, Prejean CA, Firth BR, Kloner RA, Kay GL. Dissociation between improvement in angina pectoris and myocardial perfusion after transmyocardial revascularization with an excimer laser. Am. J. Cardiol. 2001; 87:229-231.
370. Patterson MJ, Kloner RA. Basic fibroblastic growth factor and differentiation of fetal cardiac myocytes: A potential improvement for fetal cell transplant therapy. Cardiac and Vascular Regeneration 2000; 1:170-177.
371. Kloner RA, Friedewald VE. Case 6. Renovascular Hypertension. Am. J. Cardiol. 2000; 86:368-369.
372. Poizat C, Sartorelli V, Chung G, Kloner RA, Kedes L. Proteasome - mediated degredation of the coactivator p300 impairs cardiac transcription. Molecular and Cellular Biology 2000; 20:8643-8654.
373. Przyklenk K, Kloner RA. Sildenafil citrate (Viagra™) does not exacerbate myocardial ischemia in canine models of coronary artery stenosis. J. Am. College Cardiology 2001; 37:286-292.
374. Gysembergh A, Kloner RA, Przyklenk K. Pretreatment with the gap junction uncoupler heptanol does not limit infarct size in rabbit heart. Cardiovascular Pathology 2001; 10:13-17.
375. Kloner RA, Weinberger M, Pool JL, Chrysant SG, Prasad R, Harris SM, Zyczynski TM, Leidy NK, Michelson EL for the Comparison of Candesartan and Amlodipine for Safety, Tolerability, and Efficacy (CASTLE) Study Investigators. Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. Am. J. Cardiology 2001; 87:727-731.
376. Kloner RA, Sex and the patient with cardiovascular risk factor: Focus on sildenafil. Am. J. Med. 2000, 109 (9A):13S-21S.
377. Levine LA, Kloner RA, Sadovsky R. New perspectives on managing erectile dysfunction in primary care: Discussion. Am J. Medicine 2000; 109 (9A):29S-30S.
378. Gysembergh A, Simkhovich BZ, Kloner RA, Przyklenk K. p38 MAPK activity is not increased early during sustained coronary artery occlusion in preconditioned versus control rabbit heart. J. Mol Cell Cardiol. 2001; 33:681-690.
379. Dow JS, Hale SL, Kloner RA. Can moderate alcohol intake limit the size of myocardial infarction? J. of Cardiovascular Pharmacology 2001; 37:662-667.
380. Yao Mu, Hale S, Dow JS, Kloner RA. A pilot study to assess the feasibility of transplanting fetal cardiac tissue into pericardium of infarcted rat heart. Cardiac and Vascular Regeneration 2000; 1:221-227.
381. Kloner RA. Shook T, Cannon CP, Przyklenk K. Ischemic preconditioning: implications for the geriatric heart. Am J. Geriatric Cardiology 2001; 10:145-151.
382. Etzion S, Barbash IM, Granot Y, Kedes LH, Kloner RA, Battler A, Leor J. Gene-delivery to the infarcted myocardium with ex-vivo modified cardiomyoblasts is superior to direct adenovirus-mediated gene transfer. Cardiac and Vascular Regeneration 2000 (2001); 1:228-235.
383. Kloner RA, Introduction to “Stunned and Hibernating Myocardium” Coronary Artery Disease 2001; 12:341-342.
384. Kloner RA, Arimie RB, Kay GL, Cannom D, Matthews R, Bhandari A, Shook T, Pollick C, Burstein S. Evidence for stunned myocardium in humans: A 2001 Update. Coronary Artery Disease 2001; 12:349-356.
385. Etzion S, Battler A, Barbash IM, Cagnano E, Zarin P, Granot Y, Kedes LH, Kloner RA, Leor J. Influence of embryonic cardiomyocyte transplantation on the progression of heart failure in a rat model of extensive myocardial infarction. J. Mol Cell Cardiology 2001; 33:1321-1330.
386. Kloner RA. Erectile dysfunction and cardiovascular risk factors. Hospital Practice 2001; 36:41-51.
387. Kloner RA, Textor SC, Tavel ME. Renovascular hypertension: Problems in evaluation and management. Chest, 2002; 121:964-968.
388. Hale SL, Kloner RA. Combination therapy for maximal myocardial infarct size reduction. Heart Disease, 2001; 3:351-356.
389. Etzion S, Kedes LH, Kloner RA, Leor J. Myocardial regeneration. Present and future trends. Am. J. Cardiovascular Drugs 2001; 1:233-244.
390. Hale SL, Kloner RA. Ethanol does not exert myocardial preconditioning in an intact rabbit model of ischemia/reperfusion. Heart Disease 2001; 3:293-296.
391. Kloner RA, Das S, Poole WK, Perritt R, Muller J, Cannon CP, Braunwald E. Seasonal variation of myocardial infarct size. Am J. Cardiology 2001; 88:1021-1024.
392. Simkhovich BZ, Abdishoo S, Poizat C, Hale SL, Kedes LH, Kloner RA. Gene activity changes in ischemically preconditioned rabbit heart gene: discovery array study. Heart Disease 2002; 4:63-69.
393. Hale SL, Kloner RA. Effects of resveratrol, a flavinoid found in red wine, on infarct size in an experimental model of ischemia/reperfusion. J of Stud Alcohol 2001; 62:730-735.
394. Kloner RA. Preinfarct angina and exercise: yet another reason to stay physically active. J. Am. Coll. Cardiol. 2001; 38:1366-1368.
395. Muller-Ehmsen J, Whittaker P, Kloner RA, Dow JS, Sakoda T, Long TI, Laird PW, Kedes L. Survival and development of neonatal rat cardiomyocytes transplanted into adult myocardium. J. Moll. Cell Cardiol. 2002; 34:107-116.
396. Kloner RA, Jennings RB. Consequences of Brief Ischemia: Stunning, preconditioning and their clinical implications. Part I, Circulation 2001; 104:2981-2989.
397. Kloner RA, Jennings RB. Consequences of Brief Ischemia: Stunning, preconditioning and their clinical implications. Part II, Circulation 2001; 104:3158-3167.
398. Reffelmann T, Hale SL, Li G, Kloner RA. Relationship between no-reflow and infarct size as influenced by different durations of ischemia and reperfusion. Am. J. Physiol Heart Circ Physiol 2002; 282:H766-H772.
399. Reffelmann T, Kloner RA. The “No-Reflow” Phenomenon: basic science and clinical correlates. HEART 2002; 87:162-168.
400. Rezkalla SH, Kloner RA. No-Reflow Phenomenon. Circulation 2002; 105:656-662.
401. Kloner RA, Speakman M, Przyklenk K. Ischemic preconditioning: a plea for rationally targeted clinical trials. Cardiovasc. Res. 2002; 55:526-533.
402. Müller-Ehmsen J, Kedes L, Schwinger RHG, Kloner RA. Cellular cardiomyoplasty - A novel approach to treat heart disease. Congestive Heart Failure, 2002; July - August; 8(4):220-227.
403. Müller-Ehmsen J, Peterson KL, Kedes L, Whittaker P, Dow JS, Long TI, Laird PW, Kloner RA. Rebuilding a damaged heart: Long-term survival of transplanted neonatal rat cardiomyocytes after myocardial infarction and effect on cardiac function. Circulation 2002; 105:1720-1726.
404. Kloner RA, Poole K, Shook T, Przyklenk K, Perritt K, Cannon C. Comparison of acute myocardial infarct size in patients ≥ 65 years versus - < 65 years in the prethrombolytic period - versus the thrombolytic period. Am. J. Cardiology 2002; 89:1291-1293.
405. Li G, Whittaker P, Yao M, Kloner RA, Przyklenk K. The gap junction uncoupler heptanol abrogates infarct size reduction with preconditioning in mouse hearts. Cardiovascular Pathology 2002; 11:158-165.
406. Hale SL, Kloner RA. Elevated body temperature during myocardial ischemia/reperfusion exacerbates necrosis and worsens no-reflow. Coronary Artery Disease 2002; 13:177-181.
407. Phillips RA, Kloner RA, Grimm RH, Weinberger M. The effects of amlodipine compared to losartan in patients with mild to moderately severe hypertension. Journal of Clinical Hypertension 2003; 5:17-23,30.
408. Rezkalla SH, Mesa J, Sharma P, Kloner RA. Myocardial infarction temporally related to ephedra - A possible role for the coronary microcirculation. Wisconsin Medical Journal 2002; 101:64-66.
409. Reffelmann T, Kloner RA. Microvascular reperfusion injury: rapid expansion of anatomic no-reflow during reperfusion in the rabbit. Am. J. Physiol (Heart Circ Physiol) 2002; 283:H1099-H1107.
410. Kloner RA, Speakman M. Erectile dysfunction and atherosclerosis. Current Atherosclerosis Reports 2002; September; 4(5):397-401.
411. Albaugh J, Amargo IJ, Capelson R, Flaherty E, Forrest C, Goldstein I, Jensen PK, Jones K, Kloner RA, Lewis JH, Mullin S, Payton T, Rines B, Rosen RC, Sadovsky R, Snow K, Vetrosky D. Health Care Clinicians (HCC) in Sexual Health Medicine: Focus on erectile dysfunction (ED). A Guidelines Development Conference. Urologic Nursing 2002; 22:217-231.
412. Etzion S, Barbash IM, Feinberg MS, Zarin P, Miller L, Guetta E, Holbova R, Kloner RA, Kedes LH, Leor J. Cellular cardiomyoplasty of cardiac fibroblasts by adenoviral delivery of Myo D ex vivo: An unlimited source of cells for myocardial repair. Circulation 2002; 106 [Suppl I]:I-125 - I-130.
413. Padma-Nathan H, Eardley I, Kloner R, Laties AM, Montorsi F. A four-year update on the safety of sildenafil citrate (Viagra ®). Urology 2002; 60 (Suppl 3B): 67-90.
414. Reffelmann T, Kloner RA. Is microvascular protection by cariporide and ischemic preconditioning causally linked to myocardial salvage. Am J Physiol., 2003; 284:H1134-H1141.
415. Reffelmann T, Kloner RA. Cellular cardiomyoplasty – cardiomyocytes, skeletal myoblasts or stem cells for regenerating myocardium and treatment of heart failure? Cardiovascular Research, 2003; 58:358-368.
416. Lewis J, Rosen R, Goldstein I, and the Consensus Panel on Health Care Clinician Management of Erectile Dysfunction (Albaugh J, Amargo IJ, Capelson R, Flaherty E, Forest C, Goldstein I, Jensen PK, Jones K, Kloner RA, Lewis JH, Mullin S, Payton T, Rines B, Rosen RC, Sadovsky RC, Snow K, and Vetrosky D). Erectile Dysfunction: A panel’s recommendations for management. American Journal of Nursing 2003; 103:48-57.
417. Whittaker P, Müller-Ehmsen J, Dow JS, Kedes LH, Kloner RA. Development of abnormal tissue architecture in transplanted neonatal rat myocytes. The Annals of Thoracic Surgery, 2003; 75:1450-1456.
418. Simkhovich BZ, Kloner RA, Poizat C, Marjoram P, Kedes LH. Gene expression profiling - A new approach in the study of myocardial ischemia. Cardiovascular Pathology, 2003; 12:180-185.
419. Reffelmann T, Leor J, Müller-Ehmsen J, Kedes L, Kloner RA. Cardiomyocyte transplantation into the failing heart-new therapeutic approach for heart failure? Heart Failure Reviews, 2003; 8:201-211.
420. Kloner RA, Rezkalla SH. Cocaine and the Heart. N. Engl J. Med 2003; 348:487-488.
421. Reffelmann T, Kloner RA. Transthoracic echocardiography in rats: Evaluation of commonly used indices of left ventricular dimensions, contractile performance, and hypertrophy in a genetic model of hypertrophic heart failure (SHHF-Mcc-facp-Rats) in comparison with Wistar Rats during aging. Basic Res Cardiol. 2003; 98:275-284.
422. Kloner RA, Mullin SH, Shook T, Matthews R, Mayeda G, Burstein S, Peled H, Pollick C, Choudhary R, Rosen R, Padma-Nathan H. Erectile dysfunction in the cardiac patient: How common and should we treat? J. Urology 2003 Aug; 170:S46-S50.
423. Chi JS, Kloner RA. Stress and myocardial infarction. Heart, 2003; 89:475-476.
424. Reffelmann T, Dow JS, Dai W, Hale SL, Simkhovich B, Kloner RA. Transplantation of neonatal cardiomyocytes after permanent coronary artery occlusion increases regional blood flow of infarcted myocardium. J. Molecular and Cellular Cardiology, 2003;35:607-613.
425. Yao M, Dieterle T, Hale SL, Dow JS, Kedes LH, Peterson KL, Kloner RA. Long term outcome of fetal cell transplantation on postinfarction ventricular remodeling and function. J. Molecular and Cellular Cardiology, 2003; 35:661-670.
426. Kloner RA. New Therapy Update. Zetia (ezetimibe) Congestive Heart Failure, 2003; 9:109-110.
427. Chi JS, Speakman MT, Poole WK, Kandefer SC, Kloner RA and the Investigators. Hospital admissions for Cardiac Events in New York City after September 11, 2001. Am J. Cardiology 2003; 92:61-63.
428. Simkhovich BZ, Marjoram P, Poizat C, Kedes LH, Kloner RA. Brief episode of ischemia activates protective genetic program in rat heart. A gene chip study. Cardiovascular Research 2003; 59:450-459.
429. Rezkalla S, Sharma P, Kloner RA. Coronary no-flow and ventricular tachycardia associated with habitual marijuana use. Ann. Emerg. Med., 2003; 42:365-369.
430. Hale SL, Dae MW, Kloner RA. Hypothermia during reperfusion limits “no-reflow” injury in a rabbit model of acute myocardial infarction. Cardiovascular Res., 2003; 59:715-722.
431. Barbash IM, Chouraqui P, Baron J, Feinberg MS, Etzion S, Tessone A, Miller L, Guetta E, Zipori D, Kedes LH, Kloner RA, Leor J. Systemic delivery of bone marrow – derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration and body distribution. Circulation 2003; 108:863-868.
432. Reffelmann T, Kloner RA. Effects of sildenafil on myocardial infarct size, microvascular function and acute ischemic left ventricular dilation. Cardiovasc Res, 2003; 59:441-449.
433. Reffelmann T, Kloner RA. Therapeutic potential of phosphodiesterase 5 - inhibition for cardiovascular disease. Circulation 2003; 108:239-244.
434. Chi JS, Poole WK, Kandefer SC, Kloner RA. Cardiovascular mortality in New York City after September 11, 2001. Am. J. Cardiology, 2003; 92:857-861.
435. Nehra A, Steers WD, Althof SE, Andersson KE, Burnett AL 2nd , Costabile RA, Goldstein I, Kloner RA, Lue TF, Morales A, Rosen RC, Shahsigh R, Siroky MB, King L. Third International Conference on the Management of Erectile Dysfunction: Linking Pathophysiology and Therapeutic Response. J. Urology 2003 Aug; 170:S3-S5.
436. Leor J, Battler A, Kloner RA, Etzion S. Reprogramming cells for transplantation. Heart Fail Rev. 2003; 8:285-292.
437. Simkhovich BZ, Marjoram P, Poizat C, Kedes LH, Kloner RA. Age ­ related changes of cardiac gene expression following myocardial ischemia/reperfusion. Archives of Biochemistry and Biophysics 2003; 420:268-278.
438. Przyklenk K, Li G, Simkhovich BZ, Kloner RA. Mechanisms of myocardial ischemic preconditioning are age ­ related: Protein kinase C ­ ε does not play a requisite role in old rabbits. J. Appl Physiol. 2003; 95:2563-2569.
439. Reffelmann, T, Hale SL, Dow JS, Kloner RA. No-reflow phenomenon persists long-term after ischemia/reperfusion in the rat and predicts infarct expansion. Circulation 2003; 108:2911-2917.
440. Kloner RA, Dai W. Glycoprotein IIb/IIIa inhibitors and no ­ reflow. J. Am Coll Cardiology 2004; 43:284-286.
441. Dai W, Kloner RA. Effects of acetaminophen on myocardial infarct size in rats. J. Cardiovascular Pharmacology and Therapeutics 2003; 8:277-284.
442. Kloner RA, Hutter AM, Emmick JT, Mitchell MI, Denne J, Jackson G. Time course of the interaction between tadalafil and nitrates. J Am Coll Cardiology 2003; 42:1855-1860.
443. Kloner RA. Erectile dysfunction in the cardiac patient. Current Urology Reports, 2003; 4:466-471.
444. Kloner RA. New Therapy Update INSPRA (eplerenone tablets). Congestive Heart Failure 2003; November/December pages 341-342.
445. Kloner RA. Introduction: Erectile dysfunction and cardiovascular risk factors. Am J. Cardiol 2003; 92 (Suppl):1M­2M.
446. Brindis RG, Kloner RA. Sildenafil in patients with cardiovascular disease. Am. J. Cardiol 2003; 92 (Suppl):26M­36M.
447. Kloner RA, Mitchell M, Emmick JT. Cardiovascular effects of tadalafil. Am. J. Cardiol 2003; 92 (Suppl):37M­46M.
448. Kloner RA, Mitchell M, Emmick JT. Cardiovascular effects of tadalafil in patients on common antihypertensive therapies. Am. J. Cardiol. 2003; 92 (Suppl):47M­57M.
449. Kloner RA, Brindis RG, Cheitlin MD, Kuritzky L, Miller TA, Padma-Nathan H, Rosen RC. Roundtable discussion: Tadalafil Study Group. Am. J. Cardiol 2003; 92 (Suppl):58M-65M.
450. Kloner RA. Erectile Dysfunction in the cardiac patient. Comprehensive Therapy 2004; 30:50-54.
451. Dai W. Kloner RA. Relationship between cyclooxygenase-2 inhibition and thrombogenesis. J. Cardiovascular Pharmacology and Therapeutics, 2004; 9:51-59.
452. Kloner RA. Assessment of cardiovascular risk in patients with erectile dysfunction. Focus on the diabetic patient. Endocrine 2004; 23:125-130.
453. Hale SL. Kloner RA. Acetaminophen and experimental acute myocardial infarction. Cardiovascular Drugs and Therapy, 2004; 18:121-125.
454. Reffelmann T, Kloner RA. Effects of adenosine and verapamil on anatomic no-reflow in a rabbit model of coronary artery occlusion and reperfusion. Journal of Cardiovascular Pharmacology 2004; 43:580-586.
455. Kloner RA. Novel phosphodiesterase type 5 inhibitors: Assessing hemodynamic effects and safety parameters. Clin Cardiol. 2004; Vol. 27 (Suppl I), I-20-I-25.
456. Dai W, Hale SL, Kloner RA. Implantation of immature neonatal cardiac cells into the wall of the aorta in rats: A novel model for studying morphological and functional development of heart cells in an extracardiac environment. Circulation 2004; 110:324-329.
457. Kloner RA, Rezkalla SH. Cardiac protection during acute myocardial infarction: Where do we stand in 2004? J. Am. Coll Cardiology 2004; 44:276-286.
458. Simkhovich BZ, Hale SL, Kloner RA. Metabolic mechanism by which mild regional hypothermia preserves ischemic tissue. J. Cardiovascular Pharmacology and Therapeutics 2004; 9:83-90.
459. Kloner RA, Jackson G, Emmick JT, Mitchell MT, Bedding A, Warner MR, Pereira A. Interaction between the phosphodiesterase 5 inhibitor, tadalafil, and two alpha blockers, doxazosin and tamsulosin in healthy normotensive men. The Journal of Urology 2004; 172:1935-1940.
460. Kloner RA. Cardiovascular effects of the three phosphodiesterase ­ 5 inhibitors approved for the treatment of erectile dysfunction. Circulation 2004; 110:3149-3155.
461. Sesti C, Kloner RA. Gene Therapy in Congestive Heart Failure. Circulation 2004; 110:242-243.
462. Reffelmann T, Kloner RA. Microvascular alterations after temporary coronary artery occlusion: the no-reflow phenomenon. J. Cardiovasc Pharmacology and Therapeutics 2004; 9:163-172.
463. Jackson G, Kloner RA, Costigan TM, Warner MR, Emmick JT. Update on clinical trials of tadalafil demonstrates no increased risk of cardiovascular adverse events. J. of Sexual Medicine 2004; 1:161-167.
464. Poole WK, Chi JS, Walton JD, Kandefer S, Kloner RA. Increased cardiovascular mortality associated with the turn of the millennium in Los Angeles County, California. J. of Epidemiology and Community Health 2005; 59:205-206.
465. Kedes L, Kloner R, Kong K, Poizat C, Simkhovich B, Iso T, Hamamori Y. New cellular and molecular approaches for the treatment of cardiac disease. Seminars in Nephrology 2004; 24:437-440.
466. Mensah GA, Grant AO, Pepine CJ, Baddour LM, Cooper LT Jr, Dunbar SB, Froelicher ES, Greenlund KJ, Kaplan EL, Kloner RA, Labarthe DR, Luepker RV, Madjid M, Muller JE, O’connor S, Ornato JP, Robertson RM, Roy MJ, Shah PK, Taubert KA, Wilson WR, Zheng ZJ, Harrington RA, Abrams J, Anderson JL, Bates ER, Eisenberg MJ, Grines CL, Hlatky MA, Lichtenberg RC, Lindner JR, Pohost GM, Schofield RS, Shubrooks SJ Jr, Stein JH, Tracy CM, Vogel RA, Wesley DJ.. ACCF/AHA/CDC Conference Report on emerging infectious diseases and biological terrorism threats: The clinical and public implications for the prevention and control of cardiovascular diseases. J Am Coll Cardiol. 2007; 49:1373-1412 and Circulation 2007; 115:1656-1695.
467. Padma-Nathan H, Christ G, Adaikan G, Becher E, Brock G, Carrier S, Carson C, Corbin J, Francis S, DeBusk R, Eardley I, Hedlund H, Hutter A, Jackson G, Kloner R, Liu S, McVary K, McCullough A, Nehra A, Porst H, Schulman C, Seftel A, Sharlip I, Stief C, Teloken C. Pharmacotherapy for erectile dysfunction. The Journal of Sexual Medicine 2004; 1:128-140.
468. Rezkalla SH, Kloner RA. Ischemic preconditioning and preinfarction angina in the clinical arena. Nature Clinical Practice Cardiovascular Medicine (Nature Publishing) 2004; 1:96-102.
469. Kloner RA. “The Merry Christmas Coronary” and “Happy New Year Heart Attack” Phenomenon. Circulation 2004; 110:3744-3745.
470. Wold LE, Dai W, Sesti C, Hale SL, Dow JS, Martin BJ, Kloner RA. Stem cell therapy for the heart: A review. Congestive Heart Failure 2004; 10:293-301.
471. Kloner RA, Simkhovich BZ. Benefit of an exercise program before myocardial infarction. J. Am Coll Cardiology 2005; 45:939-940.
472. Kloner RA, Padma-Nathan H. Erectile dysfunction in the patient with coronary artery disease. International Journal of Impotence Research (Nature Publishing) 2005; 17:209-215.
473. Sesti C, Hale SL, Lutzko C, Kloner RA. Granulocyte colony-stimulating factor and stem cell factor improve contractile reserve of the infarcted ventricle independent of restoring muscle mass. J. Am Coll. Card., 2005; 46:1662-1669.
474. Ross AM, Gibbons RJ, Stone GW, Kloner RA, Alexander RW. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J. Am. Coll. Card. 2005; 45:1775-1780.
475. Hale SL, Kloner RA. Acetaminophen and myocardial stunning after transient ischemia in rabbit hearts. Journal of Cardiovascular Pharmacology and Therapeutics, 2005; 10:121-129.
476. Dai W, Hale SL, Martin BJ, Kuang J-Q, Dow JS, Wold LE, Kloner RA. Allogeneic mesenchymal stem cell transplantation in postinfarcted rat myocardium: Short and long-term effects. Circulation, 2005; 112:214-223.
477. Kostis JB, Jackson G, Rosen R, Barrett-Connor E, Billups K, Burnett AL, Carson C, Cheitlin M, DeBusk R, Fonseca V, Ganz P, Goldstein I, Guay A, Hatzichristou D, Hollander JE, Hutter A, Katz S, Kloner RA, Mittleman M, Montorsi F, Montorsi P, Nehra A, Sadovsky R, Shabsigh R. Sexual dysfunction and cardiac risk: The 2nd Princeton Consensus Conference. Am. J. Cardiology, 2005; 96:313-321.
478. LaRosa JC, Grundy SM, Waters DD, et al. for the Treating to New Targets (TNT) Investigators \*(\*Dr. R. Kloner listed as investigator, page 1435). Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med 2005; 352:1425-1435.
479. Dow J, Simkhovich BZ, Kedes L, Kloner RA. Washout of transplanted cells from the heart: a potential new hurdle for cell transplantation therapy. Cardiovascular Research, 2005; 67:301-307.
480. Hale SL, Sesti C, Kloner RA. Administration of erythropoietin fails to improve long ­ term healing or cardiac function after myocardial infarction in the rat. J. of Cardiovascular Pharmacology, 2005; 46:211-215.
481. Reffelmann T, Kloner RA. Pharmacotherapy of erectile dysfunction: focus on cardiovascular safety. Expert Opin. Drug Saf., 2005; 4:531-540.
482. Estes NA III, Kloner R, Olshansky B, Virmani R. Task Force 9. Drugs and performance-enhancing substances. J. Am Coll. Cardiol. 2005; 45:1368-1369.
483. Dai W, Wold L, Dow J, Kloner RA. Thickening of the infarcted wall by collagen injection improves left ventricular function in rats: A novel approach to preserve cardiac function after myocardial infarction. J. Am Coll Cardiol., 2005; 46:714-719.
484. Beasley CM, Mitchell MI, Dmitrienko AA, Emmick JT, Shen W, Costigan TM, Bedding AW, Turik MA, Bakhtyari A, Warren MR, Ruskin JN, Cantilena LR, Kloner RA. The combined use of ibutilide as an active control with intensive electrocardiographic sampling and signal averaging as a sensitive method to assess the effects of tadalafil on the human QT interval. J. Am. Coll Cardiol. 2005; 46:678-687.
485. Kloner RA, Sadovsky R, Johnson EG, Mo D, Ahuja S. Efficacy of tadalafil in the treatment of erectile dysfunction in hypertensive men on concomitant thiazide diuretic therapy. International Journal of Impotence Research (Nature Publishing) 2005; 17:450-454.
486. Rezkalla SH, Kloner RA. Coronary No-reflow phenomenon. Curr. Treat Options Cardiovasc Med 2005; 7:75-80.
487. Kloner RA, Invited comments on McMahon C. Comparison of efficacy, safety, and tolerability of on-demand tadalafil and daily dose tadalafil for the treatment of erectile dysfunction. J. Sex Med 2005; 2:424-425.
488. Nordlie MA, Wold LE, Kloner RA. Genetic contributors toward increased risk for ischemic heart disease. J. Mol. Cell Cardiol 2005; 39:667-669.
489. Dai W, Hale SL, Kloner RA. Cardiac cells implanted within the outer aortic wall of rats generate measurable contractile force. Regenerative Medicine 2006; 1:11 9-124.
490. Patterson D, Kloner R, Effron M, Emmick J, Bedding A, Warner M, Mitchell M, Braat S, MacDonald T. The effect of tadalafil on the time to exercise ­ induced myocardial ischemia in subjects with coronary artery disease. British Journal of Clinical Pharmacology 2005; 60:459-468.
491. Kloner RA. Natural and unnatural triggers of myocardial infarction. Progress in Cardiovascular Diseases 2006; 48:285-300.
492. Dai W, Hale SL, Kloner RA. Stem cell transplantation for the treatment of myocardial infarction. Transplant Immunology 2005; 15:91-97.
493. Kloner RA. Erectile dysfunction and cardiovascular risk factors. Urology Clinics of North America 2005; Nov. 32:397-402.
494. Reffelmann T, Kloner RA. Cardiovascular effects of phosphodiesterase 5 inihibitors. Current Pharmaceutical Design 2006; 12:3485-3494.
495. Rezkalla SH, Kloner RA. Preconditioning and the human heart. Panminerva Med 2005; 47:69-73.
496. Kloner RA. A case of erectile dysfunction and risk factors for coronary artery disease. International Journal of Impotence Research (Nature Publishing) 2005; 17:S7-S11.
497. Rezkalla SH, Kloner RA. Ischemic preconditioning for the clinician. Wisconsin Medical Journal 2006; 105:22-26.
498. Nordlie MA, Wold LE, Simkhovich BZ, Sesti C, Kloner RA. Molecular aspects of ischemic heart disease: ischemia/reperfusion ­ induced genetic changes and potential applications of gene and RNAi therapy. J. Cardiovascular Pharmacology and Therapeutics, 2006; 11:17-30.
499. DeBusk RF, Kloner RA. Rationale for not combining nitrates and PDE5 inhibitors. The Journal of Family Practice (Suppl.) Dec. 2005; 15-22.
500. Kloner RA. Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: Focus on α blocker interactions. Am. J. Cardiology 2005; 96 (Suppl):42M-46M.
501. Kloner RA, Dow J, Bhandari A. Postconditioning markedly attenuates ventricular arrhythmias after ischemia-reperfusion. J. Cardiovascular Pharmacology and Therapeutics 2006; 11:55-63.
502. Kloner RA, Jackson G, Hutter AM, Mittleman MA, Chan M, Warner MR, Costigan TM, Vail GM. Cardiovascular safety update of tadalafil: Retrospective analysis of data from placebo-controlled and open-label clinical trials of tadalafil with as needed, three times per week, or once a day dosing. Am. J. Cardiology 2006; 97:1778-1784.
503. Kloner RA. Can we trigger an acute coronary syndrome? Heart 2006; 92:1009-1010.
504. Kloner RA, Rezkalla SH. Preconditioning, postconditioning and their application to clinical cardiology. Cardiovascular Research 2006; 70:297-307.
505. Jackson G, Rosen RC, Kloner RA, Kostis JB. The Second Princeton Consensus on Sexual Dysfunction and Cardiac Risk: New Guidelines for Sexual Medicine. J. Sex. Med 2006; 3:28-36.
506. Kloner RA, Montorsi P, DeBusk RF. Commentaries on Jackson et al. “Successful withdrawal of oral long-acting nitrates to facilitate phosphodiesterase type 5 inhibitor use in stable coronary disease patients with erectile dysfunction. J. Sex Med 2005; 2:740-742.
507. Kloner RA. Attempts to recruit stem cells for repair of acute myocardial infarction. A dose of reality. JAMA 2006; 295:1058-1060.
508. Wold LE, Simkhovich BZ, Kleinman MT, Nordlie MA, Dow JS, Sioutas C, Kloner RA. In-vivo and in-vitro models to test the hypothesis of particle ­ induced effects on cardiac function and arrhythmias. Cardiovascular Toxicology 2006; 06:69-78.
509. Sesti C, Simkhovich BZ, Kalvinsh I, Kloner RA. Mildronate, a novel fatty acid oxidation inhibitor and antianginal agent, reduces myocardial infarct size without affecting hemodynamics. Journal of Cardiovascular Pharmacology 2006; 47:493-499.
510. Hale SL, Leeka JA, Kloner RA. Improved left ventricular function and reduced necrosis after myocardial ischemia/reperfusion in rabbits treated with ranolazine, an inhibitor of the late sodium current. Journal of Pharmacology and Experimental Therapeutics 2006; 318:418-423.
511. Dai W, Kloner RA. Myocardial regeneration by embryonic stem cell transplantation: present and future trends. Expert Review of Cardiovascular Therapy 2006; 4:375-383.
512. Kloner RA. Moving preconditioning from bench to bedside. J. Am. Coll Cardiology 2006; 48:215-21.
513. Kloner RA, Forman MB, Gibbons RJ, Ross AM, Alexander RW, Stone GW. Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction; The AMISTAD-2 Trial. European Heart Journal 2006; 27:2400-2405.
514. Sesti C, Florio V, Johnson E, Kloner RA. The phosphodiesterase-5 inhibitor tadalafil reduces myocardial infarct size. International J. Impotence Research (Nature Publishing) 2007; 19:55-61.
515. Reffelmann T, Kloner RA. Sexual function in hypertensive patients receiving treatment. Vascular Health and Risk Management 2006; 2:447-455.
516. Kloner RA. No-Reflow: Basic Science to Clinical Phenomenon. Basic Research in Cardiology 2006; 101:357-358.
517. Reffelmann T, Kloner RA. The no-reflow Phenomenon: A basic mechanism of myocardial ischemia and reperfusion. Basic Research in Cardiology 2006; 101:359-372.
518. Hale SL, Kloner RA. Ranolazine, an inhibitor of the late sodium channel current, reduces postischemic myocardial dysfunction in the rabbit. Journal of Cardiovascular Pharmacology and Therapeutics 2006; 11:249-255.
519. Kloner RA. Erectile dysfunction and hypertension. International Journal of Impotence Research (Nature Publishing) 2007; 19:296-302.
520. Rosen RC, Catania JA, Ehrhardt AA, Burnett AL, Lue TF, McKenna K, Heiman JR, Schwarcz S, Ostrow DG, Hirshfield S, Purcell DW, Fisher WA, Stall R, Halkitis PN, Latini DM, Elford J, Laumann EO, Sonenstein FL, Greenblatt DJ, Kloner RA, Lee J, Malebranche D, Janssen E, Diaz R, Klausner JD, Caplan AL, Jackson G, Shabsigh R, Khalsa JH, Stoff DM, Goldmeier D, Lamba H, Richardson D, Sadeghi-Nejad H. The Bolger Conference on PDE-5 inhibitors and HIV Risk: Implications for Health Policy and Prevention. J. Sex Med 2006; 3:960-975.
521. Dai W, Hale SL, Kloner RA. Development of a spontaneously beating vein by cardiomyocyte transplantation in the wall of the inferior vena cava in a rat: A pilot study. Journal of Vascular Surgery 2007; 45:817-820.
522. Dai W, Hale SL, Kloner RA. Role of a paracrine action of mesenchymal stem cells in the improvement of left ventricular function after coronary artery occlusion in rats. Regenerative Medicine 2007; 2:63-68.
523. Rezkalla S, Kloner RA. Preconditioning in humans. Heart Failure Reviews 2007; 12:201-206.
524. Dai W, Kloner RA. Myocardial regeneration by human amniotic fluid stem cells: challenges to be overcome. Journal of Molecular and Cellular Cardiology 2007; 42:730-732.
525. Dow J, Kloner RA. Postconditioning does not reduce myocardial infarct size in an in-vivo regional ischemia rodent model. Journal of Cardiovascular Pharmacology and Therapeutics 2007; 12:153-163.
526. Kloner RA, Cannom DS. Uncertainty on the use of aldosterone antagonists for primary therapy for sudden cardiac death in the setting of implanted devices. Circulation 2007; 115:2983-2989. Kloner RA, Cannom DS. Response to Pitt and Pitt. Circulation 2007; 115:2982.
527. Ornato JP, Muller JE, Frolicher ES, Kloner RA. Task Force II: Indirect and secondary cardiovascular effects of biological terrorism agents and diseases. J. Am. Coll. Cardiol; 2007; 49:1389-1397 and Circulation 2007; 115:1672-1680.
528. Artaza JN, Reisz,-Porszasz S, Dow JS, Kloner RA, Tsao J, Bhasin S, Gonzalez-Cadavid NF Alterations in myostatin expression are associated with changes in cardiac left ventricular mass but not ejection fraction in the mouse. J. of Endocrinology 2007; 194:63-76.
529. Kloner RA, Rezkalla SH. To drink or not to drink? That is the question. Circulation 2007; 116:1306-1317.
530. Reffelmann T, Kloner RA. Vardenafil: a selective inhibitor of phosphodiesterase-5 for the treatment of erectile dysfunction. Expert Opin. Pharmacother. 2007; 8:965-974.
531. Rezkalla SH, Kloner RA. Cocaine induced acute myocardial infarction. Clinical Medicine and Research 2007; 5:172-176.
532. Dai W, Field LJ, Rubart M, Reuter S, Hale SL, Zweigerdt R, Graichen RE, Kay GL, Jyrala AJ, Colman A, Davidson BP, Pera M, Kloner RA. Survival and maturation of human embryonic stem cell-derived cardiomyocytes in rat hearts. Journal of Molecular and Cellular Cardiology 2007; 43:504-516.
533. Reffelmann T, Kloner RA. Consequences of reperfusion. Heart Metab. 2007; 37:1-4.
534. Simkhovich BZ, Marjoram P, Kleinman MT, Kloner RA. Direct and acute cardiotoxicity of ultrafine particles in young adult and old rats. Basic Res in Cardiology 2007; 102:467-475.
535. Seftel AD, Miner MM, Kloner RA, Althof SE. Office evaluation of male sexual dysfunction. Urol Clin North Am 2007; 34:463-482.
536. Hale SL, Mehra A, Leeka J, Kloner RA. Postconditioning fails to improve no reflow or alter infarct size in an open-chest rabbit model of myocardial ischemia/reperfusion. American Journal of Physiology: Heart and Circulatory Physiology 2008; 294:H421-H425.
537. Reffelmann T, Kieback A, Kloner RA. The cardiovascular safety of tadalafil. Expert Opinion on Drug Safety. 2008; 7:43-52.
538. Kloner RA, Case studies: applying JNC-8 treatment guidelines. Journal of the American Academy of Physicians Assistants (JAAPA) 2007; Nov. Suppl Hypertension:14-18.
539. Kloner RA, Nesto RW. Glucose ­ insulin ­ potassium for acute myocardial infarction: continuing controversy over cardioprotection. Circulation 2008; 117:2523-2533.
540. Kloner RA. Erectile dysfunction: The new harbinger for major adverse cardiac events in the diabetic patient. J. Am Coll Cardiol 2008; 51:2051-2052.
541. Dow J, Bhandari A, Kloner RA. Ischemic postconditioning’s benefit on reperfusion ventricular arrhythmias is maintained in the senescent heart. J. Cardiovasc. Pharmacology and Therapeutics 2008; 13:141-148.
542. Hale SL, Belardinelli L, Shryock JC, Sweeney M, Kloner RA. Late sodium current inhibition as a new cardioprotective approach. J. Mol Cell Cardiology 2008, 44:954-967.
543. Kloner RA. Erectile dysfunction as a predictor of cardiovascular disease. Int. J. Impotence Research (Nature Publishing) 2008; 20:460-465.
544. Bahiru E, Kloner RA. A comparative literature review exploring hypertension drugs that lower target organ damage above and beyond reducing blood pressure based on research studies published between 1992 and 2006. Current Hypertension Reviews 2008; 4:167-176.
545. Hale SL, Kloner RA. The antianginal agent, ranolazine, reduces myocardial infarct size but does not alter anatomic no-reflow or regional myocardial blood flow in ischemia/reperfusion in the rabbit. J. Cardiovascular Pharmacology and Therapeutics 2008; 13:226-232.
546. Simkhovich BZ, Kleinman MT, Kloner RA. Air pollution and cardiovascular injury. Epidemiology, toxicology, and mechanisms. J. Am. Coll Cardiol. 2008; 52:719-726.
547. Hwang H, Kloner RA, Kleinman MT, Simkhovich BZ. Direct and acute cardiotoxic effects of ultrafine air pollutants in spontaneously hypertensive rats and Wistar ­ Kyoto rats. J. Cardiovasc. Pharmacology and Therapeutics 2008; 13:189-198.
548. Kloner RA, Hwang H. New insights into the open artery hypothesis. Circ. Res 2008; 103:1-3.
549. Rezkalla SH, Kloner RA. Coronary no-reflow phenomenon: From the experimental laboratory to the cardiac catheterization laboratory. Catheterization and Cardiovascular Intervention 2008; 72:950-957.
550. Kloner RA, Neutel J. Roth EM, Weiss R, Weinberger MH, Thakker KM, Schwartz B, Shi H, Gregg A-M, on behalf of the ADHT Investigators. Evaluation of blood pressure control with amlodipine add ­ on therapy in patients with hypertension and diabetes. Results of the amlodipine diabetic hypertension efficacy response evaluation trial (ADHT). The Annals of Pharmacotherapy 2008; 42:1552-1562.
551. Hale SL, Dai W, Dow JS, Kloner RA. Mesenchymal stem cell administration at coronary artery reperfusion in the rat by two delivery routes: A quantitative assessment. Life Sciences 2008; 83:511-515.
552. Reffelmann T, Könemann S, Kloner RA. Promise of blood ­ and bone marrow ­ derived stem cell transplantation for functional cardiac repair: Putting it in perspective with existing therapy. J. Am. Coll Cardiol, 2009; 53:305-308.
553. Dai W, Hale SL, Kay GL, Jyrala AJ, Kloner RA. Delivering stem cells to the heart in a collagen matrix reduces relocation of cells to other organs as assessed by nanoparticle technology. Regenerative Medicine 2009; 4:387-395.
554. Al-Ameri H, Thomas ML, Yoon A, Mayeda GS, Burstein S, Kloner RA, Shavelle DM. Complication rate of diagnostic carotid angiography performed by interventional cardiologists. Catheterization and Cardiovascular Interventions 2009; 73:661-665.
555. Dow J, Bhandari A, Kloner RA. The mechanism by which ischemic postconditioning reduces reperfusion arrhythmias in rats remains elusive. J. Cardiovasc Pharmacology and Therapeutics 2009; 14:99 -103.
556. Kloner RA. Clinical application of remote ischemic preconditioning. Circulation 2009; 119:776-778.
557. Ai L, Yu H, Dai W, Hale SL, Kloner RA, Hsiai TZ. Real ­ time intravascular shear stress in the rabbit abdominal aorta. IEEE Transactions on Biomedical Engineering 2009; 56:1755-1764.
558. Kloner RA, McDonald S, Leeka J, Poole WK. Comparison of total and cardiovascular death rates in the same city during a losing versus winning Super Bowl championship. Am. J. Cardiology 2009; 103:1647-1650.
559. Hwang H, Arcidi J, Hale SL, Simkhovich BZ, Belardinelli L, Dhalla AK, Shryock JC, Kloner RA. Ranolazine as an adjunct to cardioplegia: a potential new therapeutic application. Journal of Cardiovascular Pharmacology and Therapeutics 2009; 14:125-133.
560. Dai W, Simkhovich BZ, Kloner RA. Ischemic preconditioning maintains cardioprotection in aging normotensive and spontaneously hypertensive rats. Experimental Gerontology 2009; 44:344-349.
561. Al-Ameri H, Kloner RA. Erectile dysfunction and heart failure: The role of phosphodiesterase type 5 inhibitors. International Journal of Impotence Research 2009; 21:149-157.
562. Hwang H, Arcidi JM, Hale SL, Simkhovich BZ, Belardinelli L, Dhalla AK, Shryock J, Kloner RA. Ranolazine as cardioplegia additive improves recovery of diastolic function in isolated rat hearts. Circulation 2009; 120 (Suppl 1):S16-S21.
563. Al-Ameri H, Shin V, Mayeda GS, Burstein S, Matthews RV, Kloner RA, Shavelle D. Peripheral chronic total occlusions treated with subintimal angioplasty and a true lumen re-entry device. J of Invasive Cardiology 2009; 21:468-472.
564. Reffelmann T, Kloner RA. Phosphodiesterase – 5 inhibitors: Are they cardioprotective? Cardiovascular Research 2009; 83:204-212.
565. Kloner RA. A salute to our founding editor-in-chief, Bramah N. Singh, MD, DPhil, DSc, FRCP. Journal of Cardiovascular Pharmacology and Therapeutics 2009; 14:154-156.
566. Little GH, Saw A, Bai Y, Dow J, Marjoram P, Simkhovich B, Leeka J, Kedes L, Kloner RA, Poizat C. Critical role of nuclear calcium/calmodulin ­ dependent protein kinase II δB in cardiomyocyte survival in cardiomyopathy. Journal of Biological Chemistry 2009; 284:24857-24868.
567. Schwartz BG, Kloner RA. How to save a life during a clinical visit for erectile dysfunction by modifying cardiovascular risk factors. International Journal of Impotence Research: The Journal of Sexual Medicine (Nature, Medicine Publishing) 2009; 21:327-335.
568. Simkhovich BZ, Kleinman MT, Kloner RA. Particulate air pollution and coronary heart disease. Current Opinion in Cardiology 2009; 24:604-609.
569. Reffelmann T, Kloner RA. Intracoronary blood­ or bone marrow­derived cell transplantation in patients with ischemic heart disease. Regenerative Medicine 2009; 4:709-719.
570. Dai W, Hale S, Kay G, Jyrala A, Kloner RA. Cardioprotective effects of angiotensin II type 1 receptor blockade with olmesartan on reperfusion injury in a rat myocardial ischemia ­ reperfusion model. Cardiovascular Therapeutics, 2010 Spring; 28:30-37.
571. Dhalla AK, Wang W-Q, Dow J, Shryock JC, Belardinelli L, Bhandari A, Kloner RA. Ranolazine, an antianginal agent, markedly reduces ventricular arrhythmias induced by ischemia and ischemia ­ reperfusion. Am. J. Physiol Heart Circ Physiol 2009; 297 (5):H1923-H1929.
572. Dai W, Hale SL, Nayak R, Kloner RA. ATL313, a selective A2A adenosine receptor agonist, reduces myocardial infarct size in a rat ischemia/reperfusion model. Open Cardiovascular Medicine Journal 2009; 3:166-172.
573. Hale SL, Kloner RA. Cardioprotection with adenosine regulating agent, GP531: Effects on no-reflow, infarct size and blood flow following ischemia/reperfusion in the rabbit. Journal of Cardiovascular Pharmacology and Therapeutics 2010; 15:60-67.
574. Schwartz BG, Economides C, Mayeda GS, Burstein S, Kloner RA. The endothelial cell in health and disease: Its function, dysfunction, measurement, and therapy. International Journal of Impotence Research: The Journal of Sexual Medicine (Nature Medicine Publishing) 2010; 22:77-90.
575. Reffelmann T, Kloner RA. Ranolazine ­ an antianginal - drug with further therapeutic potential. Expert Rev. Cardiovasc. Ther. 2010; 8:319-329.
576. Hwang H, Kloner RA. Improving regenerating potential of the heart after myocardial infarction: factor ­ based approach. Life Sciences 2010; 86:461-472.
577. Landgraf J, Wishner SH, Kloner RA. Comparison of automated oscillometric versus auscultatory blood pressure measurement. Am J. Cardiology 2010; 106:386-388.
578. Jackson, G, Boon N, Eardley I, Kirby M, Dean J, Hackett G, Montorsi P, Montorsi F, Vlachopoulos C, Kloner R, Sharlip I. Erectile dysfunction (ED) and coronary artery disease (CAD) prediction: Evidence ­ based guidance and consensus. Int. J. Clin. Practice 2010; 64:848-857.
579. Leeka J, Schwartz, BG, Kloner RA. Sporting events affect cardiovascular mortality: It’s not just a game. Am. J. Med, 2010; 123:972-977.
580. Schwartz BG, Kloner RA. Drug interactions with phosphodiesterase­5 inhibitors used for treatment of erectile dysfunction or pulmonary hypertension. Circulation 2010; 122:88-95.

580. Reffelmann T, Kloner RA. Blood supply of the graft after cellular cardiomyoplasty. Regenerative Medicine 2010; 5:777-786.

581. Rezkalla SH, Kloner RA. Influenza ­ related viral myocarditis. Wisconsin Medical Journal

 2010; 109:209-213.

1. Rezkalla SH, Dharmashankar KC, Abdalrahman IB, Kloner RA. No-reflow phenomenon following percutaneous coronary intervention for acute myocardial infarction: incidence, outcome, and effect of pharmacologic therapy. Journal of Interventional Cardiology, 2010; 23:429-436.
2. Schwartz BG, Mayeda GS, Burstein S, Economides C, Kloner RA. When and why do heart attacks occur? Cardiovascular triggers and their potential role. Hospital Practice 2010; 38:144-152.
3. Kloner RA, Dow J, Bhandari A. The anti-anginal agent ranolazine is a potent anti-arrhythmic agent that reduces ventricular arrhythmias through a mechanism favoring inhibition of late sodium channel. Cardiovascular Therapeutics, 2011; 29:e36-e41.
4. Kearns-Jonker M, Dai W, Kloner RA. Stem cells for the treatment of heart failure. Current Opinion in Molecular Therapeutics, 2010; 12:432-441.
5. Gajarsa JJ, Kloner RA. Left ventricular remodeling in the post-infarction heart: A review of cellular, molecular mechanisms and therapeutic modalities. Heart Failure Reviews, 2011; 16:13-21
6. Schwartz BG, Rezkalla S, Kloner RA. The cardiovascular effects of cocaine. Circulation, 2010; 122:2558-2569.
7. Hale SL, Allison AC, Kloner RA. Diannexin reduces no-reflow after reperfusion in rabbits with large ischemic myocardial risk zones. Cardiovascular Therapeutics, 2011; 29:e42-e51.
8. Dai W, Kloner RA. Experimental cell transplantation therapy in rat myocardial infarction model including nude rat preparation. Methods Mol Biol. 2010; 660:99-109.
9. Hwang H, Hale SL, Leeka J, Kloner RA. Effects of zoledronate in the repair of chronically infarcted rat myocardium. J of Cardiovascular Pharmacology, 2010; 56:604-609.
10. Kloner RA, Simkhovich BZ. Introduction to the role of air pollution in heart disease. Air Qual Atmos Health, 2011; 4:1-3.
11. Simkhovich BZ, Kleinman MT, Mehrian-Shai R, Hsu Y-H, Meacher D, Gookin G, MacKinnon M, Salazar K, Willert P, Feng G, Lin SM, Kloner RA. Chronic exposure to ambient particulate matter alters cardiac gene expression patterns and markers of oxidative stress in rats. Air Quality, Atmosphere, and Health , 2011; 4:15-25.
12. Schwartz BG, Kloner RA. Clinical Cardiology: Physician Update. Erectile Dysfunction and Cardiovascular Disease. Circulation, 2011; 123:98-101
13. Kloner RA, Dow JS, Bhandari A. First direct comparison of the late sodium current blocker ranolazine to established antiarrhythmic agents in an ischemia/reperfusion model. Journal of Cardiovascular Pharmacology and Therapeutics, 2011; 16:192-196.
14. Schwartz B, Burstein S, Economides C, Kloner RA, Shavelle D, Mayeda G. Review of vascular closure devices. Invasive Cardiology, 2010; 22:599-607.
15. Hale SL, Kloner RA. Mild hypothermia as a cardioprotective approach for acute myocardial infarction: Laboratory to clinical application. Journal of Cardiovascular Pharmacology and Therapeutics, 2011; 16:131-139.
16. Simkhovich B, Kleinman MT, Willet P, Gookin G, Salazar K, Keebaugh A, Kloner RA. Chronically inhaled ambient particulates causes cardiac inflammation in normal, diseased and elderly rat heart. Air Quality, Atmosphere and Health, 2011; 4:27-36.
17. Kloner RA, McDonald SA, Leeka J, Poole WK. Role of age, race, and gender on cardiac and total mortality associated with losing and winning Super Bowls. Clinical Cardiology, 2011; 34:102-107.
18. Hwang H, Kloner RA. The combined administration of multiple soluble factors in the repair of chronically infarcted rat myocardium. J Cardiovasc Pharmacol, 2011; 57:282-286.
19. Schwartz B, Mayeda GS, Economides C, Kloner RA, Shavelle DM, Burstein S. Rotational atherectomy in the drug eluding stent era. A single center experience. Journal of Invasive Cardiology, 2011; 23:133-139.
20. Kloner RA, Schwartz Longacre L. State of the science of cardio-protection: challenges and opportunities. Proceedings of the 2010 NHLBI Workshop on Cardio-protection. Journal of Cardiovascular Pharmacology and Therapeutics, 2011; 16:223-232.
21. Kloner RA, Schwartz B. Cardiovascular implications of erectile dysfunction . Circulation, 2011; 123; e609-e611.
22. Dai W, Kloner RA. Potential role of renin-angiotensin system blockade for preventing myocardial ischemial/reperfusion injury and remodeling after myocardial infarction. Postgraduate Medicine, 2011; 123:49-55.
23. Kloner RA. No-reflow phenomenon. Maintaining Vascular Integrity. Journal of Cardiovascular Pharmacology and Therapeutics, 2011; 16:244-250.
24. Schwartz BG, Kloner RA. Coronary no reflow. J. Molecular Cellular Cardiology, 2012; 52:873-882.
25. Kloner RA, Schwartz Longacre L. Introduction to Proceedings of the NHLBI Workshop: New Horizons in Cardioprotection. A Focused Issue of Journal of Cardiovascular Pharmacology and Therapeutics. Journal of Cardiovascular Pharmacology and Therapeutics 2011; 16:222.
26. Schwartz Longacre L, Kloner RA, Arai AE, Baines CP, Bolli R, Braunwald E, Downey J, Gibbons RJ, Gottlieb RA, Heusch G, Jennings RB, Lefer DJ, Mentzer RM, Murphy E, Ovize M, Ping P, Przyklenk K, Sack MN, Vander Heide RS, Vinten-Johansen J, Yellon DM. New Horizons in Cardioprotection. Recommendations from the 2010 National Heart, Lung, and Blood Institute Workshop. Circulation, 2011;124:1172-1179.
27. Kloner RA, Comstock G, Levine LA, Tiger S, Stecher VJ. Investigational non-cardiovascular uses of phosphodiesterase-5 inhibitors. Expert Opinion on Pharmacotherapy, 2011; 12:2297-2313.
28. Dai W, Kloner RA. Cardioprotection of insulin-like growth factor-1 during reperfusion therapy: What is the underlying mechanism or mechanisms? Circulation: Cardiovascular Interventions, 2011;4:311-313.
29. Gerczuk PZ, Kloner RA. Protecting the heart from ischemia: An update on ischemic and pharmacologic conditioning. Hospital Practice, 2011;39:35-43.
30. Gerczuk PZ, Kloner RA. An update on cardioprotection: A review of the latest adjunctive therapies to limit myocardial infarction size in clinical trials. J Am Coll Cardiology, 2012;59:969-978.
31. Schwartz BG, Ludeman DJ, Mayeda GS, Kloner RA, Economides C, Burstein S. High risk percurtaneous coronary intervention with the Tandem Heart and Impella Devices. A Single Center Experience. J. of Invasive Cardiology, 2011;23:417-424.
32. Schwartz BG, Levine LA, Comstock G, Stecher V, Kloner RA. Cardiac uses of phosphodiesterase – 5 inhibitors. J. Am. Coll Cardiol, 2012; 59:9-15.
33. Dai W, Kloner RA. Bone marrow-derived cell transplantation therapy for myocardial infarctions: lessons learned and future questions. Am. J of Transplantation, 2011; 11:2297-2301.
34. Schwartz BG, Mayeda GS, Economides C, Kloner RA, Shavelle DM, Burstein S. Rotational atherectomy and stent implantation for calcified left main lesions. Cardiology Research, 2011;2:208-217.
35. Dai W, Kay G, Jyrala A, Kloner RA. Experience from experimental cell transplantation therapy of myocardial infarction: what have we learned? Cell Transplantation, 2013;22:563-568.
36. Levine GN, Steinke EE, Bakaeen FG, Bozkurt B, Cheitlin MD, Conti, JB, Foster E, Jaarsma T, Kloner RA, Lange RA, Lindau S, Maron B, Moser DK, Ohman EM, Seftel AD, Stewart WJ. On behalf of the American Heart Association Council on Clinical Cardiology and Council on Cardiovascular Nursing. Sexual activity and cardiovascular disease. Scientific Statement from the American Heart Association. Circulation, 2012;125:1058-1072.
37. Schwarz ER, Kloner RA, Phan A. Erectile dysfunction in heart failure patients. The Medical Roundtable: Cardiovascular Edition, Fall 2011; 2:263-268.
38. Schwartz BG, Ludeman DJ, Mayeda GS, Kloner RA, Economides C, Burstein S. Treating refractory cardiogenic shock with the Tandem Heart and Impella Devices. A Single Center Experience. Cardiology Research, 2012; 3(2):54-66.
39. Schwartz BG, Pezzullo JC, McDonald SA, Poole WK, Kloner RA. How the 2008 stock market crash and seasons affect total and cardiac death in Los Angeles County. Am. J. Cardiology, 2012; 109:1445-1448.
40. Dai W, Kloner RA. Is inhibition of phosphodiesterase type-5 by sildenafil a promising therapy for volume-overload heart failure? Circulation, 2012;125:1341-1343.
41. Schwartz BG, Kloner RA, Burstein S, Economides C, Mayeda GS. Treating peripheral arterial disease percutaneously with atherectomy. Journal of Invasive Cardiology, 2012; 24:263-269.
42. Schwartz BG, Kloner RA, Cannom DS. Unusual substrate underlying Brugada Syndrome and early repolarization syndrome revealed in unusual circadian and seasonal patterns. Journal of Cardiovascular Electrophysiology, 2012; 23:764-765.
43. Schwartz BG, French WJ, Mayeda GS, Burstein S, Economides C, Bhandari AK, Cannom DS, Kloner RA. Emotional stressors trigger cardiovascular events. The International Journal of Clinical Practice, 2012 Jul;66(7):631-9.
44. Dow J, Painovich J, Hale SL, Tjen-A-Looi S, Longhurst JC, Kloner RA. Absence of actions of commonly used Chines herbal medicines and electroacupuncture on myocardial infarct size. Journal of Cardiovascular Pharmacology and Therapeutics, 2012;17:403-411.
45. Kloner RA, Mittleman MA, Muller J, Stone PH. Triggers for Cardiovascular Events. The Medical Roundtable: Cardiovascular Edition, Winter 2012; 3:45-54.
46. Al-Ameri H, Clavijo L, Matthews RV, Kloner RA, Shavelle DM. Devices to treat peripheral chronic total occlusions. Journal of Interventional Cardiology, 2012; 25:395-403.
47. Schwartz BG, Kloner RA, Thomas JL, Bui Q, Mayeda GS, Burstein S, Hale SL, Economides C, French WJ. Therapeutic hypothermia for acute myocardial infarction and cardiac arrest. Am. J. Cardiology, 2012; 110:461-466.
48. Miner M, Seftel AD, Nehra A, Ganz P, Kloner RA, Montorsi P, Vlachopoulos C, Ramsey M, Sigman M, Tilkemeier P, Jackson G. Prognostic utility of erectile dysfunction for cardiovascular disease in younger men and those with diabetes. Am Heart Journal, 2012; 164:21-28.
49. Kloner RA, Hale SL, Dai W, Gorman RC, Shuto T, Koomalsingh KJ,. Gorman JH, Sloan RC, Frasier CR, Watson CA, Bostian PA, Kypson AP, Brown DA. Reduction of ischemia/reperfusion injury with Bendavia, a mitochondrial-targeting cytoprotective peptide. Journal of the American Heart Association, 2012, 1:doi: 10.1161/JAHA.112.001644.
50. Gerczuk PZ, Breckenridge DG, Liles JT, Budas GR, Shryock JC, Belardinelli L, Kloner RA, Dai W. An apoptosis signal-regulating kinase 1 inhibitor reduces cardiomyocyte apoptosis and infarct size in a rat ischemia-reperfusion model. Journal of Cardiovascular Pharmacology, 2012;60:276-282.
51. Nehra A, Jackson G, Miner M, Billups KL, Burnett AL, Buvat J, Carson CC, Cunningham GR, Ganz P, Goldstein I, Guag AT, Hackett G, Kloner RA, Kostis J, Montorsi P, Ramsey M, Rosen R, Sadovsky R, Seftel AD, Shabsigh R, Vlachopoulos C, Wu FCW. Erectile dysfunction and cardiovascular disease: The Princeton III Consensus. Mayo Clinic Proceedings, 2012; 87:766-778.
52. Dow J, Bhandari A, Simkhovich B, Hale S, Kloner RA. The effect of acute versus delayed remote ischemic preconditioning on reperfusion induced ventricular arrhythmias. The Journal of Cardiovascular Electrophysiology, 2012;23:1374-1383.
53. Kearns-Jonker M, Dai W, Gunthart M, Fuentes T, Yeh H-Y, Gerczuk P, Pera M, Mummery C, Kloner RA. Genetically engineered mesenchymal stem cells influence gene expression in donor cardiomyocytes and the recipient heart. Journal of Stem Cell Research and Therapy, 2012; 51:005. doi:10.4172/2157-7633. S1-005.
54. Schwarz BG, Jackson G, Stecher VJ, Campoli-Richards DM, Kloner RA. Phosphodiesterase Type-5 inhibitor-induced endothelial function improvement may benefit cardiovascular conditions. Am. J. Med. 2013;126:192-199.
55. Hale SL, Herring MJ, Kloner RA. Delayed treatment with hypothermia protects against the no-reflow phenomenon despite failure to reduce infarct size. Journal of the American Heart Association. 2013;2:e004234 doi: 10.1161/JAHA.112.004234.
56. Dai W, Gerczuk P, Zhang Y, Smith L, Kopyov O, Kay GL, Jyrala A, Kloner RA. Intramyocardial injection of heart tissue-derived extracellular matrix improves post-infarction cardiac function in rats. Journal of Cardiovascular Pharmacology and Therapeutics. 2013;18:270-279.
57. Chakrabarti AK, Feeney K, Abueg C, Brown DA, Czyz E, Tendera M, Janosi A, Giugliano RP, Kloner RA, Weaver WD, Bode C, Godlewski J, Merkely B, Gibson CM for the EMBRACE-STEMI Investigation; Rational and design of the EMBRACE STEMI Study: A Phase 2a, randomized, double-blind, placebo controlled trial to evaluate the safety, tolerability and efficacy of intravenous Bendavia on reperfusion injury in patients treated with standard therapy including primary PCI and stenting for ST-segment elevation myocardial infarction. American Heart Journal, 2013;165:509-514.e7.
58. Editors of the HEART Group Journals. Statement on matching language to the type of evidence used in describing outcomes data. Journal of Cardiovascular Pharmacology and Therapeutics, 2013:18:102.
59. Nehra A, Jackson G, Miner M, Billups KL, Burnett AL, Buvat J, Carson CC, Cunningham GR, Goldstein I, Guay AT, Hackett G, Kloner RA, Kostis J, Montorsi P, Ramsey M, Rosen RC, Sadovsky R, Seftel AD, Vlachopoulos C, Wu FC. Diagnosis and treatment of erectile dysfunction for reduction of cardiovascular risk. J Urol. 2013;189:2031-2038.
60. Kloner RA. Current state of clinical translation of cardioprotective agents for acute myocardial infarction. Circulation Research. 2013;113:451-463.
61. Kloner RA, Henderson L. Sexual function in patients with chronic angina pectoris. Am. J. Cardiology. 2013;111:1671-1676.
62. Sabbah S, Salzman MMH, Kloner RA, Simkhovich BZ, Rezkalla SH. Remote ischemic preconditioning for coronary artery bypass graft surgery. The Annals of Thoracic Surgery. 2013;96:727-736.
63. Kloner RA. A brief review of useful tips for publishing your scientific manuscript. Journal of Cardiovascular Pharmacology and Therapeutics. 2013;18:197-198.
64. Jackson G, Nehra A, Miner M, Billups KL, Burnett AL, Buvat J, Carson CC, Cunningham G, Goldstein I, Guay AT, Hackett G, Kloner RA, Kostis JB, Montorsi P, Ramsey M, Rosen R, Sadovsky R, Seftel AD, Shabsigh R, Vlachopoulos C, Wu FC. The assessment of vascular risk in men with erectile dysfunction: the role of the cardiologist and general physician. International Journal of Clinical Practice. 2013 Nov;67(11):1163-72. doi:10.1111/ijcp. 12200. Epub 2013 May 28. PubMed PMID: 23714173
65. Simkhovich B, Kloner RA, Przyklenk K. Role of protein Kinase C in ischemic “conditioning”: From first evidence to current prospectives. Journal of Cardiovascular Pharmacology and Therapeutics. 2013;18:525-532.
66. Kloner RA. Can myocardial infarct size be reduced by mechanically unloading the left ventricle? Circulation. 2013;128:318-321.
67. Herring MJ, Mesbah Oskui P, Hale SL, Kloner RA. Testosterone and the cardiovascular system. A comprehensive review of the basic science literature. Journal of the American Heart Association. 2013 July 10;2(4):e000271.
68. Schwartz BG, McDonald SA, Kloner RA. The Super Bowl outcome’s association with cardiovascular death. Clinical Research in Cardiology. 2013;102:807-811.
69. Gandaglia G, Briganti A, Jackson G, Kloner RA, Montorsi F, Montorsi P, Vlachopoulos C. A systematic review of the association between erectile dysfunction and cardiovascular disease. European Urology. 2014;65:968-978.
70. Sasaki T, Hwang H, Nguyen C, Kloner RA, Kahn M. The small molecule Wnt signaling modulator ICG-001 improves contractile function in chronically infarcted rat myocardium. PLOS ONE. 2013 Sep 12;8:e75010.doi:10.1371/journal.pone.0075010.
71. Brown DA, Hale SL, Baines CP, del Rio CL, Hamlin RL, Yueyama Y, Kijtawornarat A, Yeh ST, Frasier CR, Stewart LM, Shaikh SR, Fisher-Wellman KH, Neufer PD, Kloner RA. Reduction of early reperfusion injury with the mitochondria-targeting peptide bendavia. J Cardiovasc Pharmacol Ther. 2014, 19(1):121-132.
72. Kloner RA, Hines ME, Geunes-Boyer S. Efficacy and safety of ranolazine in patients with chronic stable angina. Postgraduate Medicine. 2013 Nov;125(6): 53-61.
73. Thomas G, Kloner RA, Rezkalla S. Adverse cardiovascular, cerebrovascular, and peripheral vascular effects of marijuana inhalation: What cardiologists need to know. Am J Cardiol. 2014;113:187-190.
74. Oskui PM, French WJ, Herring MJ, Mayeda GA, Burstein S, Kloner RA. Testosterone and the cardiovascular system: A comprehensive review of the clinical literature. 2013 Nov 15;2(6):e000272. doi:10.1161/Journal of the American Heart Association.113.000272. PubMed PMID: 24242682.
75. Hale SL, VanDeripe DR, Kloner RA. Continuous heliox breathing and the extent of anatomic zone of no-reflow and necrosis following ischemia/reperfusion in the rabbit heart. The Open Cardiovascular Medicine Journal. 2014;8:1-5.
76. Miner M, Nehra A, Jackson G, Bhasin S, Billups K, Burnett AL, Buvat J, Carson C, Cunningham G, Ganz P, Goldstein I, Guay A, Hackett G, Kloner RA, Kostis JB, LaFlamme KE, Montorsi P, Ramsey M, Rosen R, Sadovsky R, Seftel A, Shabsigh R, Vlachopoulos C, Wu F. All men with vasculogenic erectile dysfunction require a cardiovascular work-up. Am J. Medicine. 2014;127:174-182.
77. Sachdeva J, Dai W, Gerczuk P, Kloner RA. Combined remote preconditioning and postconditioning failed to attenuate infarct size and contractile dysfunction in a rat model of coronary artery occlusion. Journal of Cardiovascular Pharmacology and Therapeutics. 2014 Nov;19:567-573. DOI: 10.1177/1074248413518967. PubMed PMID: 24607766.
78. Dai W, Kay GL, Kloner RA. The therapeutic effect of cell transplantation versus noncellular biomaterial implantation on cardiac structure and function following myocardial infarction. Journal of Cardiovascular Pharmacology and Therapeutics. 2014 Jan 12;19:350-357. PubMed PMID:24414282.
79. Herring MJ, Hale SL, Shi J, Oskui PM, Kay G, Kloner RA. Supraphysiological testosterone levels shorten the QT interval but do not alter total anatomic myocardial infarct size in rabbits with acute myocardial infarction. Cardiovascular Pharmacology: Open Access. 3:115. 2014; <http://dx.doi.org/10.4172/2329-6607.1000115>.
80. Oskui PM, Mayeda G. Burstein S, Gheissari A, French W, Thomas J, Kloner RA. Improved myocardial perfusion after transmyocardial laser revascularization in a patient with microvascular coronary artery disease. SAGE Open Medical Case Reports, 2014; DOI: 10.1177/2050313X14526873.
81. Rezkalla S, Kloner RA. Recreational marijuana use: Is it safe for your patient? Journal of the American Heart Association. 2014;3:e000904doi:10.116/JAHA.114.000904.
82. Herring MJ, Dai W, Hale SL, Kloner RA. Rapid induction of hypothermia by the Thermosuit system profoundly reduces infarct size and anatomic zone of no-reflow following ischemia/reperfusion in rabbit and rat hearts. J. Cardiovasc. Pharmacol and Ther. 2014 June 6. DOI:10.1. PubMed PMID: 24839185..
83. Dow J, Simkhovich B, Hale SL, Kay G, Kloner RA. Capsaicin-induced cardioprotection. Is hypothermia or the salvage kinase pathway involved? Cardiovascular Drugs and Therapy. 2014 Aug;28:295-301. DOI: 10.1007/ s10557-014-6527-8. PubMed PMID24839185.
84. Dai W, Kopyov O, Kay GL, Kloner RA. Postinfarction chondro-osteogenic mass formation occur independent of stem cell implantation in rat hearts. Experimental and Clinical Cardiology. 2014;20 (6): 4161-4188.
85. Sachdeva J, Dai W, Kloner RA. Functional and histologic assessment of an experimental model of Takotsubo’s cardiomyopathy. Journal of the American Heart Association. 2014;3:e000921 DOI:10.1161/JAHA.114.000921.
86. Hale SL, Kloner RA. Dabigatran treatment: Effects on infarct size and the no-reflow phenomenon in a model of acute myocardial ischemia/reperfusion. Journal of Thrombosis and Thombolysis. 2015: 39(1): 50-54. PMID: 25017632.
87. Dai W, Shi J, Gupta RC, Sabbah HN, Hale SL, Kloner RA. Bendavia, a mitochondrial-targeting peptide, improves post-infarction cardiac function, prevents adverse left ventricular remodeling and restores mitochondrial-related gene expression in rats. Journal of Cardiovascular Pharmacology. 2014; 64(6): 543-553. PMID: 25165999.
88. Hale SL, Kloner RA. Ranolazine treatment for myocardial infarction: Effects on the development of necrosis, left ventricular function and arrhythmias in experimental models. Cardiovascular Drugs and Therapy. 2014; Oct; 28:469-475. DOI: 10.1007/s10557-014-6548-3. PubMed PMID: 25112450.
89. Herring MJ, Hale SL, Dai W, Oskui PM, Kloner RA. Hypothermia in the setting of experimental acute myocardial infarction: A comprehensive review. Therapeutic Hypothermia and Temperature Management. 2014 ;4:159-167. PMID: 25271792.
90. Kloner RA. Testosterone and cardiovascular health: Safety of treatment of hypogonadism. Sexual Medicine Reviews. 2015; 3: 56-62.
91. Kloner RA. New observations regarding post-ischemia/reperfusion myocardial swelling. Journal of the American College of Cardiology. 2015; 65(4):324-326. PMID: 25461691
92. Oskui PM, Kloner RA, Burstein S, Zhiroff K, Kartub BR, Economides C, Brook J, Mayeda GS. The safety and efficacy of peripheral vascular procedures performed in the outpatient setting. Journal of Invasive Cardiology; 2015; 27 (5): 243-249.
93. Kloner RA, Shi J, Dai W. New therapies for reducing post-myocardial left ventricular remodeling. Ann Transl. Med. 2015; 3 (2): 20. Doi: 10.3978/j.issn.2305-5839.2015.01-13.
94. Stankowski RV, Kloner RA, Rezkalla SH. Cardiovascular consequences of cocaine use. Trends in Cardiovascular Medicine 2015; 25 (6): 517-526
95. Dow JS, Bhandari A, Hale SL, Kloner RA. Does gender influence the incidence or serverity of reperfusion-induced cardiac arrhythmias? Springer Plus, 2015; 4:96 DOI 10.1186/s40064-015-0878-x
96. Kraus AS, Pasha EP, Mackin DR, Alkatan M, Kloner RA, Tanaka H. Bilateral upper limb remote ischemic preconditioning improves anaerobic power. The Open Sports Medicine Journal 2015: 9:1-6.
97. Dai W, Herring MJ, Hale SL, Kloner RA. Rapid surface cooling by Thermo Suit system dramatically reduces scar size, prevents psot-infarction adverse left ventricular remodeling, and improves cardiac function in rats. Journal of the American Heart Association, 2015; Jun 26; 4(7). pii: e002265.doi:10.1161/JAHA.115.002265.
98. Kloner RA, Dai W, Shi J, Hale SL, Ceste M. Rebuilding the infarcted heart with non-cellular material. Regenerative Medicine. 2015; 10: 683-685; PMID: 26439904.
99. Schwartz BG, Qualls C, Kloner RA, Laskey WK. Relation of total and cardiovascular death rates to climate system, temperature, barometric pressure and respiratory infection. Am J Cardiology; 2015; 116 (8): 1290-1297.
100. Shi J, Dai W, Hale SL, Brown DA, Wang M, Han X, Kloner RA. Bendavia restores mitochondrial energy metabolism gene expression and suppresses cardiac fibrosis in the border of the infarcted heart. Life Sciences. 2015; 141: 170-178. doi: 10.1016/j.lfs.2015.09.022. Epub 2015 Oct 6. PMID: 26431885.
101. Kloner RA, Dai W, Hale S, Shi J. Approaches to improving cardiac structure and function during and after an acute myocardial infarction: acute and chronic phases. Journal of Cardiovascular Pharmacology and Therapeutics. 2016 Jul; 21 (4) : 363-367; PMID: 26612091.
102. Gibson CM, Giugliano RP, Kloner RA, Bode C, Tandera M, Janosi A, Merkely B, Godlewski J, Halaby R, Korjian S, Daaboul Y, Chakraborti A, Weaver D. EMBRACE STEMI study. A phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous Bendavia on reperfusion injury in patients undergoing primary percutaneous coronary intervention, European Heart Journal. 2016; Apr 21; 37 ( 16): 1296-1303. PMID: 26586786
103. Kloner RA. Remote ischemic conditioning. Its benefits and limitations. Journal of Cardiovasuclar Pharmacology and Therapeutics. 2016 Mar; 21 (2): 219-221. PMID: 26740183.
104. Kloner RA, Carson III C, Dobs A, Kopecky S, Mohler III ER. Testosterone and cardiovascualar disease. Journal of the American College of Cardiology. 2016; 67: 545-557. doi: 10.1016/j.jacc.2015.12.005. PMID: 26846952.
105. Rezkalla S, Kloner RA. Cardiovascular effects of marijuana. Journal of Cardiovascular Pharmacology and Therapeutics. 2016 ; 21 (5) : 452-455; doi:10.1177/107428-415627874; PMID: 26801372.
106. Kloner RA, Braunwald E. Intravenous beta-blocker for limiting myocardial infarct size: rejuvenation of a concept. J Am Coll Cardiol 2016; May 10; 67 (18): 2105-2107. PMID: 27052689.
107. Hausenloy DJ, Botker HE, Engstrom T, Erlinge D, Heusch G, Ibanez B, Janssen S, Kloner RA, Ovize M, Yellon DM, Garcia-Dorado D. Targeting reperfusion injury in STEMI patients: trials and tribulations. Eur Heart J 2017; Apr 1; 38 (13): 935-941. PMID: 27118196
108. Kloner RA. Testosterone replacement therapy: New data on efficacy and cardiovascular safety. Joural of Cardiovascular Pharmacology and Therapeutics. 2017; 22(1): 54-55; DOI: 10.1177/ 1074248416646938. PMID: 27127193.
109. Daaboul Y, Korjian S, Weaver WD, Kloner RA, Giugliano RP, Carr J, Neal BJ, Chi G, Cochet M, Goodell L, Michalak N, Rusowicz-Orazem L, Alkathery T, Allaham H, Routray S, Szlosek D, Jain P, Gibson CM. Relation of left ventricular mass and infarct size in anterior wall ST-segment elevation acute myocardial infarction (from the EMBRACE STEMI clinical trial). Am J Cardiol 2016; 118(5): 625-31; .doi: 10.1016/j.amjcard.2016.06.025. PMID: 27392509.
110. Kloner RA, Hale SL, Dai W, Shi J et al. Cardioprotection: Where do we go from here? Cardiovasc Drugs Ther 2017; 31(1): 53-61; DOI: 10.1007/s10557.016-6691-0. ; PMID 27714476
111. Dai W, Cheung E, Alleman RJ, Perry JB, Allen ME, Brown DA,, Kloner RA. Cardioprotective effects of mitochondria-targeted pepetide SBT-20 in two different models of rat ischemia/reperfusion. Cardiovasc Drugs Ther 2016; 30(6): 559-566; DOI: 10.1007/s10557-016-6695-9; PMID: 27747447.
112. Kloner RA, Chaitman B. Angina and its management. Journal of Cardiovascular Pharmacology and Therapeutics 2017; 22(3): 199-209; DOI; 10.1177/1074248416679733. PMID: 28196437.
113. Rezkalla SH, Stankowski R, Hanna J, Kloner RA. Management of no-reflow phenomenon in the catheterization laboratory. Journal of the American College of Cardiology: Cardiovascular Interventions 2017; 10(3): 215-223. PMID: 28183461.
114. Siegel PH, Dai W, Kloner RA, Csete M, Pikov V. First millimeter-wave animal in-vivo measurements of L-glucose and D-glucose: Further steps towards a non-invasive glucometer. In 2016 41st International Conference on Infrared, Millimeter, and Terahertz Waves. 2016; 1-3. doi = 10.1109/IRMMW-THz. 2016.7758908.( IEEE.2016.978-1-4653-8485-8/16.)
115. Havakuk O, King KS, Grazette L, Yoon AJ, Fong M, Bregman N, Elkayam U, Kloner RA. Heart failure induced brain injury. Journal of the American College of Cardiology 2017; 69 (12): 1609-1616. Doi:10.1016/j.jacc.2017.01.022. PMID: 28335844.
116. Dai W, Hale SL, Kloner RA. Delayed therapeutic hypothermia protects against the myocardial no-reflow phenomenon independently of myocardial infarct size in a rat ischemia/reperfusion model. International Journal of Cardiology 2017; 236:400-404. doi: 10.1016/j.ijcard.2017.01.079. PMID: 28108128.
117. Shi J, Dai W, Kloner RA. Therapeutic hypothermia reduces the inflammatory response following ischemia/reperfusion injury in rat hearts. Therapeutic Hypothermia and Temperature Management 2017; Sep; 7(3): 162-170. PMID: 28338422.
118. Pahlevan NJ, Rinderknecht DG, Tavallali P, Razavi M, Tran TT, Fong M, Kloner RA, Csete M, Gharib M. Non-invasive iphone measurement of left ventricular ejection fraction using intrinsic frequency methodology. Critical Care Medicine 2017; 45: 1115-1120. PMID: 28441235.
119. Kloner RA, Brown DA, Csete M, Dai W, Downey JM, Gottlieb RA, Hale SL, Shi J. New and revisited approaches to preserve myocardium. Nature Reviews Cardiol 2017; Nov; 14 (11): 679-693. PMID 28748958.
120. Havakuk O, Rezkalla SH, Kloner RA. The cardiovascular effects of cocaine. J Am Coll Cardiol, 2017; 70: 101-113. PMID: 28662796.
121. Kloner RA. The importance of no-reflow/microvascular obstruction in the STEMI patient. European Heart Journal 2017; 38(47): 3511-3513. PMID: 29020371.
122. Kloner RA. Mitochondrial protective agents for ischemia/reperfusion injury. Circulation: Cardiovascular Interventions. 2017 Sep; 10 (9). Pii: e005805.doi: 10.1161/CIRCINTERVENTIONS.117.005805. PMID:28916611.
123. Lindsey ML, Bolli R, Canty J, Xiao-Jun D, Frangogiannis NG, Frantz S, Gourdie R, Homes JW, Jones SP, Kloner RA, Lefer D, Liao R, Murphy E, Ping P, Przyklenk K, Recchia FA, Schwartz LL, Ripplinger CM, Van Eyk J, Heusch G. Guidelines for animal models of myocardial ischemia and infarction. Am J Physiol- Heart and Circulatory Physiology. 2018; Apr 1; 314 (4): H812-H838. doi:10.1152/ajpheart.00335.2017. PMID: 29351451.
124. Davies JMS, Cillard J, Friguet B, Cadenas E, Cadet J, Cayce R, Fishmann A, Liao D, Bulteau A-L, Debre F, Rebillard A, Burstein S, Hirsch E, Kloner RA, Jakowec M, Petzinger G, Sauce D, Sennlaub F, Limon I, Ursini F, Maiorino M, Economides C, Pike C, Cohen P, Salvayre AN, Halliday MR, Lundquist AJ, Jakowec NA, Mechta-Grigoriou F, Mericskay M, Mariani J, Li Z, Huang D, Grant E, Forman HF, Finch CE, Sun PY, Pomatto LCD, Agbulut O, Warburton D, Neri C, Rouis M, Cillard P, Capeau J, Rosenbaum J, Davies KJA. The oxygen paradox, the French paradox, and age related diseases. GeroScience. 2017; 39 (5-6): 499-550. PMID: 29270905.
125. White WB, Kloner RA, Angiolillo DJ, Davidson MH. Cardiorenal safety of over-the-counter analgesics. Journal of Cardiovacular Pharmacology and Therapeutics. 2018; 23 (2): 103-118. PMID: 29421936.
126. Dai W, Kloner RA, Shi J, Carreno J, Korjian S, Daaboul Y, Gibson MC, Bouly M, Isabelle M. Effect of diabetes on myocardial infarct and no reflow size in an experiemental rat model and clinical trial. Journal of Clincial and Experimental Cardiology. 2017; 8:12 DOI: 10.4172/2155-9880.1000560.
127. Kloner RA, Dai W, Hale SL. No-reflow phenomenon. A new target for therapy of acute myocardial infarction independent of myocardial infarct size. Journal of Cardiovascular Pharmacology and Therapeutics. 2018 May; 23(3): 273-276. PMID: 29658348.
128. Kloner RA, Goggin P, Goldstein I, Hackett G, Kirby MG, Osterloh I, Parker J, Sadovsky R. A new perspective on the nitrate phosphodiesterase type 5 inhibitor interaction. Journal of Cardiovascular Pharmacology and Therapeutics 2018. Sep ; 23(5): 375-386. Doi: 10.1177/1074248418771896. [Epub 2018 May 8 ] PMID: 29739235..
129. Kloner RA, Goldstein I, Kirby MG, Parker JD, Sadovsky R. Cardiovascular safety of phosphodiesterase type 5 inhibitors after nearly 2 decades on the market. Sexual Medicine Reviews. 2018 Jun27.pii:S2050-0521 (18)30053-2. Doi:10.1016/j.sxmr.2018.03.008. [Epub ahead of print].PMID:29960874.
130. Sharkey SW, Maron BJ, Kloner RA. The case for Takotsubo cardiomyopathy (syndrome) as a variant of acute myocardial infarction. Circulation 2018; 138: 855-857. PMID: 30354447.
131. Kloner RA, King KS, Harrington MG. No-reflow phenomenon in heart and brain. American Journal of Physiology-Heart and Circulatory Phsyiology 2018 Sep 1; 315(3): H550-H562; doi:10.1152/ajpheart.00183.2018. [Epub 2018 Jun 8.]. PMID: 29882685.
132. Kloner RA, Gross C, Yuan J, Conrad A, Pergola PE. Effect of patiromer in hyperkalemic patients taking and not taking RAAS inhibitors. Journal of Cardiovascular Pharmacology and Therapeutics 2018 Nov; 23 (6):524-531. doi:10.1177/1074248418788334.[Epub 2018 Aug 14.]. PMID: 30103622
133. Taylor DG, Giuliano F, Hackett G, Hermes-DeSantis E, Kirby MG, Kloner RA, Magguire T, Strecher V, Goggin P. The pharmacist’s role in improving the treatment of erectile dysfunction and its underlying causes. Res Social Adm Pharm . 2019 May ; 15(5): 591-599. PMID:30057329.
134. Schwartz BG, Kloner RA, Naghavi M. Acute and sub-acute triggers of cardiovascular events. Am J Cardiol, 2018 Dec 15: 122 (12):2157-2156.doi: 10.1016/j.amjcard.2018.08.049. Epub 2018 Sep 13. PMID: 30309628.
135. Kloner RA. A thank you from the Editor-in-Chief. Journal of Cardiovascular Pharmacology and Therapeutics. 2019 , 24 (1) 90-91. PMID 30428713.
136. Allencherril J, Alam M, Levine G, Jneid H, Atar D, Kloner RA, Birnbaum Y. Do we need potent antiplatelet inhibition at the time of reperfusion during ST-elevation myocardial infarction? Journal of Cardiovascular Pharmacology and Therapeutics. 2019; May; 24(3):215-224. PMID: 30563349.
137. Rezkalla S, Kloner RA. Cardiovascular Effects of Marijuana. Trends in Cardiovascular Disease. 2019; Oct; 29(7); 403-407.PMID: 30447899.
138. Curran J, Burkhoff D, Kloner RA. Beyond reperfusion: Acute ventricular unloading and cardioprotection during myocardial infarction. Journal of Cardiovascular Translational Research, 2019 Apr; 12(2): 95-106. PMID: 30671717.
139. Dai W, Shi J, Carreno J, Hale SL, Kloner RA. Improved long-term survival with remote limb ischemic preconditioning in a rat fixed-pressure hemorrhagic shock model. Cardiovascular Drugs and Therapy. 2019; Apr;33(2): 139-147. PMID: 30747397.
140. Chandrasekaran U, Burkhoff D, Ishikawa K, Swain L, Sunagawa K, Moller J, Santos-Gallego C, Annamalai S, Udelson J, Westenfeld R, Kapur N, Qiao X, Wiora J, Schafer A. Bernhardt A, Kochar A, Kloner R, Faraz H. Proceedings of the 3rd Annual Acute Cardiac Unloading and REcovery ( A-CURE) symposium. BMC Cardiovascular Disorders 2019, Feb 7; 19 ( Suppl 2): 27 https;//doi.org/10.1186/s12872-019-1000-z. PMID: 30732562.
141. Kloner RA. The brain-heart connection and the Northridge Earthquake. Cardiology in Review. 2019 Jul/Aug: 27 (4): 171-172. PMID: 31008772.
142. Shi J, Dai W, Carreno J, Hale SL , Kloner RA, Kay Gl. Myocardial hypothermia induced after reperfusion does not prevent adverse left ventricular remodeling nor improve cardiac function. Life Sciences. 2019; 229: 98-103. PMID: 30991060.
143. Naghavi M, Maron DJ, Kloner RA, Berman DS, Budoff M, Superko HR, Shah PK. Coronary artery calcium testing: A call for universal coverage. Preventive Medicine Reports. 2019; May 2; 15: 100879. doi:10.1016/j.pmedr.2019.100879. eCollection 2019 Sep. PMID: 31193256.
144. Kloner RA, Hale SL, Dai W. Potential for stem cell derived biologic pumps for cardiovascular and other medical therapies. Regenerative Medicine. 2019 Jul;14(7):617-619. PMID 31313635.
145. Kloner RA. Lessons learned about stress and the heart after major earthquakes. American Heart Journal. 2019 Sep; 215: 20-26. PMID: 31260902.
146. Allencherril J, Alam M, Levine G, Jneid H, Atar D, Kloner RA, Birnbaum Y. Pathophysiology, Diagnosis, and Management of the No-Reflow Phenomenon. Cardiovascular Drugs and Therapy. 2019 Oct; 33(5): 589-597. PMID: 31418141.
147. Kloner RA. Editorial commentary: Continuing concerns about the cardiovascular safety of marijuana. Trends in Cardiovascular Medicine 2019 Sep 3.pii:S1050-1738(19)30126-4. Doi:10.1016/j.tcm.2019.08.008.[Epub ahead of print]. PMID 31506214.
148. Kloner RA, Shi J, Dai W, Carreno J, Zhao L. Remote ischemic conditioning in acute myocardial infarction and shock states. J Cardiovascular Pharmacology and Therapeutics. 2020 Mar;25(2):103-109. PMID: 31823646 [ -in process].
149. Konijnenberg LSF, Damman P, Duncker DJ, Kloner RA, Nijveldt R, van Guens RJ, Berry C, Riksen NP, Escaned J, van Royden N. Pathophysiology and diagnosis of coronary microvascular dyfunction in ST-elevation myocardial infarction. Cardiovasc Res 2020;116(4):787-805. Doi:10.1093/cvr/cvz301.
150. Kloner RA. Stunned and hibernating myocardium: Where are we nearly 4 decades later? Journal of the American Heart Association. 2020 Feb 4;9(3):e015502.doi:10.1161/JAHA.119.015502. Epub 2020 Feb 4. PMID: 32013699 [-in process].
151. Dai W, Shi J, Carreno J, Hale S, Kloner RA. Different effects of volatile and non-volatile anesthetic agents on long-term survival in an experimental model of hemorrhagic shock. Journal of Cardiovascular Pharmacology and Therapeutics. 2020; Jul;25(4):346-353. Doi: 10.1177/1074248420919221. Epub 2020 Apr 15. PMID: 32292050.
152. Mogadam E, King K, Shriner K, Chu K, Sondergaard A, Young k, Naghvi M, Kloner RA. The association of nadir CD4-T cell count and endothelial dysfunction in a healthy HIV cohort without major cardiovascular risk factore. SAGE Open Medicine 2020 May 26;8:2050312120924892. DOI:10.1177/2050312120924892. eCollection 2020. PMID:32537154.
153. Shi J, Dai W, Carreno J, Zhao L, Kloner RA. Therapeutic hypothermia improves long term survival and blunts inflammation in rats during resuscitation and hemorrhagic shock. Therapeutic hypothermia and temperature management. 2020 Dec; 10(4);237-243. doi:10.1089/ther.2020.0024.Epub 2020 Aug 20. PMID: 32833603.
154. Page RL 2nd, Allen LA, Kloner RA, Carriker CR, Martel C, Morris AA, Piano MR, Rana JS, Saucedo JF, American Heart Association et al. Medical Marijuana, recreational cannabis, and cardiovascular health: A scientific statement from the American Heart Association. Circulation. 2020 Sep 8 ;142(10):e131-e152.doi:10.1161/CIR.0000000000000883. Epub 2020 Aug5. PMID: 32752884.
155. Kleinman MT, Arechavala RJ, Herman D, Shi J, Hasen I, Ting A, Dai W, Carreno J, Chavez J, Zhao L, Kloner RA. EVALI produced in an animal model from electronic cigarette (eC) vapor exposure without TCH or Vitamin E oil. Journal of the American Heart Association; 2020 Sep 15;9 (18):e017368. Doi: 10.1161/JAHA.120.017368.Epub 2020 Sep 8. PMID: 32896206.
156. Zhao L, Dai W, Carreno J, Shi J, Kleinman M, Kloner RA. Acute administration of nicotine induces transient elevation of blood pressure and increases myocardial infarct size in rats. Heliyon. 2020 Nov 16;6(11):e05450.doi:10.1016/j.heliyon.2020.e05450. eCollection 2020 Nov. PMID:33251352.
157. Dai W, Amoedo ND, Perry J, Le Grand B, Boucard A, Carreno J, Zhao L, Brown DA, Rossignol R, Kloner RA. Effects of OP2113 on myocardial infarct size and no reflow in a rat myocardial ischemia/reperfusion model. Cardiovascular Drugs and Therapy. 2021 Feb 8. Doi: 10.1007/s10557-020-07113-7. Online ahead of pirnt. PMID: 33555510.
158. Umbrajkar S, Stankowski RV, Rezkalla S, Kloner RA. Cardiovascular health and disease in the context of COVID-19. Cardiology Research. 2021 Apr;12(2):67-79.doi:10.14740/cr1199. Epub 2021 Feb 23. PMID: 33738009.
159. Rezkalla SH, Kloner RA. Viral myocarditis: 1917-2020: From the influenza A to the COVID-19 pandemics. Trends in Cardiovascular Medicine. 2021 Apr;31(3):163-169.doi: 10.1016/j.tcm.2020.12.007. Epub 2020 Dec 29. PMID:33383171.
160. Tarran R, Barr RG, Benowitz NL, Bhatnagar A, Chu HW, Dalton P, Doerschuk CM, Drummond MB, Gold DR, Goniewicz ML, Gross ER, Hansel NN, Hopke PK, Kloner RA, Mikheev VB, Neczypor EW, Pinkerton KE, Postow L, Rahman I, Samet JM, Salathe M, Stoney CM, Tsao PS, Widome R, Xia T, Xiao D, Wold LE. E-cigarettes and cardiopulmonary health. Function (Oxf). 2021 Feb 8;2(2):zqab004. Doi:10.1093/function/zqab004.eCollection 2021. PMID: 33748758.
161. Beijnink C, van der Hoeven N, Konijnenberg L, Kim R, Bekkers S, Kloner RA, Everaars H, el Messaoudi S, van Rossum AC, van Royen, N, Nijveldt R. Cardiac magnetic resonance to visualize myocardial damage after ST-elevation myocardial infarction: A review of its histologic validation. Radiology. 2021 Oct; 301( 1):4-18 .doi:10.1148/radiol.2021204265. Epub 2021 Aug 24. PMID: 34427461.
162. Rollman JE, Kloner RA, Bosson N, Niemann JT, Gausche-Hill M, Williams M, Clare C, Tan W, Wang X, Shavelle DM, Rafique AM. Emergency medical services respsonses to cardiac arrest and suspected ST-elevation during the COVID-19 pandemic in Los Angeles County. Journal of the American Heart Association. 2021; 10:e019635.DOI: 10.1161/JAHA.120.019635. PMID: 34058862.
163. Rezkalla S, Kloner RA. Post-acute sequelae of SARS-COVID-2 ( PASC) Syndrome: Just the beginning. Cardiology Research. 2021; Oct.12 (5): 279-285. Doi:10.14740/cr1290. Epub 2021 Aug 31. PMID: 34691325.
164. Kloner RA. Treating acute myocardial infarctions with anti-inflammatory agents. Journal of Cardiovascular Pharmacology and Therapeutics. 2021 Nov; 26(6): 736-738. Doi:10.1177/10742484211033711. Epub 2021 Jul 30. PMID: 34328816.
165. Kloner RA, Creech JL, Stone GW, O’Neill WW, Burkhoff D, Spears JR. Update on cardioprotective strategies for STEMI: Focus on supersaturated oxygen delivery. Journal of the American College of Cardiology: Basic to Translational Science. 2021; [Volume 6, Issue 12](https://www.sciencedirect.com/science/journal/2452302X/6/12), December 2021, Pages 1021-1033 ; <https://doi.org/10.1016/j.jacbts.2021.07.011>. PMID: 35024508.
166. Alavi R, Dai W, Amlani F, Rinderknecht DG, Kloner RA, Pahlevan NM. Scalability of cardiovascular intrinsic frequencies: validation in preclinical modesl and non-invasive clinical studies. Life Sciences. 2021. Nov 1;284; 119880. doi: 10.1016/j.lfs.2021.119880. Epub 2021 Aug 10. PMID: 34389404.
167. Roy S, Kloner RA, Salloum FD, Jovin IS. Cardiac effects of phosphodiesterase-5 inhibitors: Efficacy and safety. Cardiovascular Drugs and Therapy. 2021 Oct 15.doi: 10.1007/s10557-021-07275-y. Online ahead of print PMID: 34652581.
168. Arechavala RJ, Rochart R, Kloner RA, Liu A, Wu D-A, Hung S-M, Shimojo S, Fonteh AN, Kleinman MT, Harrington MG, Arakaki X. Task switching reveals abnormal brain-heart electrophysiological signatures in cognitively healthy individuals with abnormal amyloid/tau, a pilot study. International Journal of Psychophysiology. 2021 Oct 17;170: 102-111.doi:10.1016/j.ijpsycho.2021.10.007.online ahead of print. PMID:34666107.
169. Kloner RA, Kostis J, Qiu C, Gupta A, McGraw T. Analysis of integrated clinical safety data of tadalafil in patients receiving concomitant antihypertensive medications. The Journal of Clinical Hypertension. (Greenwich). 2022 Feb; 24(2): 167-178. PMID: 35099113.
170. Agrud A, Subburaju S, Goel P, Ren J, Kumar AS, Caldarone BA, Dai W, Chavez J, Fukumura, Jain Rk, Kloner RA, Vasudevan A. Gabrb3 endothelial cell-specific knockout mice display Abnormal blood flow, hypertension, and behavioral dysfunction. Sci Rep 2022 Mar 22: 12(1): 4922. Doi: 10.1038/s41598-022-08806-9. PMID: 35318369.
171. Bosson N, Rollman JE, Kloner RA, Shavelle DM, Saver JL, Niemann JT, Rafique AM, Wang X, Clare C, Gausce-Hill M. The correlation between COVID-19 hospitalizations and emergency medical services responses for time-sensitive emergencies during the COVID-19 pandemic. Prehospital Emergency Care. 2023; Vol 27; No.3: 321-327. doi: 10.1080/10903127.2022.2112792. PMID: 35969017.
172. Kloner RA, Stanek E, Crowe CL, Singhal M, Pepe RS, Bradsher J, Rosen RC. The effect of PDE-5 inhibitors on major cardiovascular events and overall mortality in a large, nationwide cohort of men with erectile dysfunction and cardiovascular risk factors: A retrospective, observational study based on healthcare claims and national death index data. Journal of Sexual Medicine, 2023, Jan 14; 20(1):38-48. Doi: 10.1093/jsmed/qdac005.PMID:36897243.
173. Kloner RA. Marijuana and electronic cigarettes on cardiac arrhtyhmias. Heart Rhythm. 2023; 20:87-88:PMID: 36603938.
174. Shi J, Dai W, Chavez J, Carreno J, Zhao L, Kleinman MT, Arechavala RJ, Hasen I, Ting A, Bliss B, Monterrosa Mena JE, Kloner RA. One acute exposure to e-cigarette smoke using various heating elements and power levels induces pulmonary inflammation. Cardiology Research, 2022; 13: 323-332. PMID: 36660061.
175. Dai W, Shi J, Siddarth P, Zhao L, Carreno J, Kleinman MT, Herman DA, Arechavala R, Renusch S, Hasen I, Ting A, Kloner RA. Effects of electronic cigarette exposure on myocardial infarction and no-reflow, and cardiac function in a rat model. Journal of Cardiovascular Pharmacology and Therapeutics. 2023 Jan-Dec; 28:10742484231155992. Doi: 10.1177/10742484231155992. PMID: 36799436.
176. Arakaki X, Arechavala R, Choy EH, Bautista J, Bliss B, Molloy C, Wu D-A, Shimojo S, Jiang Y, Kleinman MT, Kloner RA. The connection between heart rate variability (HRV), neurological health, and congnition. Frontiers of Neuroscience, 2023 Mar1:17:1055445. Doi: 10.3389/fnins.2023.1055445.PMID: 36937689.
177. Rezkalla SH, Kloner RA. Invasive versus conservative management in coronary artery disease. Clinical Medicine and Research. 2023; 21: 95-104. PMID: 37407216.
178. Molloy C, Choy EH, Arechavala RJ, Buennagel D, Nolty A, Spezzaferi M, Sin C, Rising S, Yu J, Al-Ezzi A, Kleinman MT, Kloner RA, Arakaki X. Resting heart rate (variability) and cognition relationships reveal cognitively healty individuals with pathological amyloid/tau ratio. Frontiers in Epidemiology. 2023; May 26. DOI: 10.3389/fepid.2023.1168847. PMID: 37587981.
179. Demirkiran A, Beijnink C, Kloner RA, Hopman LHGA, van der Hoeven NW, van Pouderoijen N, Janssens GN, Everaars H, van Leeuwen MAH, van Rossum AC, van Royen N, Robbers LFHJ, Nijveldt R. Impact of symptom-to-reperfusion-time on transmural infarct extent and left ventricular strain in patients with ST-segment elevation myocardial infarction: a 3-dimensional view on the wavefront phenomenon. European Heart Journal-Cardiovascular Imaging., European Heart Journal-Cardiovascular Imaging 2024; 25: 347-355. PMID : 37812691.
180. Alavi R, Dai W, Matthews RV, Kloner RA, Pahlevan NM. Instantaneous detection of acute myoardail infarction and ischemia from a single carotid pressure wavefrom in rats. European Heart Journal Open. 2023 Oct 3; 3(5) : oead099.doi:10.1093/ehjopen/oead099.PMID: 37849787.
181. Kloner RA, Burnett A, Miner M, Blaha MJ, Ganz P, Goldstein I, Kim NN, Kohler T, Lue T, McVary KT, Mulhall J, Parish SJ, Sadeghi-Nejad H, Sadovsky R, Sharlip ID, Rosen RC. Princeton IV Consensus Guidelines: PDE-5 inhibitors and cardiac health. Journal of Sexual Medicine. 2024; Jan 30; 21 (2): 90-116. PMID: 38148297.
182. Sachdeva J, Karunananthan A, Shi S, Dai W, Kleinman MT, Herman D, Kloner RA. ( Nov 18, 2023) Flavoring agents in e-cigarette liquids: A comprehensive analysis of multiple health risks. Cureus. 2023 Nov 18; 15 (11): e48995.doi:10.7759/cureus.48995. PMID: 38111420.
183. Shavelle DM, Bosson N, French WJ, Thomas JL, Niemann JT, Gausche-Hill M, Rollman JE, Rafque AM, Klomhaus AM, Kloner RA. Association of the COVID-19 pandemic on treatments times for ST-elevation myocardial infarction. Observations from the Los Angeles County Regional System. Am J Cardiology, 2024; Feb 15; 213:93-98. PMID:38016494.
184. Corradetti G, Oncel D, Kadamoto S, Arakaki X, Kloner RA, Sadun AA, Sadda SV, Chan JW. Choriocapillaris and Retinal Vascular Alterations in Presymptomatic Alzheimer’s Disease. IVOS. Investigative Ophthalmology and Visual Science. 2024; Jan 2; 65(1): 47.doi:10.1167/ivos.65.1.47.PMID:38294804.
185. Kloner RA, Stanek E, Desai K, Crowe CL, Paige Ball K, Haynes A, Rosen RC. The association of tadalafil exposure with lower rates of major adverse cardiovascular events and mortality in a general population of men with erectile dysfunction. Clinical Cardiology 2024; Feb; 47(2):e24234. Doi: 10.1002/clc.24234. PMID: 38377018.
186. Rezkalla SH, Kloner RA. An urgent call for studies that address the cardiovascular consequences of legalization of marijuana. Cardiology Research. 2024; Apr; 15 (2) : 86-89.
187. Dai W, Shi J, Siddarth P, Carreno J, Kleinman MT, Herman DA, Arechavala RJ, Renusch S, Hasen I , Ting A, Kloner RA. Effects of electronic cigarette vaping on cardiac and vascular function, and post-myocardial infarction remodeling in rats. Cardiovascular Toxicology. 2024 Feb; 24(2): 199-208. PMID: 38340234. <https://doi.org/10.1007/s12012-024-09835-8>.
188. Rosen RC, Miner M, Burnett AL, Blaha MJ, Ganz P, Goldstein I, Kim NN, Kohler T, Lue T, McVary KT, Mulhall J, Parish SJ, Sadeghi-Nejad H, Sadovsky R, Sharlip ID, Kloner RA. Proceedings of Princeton IV: PDE-5 inhibitors and cardiac health symposium. Sexual Med Rev. 2024 Jun 27: qeae043.doi:10.1093/sxmrev/qeae043. Epub ahead of print. PMID: 38936840 .
189. Kohler TS, Kloner RA, Rosen RC, Burnett AL, Blaha MJ, Ganz P, Goldstein I, Kim NN, Lue T, McVary KT, Mulhall JP, Parish SJ, Sadeghi-Nejad H, Sadovsky R, Sharlip ID, Miner M. The Princeton IV consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clinic Proceedings. In press, 2024.
190. Alavi R, Dai W, Mazandarani S, Arechavala R, Herman D, Kleinman M, Kloner R, Pahlevan N. Adverse cardiovascular effects of nicotine delivered by chronic E-cigarete or standard cigarette captured by cardiovascular intrinsic frequencies Journal of the American Heart Association. In press, 2024.
191. Al-Ezzi, Arechavala RJ, Butler R, Nolty A, Kang JJ, Shimojo S, Wu D-A, Fonteh AN, Kleinman M, Kloner RA, Arakaki X. Dispruted brain functional connectivity as early signature in cognitively healthy individuals with pathological CSF amyloid/tau. Communications Biology, in press 2024.

**RECENT LETTERS**

1. Cohen JS, Kloner RA, Siegel RL. Sildenafil and non-nitrate antihypertensive medications. JAMA, January 2000; 283:201-202
2. Rezkalla SH, Kloner RA. Response to “No ­ Reflow Phenomenon.” Hellstrom HR. Circulation 2002; 106:e143.
3. Reffelmann T, Kloner RA. Cardiovascular effects of sildenafil in experimental ischemia ­ reperfusion (reply to “sildenafil ­ induced cardioprotection in rabbits” by Kukreja RC, Ockaili R, Solloum F, Xi L). Cardiovasc. Res 2003; 60:702-703.
4. Philips RA, Kloner RA, Grimm R, Weinberger M. Author’s response to “Amlodipine and Losartan: Reaction to Comparison,” Gleim GW, Smith RD. J. Clin Hypertension 2003:V:424.
5. Kloner RA, Hutter AM, Emmick JJ, Mitchell MI, Denne J, Jackson G. Reply to letter to the editor by Abrams J. Re: “Time course of the interaction between tadalafil and nitrates.” J. Am. Coll. Cardiol 2004; 43:2150-2151.
6. Ross AM, Gibbons RJ, Stone GW, Kloner RA, Alexander RW. Reply. J Am Coll Cardol 2006; 47:1236-1237.
7. Kloner RA, Rezkalla S. Response to letter by Stranges. Circulation 2008; 117(6):e160.
8. Kloner RA, Wishner SH, Landgraf J. Reply. Am J. Cardiol 2010; 106:1524-1525.
9. Kloner RA, McDonald S. Authors reply to letter by Culic. Clin Cardiol, 2011; 34:462.
10. Schwartz B, Kloner RA. Authors reply to letter by Nunes regarding article “Physician update: Erectile dysfunction and cardiovascular disease.” Circulation, 2011;124:e253.
11. Stankowski RV, Kloner RA, Rezkalla SH. Letter to the editor, Response. Trends in Cardiovasc Med 2015; May12.pii.S1050-1738 (15) 00140-1. Doi: 10.10161j.tcm2015.05.003.

**CHAPTERS, BOOKS, MONOGRAPHS**

1. Braunwald E, Kloner RA, Hillis LD, Maclean D, Maroko PR. The use of hyaluronidase in the limitation of infarct size following acute coronary occlusion. Experimental and clinical results. In: Hjalmarson A, Wilhelmsen L, eds, Acute and Long-Term Management of Myocardial Ischemia. Sweden, 1978;358-372.
2. Maroko PR, Kloner RA, Yasuda T, Ribeiro LGT, Maclean D, Braunwald E. Recent investigations on attempts to limit infarct size. In: Hjalmarson A, Wilhelmsen L, eds, Acute and Long-Term Management of Myocardial Ischemia, Sweden, 1978;203-220.
3. Maroko PR, Kloner RA, Gold HK, Braunwald E. Propranolol in acute myocardial infarction: Experimental and clinical consideration. In: Beta-Adrenergic Blockade, A New Era in Cardiovascular Medicine. Excerpta Medica 1978;154-170.
4. Braunwald E, Kloner RA, Maroko PR. Effects of beta adrenergic blockade on myocardial ischemia and infarct size. In: Gross F, ed, Modulation of Sympathetic Tone in the Treatment of Cardiovascular Diseases. Bern Stuttgart, Vienna: Hans Huber Publishers, 1979;79-92.
5. Maroko PR, Muller JE, Kloner RA, Braunwald E. The use of electrocar­diographic parameters to assess alterations in myocardial ischemic damage. In: Rapaport E, ed, Current Controversies in Cardiovascular Disease. Philadelphia: WB Saunders, 1980;257-280.
6. Kloner RA, Braunwald E. Review: Observations on experimental myocardial ischemia. Cardiovasc Res 1980;14:371-395.
7. Muller JE, Kloner RA, Mudge GH, Barry WH, Koster JK, Cohn LH. The complementary use of nifedipine and coronary artery bypass grafting in patients with Prinzmetal's angina. In: Mason DT, Collins JJ Jr, eds, Myocardial Revascularization. Yorke Medical Books, 1981;104-113.
8. Jennings RB, Kloner RA, Ganote CE, Hawkins HK, Reimer KA. Changes in capillary fine structure and function in acute myocardial ischemia. In: Tillmanns H, Kuebler W, Zebe H, eds, Microcirculation of the Heart. Berlin: Springer-Verlag, 1982;87-97.
9. Kloner RA, Lange R, Ellis SE, Hammerman H, Braunwald E. Reducing myocardial infarct size by coronary reperfusion and pharmacologic interventions. In: Wellens HJJ, Kulbertus HE, eds, The First Year After a Myocardial Infarction. New York: Futura Publishing Co., Inc. 1983;105-117.
10. Kloner RA. Reducing myocardial infarct size. Drug Therapy 1983;8:64-75.
11. Chapters in: Cardiology Reference Book. New York: Science and Medicine Publishing Co., 1980.
	1. Kloner RA. Acute myocardial infarction. In: Cardiology Reference Book. New York: Science and Medicine Publishing Co., 1980;35-55.
	2. Kloner RA. Mitral and aortic valve disease. In: Cardiology Reference Book. New York: Science and Medicine Publishing Co., 1980;100-110.
	3. Kloner RA. Cardiomyopathies. In: Cardiology Reference Book. New York: Science and Medicine Publishing Co., 1980;90-96.
	4. Kloner RA. Etiologies of pericarditis. In: Cardiology Refer­ence Book. New York: Science and Medicine Publishing Co., 1980;97-99.
12. Kloner RA. The coronary microvasculature and ischemic injury. In: Kalsner S, ed, The Coronary Artery. London: Croom Helm Ltd, 1982;621-643.
13. Braunwald E, Muller JE, Kloner RA. Effects of beta-adrenergic blockade in acute myocardial infarction. In: Riemersma RA, Oliver MF, eds, Catechol­amines in the Non-ischaemic and Ischaemic Myocardium. Amersterdam: Elsevier Biomedical Press, 1982;225-240.
14. Glogar DH, Clark LC Jr, Kloner RA, DeBoer LWV, Muller JE, Braunwald E. Reduction of myocardial ischemia by a stabilized F-Decalin emulsion. In: Frey R, Beisbarth H, Stosseck K, eds, Oxygen Carrying Colloidal Blood Substitutes. Germany: W. Zuckschwerdt Verlag, 1982;109-115.
15. Kloner RA, Glogar D, Rude RE, Khuri SF, Muller JE, Clark LC Jr, Braunwald E. The effect of fluorocarbons on experimental myocardial ischemia and infarction. In: Geyer RP, Bolin RB, eds, Proceedings of the International Symposium on Blood Substitutes. Prog Clin Biol Res, New York, Alan R Liss, Inc., 1983;381-390.
16. Chapters in: Cardiology Reference Book. Second Edition. New York: Co Medica, Inc., 1984.
	1. Kloner RA. Acute myocardial infarction. In: Cardiology Reference Book. New York: Co Medica, Inc., 1984; 2nd edition, 64-85.
	2. Kloner RA. Mitral and aortic valve disease. In: Cardiology Reference Book. New York: Co Medica, Inc., 1984; 2nd edition, 111-124.
	3. Kloner RA. Etiologies of Pericarditis. In: Cardiology Reference Book. New York: Co Medica, Inc., 1984; 2nd edition, 107-108.
17. Chapters in: Kloner RA, ed, the Guide to Cardiology. New York: John Wiley and Sons, Inc., 1984.
	1. Kloner RA. The cardiac history. In: Kloner RA, ed. The Guide to Cardiology. New York: John Wiley and Sons, Inc., 1984;1-7.
	2. Kloner RA. Physical examination. In: Kloner RA, ed. The Guide to Cardiology. New York: John Wiley and Sons, Inc., 1984;9-25.
	3. Orringer CE, Kloner RA. Echocardiography, jugular and arterial pulse tracings. Section 3: Systolic time intervals. In: Kloner RA, ed. The Guide to Cardiology. New York: John Wiley and Sons, Inc., 1984;106-110.
	4. Brown EJ Jr., Kloner RA. Angina pectoris. In: Kloner RA, ed. The Guide to Cardiology. New York: John Wiley and Sons, Inc., 1884;181-208.
	5. Kloner RA. Acute myocardial infarctions. In: Kloner RA, ed. The Guide to Cardiology. New York: John Wiley and Sons, Inc., 1984;221-250.
	6. Rutherford JD, Kloner RA. Newer modes of therapy for acute myocardial infarction. In: Kloner RA, ed, The Guide to Cardiology. New York: John Wiley and Sons, Inc., 1984;251-263.
	7. Kloner RA. Valvular Heart Disease. In: Kloner RA, ed. The Guide to Cardiology. New York: John Wiley and Sons, Inc., 1984;265-295.
	8. Kloner RA. Cardiomyopathy. In: Kloner RA, ed. The Guide to Cardiology. New York: John Wiley and Sons, Inc., 1984;297-312.
	9. Kloner RA. Myocarditis. In: Kloner RA, ed. The Guide to Cardiology. New York: John Wiley and Sons, Inc., 1984;313-317.
	10. Dzau VJ, Kloner RA. Heart failure. In: Kloner RA, ed. The Guide to Cardiology. New York: John Wiley and Sons, Inc., 1984;377-405.
	11. Hammerman H, Kloner RA. Pericardial disease. In: Kloner RA, ed. The Guide to to Cardiology. New York: John Wiley and Sons, Inc., 1984;407-423
	12. Lilly L, Kloner RA. Endocarditis. In: Kloner RA, ed. The Guide to Cardiology. New York: John Wiley and Sons, Inc., 1984;425-437.
	13. Kloner RA. Cardiac tumors. In: Kloner RA, ed. The Guide to Cardiology. New York: John Wiley and Sons, Inc., 1984;439-445.
	14. Kloner RA. Pulmonary hypertensions. In: Kloner RA, ed. The Guide to Cardiology. New York: John Wiley and Sons, Inc., 1984;475-482.
18. Kloner RA, Glogar D. An overview of the use of fluorocarbons for myocardial ischemic rescue. In: Tremper KK, ed, International Anesthe­siology Clinics on Perfluorochemical Oxygen Transport, 1985;23:115-130.
19. Kloner RA, Mudge GH. Left ventricular pseudoaneurysm after myocardial infarction and steroid therapy. In: Clinical Dilemmas in Cardiology. New Jersey: HealthScan, Inc.,1983;1:1-3.
20. Internal Medicine Case Studies. New York: Medical Examination Publishing Co., Inc., 1984.
	1. Lee T, Kloner RA. Hypertrophic obstructive cardiomyopathy. In: Case Studies in Internal Medicine. New York: Medical Examination Publishing Co., Inc., 1984;3-16.
	2. Lee T, Kloner RA. Aortic insufficiency. In: Case Studies in Internal Medicine. New York: Medical Examination Publishing Co., Inc., 1984;17-25.
	3. Lee T, Kloner RA. Viral Myocarditis. In: Case Studies in Internal Medicine. New York: Medical Examination Publishing Co., Inc., 1984;26-34.
	4. Lee T, Kloner RA. Effusive-constrictive pericarditis. In: Case Studies in Internal Medicine. New York: Medical Examination Publishing Co., Inc., 1984;35-46.
	5. Lee T, Kloner RA. Acute myocardial infarction. In: Case Studies in Internal Medicine. New York: Medical Examination Publishing Co., Inc., 1984;47-58.
21. Lee T, Kloner RA. Critical Decisions in Medicine: "Sudden Onset Back Pain." New York: Park Row Publishers, 1984;1-13. Also video-cassette "Critical Decisions in Medicine: Sudden Onset Back Pain." New York: Park Row Publishers, 1984 (winner of Red Ribbon Award [tie] at 27th Annual American Film Festival in category of Medical Sciences, 1985).
22. Kloner RA, Przyklenk K, Lange R, Ellis S. Reperfusion Pathophysiology. In: Roberts AJ, ed. Myocardial Protection in Cardiac Surgery. New York and Basel: Marcel Dekker, Inc., 1987;29-52.
23. Kloner RA. The effect of non-steroidal anti-inflammatory agents on myocardial infarct healing. Clinical Cardiology Alert, 1985;4:30.
24. Kloner RA. Spotlight on Health: Heart Murmurs. In: Health and Medical Horizons. Macmillan Educational Co., New York, 1986;209-211.
25. Kloner RA. Comments on "Intravenous recombinant tissue-type plasminogen activator in patients with acute myocardial infarction: a report from the NHLBI thrombolysis in myocardial infarction trial" by Williams D.O. et al, in Cardiac Chronicle, 1986;Vol. 1, No. 2:9-10.
26. Kloner RA, Aldajani O. Critical Decisions in Medicine: "Cardiac Complications in a Woman with Transient Ischemia Attacks." New York: Park Row Publishers, 1986;Vol. 3:1-7. Also video cassette (same title, 1986).
27. Przyklenk K, Kloner RA. Free Radicals: Role in Ischemia and Infarction. CARDIO, 1986;Vol. 3, No. 11:55-58.
28. Kloner RA. Comments on "Myocardial Protection During Transient Coronary Artery Occlusion in Man: Beneficial Effects of Regional Beta-Adrenergic Blockade," by Zalewski et al. In: Cardiac Chronicle, 1986;Vol. 1, No. 10: 10-11.
29. Kloner RA, Kirshenbaum JM. Short-action beta blockade with esmolol. CARDIO, 1987;Vol. 4, No. 3:69.
30. Kloner RA, Peters P, Bassett J, Wynne J. The Sandoz Diagnostic Challenge: Diagnostic Challenges in Cardiology. Case 2: Dyspnea and chest discomfort in a young patient post MI and ventricular aneurysmectomy. Presented at the American College of Cardiology meetings, March 10, 1987.
31. Przyklenk K, Kloner RA. Acute effects of antioxidants on in vivo models of experimental myocardial ischemia and infarction. In: Singal PK, ed, Oxygen Radicals in the Pathophysiology of Heart Disease. Kluwer Academic Publishers, Boston, 1988;pp 227-237.
32. Kloner RA, Campbell C, Lehmann MH. Cardiac effects of cocaine. CARDIO, 1987;Vol. 4, No. 9, 73-74.
33. Kloner RA, Przyklenk K. Recent advances in stunned myocardium. Cardiovascular Reviews & Reports, Vol. 8, No. 10, 1987;25-29.
34. Kudesia VS, Kloner RA. The Elderly Patient: The Cardiac History and Examination. Cardiovascular Reviews and Reports; Vol 9, No 11:26-29,1988.
35. Kudesia VS, Kloner RA. The Elderly Patient: Cardiac Diagnostic Techniques. Cardiovascular Reviews and Reports; Vol 9, No 12:19-24,1988.
36. Kloner RA, Peters P, Bassett J, Wynne J. Rounds with Kloner. A case of pseudoaneurysm following ventricular aneurysm repair. Cardiovascular Reviews and Reports 1988;Vol. 9, No. 1, 41-42,44.
37. Kloner RA, Nesto RW, Rice KR, Robinson KC, Vetrovec GW. Myocardial ischemia and left ventricular function. New perspectives on the clinical role of the stunned and hibernating myocardium. Selected proceedings of a roundtable discussion published by AM Medica Communications, Ltd., 1988, Pfizer Inc.
38. Kloner RA, Braunwald E. Adjuvant therapy for coronary reperfusion in evolving acute myocardial infarction in Limitation of Infarct Size. ed. H. Schmutzler, W. Rutsch, FC. Springer-Verlag. , Berlin 1989; 137-146.
39. Jafri SM, Levine TB, Kloner RA. Recent advances in the medical management of congestive heart failure. Modern Medicine 56:50-67,1988.
40. Kloner RA, Morse JR, Nesto RW, Rice KR, Robinson KC, Vetrovec GW: Cardiovascular therapy: the next step. Emerging concepts of myocardial protection in angina, AM Medica Communications;1988; p 1-25.
41. Kloner RA. The stunned myocardium: A new concept in myocardial protection for patients with angina. AM Medica;1988;1-9.
42. Kloner RA, Przyklenk K. Coronary artery reperfusion in the treatment of acute myocardial infarction. Internal Medicine for the Specialist; 1989;10:54-65.
43. Rezkalla S, Boden WE, Kloner RA. Identification and management of patients at risk for myocardial infarct extension. Practical Cardiology,1989;15:50-59.
44. Przyklenk K, Kloner RA. The 'Stunned Myocardium': Characteristics, Causes and Clinical Implications. CARDIO; April 1989; 130-134.
45. Kloner RA, Nesto RW, Tempkin LP, Vetrovec GW. Angina, myocardial ischemia and the stunned myocardium. Highlights from a roundtable discussion. Science and Medicine (Monograph) New York, NY, 1-30, 1989.
46. Kudesia VS, Kloner RA. The elderly patient: valvular heart disease. Cardiovascular Reviews and Reports Vol. 10, No. 1, Jan. 1989; p 30-39.
47. Przyklenk K, Whittaker P, Kloner RA. Zofenopril, a newly developed sulfhydryl-containing converting enzyme inhibitor, enhances contractile function of 'stunned' myocardium. in Current Advances in ACE inhibition Ed. GA MacGregor, PS Sever. Churchill Livingstone, Edinburgh, 1989, p 279-282.
48. Kloner RA. The Guide to Cardiology (Second Edition): The Introduction and Cardiac History. in Cardiovascular Reviews and Reports. Vol. 10, No. 2, Feb. 1989; 19-23.
49. Kloner RA. The Guide to Cardiology: The Physical Examination. in Cardiovascular Reviews and Reports. Vol. 10, No. 3, March 1989; 59-63.
50. Kloner RA. The Guide to Cardiology: The Physical Examination: Heart Murmurs; Abdomen; Skin and Extremities. in Cardiovascular Reviews and Reports. Vol. 10, No.4, Apr. 1989; 48-54.
51. Kudesia VS, Kloner RA. Cardiac diagnosis in the elderly: Congestive heart failure and cardiomyopathies. Cardiovascular Reviews and Reports. Vol. 10, No. 2, Feb. 1989; 50-53.
52. Whittaker P, Kajani SS, Kloner RA. The elderly patient: Changes in structure and function of the aging heart. Cardiovascular Reviews and Reports. Vol. 10, No. 3, March 1989; 25-29.
53. Sola R, Kloner RA. The elderly patient: Coronary artery disease in the elderly I.) Acute myocardial infarction. Cardiovascular Reviews and Reports. Vol. 10, No. 4, April 1989, 27-30.
54. Sola R, Kloner RA. The elderly patient: Coronary artery disease II. Complications of acute infarction; chronic coronary artery disease. Cardiovascular Reviews and Reports. Vol. 10, No. 6, June 1989, 50-54.
55. Kloner RA, Hale SL. Effects of coronary reperfusion on the late phases of acute myocardial infarction. Cardiovascular Reviews and Reports. Vol. 10, No. 7, July 1989, 39-41.
56. O'Neill WW, Kloner RA. Cardiogenic Shock, Emergency Angioplasty, and Stunned Myocardium in a Young Myocardial Infarction Patient. (Monograph) NCM Publishers, 1990.
57. Kloner RA, Przyklenk K. Author Update 1990 to Recent Advances in Stunned Myocardium (originally published October 1987). in Cardiovascular Reviews and Reports. II. June 1990:73-74.
58. Kloner RA. Comments on "Myocardial Protection with autoperfusion: Cardiac Chronicle 1990;4:7-8.
59. Kloner RA, Przyklenk K, Rahimtoola S. Braunwald E. Myocardial stunning and hibernation: Mechanisms and Clinical Implications in Heart Disease: Update 11, ed. E. Braunwald: W. B. Saunders, Philadelphia 1990; pg 241-256. Also in Stunning, Hibernation, and Calcium in Myocardial Ischemia and Reperfusion ed. L.H. Opie. Kluwer Academic Publishers Norwell, Mass. 1992; 251-280.
60. Scheidt S, Kloner RA, Guerci A, Verstraete M, Ross A. Thrombolytic Therapy: Medical Panel Discussion. Cardiovascular Reviews and Reports 11; Jan 1990:35-55.
61. Hagar JM, Kloner RA. Systolic Murmurs in Difficult Diagnosis II. ed. RB. Taylor, W.B. Saunders, Philadelphia 1991; pages 444 - 453.
62. Sections in Cardiology Reference Book Third Edition ed. RA. Kloner Co Medica Inc. New York, New York 1990
	1. Gupta VK, Kloner RA. Major risk factors for CAD. pages 8-9.
	2. Gupta VK, Kloner RA. Lipids and CAD. pages 10-15.
	3. Gupta VK, Kloner RA. Risk-factor approach in hypertensive patients pages 18-21
	4. Kloner RA, Gupta VK. ECG changes suggesting myocardial ischemia pages 26-27.
	5. Kloner RA, Gupta VK. False-negative test. pages 31-34.
	6. Kloner RA, Gupta VK. Indications for thallium testing. pages 39-41.
	7. Kloner RA, Gupta VK. Angina Pectoris: Pathophysiology and Pharmacologic Therapy. Pages 56-73.
	8. Kloner RA, Gupta VK. Silent myocardial ischemia. pages 74-88.
	9. Kloner RA, Gupta VK. Coronary angioplasty (PTCA) pages 89-94.
	10. Gupta VK, Kloner RA. Surgical versus medical therapy in CAD. pages 95-102.
	11. Goel S, Kloner RA. Acute MI: Pathophysiology, diagnosis and complications pages 103-138.
	12. Kloner RA, Gupta VK, Goel S. Therapy for acute MI: Role of thrombolytic therapy, chronic beta blockade, and aspirin. pages 139-166.
	13. Kloner RA. Stunned and hibernating myocardium. pages 167-173.
63. Chapters in The Guide to Cardiology, Second Edition; ed. R.A. Kloner. LeJacq Communications Inc. Greenwich, Connecticut 1990. [Some of these chapter also appear as articles in Cardiovascular Reviews and Reports and are also listed in the C.V. for reference].
	1. Kloner RA. Preface. pages v-vi.
	2. Kloner RA. The Cardiac History. pages 1-6.
	3. Kloner RA. The Physical Examination. pages 7-17.
	4. Brown EJ, Kloner RA. Angina Pectoris. pages 173-198.
	5. Hagar JM, Kloner RA. Acute Myocardial Infarction. pages 207-239.
	6. Mamby SA, Kloner RA. Valvular Heart Disease: pages 261-282.
	7. Rezkalla S, Kloner RA. Myocarditis and Cardiomyopathy. pages 283-300.
	8. Kloner RA, Dzau VJ. Heart Failure. pages 359-382.
	9. Hammerman H, Kloner RA. Pericardial Disease. pages 383-394.
	10. Kloner RA. Cardiac Tumors. pages 403-407.
	11. Kloner RA. Pulmonary hypertension and cor pulmonale. pages 437-448.
64. Kloner RA, Przyklenk K. Stunned and hibernating myocardium. Annual Review of Medicine. 1991; 42:1-8.
65. Brown E, Kloner RA. Angina Pectoris in The Guide to Cardiology. Cardiovascular Reviews and Reports. Aug. 1990 Vol 11 Pages 21 - 51.
66. Hagar JM, Kloner RA. Reperfusion arrhythmias: experimental and clinical aspects. The Age of Reperfusion. September 1990; Vol II; Pages 1-5.
67. Kloner RA. Ischemic Cardiomyopathy: A Manifestation of stunned myocardium? Heart Failure 1991;7:5-8.
68. Kloner RA. Clinical aspects of stunned myocardium following thrombolytic therapy. The Age of Reperfusion. December 1991; Vol II; Pages 1-4.
69. Hagar JM, Kloner RA. Acute myocardial infarction. Cardiovascular Reviews and Reports Oct. 1990; Volume 11; 39-67.
70. Kloner RA. Comments on "Critically Ischemic Myocardium in clinically stable patients following thrombolytic therapy for acute myocardial infarction," by AS Lew et al, in Cardiac Chronicle. 1991; 5:9.
71. Mamby SA, Kloner RA. Valvular Heart Disease. Cardiovascular Reviews and Reports. Jan. 1991; 12:27-47.
72. Rezkalla S, Kloner RA. Myocarditis and Cardiomyopathy. Cardiovascular Reviews and Reports. Feb. 1991; 12:48-77.
73. Kloner RA, Przyklenk K. Reperfusion injury to the heart: Is it a phenomenon?" in Cardiovascular Toxicology Second Edition. ed. D. Acosta; Raven Press, New York 1992; 131-140.
74. Kloner RA, Przyklenk K. Consequences of ischemia/reperfusion on the coronary microvasculature in Myocardial Protection: The Pathophysiology of Reperfusion and Reperfusion Injury ed. D. Yellon, RB Jennings. Raven Press, New York, New York, 1992; 85-103.
75. Kloner RA. The stunned myocardium: definition and pathophysiology. J. Preventive Card. 1991; 2:6-9, 1991.
76. Whittaker P, Kloner RA. Ventricular remodeling of the Heart. Current Opinion in Cardiology, 1991; 6:346-351.
77. Kloner RA, Dzau V. Heart Failure. Cardiovascular Reviews and Reports, July 1991; 12:19-59.
78. Hammerman H, Kloner RA. Pericardial Diseases. Cardiovascular Reviews and Reports Aug. 1991; 12:19-32.
79. Kloner RA. Cardiac Tumors. Cardiovasc. Reviews and Reports; Oct 1991; 12: 38-46.
80. Mehta PM, Kloner RA. Metabolic and toxic effects on the cardiovascular system in Principles and Practice of Medial Intensive Care. ed Geheb MA, Carlson RW. Saunders, Philadelphia; 1992 pages 1038-1049.
81. Kloner RA. Pulmonary Hypertension and Cor Pulmonale. Cardiovascular Reviews and Reports 12; Nov.1991;27-45.
82. Chapters and Sections & Introductions in: The Stunned Myocardium: Properties, Mechanisms, and Clinical Implications. ed. RA Kloner, K. Przyklenk; Marcel Dekker, New York, New York, 1993.
	1. Kloner RA, Przyklenk K. Preface pages vii - ix.
	2. Kloner RA, Przyklenk K. What is stunned myocardium? (Introduction) pages 1 - 2.
	3. Kloner RA, Przyklenk K. First Evidence: Postischemic dysfunction of viable myocardium. Pages 17 - 39. Also reprinted in Cardiovascular Reviews and Reports. May 1995; 16:22-36.
	4. Kloner RA, Przyklenk K. Mechanisms of Postischemic Dysfunction (Introduction) pages 153 - 154.
	5. Przyklenk K, Kloner RA. Treatment for the stunned myocardium (Introduction) pages 265.
	6. Przyklenk K, Kloner RA. Calcium antagonists as treatment for the stunned myocardium pages 281-301.
	7. Kloner RA. Stunned Myocardium and the Clinician (Introduction) pages 337 - 338.
	8. Kloner RA. Stunned myocardium in patients reperfused for the treatment of acute myocardial infarction pages 339 -348.
	9. Kloner RA, Allen J. Stunned myocardium post exercise pages 369 - 377.
83. Bellows SD, Kloner RA. Our Silent Enemy. In Heart to Heart Newsletter of the American College of Cardiovascular Invasive Specialists. 7; 5 - 6, March/April, 1992.
84. Ovize M, Li Y, Przyklenk K, Kloner RA. Evidence from experimental models for myocardial protection during ischemia. Current Opinion in Cardiology. 1992;7:563-570.
85. Whittaker P, Kloner RA. Remodeling of the left ventricle after myocardial infarction. The Age of Reperfusion. Vol. 4 No. 2, pages 1-6, 1992.
86. Rezkalla S, Kloner RA. Cocaine and vascular thrombosis. Cardiovas. Res and Report. 1992 (Dec.);13:54-57.
87. Frishman WH, Kloner RA. Norvasc (amlodipine besylate). Profile of a novel calcium channel blocker. Chiasma Inc.; N.Y., N.Y. 1992; pages 1-16.
88. Bellows SD, Kloner RA. Classifications and pathogenesis of atherosclerosis. Heart to Heart 1992; 7 (Nov/Dec '92):7-8.
89. Allen JW, Cox TA, Kloner RA, Ruiz CE. A review of myocardial stunning in coronary artery patients following treadmill exercise tests, in Proceedings of the Vth World Congress on Cardiac Rehabilitation ed. J.P. Broustet Intercept Publishers, Hampshire, U.K., 1993; pages 211-217.
90. Kloner RA. Comments on paper by Camici et. al. Coronary Reserve and Exercise ECG in patients with chest pain and normal coronary angiogram. Cardiac Chronicle Volume 6, No. 12 7-8, 1993.
91. Przyklenk K, Ovize M, Bauer B, Kloner RA. Ischemic preconditioning: An endogenous cardioprotective mechanism? J. Myocardial Ischemia. 1993; 5:13-24.
92. Chapters in Ischemic "Preconditioning": The Concept of Endogenous Cardioprotection. ed. by Przyklenk K, Kloner RA, Yellon DM. Kluwer Academic Publishers, Norwell, Mass, 1994.
	1. Bauer B, Kloner RA, Przyklenk K. Preconditioning and the coronary vasculature pages 61 - 72.
	2. Ovize M, Kloner RA, Przyklenk K. Preconditioning and myocardial contractile function pages 41 - 60.
	3. Kloner RA, Przyklenk K. Is preconditioning relevant to clinical medicine? Pages 173 - 187.
	4. Przyklenk K, Kloner RA, Whittaker P. Synopsis of ischemic preconditioning: What have we learned since 1986? Pages 153 - 170.
93. Ovize M, Przyklenk K, Kloner RA. Pathophysiology of acute coronary ischemia and reperfusion in Current Therapy for Acute Coronary Ischemia. ed. HL Lazar. Futura Publishing Co. Inc. Mount Kisco, New York 1993 pages 1 - 32.
94. Hale SL, Kloner RA. Role of leukocytes in reperfusion injury in H. M. Piper and C.J. Preusse (eds): Ischemia - Reperfusion in Cardiac Surgery - 1993 Kluwer Academic Publishers Netherlands pages 67-80.
95. Rezkalla S, Kloner RA. Monoclonal antimyosin antibody in detection of experimental murine myocarditis in Monoclonal Antibodies in Cardiovascular Diseases ed. B-A. Khaw, J. Narula, H.W. Strauss. Lea and Febiger; Philadelphia P.A. 1994; pages 127-132.
96. Przyklenk K, Kloner RA. Stunned and Hibernating Myocardium in New Types of Cardiovascular Diseases ed. J. Willis Hurst. Igaku Shoin, N.Y., 1994 pages; 24 - 45.
97. Li Y-W, Kloner RA. The nature of myocardial ischemic preconditioning in the rat heart in Progress in Microcirculation Research ed. H. Niimi, M. Oda, T. Sawada, R-J Xiu, Pergamon - Elsevier, Science (Oxford) 1994; 375-379.
98. Przyklenk K, Kloner RA. Diagnosis of Stunned and hibernating myocardium in Cura Intensiva Cardiologica 1993;ed. G. Caturelli, Viale G. Mazzini, Milano, Italy pages 36-44.
99. Hale SL, Kloner RA. Experience from experimental models in the quest to protect myocardium from ischemic damage. Update on preconditioning strategies. Current opinion in Cardiology 1994; 9:411-416.
100. Hammerman H, Kloner RA. Q Wave Myocardial Infarction in Cardiology Current Practice of Medicine Vol. 1 ed. R. C. Bone. Churchill Livingston Inc., Current Medicine Inc. N.Y., N.Y. 1996 II 11.2 - II 11.9; also in Cardiology for the Primary Care Physician ed. J. Alpert Current Medicine Inc. N.Y., N.Y. 1996:149-157.
101. Bankwala Z, Kloner RA. Cardiac reperfusion injury: The role of Pharmacotherapy. Cardiovascular Reviews and Reports May 1996; 17:11-45.
102. Przyklenk K, Kloner RA. Prevention of lethal myocardial reperfusion injury: A clinically relevant issue. Monograph. Exerpta Medical 1994; 1-24.
103. Kloner RA, Przyklenk, Shook T. The role of preconditioning ischemia in the reduction of myocardial infarct size. Editorials in Cardiology 1995; 1:67-71.
104. Kloner RA. A guide for the diagnosis and treatment of angina. Pfizer Pharmaceutical Monograph, 1995.
105. Chapters in The Guide to Cardiology, Third Edition ed. R.A. Kloner. LeJacq Communications Inc. Greenwich, Connecticut, 1995.
	1. Kloner RA. Preface. Pages V-VI.
	2. Kloner RA. The Cardiac History. Pages 1-6.
	3. Kloner RA. The Physical Examination. Pages 7-21.
	4. Brown EJ, Kloner RA. Angina Pectoris. Pages 223-254.
	5. Hagar JM, Olson HG, Kloner RA. Acute Myocardial Infarction. Pages 265-316.
	6. Rezkalla S. Kloner RA. Myocarditis and Cardiomyopathy. Pages 387-405.
	7. Kloner RA, Fowler MB, Dzau V. Heart Failure. Pages 407-427.
	8. Hammerman H, Kloner RA. Pericardial Diseases. Pages 539-551.
	9. Leor J, Kloner RA. Cardiac Tumors. Pages 565-573.
106. Kloner RA. Introduction aux notions de sidèration et d'hibernation. Realities Cardiologiques. No. 82. September 1995.
107. Leor J, Kloner RA. The hibernating myocardium in Myocardial Ischemia: Mechanism, Reperfusion, Protection ed. M. Karmazyn. Birkhauser Verlag Basel/Boston/Berlin 1996; pages 453-462.
108. Allen JW, Cox TA, Kloner RA. Myocardial stunning: A post-ischemic syndrome with delayed recovery in Myocardial Ischemia: Mechanisms, Reperfusion, Protection. ed. M. Karmazyn. Birkhauser Verlag Basel/Boston/Berlin 1996; pages 443-452.
109. Kloner RA. Management of hypertension in elderly and black patients: The role of amlodipine. Cardiovascular Reviews and Reports, May, 1996; 17:46-65.
110. Kloner RA. A Clinical overview of preconditioning. In Ischaemia: preconditioning and adaptation. edited by M. Marber and D.M. Yellon. BIOS Scientific Publishers Ltd, Oxford, 1996: 225-230.
111. Kloner RA, Fowler MB, Dzau V. Heart Failure - Reprinted from The Guide to Cardiology, Third Edition in Congestive Heart Failure March/April 1996 pgs 17-34.
112. Kloner RA, Leor J, Birnbaum Y. Remodeling, hibernating and stunning in Heart Failure: Scientific Principles and Clinical Practice. ed. P. A. Poole-Wilson, W. Colucci, K. Chatterjee, B. Massie, A. Coats. Churchill Livingstone, N.Y., N.Y. 1997; 109-125.
113. Birnbaum Y, Kloner RA. Cardiovascular Trials Review ed. RA Kloner, Y. Birnbaum. LeJacq Communications Inc., Greenwich, Conn. 1996; pgs 1-312.
114. Kloner RA, Sowers JR, DiBona GF. Influence of Age, Sex, and Race on Antihypertensive Effects of Amlodipine. Cardiology Review 1996; 13:32-34.
115. Leor J, Kloner RA. Earthquakes: A significant trigger of sudden cardiac death. Cardiology Review 1996; 13:18-21.
116. Kloner RA. The Beta Virus - A Novel. A LeJacq Medical Fiction Book. LeJacq Communications Inc, Greenwich, Conn. 1996; pgs 1-251.
117. Kloner RA. Introduction aux notions de sideration et d'hibernation in LaViabilitè Myocardique edited D. Palsky, Performances Medicales. Paris, France; 7-9, 1996.
118. Birnbaum Y, Kloner RA. Viabilitè myocardique synthese in LaViabilitè Myocardique edited by D. Palsky. Performances Medicales. Paris, France, 69-87, 1996.
119. Przyklenk K, Whittaker P, Ovize M, Kloner RA. Reduction of infarct size- "Preconditioning at a distance." in Myocardial Preconditioning ed. Wainwright CL and Parratt JR. R.G. Landes Co, Austin Texas;79-96, 1996.
120. Birnbaum Y, Kloner RA. Clinical aspects of ischemic preconditioning in Stunning, Hibernation, and Preconditioning: Clinical Pathophysiology of Myocardial Ischemia ed. GR Heyndrickx, SF Vatner, , W. Wijns, Lippincott-Raven Press Philadelphia 1998; 137-157.
121. Birnbaum Y, Kloner RA. Adenosine, cardioprotection and its clinical application in Adenosine, Cardioprotection and Clinical Application ed. Mentzer RM, Kitakaze M, Downey JM, Hori M. Kluwer Academic Publishers, Norwell, MA. 1997; pgs 177-185.
122. Kloner RA, Rezkalla S. Substance abuse and the heart in Textbook of Cardiovascular Medicine ed. E. Topol. Lippincott-Raven Publishers, Philadelphia, PA 1998; 947-970.
123. Kloner RA, Yellon DM. Cardiac preconditioning in humans, in New Ischemic Syndromes: ed. Yellon D, Rahimtoola S, Opie L. Author's Publishing House Lippincott-Raven Publishers, Philadelphia, PA; 1997; 76-89.
124. Schwarz ER, Przyklenk K, VomDahl J, Schoendube FA, Hanrath P, Kloner RA. Chronic hibernating myocardium: concepts and controversies. Congestive Heart Failure May/June 1997; 12-23.
125. Kloner RA, Braunwald E. La Sideration Myocardique Cardinale Tome IX, No 5; May 1997; 13-15.
126. Birnbaum Y, Kloner RA. Cardiovascular Trials Review: Second Edition. R. A. Kloner, Y. Birnbaum. LeJacq Communications Inc. Greenwich, Conn. 1997; pages 1 - 397.
127. Speakman MT, Kloner RA. Congestive Heart Failure. In Conn’s Current Therapy 1999 ed. Robert E. Rakel. W.B. Saunders, Philadelphia, 1999; 293-297.
128. Kloner RA, Illicit drug use in the athlete as a contributor to cardiac events. in Sudden Cardiac Death in the Athlete. Estes NAM, Salem DN, Wang PJ. Futura Publishing Co., Inc. Armonk, NY., 1998:441-451.
129. Kloner RA. Mind Cure (A Novel). A LeJacq Medical Fiction Book. LeJacq Communications Inc. Greenwich, Conn. 1998; 1-274.
130. Speakman MT, Schwarz ER, Kloner RA. Stress and the Heart. In Medicine and Behavior. April 1998. CME, Inc. April 1998 pages 42-43.
131. Kloner RA. Forum: The New Era for CCBs - Through Criticism and Controversies. Therapeutic Research Report Vol. 19 R4. Life Sciences Publishing Co. Ltd. Tokyo, Japan 1998; page 17.
132. Schwarz ER, Speakman MT, Kloner RA. The impact of heart disease on sexual function. Medicine and Behavior. August 1998; 1:35-38.
133. Kloner RA, Birnbaum Y, Cardiovascular Trials Review: Third Edition, Edited by Kloner RA, Birnbaum Y. LeJacq Communications, Inc. Greenwich, Conn. 1998; pages 1-640.
134. Jarow J, Kloner RA, Holmes AM. Viagra. M. Evans and Company, Inc. New York, New York 1998; pages 1-150.
135. Kloner RA. Are long-acting dihyropyridine calcium channel blocking agents safe in hypertension? Cardiology Review 1998 (Nov); 15:20-23.
136. Schwarz ER, Hammerman H, Kloner RA. Q-wave myocardial infarction. In Current Practice of Medicine 1998 ed. Joseph S. Alpert. Volume 1; Issue 3 Current Medicine Inc. Philadelphia, PA. pages 521-533.
137. Przyklenk K, Kloner RA, Whittaker P. Increased perfusion via laser – mediated myocardial channels? Importance of appropriate models and endpoints in Direct Myocardial Revascularization: History, Methodology, Technology. Ed. P. Whittaker. G.S. Abela. Kluwer Academic Publishers, Boston, 1999; pages 61-80.
138. Kloner RA. Cardiovascular risk factors and erectile dysfunction: What are the links? (Monograph) Report of a symposium held in Dallas, Texas, November 8, 1998 entitled Heart Disease and Sexual Health: What do cardiologists need to know? Pages 2 –3, AM Medica, Jan. 1999.
139. Kloner RA. Cardiovascular Disease and Erectile Dysfunction. Harrison’s Online, 1999.
140. Rezkalla SH. Kloner RA. Substance abuse and athletes: A cardiovascular nightmare in Am. J. Med. Sports, 1999; 1:113-120.
141. Schwarz ER, Hammerman H, Kloner RA. Q-wave myocardial infarction. In Current Practice of Medicine 1999, ed. J.L. Ritchie 1999; 2:2201-2215.
142. Kloner RA. Cardiovascular Safety Profile for Sildenafil. In Sexual Dysfunction in Medicine 2000; 1:66-69.
143. Kloner RA, Birnbaum Y. Cardiovascular Trials Review: Fourth Edition. Edited by Kloner RA, Birnbaum Y. LeJacq Communications, Inc. Greenwich, Conn. 1999; pages 1-956.
144. Kloner RA. Daily, seasonal, and event-related variations in the incidence of myocardial infarction in Heart Disease Updates. Ed. E. Braunwald, W.B. Saunders, Philadelphia; Volume 2; Number 1; 2000; pages 1 – 9.
145. Rezkalla SH, Kloner RA. Drug ­ related diseases of the coronary artery in Pan Vascular Medicine. Integrated Clinical Management ed. Lanzer P, Topol EJ. Springer-Verlag, Berlin, 2002; pages 970-979.
146. Kloner RA, Przyklenk K. Current Comment from the Author (Update of paper recent advances in stunned myocardium). Cardiovascular Reviews and Reports Vol. 21; pages 385-390; page 399, July, 2000.
147. Kloner RA, Birnbaum Y. Cardiovascular Trials Review: The Millennium Edition (5th Edition). Edited by Kloner RA, Birnbaum Y. LeJacq Communications Inc. Greenwich Conn. 2000; pages 1 - 1218.
148. Kloner RA. Cardiac Triggers: The issue of seasonal variability. Cardiovascular Reviews and Reports 2000; 22:151-152.
149. Kloner RA, Rezkalla S. Substance abuse and the heart in Textbook of Cardiovascular Medicine. 2nd Edition. Ed E. Topol, Lippincott-Raven Publishers, Philadelphia, PA 2002; pages 865-887.
150. Kloner RA. LV function: Stunning, hibernation, preconditioning, contractile reserve. American College of Cardiology Self Assessment Program (ACCSAP) V, 2002; (Chapter 3) 33-37.
151. Yao M, Kloner RA. Cell transplantation: Its application in the treatment of cardiac dysfunction and its effect on angiogenesis, in Myocardial Revascularization: Novel Percutaneous Approaches. Edited by George S. Abela, Wiley-Liss Inc. NY, NY 2002, pages 249-261.
152. Kloner RA. The Deity Genes (A Novel) A LeJacq Medical Fiction Book. LeJacq Communications Inc. Greenwich, Conn. 2001, 1 - 276.
153. Kloner RA, Birbanum Y. Cardiovascular Trials Review: Sixth Edition. Edited by Kloner RA, Birnbaum Y. LeJacq Communcications, Inc. Greenwich, Conn. 2001; 1-1471.
154. Kloner RA. Cardiovascular Disease and Erectile Function in Harrison's Advances in Cardiology ed. E. Braunwald. McGraw-Hill NY, NY 2002; 208-213.
155. Leor J, Barbash IM, Battler A, Kloner RA. Treatment of Cardiogenic Shock. Future Perspective From: Contemporary Cardiology: Cardiogenic Shock: Diagnosis and Treatment. Ed. David Hasdai et al. Humana Press, Inc. 2002; Totowa, N.J. pages 357-371.
156. Kloner RA, DeBusk RF, Shabsigh R. Doctors on Call #2: Treating erectile dysfunction: current cardiovascular issues and novel therapeutic options. Monograph from Consortium for Improvement in Erectile Function. Pages 1 – 24, 2002.
157. Chi J, Birnbaum Y, Kloner RA. Cardiovascular Trials Review Updates. Cardiovascular Reviews and Reports. January 2003; 24:44-46.
158. Chi J, Birnbaum Y, Kloner RA. Cardiovascular Trials Review Updates. Cardiovascular Reviews and Reports. February 2003; 24:104-106.
159. Kloner RA; Birnbaum Y. Cardiovascular Trials Review: Seventh Edition. Edited by Kloner RA, Birnbaum Y. LeJacq Communications, Inc. Darien, CT. 2002; 1- 1537.
160. Chi J, Birnbaum Y, Kloner RA. Cardiovascular Trials Review Updates. Cardiovascular Reviews and Reports. March 2003; 24:172-173, 180.
161. Kloner RA. Cardiovascular Safety of Sexual Activity and Phosphodiesterase Type 5 Inhibition in: Sexual Dysfunction. Ed. A Seftel; Mosby-New York 2004; pages 159-181.
162. Murry CE, Kloner RA. Keith Reimer, MD, Ph.D. 1945-2002. Cardiovasc. Pathol 2003; 12:57-58, and J. Mol and Cell Caridology 2003; 35:131-132.
163. Kloner RA, Müller-Ehmsen J, Yao M, Leor J, Reffelmann T, Etzion S, Hale S, Dow J, Simkhovich B, Peterson KL, Kedes L. Long term effects of fetal and neonatal cardiac myocyte transplantation on the infarcted heart. In Handbook of Cardiovascular Cell Transplantation. Ed. N. Kipshidze and P. Serruys. Martin Dunitz, London, U.K. 2004; pages 57-71.
164. Kloner RA, DeBusk RF, Muller JE. Current issues in managing erectile dysfunction. The favorable safety profile of PDE5 inhibitors when treating erectile dysfunction in cardiovascular patients. Monograph jointly sponsored by the Annenberg Center for Health Sciences at Eisenhower and CogniMed Inc. 2003; pages 1 - 44.
165. Chi J, Birnbaum Y, Kloner RA. Cardiovascular Trials Review Updates. Cardiovascular Reviews and Reports April 2003; Vol 24: pages 231 - 232, 236.
166. Chi J, Birnbaum Y, Kloner RA. Cardiovascular Trials Review Updates. Cardiovascular Reviews and Reports May 2003; Vol 24: pages 280-282.
167. Chi J, Birnbaum Y, Kloner RA. Cardiovascular Trials Review Updates. Cardiovascular Reviews and Reports June 2003; Vol 24: pages 337-338.
168. Chi J, Birnbaum Y, Kloner RA. Cardiovascular Trials Review Updates. Cardiovascular Reviews and Reports. July 2003; Vol 24: pages 395-396.
169. Kloner RA. Erectile Dysfunction and the Cardiovascular Patient. Cardiology Special Edition. 2003; Vol 9; 17-20.
170. Kloner RA. Coronary disease and treatment of erectile dysfunction. Contemporary Urology 2003; 15:50-55.
171. Chi J, Birnbaum Y, Kloner RA. Cardiovascular Trials Review Updates. Cardiovascular Reviews and Reports. September 2003; Vol. 24: pages 489-490.
172. Flack JM, Franklin SS, Grimm RH, Kloner RA. Hypertension Management Update. Expert Commentary on Recent Clinical Trials. QD Healthcare Group Monograph 2003, pages 1 ­ 13.
173. Chi J, Birnbaum Y, Kloner RA. Cardiovascular Trials Review Updates. Cardiovascular Reviews and Reports. October 2003; Vol 24, pages 539 ­ 540.
174. Kloner RA, Birnbaum Y, Chi JS. Cardiovascular Trials Review: Eighth Edition. Edited by Kloner RA, Birnbaum Y. LeJacq Communications Inc., Darien CT. 2003; pages 1-1226.
175. Muller-Ehmsen J, Leor J, Kedes L, Peterson RL, Kloner RA. Fetal and neonatal cardiomyocyte transplantation for the treatment of myocardial infarction. Pathophysiology of Cardiovascular Disease ed. N.S. Dhalla, H. Rupp, A. Angel and G.N. Pierce. Kluwer Academic Publishers, Boston, Mass, 2004; pages 535-544.
176. Kloner RA. Therapy for erectile dysfunction in the cardiac patient. Cardiology Special Edition 2004; 10:23-25.
177. Kloner RA, Birnbaum Y. Cardiovascular Trials Review Updates. Cardiovascular Reviews and Reports. January/February 2004; 25:31-34.
178. Chapters in Heart Disease and Erectile Dysfunction. Ed. R.A. Kloner, Humana Press, Totowa New Jersey 2004
	1. Kloner RA. Preface in Heart Disease and Erectile Dysfunction. Ed. R.A. Kloner, Humana Press, Totowa New Jersey 2004; page V.
	2. Kloner RA. Erectile dysfunction and cardiovascular risk factors in Heart Disease and Erectile Dysfunction. Ed. R.A. Kloner, Humana Press, Totowa New Jersey 2004; pages 39-49.
	3. Kloner RA. Cardiovascular safety of phosphodiesterase-5 inhibitors in Heart Disease and Erectile Dysfunction. Ed. R.A. Kloner, Human Press, Totawa, New Jersey 2004; pages 139-161.
	4. Kloner RA. Sexual activity as a trigger of myocardial infarction/ischemia. Implications for treating erectile dysfunction in Heart Disease and Erectile Dysfunction. Ed. R.A. Kloner, Humana Press, Totawa, New Jersey 2004; pages 251-260.
179. Kloner RA, Birnbaum Y. Cardiovascular Trials Review Updates. Cardiovascular Reviews and Reports. March/April 2004; 25:77-78.
180. Kloner RA. PDE5 ­ Inhibitors and CAD: A Cardiologist’s Perspective in Erectile Dysfunction Alert. Monograph Vol 1, Number 1, May 2004 page 2.
181. Kloner RA, Birnbaum Y. Cardiovascular Trials Reviews Updates. Cardiovascular Reviews and Reports. May/June 2004; 25:127-128.
182. Kloner RA. Erectile dysfunction ­ The Cardiovascular Connection. Cardiology Review 2004; 21:35-38.
183. Kloner RA. Erectile dysfunction in the cardiac patient. AUA News (The Official Newsmagazine of the American Urological Association, Inc.). Vol 9, issue 3, pages 7 ­ 9, 2004.
184. Kloner RA, Birnbaum Y. Cardiovascular Trials Review Updates. Cardiovascular Reviews and Reports. July/August 2004; 25:179-180.
185. Kloner RA. Successfully diagnosing and treating the “silent” disease. Managing Hypertension: A Supplement to “The Clinical Advisor.” October 2004; 3 ­ 8.
186. Reffelmann T, Kloner RA. Erectile dysfunction. Assessing risk and managing the cardiac patient. In Oral Pharmacothrapy for Male Sexual Dysfunction. A Guide to Clinical Management Ed. by: G. Broderick, Humana Press Inc., Totowa NJ; 2005: pages 199-221.
187. Hale SL, Kloner RA, Katada S, Ohbayashi T, Ishii T, Nakajima S, Yahagi N. Myocardial ischemia and infarction in Therapeutic Hypothermia ed. S. Tisherman, Springer-Science and Business Media, Inc. NY, NY 2005; pages 191-209.
188. Kloner RA. LV Function ­ stunning, hibernation, preconditioning, contractile reserve. ACCSAP 6, 2005 pages 10.59 ­ 10.65.
189. Kloner RA, Birnbaum Y. Cardiovascular Trials Review: Ninth Edition, Edited by Kloner RA, Birnbaum Y. LeJacq Communications Inc., Darien, CT 2004; pages 1 ­ 1402.
190. Kloner RA, Birnbaum Y. Cardiovascular Trials Review. Ninth Edition CME Supplement. Edited by Kloner RA, Birnbaum Y. LeJacq Communications Inc., Darien CT and CME Consultants, Inc. 2004; pages 1 ­ 31.
191. Kloner RA, Rezkalla S. Substance abuse and the heart in Textbook of Cardiovascular Medicine, Third Edition; Edited by E. Topol. Lippincott Williams and Wilkins, Philadelphia, PA; 2006; pages 669-685.
192. Reffelmann T, Kloner RA. Cell Therapy for Heart Failure in Stem Cell and Gene Based Therapy: Frontiers in Regenerative Medicine. Edited by A. Battler and J. Leor, Springer-Verlag. London 2006; pages 59 ­ 69.
193. Wold LE, Dai W, Dow JS, Kloner RA. Stem cell therapy in the heart and vasculature in Methods Mol Med. 2007; 139:355-366.
194. Kloner RA. Guidelines for treating men with ED and CVD. ED Times, Vol 1, Number 4. Pages 1 ­ 2, 2005.
195. Kloner RA. Safety of PDE-5 Inhibitors: A Case Study. Primary Care Update. Erectile Dysfunction. January 2006, Vol 1; No. 3 pages 3 ­ 8.
196. Kloner RA, Birnbaum Y. Cardiovascular Trials Review: Tenth Edition. Edited by Kloner RA, Birnbaum Y, LeJacq Communication Inc., Darien CT. 2005; pages 1-1311.
197. Appel GB, Flack JM, Kloner RA. CV Risk Treatment Strategies: Implications of ASCOT Trial Results. Monograph. Continuing Education Alliance, 2006; pages 1-14.
198. Reffelmann T, Kloner RA. Cardiac issues related to erectile dysfunction in Male Sexual Function. A Guide to Clinical Management. Second Edition. Ed. John J. Mulcahy. Humana Press, Totowa, N.J. 2006; pages 61-75.
199. Kloner RA, DeBusk RF, Kuritzky L. Evaluating erectile dysfunction and cardiovascular risk in daily practice. Doctors On Call ­ Volume 5; Number 11; pages 1 ­ 25 2006 (Monograph).
200. Kloner RA. Hypertension and dyslipidemia: Taking aim at moving targets and increasing treatment adherence. Beyond Hypertension: Targets and Goals to Reduce Cardiovascular Risk. Supplement to Clinical Advisor October 2006; pages 6 ­ 12.
201. Kloner RA, Jackson G. (CME supplement, Monograph). Understanding the link between erectile dysfunction and cardiovascular disease. Men’s Sexual Heath Consult Collection November 2006; pages 4 ­ 7. From the Sexual Medicine Society of North America and Annenberg Center for Health Sciences.
202. Kloner RA, Bankhead C. Applying associations between erectile dysfunction and CV disease in clinical practice. Clinical perspectives in ED. A Supplement to Cardiology Review. October 2006 CME; Ascend Media Healthcare. Princeton, NJ; pages 1 - 12.
203. Broderick GA, Costabile RA, Kloner RA, Rosen RC, Sadovsky R. Evolving strategies in ED management. Focus on a novel dosing regimen. Renal and Urology News (Supplement to Cortland Forum) March 2007; pages 1 ­ 15.
204. Dai W, Kloner RA. Potential therapeutic application of injectable biomaterials in cardiac repair. Meeting Reports. International Circulation 2007; 5:8-9.
205. Dai W, Kloner RA. Mesenchymal stem cell therapy for the injured heart. In Rebuilding the Infarcted Heart ed. K.C. Wollert, LJ Field, Informa Healthcare; London, England 2007; 55-72.
206. Kloner RA, Leeka J. The holiday season as a trigger for cardiac events. Worcester Medicine November/December 2007; 71:7-8.
207. Reffelmann T, Kloner RA. Cardioprotection at the time of an acute coronary syndrome: Pharmacological adjunctive therapy to myocardial reperfusion. In Cardioprotection ed. D.M. Yellon and D. Hausenloy; Oxford University Press; Oxford, UK 2009; pages 89-99.
208. Dai W, Kloner RA. Chapter 11. Cell transplantation therapy for myocardial repair: Current status and future challenges in Stem Cell Research and Therapeutics eds. Y Shi, D.O. Clegg Springer Science ­ Business Media B. V. 2008; pages 193-212.
209. Lewis EF, Kloner RA. Chapter ll.7: Chronic coronary disease. Stunning, hibernation, preconditioning, and postconditioning ACCSAP-7 2009; 11.7.1 ­ 11.7.11
210. Hwang H, Kloner RA, Dai W, Kleinman MT, Poole WK, McDonald SA, Simkhovich BZ. Isolated heart preparation in Comprehensive Toxicology 2nd Edition. Ed. M Walker, M Campen. Elsevier; 2010; pages 149-159.
211. Dai W, Kloner RA. Stem cell transplantation therapy for heart disease in Biomedical Engineering. Principles of the Bionic Man. Series on Bioengineering and Biomedical Engineering. Volume 5. Ed. Hung G, World Scientific, Singapore 2009; pages 377-413.
212. Reffelmann T, Kloner RA. Erectile Dysfunction in Comprehensive Cardiovascular Medicine in the Primary Care Setting. Ed Peter P. Toth, Christopher Cannon. Humana Press, Springer, New York; 2010; pages 411-422.
213. Reffelmann T, Kloner RA. Microvascular Obstruction: The no-reflow phenomenon in animal models of myocardial ischemia and reperfusion in Management of Myocardial Reperfusion Injury. Ed. JC Kaski, DJ Hausenloy, BJ Gersh, DM Yellon. Springer-Verlag, London 2012; pages 29-50.
214. Kloner RA, Reffelmann T, and Schwarz ER. Causes and risk factors for erectile dysfunction. In Erectile Dysfunction ed. E.R. Schwarz. Oxford American Urology Library, Oxford University Press. 2013. Pages 21-28.
215. Rezkalla SH, Kloner RA. Drug-related diseases of the coronary artery. Pan Vascular Medicino, 2nd Edition. Ed: Dr. Peter Lazer, Springer, Berlin, Heidelberg, 2015. Pages 1917-1938; DOI 10.1007/978-3-642-37078-6\_65.
216. Kloner RA, Hale SL. Reperfusion injury. Chapter in Myocardial Infarction: A companion to Braunwald’s Heart Disease. Ed. D Morrow. Elsevier; Philadelphia; 2016; pages 286-294.
217. Kloner RA. Troponin. Its role in detecting acute myocardial infarction. ADVANCE for Administrators of the Laboratory. October 2015; Vol 24; No. 10. Pages 16-19.
218. Reffelman T, Kloner RA. Erectile Dysfunction. In: Comprehensive Cardiovascular Medicine in the Primary Care Setting, Second Edition. Ed Peter J Toth, Christopher Cannon, Humana Press, Springer Nature Switzerland, Cham, Switzerland, 2019. Pages 379-387.
219. Kloner RA. Remote ischemic conditioning as a form of hormesis. In; The Science of Hormesis in Health and Longevity. Eds: Suresh I.S. Rattan and Marios Kyriazis ; Academic Press, Elsevier, London, United Kingdom. 2019; pages 55-61.
220. Kloner RA, Rezkalla SH. Chapter 84. Cardiomyopathies Induced by Drugs or Toxins. In Braunwald’s Heart Disease; 12th Edition. Elsevier, Philadelphia, 2021; Pages 1593-1602.
221. Burkhoff D, Kloner RA. SSO2 therapy: The next frontier in STEMI care. Insert to Cardiac Intervention Today; September/October 2021; Vol 15; No. 5: Pages 24-27.
222. Kloner RA. A commentary on: Adverse Events Associated With Coprescription of Phosphodiesterase Type 5 Inhibitors and Oral Organic Nitrates in Male Patients With Ischemic Heart Disease : A Case-Crossover Study. PracticeUpdate website. Available at: <https://link.edgepilot.com/s/17fed9bb/5YIIod-Pu0Wft6rTcpslFQ?u=https://www.practiceupdate.com/content/adverse-cardiovascular-outcomes-associated-with-coprescription-of-pde5-and-oral-organic-nitrates-in-male-patients-with-ischemic-heart-disease/134941/65/2/1>. Accessed May 11, 2022

**INTERNET PUBLICATIONS (Through 2007)**

1. Kloner RA, Friedewald VE Jr (1999, December 15). Case 1: A patient with isolated systolic hypertension. In *Interactive Grand Rounds in Cardiology: Hypertension* [Online]. Available: http://igr.medsite.com/cardio/.
2. Friedewald VE Jr, Kloner RA (1999, December 15). Isolated systolic hypertension in the elderly: prevalence, clinical relevance, and healthcare Implications. In *Interactive Grand Rounds in Cardiology: Hypertension* [Online]. Available: http://igr.medsite.com/cardio/.
3. Polsdorfer JR, Kloner RA, Friedewald VE Jr (1999, March 15). Case 2: A patient with hypertension and diabetes mellitus. In *Interactive Grand Rounds in Cardiology: Hypertension* [Online]. Available: http://igr.medsite.com/cardio/.
4. Kloner RA, Friedewald VE Jr (1999, March 15). The diabetic hypertensive. In *Interactive Grand Rounds in Cardiology: Hypertension* [Online]. Available: http://igr.medsite.com/cardio/.
5. Kloner RA, Friedewald VE Jr (1999, May 15). Case 3: A patient with hypertension and left ventricular hypertrophy. In *Interactive Grand Rounds in Cardiology: Hypertension* [Online]. Available: http://igr.medsite.com/cardio/.
6. Kloner RA, Friedewald VE Jr (1999, May 15). Hypertension and left ventricular hypertrophy. In *Interactive Grand Rounds in Cardiology: Hypertension* [Online]. Available: http://igr.medsite.com/cardio/.
7. Kloner RA, Friedewald VE Jr (1999, May 1). Case 4: A patient with hypertension and congestive heart failure. In *Interactive Grand Rounds in Cardiology: Hypertension* [Online]. Available: http://igr.medsite.com/cardio/.
8. Kloner RA, Friedewald VE Jr (1999, May 1). Hypertension in the Setting of Congestive Heart Failure. In *Interactive Grand Rounds in Cardiology: Hypertension* [Online]. Available: http://igr.medsite.com/cardio/.
9. Tennant LB, Kloner RA, Friedewald VE Jr (1999, April 1). Case 5: A patient with hypertension and coronary heart disease. In *Interactive Grand Rounds in Cardiology: Hypertension* [Online]. Available: http://igr.medsite.com/cardio/.
10. Kloner RA, Friedewald VE Jr (1999, April 1). Antihypertensive Therapy In the Patient with Coronary Heart Disease. In *Interactive Grand Rounds in Cardiology: Hypertension* [Online]. Available: <http://igr.medsite.com/cardio/>.
11. Kloner RA. (September 2000-2001). Hypertension and special populations I: Rationale for intensive therapy – clinical trials. Available CMEacademy.com.
12. Kloner RA. (September 2000-2001). Hypertension and special populations II. Implementing polulation - specific strategies CMEacademy.com.
13. Kloner RA. Cardiovascular Disease and Erectile Dysfunction. Harrison’s Online.1999.
14. Kloner RA. Erectile dysfunction and the Cardiovascular disease connection: An update for clinicians. Medscape August 22 ’06 ­ August 22 ’07. Available: <http://www.medscape.com/viewprogram/5895>.
15. Dai W, Kloner RA. Potential therapeutic application of injectable biomaterials in cardiac repair. acc2007.icirculation.com.

**ABSTRACTS**

1. Jennings RB, Ganote CE, Kloner RA, Whalen DA Jr, Hamilton GE. Explosive swelling of myocardial cells irreversibly injured by transient ischemia. In: Group for Research in Cardiac Metabolism. Friedberg, Germany. September 1973.
2. Kloner RA, Ganote CE, Reimer KA, Jennings RB. Coronary flow during acute myocardial ischemia. Fed Proc 1974;33:592.
3. Kloner RA, Ganote CE, Jennings RB, Reimer KA. Demonstration of the "no-reflow phenomenon" in the dog after temporary ischemia. Presented at the Seventh Annual Meeting of the International Study Group for Research in Cardiac Metabolism, Quebec City, Canada, June 1974.
4. Jennings RB, Reimer KA, Kloner RA, Rasmussen MM. Factors influencing size of myocardial infarct. Studies with propranolol in experimental myocardial infarction. Presented at the 19th Annual Meeting of the Royal College of Pathologists of Australia, Auckland, New Zealand, August 26-30, 1974.
5. Kloner RA. Vascular phenomenon in acute myocardial ischemia. Dissertation Abstracts International 1975;35:4971B.
6. Kloner RA, Reimer KA, Willerson JT, Jennings RB. Reduction of infarct size by mannitol during acute coronary occlusion in the dog. Am J Pathol 1975;78:62A.
7. Kloner RA, Reimer KA, Jennings RB. Distribution of local collateral flow after coronary occlusions in dogs: Effect of propranolol. Am J Pathol 1975;78:33a.
8. Reimer KA, Kloner RA, Jennings RB. Distribution of local collateral flow after coronary occlusion in dogs. Fed Proc 1975;34:847.
9. Reimer KA, Kloner RA, Willerson JT, Jennings RB. Reduction of infarct size by mannitol during acute myocardial ischemia. Circulation 1975;52 (Suppl II);II-64.
10. Kloner RA, Reimer KA, Willerson JT, Jennings RB. Histologic evidence of the ability of hypertonic mannitol to reduce infarct size in experimental animals. Clin Res 1975;23:190A.
11. Kloner RA, Fishbein MC, Maclean D, Braunwald E, Maroko PR. Effect of hyaluronidase on myocardial ultrastructure following coronary artery occlusion in the rat. Circulation 1976;54 (Suppl II):II-88.
12. Kloner RA, Fishbein MC, Cotran RA, Braunwald E, Maroko PR. Effect of propranolol on microvascular injury after experimental coronary artery occlusion. Am J Cardiol 1977;39:280.
13. Kloner RA, Fishbein MC, Cotran RA, Braunwald E, Maroko PR. Effect of hyaluronidase on myocardial ischemia. An ultrastructure study. Am J Path 1977;86:43A.
14. Kloner RA, Fishbein MC, Cotran RS, Braunwald E, Maroko PR. Microvascular injury in acute myocardial ischemia. The effect of propranolol. Am J Pathol 1977;86:44A.
15. Kloner RA, Maroko PR, Fishbein MC, Braunwald E. Microcirculatory changes during acute myocardial ischemic injury. Presented at the meeting of the American Section of the International Society for Heart Research, Pasadena, California, May 14, 1977.
16. Kloner RA, Fishbein MC, Maroko PR, Braunwald E. The effect of propranolol on the ultrastructure of the myocardium following an experimental coronary artery occlusion. Circulation 1977;56(III):794.
17. Lew H, Kloner RA, Fishbein MC, Maroko PR, Braunwald E. Mummification of myocytes by high doses of glucocorticoids after experimental coronary artery occlusion. Circulation 1977;56(III):797.
18. Kloner RA, Maroko PR, Braunwald E. Anatomic evidence for long-term reduction of infarct size by hyaluronidase. Am J Cardiol 1978;41:393.
19. Hillis LD, Khuri SF, Kloner RA, Tow D, Barsamian EM, Maroko PR, Braunwald E. Direct evidence for the beneficial effect of propranolol on myocardial ischemia following coronary artery occlusion. Am J Cardiol 1978;41:359.
20. Braunwald E, Maclean D, Fishbein M, Kloner RA, Ribeiro LGT, Maroko PR. Can myocardial damage following coronary occlusion really be reduced? Presented at the Association of University Cardiologists, Phoenix, Arizona, January 19-20, 1978.
21. Kloner RA, Maroko PR. The geometry of the salvageable anatomic border of myocardial infarction. Circulation 1978;57 and 58(II):II-35.
22. Maroko PR, Ribeiro LGT, Kloner RA, Hale SL, Ingwall JS, Caride VJ. Transport of ATP by liposomes into the ischemic myocardium. Circulation 1978;57 and 58(II):II-58.
23. Khuri SF, Couch N, Kloner RA, Karaffa S, Barsamian EM. The signifi­cance of late intramyocardial pCO2 and pH changes following acute coronary occlusion. Clin Res 1979;27:180A.
24. Khuri SF, Kloner RA, Karaffa S, Couch N, Lai NCJ, Tow D. A new intramural pH electrode for the assessment of myocardial ischemia. Circulation 1979; 60:II-96.
25. Rude RE, Kloner RA, DeBoer LWV, Hale SL, Davis MA, Maroko PR, Braunwald E. A predictive index of subendocardial ischemic damage following coronary artery occlusion. Circulation 1979;60:II-96.
26. Kloner RA, Rude RE, Maroko PR, Braunwald E. Microvascular damage and myocardial cell injury following coronary artery occlusion: Which comes first? Circulation 1979;60:II-42.
27. Ingwall J, Kramer M, Kloner RA, Alpert NM, Newell JB, Pohost GM. T1+ accumulation: Differentiation between reversible and irreversible myocardial injury. Circulation 1979;60:II-173.
28. Rude RE, DeBoer LWV, Ingwall JS, Kloner RA, Hale SL, Davis M, Maroko PR, Braunwald E. Prediction of biochemical derangement in ischemic myocardium following experimental coronary artery occlusion. Am J Cardiol 1980;45:415.
29. Rude RE, Kloner RA, Tumas J, DeBoer LWV, Gunst M, Laver M, Maroko PR. Reduction of experimental myocardial infarct size by orthoiodo sodium benzoate. Am J Cardiol 1980;45:485.
30. DeBoer LWV, Ingwall JS, Rude RE, Maroko PR, Kloner RA, Braunwald E. Characterization of myocardial ATP degradation following coronary artery occlusion. Am J Cardiol 1980;45:415.
31. Khuri SF, Karaffa S, Kloner RA. The significance of the late fall in myocardial PCO2 following acute coronary occlusion. Am J Cardiol 1980;45:416.
32. DeBoer LWV, Strauss HW, Kloner RA, Rude RE, Davis RF, Braunwald E, Maroko PR. Autoradiography with 99Tc labeled albumin microspheres, a new method for delineation of ischemic tissue at risk of infarction: demonstra­tion of the protective effect of verapamil. Am J Cardiol 1980;45:485.
33. Wolf RA, Chuang L, Muller J, Kloner RA, Braunwald E. Intravenous bovine testicular hyaluronidase depolymerizes myocardial hyaluronic acid in dogs with coronary artery occlusion. Fed Proc 1980;39:634.
34. Ertl G, Kloner RA, Alexander RW, Braunwald E. Activation of the renin-angiotensin system following coronary occlusion. Clin Res 1980;28:610A.
35. DeBoer LWV, Kloner RA, Ingwall JS, Hale S, Dinello A, Braunwald E. Failure of recovery of myocardial ATP and purine concentrations after transient myocardial ischemia. Clin Res 1980;28:610A.
36. Glogar DH, Clark LC, Kloner RA, Inscho EW Jr, DeBoer LWV, Tumas J, Muller JE, Braunwald E. Fluorocarbons: Increased oxygen delivery and limitation of infarct size. Clin Res 1980;28:612A.
37. Rude RE, Glogar DH, Khuri SF, Karaffa S, Kloner RA, Clark LC Jr, Muller JE, Braunwald E. Beneficial effects of fluorocarbons (synthetic oxygen-carrying compounds) on intramyocardial pO2 and pCO2 during acute myocardial ischemia. Clin Res 1980;28:617A.
38. Khuri SF, Karaffa S, Kloner RA, Folland ED, Tow D, Parisi AF, Moynihan PF. Intraoperative identification of ischemic versus infarcted myocardium. Clin Res 1980;28:614A.
39. Glogar D, Clark LC Jr, Kloner RA, DeBoer LWV, Muller J, Braunwald E. Fluorocarbons-synthetic oxygen carrying compounds which reduce myocardial ischemia. Circulation 1980;62:III-144.
40. Ertl G, Kloner RA, Alexander RW, Braunwald E. Limitation of infarct size by angiotensin converting enzyme inhibitor (CEI) SQ 14225. Circulation 1980;62:III-239.
41. Ertl G, Kloner RA, Alezander RW, Braunwald E. Influence of the renin-angiotensin system on systemic and coronary resistance following coronary occlusion. Circulation 1980;62:III-144.
42. DeBoer LWV, Kloner RA, Ingwall JS, Hale S, DiNello A, Braunwald E. ATP resynthesis and purine metabolism after brief ischemia and prolonged reperfusion. Circulation 1980;62:III-176.
43. DeBoer LWV, Kloner RA, Nosta J, Tumas J, Glogar D, Braunwald E. Effects of amiodarone on experimental infarct size and hemodynamics. Circulation 1980;62:III-243.
44. Glogar DH, Kloner RA. Reduction of myocardial ischemia by balanced alpha and beta blockade with labetalol. Am J Cardiol 1981;47:II-430.
45. Rude RE, Glogar DH, Khuri SF, Karaffa S, Kloner RA, Clark LC Jr, Muller JE, Braunwald E. Effects of fluorocarbons and supplemental oxygen and supplemental oxygen on acute myocardial ischemia assessed by intramyocardial gas tension measurement. Am J Cardiol 1981;47:II-436.
46. Khuri SF, Karaffi S, Kloner RA, Folland E, Parisi A, Moynihan P, Barsamian EM. Metabolic characterization of reversible versus irreversible ischemic damage. Am J Cardiol 1981;47:II-436.
47. Franco WP, Glogar D, Kloner RA, DeBoer LWV, Muller JE, Hufnagel CA. Effects of fibroblastic growth factor on experimental myocardial ischemia. Fed Proc 1981;40:I-751.
48. DeBoer LWV, Ingwall JS, Kloner RA, Braunwald E. Reversible and irreversible ischemic injury: metabolic and ultrastructural correlates. Fed Proc 1981;40:I-758.
49. Ertl G, Kloner RA, Alexander RW, Braunwald E. Verkleinerung des experimentellen Myokardinfarktes durch Substanzen, die das Renin-Angiotensin System hemmen. Z Kardiol 1981;70:283.
50. Glogar D, Franco WP, Kloner RA, DeBoer LWV, Muller J, Braunwald E. Fibroblastenkolonie Stimulationsfaktor (FGF) und experimentelle Myokardischamie. Z Kardiol 1981;70:340.
51. Glogar D, Rude RE, Clark LC Jr, Kloner RA, Muller JE, Braunwald E. Fluorcarbone-Verringerung der Myokardischamie durch Erhohung des Sauerstoff-Angebotes. Z Kardiol 1981;70:316.
52. Ertl G, Kloner RA, Alexander RW, Braunwald. Zur Bedeutung des Renin-Angiotensin Systems fur den systemischen und koronaren Gefasswiderstand nach Koronarverschluss. Z Kardiol. 1981;70:283.
53. Kloner RA, Rutherford JD, Muller JE, Maroko PR, Braunwald. Effects of hyaluronidase following myocardial infarction in animals and humans. First Intl Symposium Hyaluronidase, Rotterdam, Netherlands. 1981.
54. DeBoer LWV, Nosta JJ, Johnson HG, Kloner RA. Reduction of myocardial infarct size by lodoxamide (U42-585E), a mast-cell inhibitor. Clin Res 1981;29:185A.
55. Glogar D, Clark LC Jr, Kloner RA, DeBoer LWV, Muller JE, Braunwald E. Reduction of myocardial ischemia by a stabilized F-Decalin Emulsion. Intl Symposium Oxygen Carrying Colloidal Blood Substitutes, Mainz, W. Germany. 1981.
56. DeBoer LWV, Ingwall JS, Kloner RA, Braunwald E. Importance of purine pool depletion during recovery from myocardial ischemia. Eur J Physiol 1981;389:(Suppl R-2).
57. Kloner RA, Kloner JA. Exercise induced scar thinning following experimental myocardial infarction. Clin Res 1981;29:653A.
58. Brown EJ Jr, Kloner RA. The effect of sulfinpyrazone on infarct size and ventricular ectopy. Clin Res 1981;29:646A.
59. Brown EJ Jr, Holman BL, Cohn PF, Wynne J, Kloner RA. Time course of regional wall dysfunction produced by exercise induced ischemia. Clin Res 1981;29:645A.
60. Kloner RA, Kloner JA. The effect of exercise on healing of myocardial infarction. Circulation 1981;64:IV-99.
61. Kloner RA, Carlson N, Braunwald E. Ultrastructure and histochemistry of post-ischemic myocardium salvaged by reperfusion. Circulation 1981;64:IV-15.
62. Ellis SG, Henschke CI, Sandor T, Wynne J, Braunwald E, Kloner RA. Biochemical and functional recovery of subepicardial border zone salvaged by reperfusion. Am J Cardiol 1981;49:1046.
63. Kloner RA, DeBoer LWV, Carlson N, Braunwald E. Effect of verapamil in cardiac ultrastructure during and following release of coronary occlusion. Am J Cardiol 1981;49:1038.
64. Brown EJ, Kloner RA, Schoen FJ, Hammerman H, Hale S, Braunwald E. Scar thinning due to ibuprofen administration following experimental myocardial infarction. Am J Cardiol 1981;49:1005.
65. Hammerman H, Kloner RA, Schoen FJ, Brown EJ,Jr, Hale S, Braunwald E. Scar thinning due to indomethacin administration following experimental myocardial infarction. Clin Res 1982;30:547A.
66. Brown EJ Jr, Holman BL, Cohn PF, Wynne J, Kloner RA. Time course of regional wall dysfunction proceeded by exercise induced ischemia. Clin Res 1982;30:175A.
67. Nieminen MS, Zierler M, O'Boyle J, Parisi A, Kloner RA, Khuri SF. Relationships of myocardial gas tensions following coronary occlusion to mural dysfunction and infarct size. Clin Res 1982;30:209A.
68. Lange R, Zierler M, Kloner RA, Carlson N, Sieler M, Khuri SF. Time course of ischemic damage to the normo- and hypothermic arrested heart and its relation to myocardial pH. Is there a role for intraoperative pH measurement? Arch Chirurgie 1982;357:214.
69. Khuri S, Reifart N, Lange R, Kloner RA, Zierler M. A new electrode to monitor myocardial ischemia and preservation. World Congress of Cardiology, Moscow, USSR, 1982.
70. Glogar D, Clark LC, Kloner RA, Muller JE, Braunwald E. Improvement of regional myocardial blood flow (RMBF)- Hemodilution with perfluorocarbon (PFC) emulsions. World Congress of Cardiology, Moscow, 1982.
71. Nieminen MS, O'Boyle JE, Folland ED, Khuri S, Kloner RA. Serial assessment of myocardial infarct size by two-dimensional echocardiography: Evidence for a functional "border zone." World Congress of Cardiology, Moscow, USSR, 1982;1:0316.
72. Ellis SG, Henschke C, Wynne J, Kloner RA. Causes and effects of reperfusion associated myocardial hemorrhage. Clin Res 1982;30:668A.
73. Roberts CS, Maclean D, Maroko PR, Braunwald E, Kloner RA. Is myocar­dial infarction size a determining factorain scar thinning? Clin Res 1982;30:678A.
74. Lange R, Kloner RA. A series of brief occlusions: Is there a cumulative deterioration in myocardial blood flow and regional function? Clin Res 1982;30:673A.
75. Hammerman H, Kloner RA, Brown EJ Jr, Braunwald E. Detection of in vivo scar thinning due to antiinflammatory agents following myocardial infarction. Clin Res 1982;30:671A.
76. Lange R, Kloner RA, Braunwald E. Segmental wall function, blood flow, and the development of infarction during repetitive brief occlusions. Circulation 1982;66:1025.
77. Hammerman H, Kloner RA. Early short-term exercise has prolonged effect on myocardial infarct scar formation. Circulation 1982;66:260.
78. Hammerman H, Schoen FJ, Kloner RA. Early myocardial infarct expansion due to indomethacin administration. Circulation 1982;66:332.
79. Lange R, Kloner RA, Braunwald E. The first ultrashort acting beta blocker: Effects on size and segmental wall dynamics of the reperfused infarct. J Am Coll Cardiol 1983;1:668.
80. Tumas J, Deth RC, Kloner RA. Effects of nisoldipine on experimental infarct size and hemodynamics. XII Annual Meeting-New England Pharmacolo­gists, Boston, MA 1983;XII:57.
81. Roberts CS, Schoen FJ, Kloner RA. Does hemorrhagic myocardial infarction induced by early coronary reperfusion affect infarct healing? Clin Res 1983;31:214A.
82. Hammerman H, Kloner RA, Hale SL, Schoen FJ, Braunwald E. Is scar thinning and LV topographic alterations induced by antiinflammatory agent of functional significance? Clin Res 1983;31:190A.
83. Kemper A, O'Boyle J, Sharma S, Cohen C, Khuri S, Kloner RA, Parisi A. In vivo echocardiographic quantification of acute myocardial ischemia using supraaortic hydrogen peroxide injection. Clin Res 1983;31:195A.
84. Lange R, Hale SL, Alker KJ, Kloner RA. Recurrent ischemia: Are functional, biochemical and structural alterations exacerbated? Clin Res 1983;31:198A.
85. Lange R, Kloner R, Marston W, Khuri S. Significance of the rise in myocardial tissue pH following cardioplegia administration: A function of temperature or the alkalinity of the solution? Clin Res 1983;31:198A.
86. Hammerman H, Kloner RA, Briggs LL, Braunwald E. Combination therapy for early treatment of myocardial infarction: beta blockade plus reperfu­sion. Clin Res 1983;31:524A.
87. Ellis SG, Wynne J, Henschke C, Braunwald E, Kloner RA. Does reperfusion-salvaged, stunned myocardium respond to inotropic stimulation? Fed Proc 1983;42:4915.
88. Ellis SG, Henschke C, Wynne J, Kloner RA. Determinants and consequences of hemorrhagic myocardial infarction induced by coronary reperfusion. Fed Proc 1983;42:2931.
89. Lange R, Kloner RA, Braunwald E. The first ultra short acting beta blocker: effects on size and segment function of the reperfused infarct. Thorac Cardiovasc Surg 1983;31:40.
90. Henschke CI, Ellis SG, Risser TA, Wynne J, Kloner RA, Sandor T. Quantitative computer assisted analysis of left ventricular wall motion and wall thickness using two dimensional cardiac ultrasound. Am Roent Ray Soc, Atlanta, Georgia, 1983.
91. Lange R, Nieminen MS, Kloner RA. Failure of pindolol and metoprolol to reduce the size of nonreperfused infarcts as a function of the area at risk. Clin Res 1983;31:667A.
92. Tumas J, Deth RC, Kloner RA. Effects of nisoldipine on myocardial infarct size, hemodynamics, and myocardial performance. Clin Res 1983;31:673A.
93. Kloner RA, Alker K. The effect of streptokinase on myocardial hemorrhage and infarct size. Clin Res 1983;31:666A.
94. Lange R, Ingwall J, Alker K, Kloner RA. Importance of intermittent reperfusion for the preservation of myocardial nucleotides and function during recurrent ischemia. Circulation 1983;68:III-389.
95. Lange R, Kloner RA, Marston WA, Khuri SF. Is the alkalinity of crystalloid cardioplegia important in myocardial protection? Circulation 1983;68:III-184.
96. Hale SL, Lange R, Alker KJ, Kloner RA. Spontaneous ventricular fibrillation upon reperfusion: A flow dependent phenomenon? Circulation 1983;68:III-192.
97. Hammerman H, Kloner RA, Briggs LL, Braunwald E. Enhancement of reperfusion salvage by early beta adrenergic blockade. Circulation 1983;68:III-187.
98. Hammerman H, Schoen FJ, Braunwald E, Kloner RA. Ventricular topo­graphic alterations caused by afterload increase during experimental myo­cardial infarction. J Am Coll Cardiol 1984;3:591.
99. Lange R, Kloner RA, Braunwald E. Enhancement of functional recovery of "stunned," reperfused myocardium by a new ultrashort-acting beta-blocker. J Am Coll Cardiol 1984;3:545.
100. Ellis S, Wynne J, Henschke C, Sandor T, Kloner RA. Relation of myocardial salvage with coronary reperfusion to function at 14 days: Importance of transmurality of infarction. J Am Coll Cardiol 1984;3:523.
101. Przyklenk K, Vivaldi MT, Arnold JMO, Schoen FJ, Kloner RA. Capillary anastomoses between coronary beds: Microvascular evidence for a border zone. Fed Proc 1984;43:4218.
102. Vivaldi MT, Kloner RA, Taajes D, Schoen FJ. Triphenyltetrazolium chloride accurately delineates myocardial infarcts. Fed Proc 1984;43:2487.
103. Arnold JMO, Alvarez PH, Przyklenk K, Antman E, Vivaldi MT, Schoen FJ, Kloner RA. Does coronary reperfusion increase the incidence of late ven­tricular arrhythmias? Clin Res 1984;32:149A.
104. Brown EJ, Holman BL, Cohn PF, Wynne J, Kloner RA. What is the time course of exercise induced myocardial ischemia in humans? Clin Res 1984;32:151A.
105. Kirshenbaum JM, Kloner RA, Antman EI, Braunwald E. Use of an ultra-short acting beta blocker in patients with acute myocardial ischemia: hemodynamic and electrical consequences. Circulation 1984;70:II-45.
106. Hale SL, Alker KJ, Ingwall JS, Lo H-M, Kloner RA. Alterations in high energy phosphates and catabolites in a canine model of reperfusion-induced ventricular fibrillation. Circulation 1984;70:II-81.
107. Vivaldi MT, Eyre DR, Schoen FJ, Kloner RA. Collagen content, types and crosslinking in myocardial infarct scar tissue: effect of methylprednisone. Circulation 1984;70:II-243.
108. Lo H-M, Braunwald E, Kloner RA. Intracoronary calcium blockade at the time of reperfusion. Circulation 1984;70:II-260.
109. Vivaldi MT, Kloner RA, Schoen FJ. Simulated autopsy detection of early myocardial infarcts: effects of duration of ischemia and autolysis. J Am Coll Cardiol 1985;5:400.
110. Arnold JMO, Kloner RA, Sandor T, Braunwald E. Does inotropic stimulation of stunned myocardium increase infarct size or result in an eventual deterioration of function? J Am Coll Cardiol 1985;5:509.
111. Kemper A, Force T, Kloner RA, Hale SL, Alker KJ, Gilfoil M, Perkins L, Parisi AF. Contrast echocardiographic estimation of regional blood flow following coronary occlusion. Clin Res 1985;199A.
112. Arnold JMO, Przyklenk K, Sandor T, Braunwald E, Kloner RA. Salvage of ventricular function by coronary reperfusion. Clin Res 1985;33:166A.
113. Warner KG, Khuri SF, Kloner RA, Josa M, Lee SS, Seiler M. Preserva­tion of the hyperptophied myocardium during valvular heart surgery: ultra­structure and metabolic assessment. Clin Res 1985;33:235A.
114. Holman BL, Campbell CA, Lister-James J, Jones AG, Kloner RA. The effect of reperfusion and hyperemia on the biodistribution of the myocardial imaging agent, TC-99m TBI. J Nucl Med 1985;25:P13.
115. Przyklenk K, Lange R, Kloner RA. The "stunned myocardium." Interna­tional Symposium on Myocardial Protection, Boston, MA, 1985, p.7.
116. Warner KG, Josa M, Kloner RA, Lee S, Sieler M, Khuri SF. The limita­tion of current cardioplegia techniques in protecting the hyper­trophied myocardium in man. International Symposium on Myocardial Protec­tion, Boston, MA, 1985, p.80.
117. Warner KG, Khuri SF, Kloner RA, Josa M, Lee SS, Sieler M. Preserva­tion of ultrastructure in the hypertrophied myocardium during valvular heart surgery and its relationship to metabolic and clinical indices. Society of Veterans Administration Surgeons Meeting, Tampa, FL, 1985.
118. Kloner RA. The no-reflow phenomenon and the stunned myocardium. Graduate Hospital Research Symposium, Acute Myocardial Infarction: Emerging concepts of pathogenesis and treatment. 1985, p.21.
119. Przyklenk K, Vivaldi MT, Arnold JMO, Schoen FJ, Kloner RA. Myocardial protection by coronary reperfusion: analysis of infarct size, ventricular function, and spontaneous arrhythmias. Clin Invest Med 1985;8:B42.
120. Alker KJ, Hale SL, Ingwall JS, Kloner RA. Difference in recovery of adenosine triphosphate versus creatine phosphate in the stunned myocardium: effect of l-hydroxyphenylglycine. Clin Res 1985;33:797A.
121. Campbell CA, Kloner RA. Intermittent coronary reperfusion does not reduce anatomic infarct size. Clin Res 1985;33:800A.
122. Hale SL, Kloner RA. Fluorescent microspheres: a new method for measurement of myocardium at risk after coronary artery occlusion. Clin Res 1985;33:807A.
123. Przyklenk K, Connelly CM, McLaughlin RJ, Kloner RA, Apstein CS. Why doesn't necrotic myocardium rupture more often? Clin Res 1985;33:814A.
124. Hale SL, Vivaldi MT, Kloner RA. Fluorescent microspheres: a new tool for visualization of coronary blood flow patterns during ischemia. Circulation 1985;72:III-21.
125. Przyklenk K, Kloner RA. Free radical scavengers improve contractile function but not adenosine triphosphate content of the "stunned myocardium." Circulation 1985;72:III-350.
126. Patel B, Kloner RA. A critical analysis of streptokinase therapy for acute myocardial infarction. Circulation 1985;72:III-412.
127. Campbell CA, Wynne J, Mehta P, Kloner RA. The inotropic agent amri­none does not increase myocardial infarct size. J Am Coll Cardiol 1986;7:89A.
128. Przyklenk K, Tetef M, Kloner RA. Role of free radicals in regional myocardial ischemia and infarction. Presented at Free Radicals in Biology and Medicine: Ischemia/Reperfusion Injury, March 17-19, 1986, Point Clear, AL, p.39.
129. Patel B, Kloner RA, Ensley J, Al-Sarraf M, Kish J, Wynne J. Cardio­toxicity simulating myocardial ischemia with left ventricular dysfunction in patients receiving 5-fluorouracil. Clin Res 1986;34:405A.
130. Kloner RA, Braunwald E. Effects of calcium antagonists on infarcting myocardium. Presented at Calcium Antagonists: Emerging Clinical Oppor­tunities--A Worldwide Perspective, September 11-12, 1986, Boston, MA.
131. Lavine SJ, Campbell CA, Gunther SJ, Kloner RA. Effect of increased left ventricular size and filling pressure on diastolic filling. Presented at Ohio-Genessee Cardiovascular Conference, June 6, 1986, Ann Arbor, MI.
132. Przyklenk K, Tetef M, Kloner RA. Role of free radicals in regional myocardial ischemia and infarction. Presented at the Sixteenth Annual Cardiovascular Research Forum of the American Heart Association of Michigan, Sept. 11, 1986, Detroit, MI.
133. Przyklenk K, Kloner RA. Effect of free radical scavengers on infarct size during coronary occlusion: salvage or delay of myocyte necrosis? Presented at X World Congress of Cardiology, Sept. 14-19, 1986, Abstract Book, pg. 112.
134. Hale SL, Kloner RA. Temporal progression of necrosis in a model of low collateral blood flow. Clin Res 1986;34:894A.
135. Przyklenk K, Hale SL, Kloner RA. Adenosine triphosphate depletion and creatine phosphate overshoot in postischemic stunned myocardium: effect of verapamil. Clin Res 1986;34:899A.
136. Whittaker P, Przyklenk K, Boughner DR, Canham PB, Hammerman H, Kloner RA. Maturation of myocardial scar collagen assessed by polarized light microscopy. Clin Res 1986;34:905A.
137. Lavine SJ, Campbell CA, Gunther SJ, Kloner RA. Effect of increased left ventricular size and filling pressure on diastolic filling. Clin Res 1986; 34:944A.
138. Przyklenk K, Ghafari GB, Kloner RA. Slow calcium channel blockade with verapamil attenuates postischemic myocardial stunning. Circulation 1986; Suppl. II, 74:II-69.
139. Hale SL, Kloner RA. Salvage of ischemic myocardium by reperfusion in a model of minimal coronary collateral blood flow. Circulation 1986;Suppl. II, 74:II-261.
140. Alker KJ, Kloner RA. Is digoxin deleterious during acute myocardial infarction? Circulation 1986;Suppl. II, 74:II-267.
141. Kirshenbaum JM, Antman E, McGowan N, Kloner RA. Use of esmolol in patients with acute myocardial ischemia and contraindications to beta blockade. J Am Coll Cardiol 1987;9:24A.
142. Turi Z, Campbell CA, Kloner RA. The autoperfusion balloon angio­plasty catheter prevents ischemia during prolonged balloon inflation. J Am Coll Cardiol 1987;9:106A.
143. Przyklenk K, Patel B, Kloner RA. Isovolumic relaxation and systolic contraction of postischemic stunned myocardium: divergent effects of verapamil. J Am Coll Cardiol 1987;9:93A.
144. Campbell CA, Turi ZG, Gottimukkala MV, Kloner RA. The effect of non-inflated angioplasty catheters on regional myocardial blood flow. Clin Res 1987;35:265A.
145. Campbell CA, Lavine SJ, Gunther SJ, Kloner RA. Left ventricular dilatation assessed by echocardiography in a canine model of microsphere-induced acute heart failure. Clin Res 1987;35:265A.
146. Campbell CA, Clavenna C, Wynne J, Kloner RA. The hemorheologic agent pentoxifylline does not reduce infarct size. Clin Res 1987;35:265A.
147. Rezkalla S, Khatib R, Khatib G, Walsh M, Sowers J, Smith FE, Kloner RA. Effect of indomethacin in the late phase of coxsackievirus B3 murine myocarditis. Clin Res 1987;35:319A.
148. Rezkalla S, Khatib R, Khaw BA, Haber E, Smith FE, Kloner RA. Monoclonal antimyosin antibody in coxsackievirus B3 murine myocarditis. Clin Res 1987;35:319A.
149. Kloner RA. The no-reflow phenomenon following acute myocardial infarction. Annals of Biomedical Engineering 1987;15:108.
150. Pazdur R, Chabot GG, Campbell CA, Kloner RA, Baker LH. Acodazole Phase I trial and evaluation of cardiac toxicity. Proceedings of the American Association for Cancer Research, 1987.
151. Kloner RA, Braunwald E. Adjuvant therapy for coronary reperfusion during evolving myocardial infarction. Presented at the International Symposium on Limitation of Infarct Size, European Society of Cardiology, June 4-6, 1987, Berlin, Germany.
152. Patel B, Kloner RA. Analysis of randomized trials of streptokinase therapy for acute myocardial infarction in the 1980s. International Synopses, 1987.
153. Kloner RA, Przyklenk K. Recent advances in stunned myocardium. Presented at The Ischemic Cascade Regional Symposia, June 13-14, 1987, Orlando, FL, and July 18, 1987, San Francisco, CA.
154. Rezkalla S, Khatib R, Khatib G, Walsh M, Sowers J, Smith FE, Kloner RA. Effect of indomethacin in the late phase of coxsackievirus B-3 murine myocarditis. Presented at the American College of Physicians, Michigan chapter regional meeting, September 18, 1987, Traverse City, MI.
155. Kloner RA. The "stunned" myocardium: the pathophysiology of the failing ischemic heart. Presented at New York State Society of Anesthesiologists, Inc., Postgraduate Assembly, December 12-16, 1987, New York, NY.
156. Kloner RA, Przyklenk K. Myocardial stunning: an emerging new clinical concept. Presented at Cardiovascular Therapy: The Next Step (symposium), September 18, 1987, Southampton, Bermuda.
157. Rezkalla S, Khatib R, Walsh M, Sowers J, Smith FE, Kloner RA. Atrial natriuretic peptide in acute coxsackievirus B3 murine myocarditis. Clin Res 1987;35:836A.
158. Whittaker P, Boughner D, Kloner RA. Myocardial disarray adjacent to healed infarcts. Clin Res 1987;35:841A.
159. Przyklenk K, Kloner RA. Reliable detection of postischemic "stunned myocardium" by two-dimensional echocardiography. Clin Res 1987;35:836A.
160. Turi ZG, Rezkalla S, Campbell CA, Kloner RA. Coronary angioplasty in patients with proximal epicardial stenoses: results of a study of the "autoperfusion" balloon catheter in humans. Circulation 1987;76 (Suppl IV):IV-28.
161. Przyklenk K, Kloner RA. Nifedipine administered postreperfusion ablates the phenomenon of the "stunned myocardium." Circulation 1987;76 (Suppl IV):IV-198.
162. Przyklenk K, Kloner RA. "Reperfusion injury" by oxygen-derived free radicals: a flow dependent phenomenon. Circulation 1987;76 (Suppl IV): IV-230.
163. Turi ZG, Rezkalla S, Campbell CA, Kloner RA. Left main coronary angioplasty: preservation of distal blood flow using a new "autoperfusion" balloon catheter. Circulation 1987;76 (Suppl IV):IV-466.
164. Przyklenk K, Kloner RA. Postischemic "stunned" myocardium is characterized by prolonged diastolic relaxation time. Circulation 1987;76 (Suppl IV):IV-542.
165. Przyklenk K, Kloner RA. Superoxide dismutase plus catalase improve contractile function in the canine model of the "stunned myocardium." In: Rogers MC (ed), The Yearbook of Critical Care Medicine. Chicago: Year Book Medical Publishers, Inc., 1987;pp. 236-240.
166. Campbell CA, Alker KJ, Kloner RA. Does tissue plasminogen activator reduce infarct size in an experimental model of mechanical coronary artery occlusion and reperfusion in dogs? J Am Coll Cardiol 1988;11 (Suppl A): 54A.
167. Przyklenk K, Kloner RA. What factors predict recovery of contractile function of postischemic stunned myocardium? J Am Coll Cardiol 1988;11 (Suppl A):92A.
168. Przyklenk K, Kloner RA. Does reduced oxygen demand improve con­tractile function of postischemic "stunned" myocardium? J Am Coll Cardiol 1988; 11 (Suppl A):93A.
169. Campbell CA, Rezkalla S, Kloner RA, Turi ZG. The autoperfusion balloon angioplasty catheter limits myocardial necrosis during 90 minutes of balloon inflation. J Am Coll Cardiol 1988;11 (Suppl A):149A.
170. Rezkalla S, Khatib R, Khatib G, Smith FE, Kloner RA. Effect of metoprolol in acute coxsackievirus B3 murine myocarditis. J Am Coll Cardiol 1988; 11 (Suppl A):196A.
171. Kloner RA, Przyklenk K. Cardioprotective effect of ACE inhibitor therapy. New Developments in Cardiovascular Disease for Primary Care Physicians symposium, February 27, 1988, Newport Beach, CA.
172. Ghafari GB, Eitzman DT, Kloner RA, Przyklenk K. Delayed treatment with nifedipine abolishes postischemic myocardial "stunning." American College of Physicians 69th Annual Session, New York, NY, 1988, pg. 30.
173. Przyklenk K, Kloner RA. Does superoxide dismutase plus catalase enhance recovery of regional contractile function following prolonged coronary artery occlusion? Free Radicals in Biology and Medicine: Ischemia/Reperfusion Injury symposium, March 6-9, 1988, Point Clear, AL., pg. 18. also in Free Rad Res Comm Vol. 5, No. 3, p 205, 1988.
174. Kloner RA, Przyklenk K. Reperfusion-induced myocardial injury and free radicals. Cardioprotective Effects of Angiotensin-Converting Enzyme Inhibitors symposium, March 26, 1988, Atlanta, GA.
175. Kloner RA, Przyklenk K. Recent advances in myocardial stunning: an introduction to therapeutic considerations. The Spectrum of Myocardial Ischemia symposium, March 26, 1988, Atlanta, GA.
176. Hale SL, Alker KJ, Kloner RA. Colored (nonradioactive) microspheres vs radioactive microspheres for regional myocardial blood flow measurement. Clin Res 1988;36:282A.
177. Rezkalla S, Kloner RA, Al-Sarraf M, Bhasin S, Revels S, Ensley J, Kerpel-Fronius S, Olivenstein A, Turi ZG. Continuous ambulatory electro-cardiographic monitoring during 5-fluorouracil therapy: a prospective study. Clin Res 1988;36:499A.
178. Kloner RA. The stunned myocardium: an update. Symposium: Advanced Cardiovascular Therapy: Redefining Clinical Goals. St. George, Bermuda, April 15, 1988.
179. Kloner RA, Przyklenk K. Free radical scavengers and preservation of myocardial structure and function. Presented at XIIth meeting of the International Society on Oxygen Transport to Tissue. Ottawa, Ontario, Canada. August 7-11, 1988.
180. Przyklenk K, Kloner RA. Oxygen free radicals and reperfusion induced myocardial injury. Presented at Evolving Concepts in Clinical Cardiology. Boston, MA, August 5, 1988.
181. Kloner RA, Przyklenk K, Whittaker P. Free Radical Scavengers. Presented at Fosinopril and Zofenopril Worldwide Investigators Seminar. Southampton, Bermuda. October 2-5, 1988.
182. Kloner RA. Myocardial Stunning: Pathophysiology and Clinical Implications. Presented at Newer Aspects of Ischemic Heart Disease. St. George, Bermuda. October 20-23, 1988.
183. Kloner RA, Przyklenk K. Reperfusion-Induced Myocardial Injury and Free Radicals. Presented at 2nd Canadian Update on ACE-Inhibition. Nassau, Bahamas. November 24-27, 1988.
184. Kloner RA, Przyklenk K. Reperfusion-Induced Myocardial Injury and Free Radicals. Presented at Cardioprotective Effects of Angiotensin Converting Enzyme Inhibition, Washington, DC. November 13, 1988.
185. Kloner RA, Przyklenk K, Ghafari G. The Stunned Myocardium: Heart Muscle Weakness and Recovery Following Ischemia. In the proceedings of the 82nd Annual Scientific Assembly of the Southern Medical Association 1988 Abstracts Book (Scientific Exhibits) p. 124.
186. Whittaker P, Kloner RA, Pryzklenk K. In Vivo Damage by Exogenous Oxygen Radicals Mimics Ischemia/Reperfusion Injury. Circulation 78 (Suppl II):II-30,1988.
187. Hale S, Lehmann MH, Kloner RA. Electrocardiographic and Ultrastructural Changes in Cocaine-Induced Cardiotoxicity. Circulation 78 (Suppl II):II-146,1988.
188. Przyklenk K, Whittaker P, Kloner RA. Direct Evidence that Oxygen Free Radicals Cause Contractile Dysfunction In Vivo. Circulation 78 (Suppl II):II-264,1988.
189. Hale S, Kloner RA. Late Coronary Artery Reperfusion Has Beneficial Effects Unrelated to Infarct Size Reduction. Circulation 78 (Suppl II):II-643,1988.
190. Hale S, Alker KJ, Rezkalla S, Figures G, Kloner RA. Cardiopressant Effects of Cocaine. J Am Coll Cardiol. 13;78A,1989.
191. Przyklenk K, Hale S, Kloner RA. Does Acute Pharmacologic Stimulation of Stunned Myocardium Have Chronic Deleterious Effects? J Am Coll Cardiol. 13;219A,1989.
192. Kloner RA, Alker K, Eisenhauer A, Campbell C. The effect of TPA on myocardial cells, the no-reflow phenomenon, and intramyocardial hemorrhage. J Am Coll Cardiol 13;124A;1989.
193. Przyklenk K, Ghafari GB, Eitzman DT, Kloner RA. The calcium channel blocking agent Nifedipine improves contractile function of stunned myocardium by a direct cellular mechanism. J Mol Cell Cardiol. 21(Suppl II);53,1989.
194. Hale S, Alker KJ, Rezkalla S, Figures G, Kloner RA. Does Cocaine Cause Myocardial Ischemia? Clin Research 37; 94A, 1989.
195. Przyklenk K, Whittaker P, Kloner RA. Zofenopril, a Newly Developed Sulfhydryl-Containing Converting Enzyme Inhibitor, Enhances Recovery of Contractile Function of "Stunned" Myocardium. International Symposium on ACE Inhibition, London UK, February 1989.
196. Kloner RA. Reperfusion Injury - Pathophysiology and Implications at "Frontiers of Cardiovascular Therapy and Cardiac Protection; Resolved and Unresolved Issues" - Antigua, January 5-6, 1989.
197. Whittaker P, Przyklenk K, Boughner DP, Kloner RA. Collagen damage in two different models of stunned myocardium. J Mol Cell Cardiol 21(Suppl II). S 163;1989.
198. Mamby SA, Kloner RA, Zalewski A, Goldberg S, Turi ZG. Does reperfusion with tissue plasminogen activator correlate with EKG parameters of myocardial infarct size? Clin Res 37;276A,1989.
199. Rezkalla S, Turi ZG, Keedy D, Prcevski P, Kloner RA. Left main coronary angioplasty in sheep using a new left main autoperfusion balloon catheter. Clin Res 37;289A,1989.
200. Rezkalla S, Kloner RA, Khatib G, Khatib R. Beneficial effects of captopril on acute coxsackievirus B3 murine myocarditis. Clin Res 37;438A,1989.
201. Reddy R, Wynne J, Kloner RA, Przyklenk K. Deferoxamine fails to provide sustained protection against ischemia/reperfusion injury Circ 80(Suppl II):II 238-1989.
202. Kloner RA, Alker KJ, Giacomelli F. Influx of neutrophils into the walls of large epicardial coronary arteries in response to ischemia/reperfusion. Circ.80 (Suppl II): II-401, 1989.
203. Rezkalla S, Kloner RA, Khatib G, Khatib R. Effect of captopril on experimental acute coxsackievirus B3 murine myocarditis. Circ. 80 (Suppl II): II-665, 1989.
204. Przyklenk K, Kloner RA, Oxygen free radicals cause systolic, but not diastolic dysfunction. J. Am Coll. Cardiol. 15 (Suppl. A); 9A, 1990.
205. Hagar JM, Hale S, Kloner RA. Effect of preconditioning ischemia on reperfusion arrhythmias and high energy phosphates after coronary artery occlusion and reperfusion. J. Am Coll. Cardiol. 15 (Suppl A); 31A, 1990.
206. Hale SL, Kloner RA. Time course of infiltration and distribution of neutrophils following coronary artery reperfusion. J. Am Coll. Cardiol 15(Suppl A); 32A, 1990.
207. Hale SL, Kloner RA, Dawson RL, Alker KJ, Eisenhauer AC, Rezkalla S. Nifedipine protects the heart against the acute deleterious effects of cocaine. J. Am Coll. Cardiol. 15 (Suppl A); 87A, 1990.
208. Kloner RA, Allen J, Zheng Y, Ruiz C. Myocardial stunning following exercise treadmill testing in man. J. Am Coll Cardiol. 15 (Suppl A); 203A, 1990.
209. Whittaker P, Boughner DR, Kloner RA. Early infarct expansion and collagen damage. Structural changes and temporal relationships. J. Am Coll Cardiol 15(Suppl A); 206 A, 1990.
210. Khatib R, Reyes MP, Rezkalla S, Khatib G. Smith F. Kloner RA. Augmentation of cardiac injury and focal ventricular thinning due to indomethacin in the late phase of coxsackieverus B4 murine myocarditis. Clin. Res. 38:255A, 1990. (Winner of the Henry Cushing Award; American Federation of Clinical Research, Washington D.C; May 1990).
211. Whittaker P, Boughner DR, Kloner RA. Early infarct expansion and collagen damage: Structural changes and temporal relations. Abstract at Leverna Titus Young Investigators Forum of the Greater Los Angeles Affiliate of the American Heart Association at Cedars Sinai Medical Center, Los Angeles, California. May 17, 1990. (Dr. Whittaker tied for first place in young investigators competition).
212. Whittaker P, Cole JH, Kloner RA. Laser mediated thermal injury revealed by polarized light microscopy. Circ. 82 (Suppl III) III-47, 1990.
213. Przyklenk K, Kloner RA. Angiotensin converting enzyme inhibitors enhance contractile function of "stunned" myocardium by different mechanisms of action. Circ. 82 (Suppl III), III-264, 1990.
214. Przyklenk K, Bauer B, Kloner RA. Contractile function of hibernating myocardium. Effect of collateral vs. stenotic perfusion. Circ. 82 (Suppl III), III-273, 1990.
215. Whittaker P, Kloner RA. Growth hormone treatment accelerates collagen deposition in myocardial scars. Circ. 82 (Suppl III), III-289, 1990.
216. Kloner RA, Alker KJ, Hale SL. Effect of neutrophil infiltration into large epicardial coronary arteries after reperfusion. Circ. 82 (Suppl III), III-766, 1990.
217. Przyklenk R, Bauer B, Kloner RA. Early but transient postischemic contraction: A reliable indicator of viable myocardium? J. Am Coll. Cardiol. 1991;17:118A.
218. Li Y, Whittaker P, Kloner RA. Reduction of infarct size by preconditioning ischemia: A transient phenomenon? J. Am Coll. Cardiol. 1991;17:311A.
219. Simkhovich BZ, Hale SL, Kloner RA. Brief periods of preconditioning ischemia prevent deleterious changes in carnitine dependent metabolism in rabbits with sustained myocardial ischemia. FASEB Journal. 1991;5:A1047.
220. Alker KJ, Rezkalla S, Hale SL, Kloner RA. Acute cocaine causes a prolonged depression in coronary blood flow but not in left ventricular systolic function. Clin Res 1991; 39:231A.
221. Rezkalla S, Hale SL, Alker KJ, Kloner RA. Effect of cocaine on diastolic function of canine myocardium. Clin Res 1991; 39:460A.
222. Whittaker P,Kloner RA, Przyklenk K. Do laser-mediated transmural myocardial channels salvage ischemic myocardium? Circ 84 (Suppl II), II-285, 1991.
223. Ovize M, Przyklenk K, Kloner RA. Does ischemic "preconditioning preserve regional contractile function. Circ. 84 (Suppl II), II-431, 1991.
224. Przyklenk K, Bauer B, Ovize M, Kloner RA, Whittaker P. Regional ischemic "preconditioning" protects remote virgin myocardium from subsequent sustained ischemia. Circ. 84 (Suppl II), II-433, 1991.
225. Ovize M, Przyklenk K, Kloner RA. Repeated coronary thrombus formation protects canine myocardium from subsequent sustained ischemia. Circ. 84 (Suppl II), II-619, 1991.
226. Li Y, Kloner RA. Ischemic "preconditioning" mediated by cardioprotective prostanoids? Circ. 84 (Suppl II), II- 619, 1991.
227. Hagar J, Matthews RV, Kloner RA. Use of an intravascular ultrasound catheter for quantitative 2-D echocardiography in the rat. Circ. 84 (Suppl II), II-703, 1991.
228. Kloner RA. Clinical applicability and limitations of animal models in assessing progression of myocardial necrosis and reperfusion after coronary occlusion. Scientific Abstract Book. From a symposium entitled "Pharmacologic and Mechanical Interventions in Ischemic Heart Disease," New York City. Sponsored in the New York State Chapter, American College of Cardiology. September 27-28, 1991.
229. Kloner RA. Modification of reperfusion injury, myocardial stunning, and infarct expansion in the experimental animal. Scientific Abstract Book. From a symposium entitled "Pharmacologic and Mechanical Interventions in Ischemic Heart Disease," New York City. Sponsored by the New York Cardiological Society and the New York State Chapter, American College of Cardiology, September 27 - 28, 1991.
230. Hagar JM, Newman LG, Kloner RA. Effects of Amlodipine on Acute Myocardial Infarction, Infarct Expansion and Ventricular Geometry. J. Am Coll. Cardiol. 1992; (Suppl A) 19:45A.
231. Hale SL, Kloner RA. Preconditioning Ischemia Attenuates Low-Reflow After Coronary Occlusion in the Rabbit Heart. J. Am Coll. Cardiol. 1992; (Suppl A) 19:58A.
232. Simkhovich BZ, Ovize M, Kloner RA. Ischemic "Preconditioning" by Repeated Coronary Thrombus Formation is Associated with Favorable Alterations in Carnitine-Linked Metabolism in the Heart. J. Am Coll. Cardiol. 1992: (Suppl A) 19:118A.
233. Ovize M, Przyklenk K, Kloner RA. Preconditioning Does Not Prevent Myocardial Stunning. J. Am Coll. Cardiol. 1992; (Suppl A) 19:132A.
234. Rezkalla S, Mazza JJ, Kloner RA, Pillema V, Chang SH. The Effect of Cocaine on Human Platelets. J. Am Coll. Cardiol. 1992; (Suppl A) 19:322A.
235. Li Y, Whittaker P, Kloner RA. Reduction of infarct size by preconditioning ischemia: A transient phenomenon? In Abstract Book. American Heart Association, Greater Los Angeles Affiliate. Laverna Titus Young Investigators Forum. Page 31.
236. Ovize M, Przyklenk K, Kloner RA. Repeated coronary thrombus formation protects myocardium from subsequent sustained ischemia, In abstract booklet. American Heart Association, Greater Los Angeles Affiliate. Laverna Titus Young Investigators Forum. Page 41.
237. Prentice H, Newman K, Kloner RA, Kedes L. Regulatory analysis of the human fast and cardiac troponin C genes by direct DNA injection in rat hearts. In Abstract Book. American Heart Association, Greater Los Angeles Affiliate. Laverna Titus Young Investigators Forum. Page 45.
238. Ovize M, Kloner RA, Przyklenk K. Effect of Preconditioning on Regional Contractile Function: Combined Experience from Three Protocols. J Mol Cell Cardiol. 24(Suppl III);S13,1992.
239. Whittaker P, Kloner RA. Assessment of Myocardial Fibrosis: Underestimation Using Trichrome Staining. J Mol Cell Cardiol. 24(Suppl III);S39,1992.
240. Li Y, Kloner RA. Ischemic "preconditioning" is not mediated by adenosine receptors in the rat heart. Circ. 1992 (Suppl I) 86:I-24.
241. Ovize M, Przyklenk K, Kloner RA. Myocardial dilation, in the absence of ischemia, preconditions the canine heart. Circ. 1992 (Suppl I) 86:I-32.
242. Bauer B, Kloner RA, Przyklenk K. Does preconditioning attenuate the loss of coronary vasodilator reserve following sustained ischemia/reperfusion? Circ. 1992 (Suppl I) 86:I-220.
243. Prentice HM, Kloner RA, Newman L, Li Y, Christensen T, Kedes L. Transcriptional regulation of the human cardiac and fast tropinin C genes in adult rat myocardium. Circ. 1992 (Suppl I) 86:I-353.
244. Gardin JM, Wong N, Alker K, Hale S, Paynter J, Bellows S, Knoll M, Jamison B, Patterson M, Kloner RA. Acute cocaine induces ventricular regional wall motion and ultrastructural abnormalities. Circ 1992 (Suppl I) 86:I-440.
245. Bauer B, Kloner RA, Przyklenk K. Effect of "preconditioning" on myocardial perfusion following relief of sustained ischemia. Eur. Heart J. 1992; 13:53.
246. Bauer B, Kloner RA, Przyklenk K. Does "preconditioning" attenuate the loss of coronary vasodilator reserve following sustained ischemia/reperfusion? Eur. Heart J 1992;13:245.
247. Ovize M, Przyklenk K, Kloner RA. Preconditioning with one very brief episode of ischemia does not enhance recovery of function in peri-infarct tissue. Eu. Heart J. 1992; 13:438.
248. Ruiz CE, Gamra H, Whittaker P, Bellows SD, Zhang HP, Kloner RA. Localized intracoronary drug delivery using a newly designed balloon catheter. Eur. Heart J 1992;13:83.
249. Sowers JR, DiBona GF, Kloner RA, Puente JG and ACCT Study Group. Antihypertensive and metabolic effects of amlodipine (AML) in patients with essential hypertension. J. Am Soc. Nephrology 1992; 3:537-538.
250. Sowers JR, BiBona GF, Kloner RA, Puente J and ACCT Study Group. Influence of age on the antihypertensive and metabolic effects of amlodipine (AML) in patients with essential hypertension. J. Am. Soc. Nephrology 1992;3:537-538.
251. Sowers JR, DiBona GF, Kloner RA, Puente JG, and ACCT Study Group. Influence of sex on the antihypertensive and metabolic effects of amlodipine (AML) in patients with essential hypertension. J. Am. Soc. Nephrology 1992;3:537-538.
252. Whittaker P, Zheng S, Kloner RA. Chronic response to direct myocardial revascularization: differential effects of laser versus needle channels. Biomedical Optics '93 Technical abstracts page 30.
253. Prentice HM, Kloner RA, Li Y, Newman L, Kedes L. High level RSV-luciferase expression following direct DNA injection into ischemic/reperfused myocardium. J. Am Coll. Cardiol. 1993;21:163A.
254. Hale SL, Bellows SD, Hammerman H, Kloner RA. Can high dose intracoronary adenosine mimic ischemic preconditioning? Clin. Res. 1993; 41:388A.
255. Przyklenk K, Kloner RA. Diagnosis of stunned and hibernating myocardium. Abstract volume of International Symposium Cardiological Intensive Care '93. May 11 - 14, 1993, Venice, Italy.
256. Simkhovich BZ, Alker KJ, Kloner RA. Direct cardiotropic effects of cocaine in the isolated rabbit heart. J. Mol. Cell Cardiol 1993; 25 (Suppl III): S24.
257. Kloner RA, Shook T, Przyklenk K, Davis V, Junio L, Matthews RV. Burstein S, Gibson CM, Poole K, Cannon CP, McCabe C, Braunwald E. for TIMI 4 Study Group. Previous angina alters In-Hospital Outcome in TIMI 4. Circ. 1993; 88 (Suppl. Part 2) I-49.
258. Li Y, Kloner RA. The beneficial effects of preconditioning can be recaptured after they are lost. Circ. 1993; 88 (Suppl Part 2) I-138.
259. Whittaker P, Zheng S, Kloner RA. Beneficial effects of transmural myocardial channels: Chronic response to laser and needle treatment. Circ. 1993; 88 (Suppl Part 2) I-435.
260. Prentice H, Kloner RA, Sartorelli V, Bellows SD, Alker K, Kedes L. Transformation of cardiac fibroblasts into the skeletal muscle phenotype by injection of a Myo-D expressing retrovirus into ischemic heart. Circ. 1993; 88 (Suppl Part 2) I-475.
261. Bankwala Z, Hale SL, Kloner RA. Alpha adrenoceptor stimulation with exogenous norepinephrine, mimics ischemic preconditioning. Circ 1993; 88 (Suppl Part 2), I-488.
262. Przyklenk K, Ovize M, Bauer B, Kloner RA. Does gender influence myocardial injury and dysfunction following experimental myocardial ischemia/reperfusion? JACC Feb 1994; 231A.
263. Whittaker P, Li Y, Kloner RA. Intramyocardial injection of adenosine and saline stimulate a cardioprotective effect in rats. JACC Feb 1994; 232A.
264. Przyklenk K, Kloner RA. Acetylcholine acts as a "preconditioning-mimetic" in the canine model. JACC Feb 1994; 396A.
265. Hale SL, Kloner RA. Protection of myocardium by transient, pre-ischemic, alpha 1-adrenoceptor activation in the rabbit. JACC Feb 1994; 397A.
266. Bellows S, Hale S, Simkhovich B, Kay G, Kloner R. Do antioxidants vitamins reduce infarct size following acute myocardial ischemia/reperfusion? The FASEB Journal 1994;8:A607.
267. Whittaker P, Kloner RA. Assessment of radiofrequency-induced thermal injury using polarized light microscopy. The FASEB Journal 1994; 8:A795.
268. Hale SL, Hammerman H, Kloner RA. Effect of two perfluorocarbon emulsions on myocardial infarct development in rabbits. The FASEB Journal 1994; 8:A856.
269. Przyklenk K, Kloner RA. The protein kinase C inhibitor H-7 fails to attenuate the cardioprotective effects of ischemic preconditioning in the canine model. The FASEB Journal 1994; 8:A118.
270. Alhaddadt IA, Kloner RA, Hakin I, Brown EJ. Salvage of infarct shape by late reperfusion progresses as a wave-front over time: relationship to viable subepicardial myocytes. Clin. Res. 1994;42:162A.
271. Pollick C, Hale SL, Kloner RA. Echocardiographic and cardiac doppler assessment of mice. J. of Am Soc. of Echocardiography 1994; 7:S64.
272. Kloner RA, Przyklenk K, Hale S, Whittaker P. Preconditioning-like phenomena and "inadvertent preconditioning." J. Molecular and Cellular Cardiology 1994; 26:CXLV.
273. Przyklenk K, Kloner RA. Preconditioning does not attenuate ventricular ectopy in the canine model. J. Molecular and Cellular Cardiology 1994; 26:CLXXXIV.
274. Przyklenk K, Kloner RA. The PKC inhibitor H-7 does not attenuate preconditioning in the canine model. J. Molecular and Cellular Cardiology 1994:26:CLXXXIV.
275. Li Y, Kloner RA. Does protein kinase C play a role in ischemic preconditioning in the rat? J. Molecular and Cellular Cardiology 1994; 26:CLXXXV.
276. DiBona GF, Kloner RA, Sowers JR, Cobb MM, Gaffney M, Wein M for the ACCT Study Group. The influence of dietary sodium intake on blood pressure (BP) in the amlodipine community cardiovascular trial (ACCT). J. Am. Soc. Nephrology 1994;5:559.
277. Kloner RA, Sowers JR, DiBona GF, Cobb MM, Gaffney M, and Wein M. The amlodipine cardiovascular community trial (ACCT): A prospective, large-scale multicenter study in a diverse population of patients with mild to moderate hypertension. J. Am. Soc. Nephrology 1994; 5:563.
278. Whittaker P, Kloner RA. Direct myocardial revascularization: Fad or Fact? Proceedings of the American Society for Artificial Organs. Pg. 65, 1994.
279. Simkhovich, BZ, Kloner RA, Przyklenk K. Brief preconditioning ischemia does not trigger translocation of protein kinase C in canine myocardium. Circulation 1994; 90: (No. 4, Part 2 Suppl) I-208.
280. Li Y, Kloner RA. Does inhibition of protein kinase C with H7 block the cardioprotective effects of ischemia preconditioning in the rat? Circulation 1994; 90 (No. 4, Part 2 Suppl): I-371.
281. Przyklenk K, Sussman MA, Kloner RA. Fluorescence microscopy reveals no evidence of protein kinase C activation in preconditioned canine myocardium. Circulation 1994; 90 (No. 4, Part 2, Suppl):I-647.
282. Kloner RA, Sowers JR, DiBona GF, Cobb M, Wein M, Gaffney M. for the ACCT Investigators. Effect on amlodipine on ventricular mass in hypertensive patients: aspects of age, gender, race. Circulation 1994; 90 (No. 4, Part 2 Suppl) I-656.
283. Kloner RA, Sowers, JR, DiBona GF, Cobb M, Wein M, Gaffney M, ACCT Investigators. Women have a higher response rate than men to the antihypertensive calcium channel blocker amlodpine. JACC Feb 1995; 32A.
284. Przyklenk K, Kloner RA. The Protein Kinase C Inhibitor Polymyxin-B does not block preconditioning-induced cardioprotection in the canine model. JACC Feb 1995; 43A.
285. Leor J, Kloner RA. The January 17, 1994 Los Angeles Earthquake as a Trigger for Acute Myocardial Infarction. JACC Feb. 1995; 105A.
286. Chandraratna PAN, Whittaker P, Kloner RA, Jones JP, Gallet J. Detection of Experimental and Clinical Myocardial Infarction by high frequency ultrasound. JACC Feb. 1995; 162A.
287. Leor J, Kloner RA. Does magnesium have a place in the therapy of acute myocardial infarction? Significance of early vs. late reperfusion. JACC Feb. 1995; 189A.
288. Hale S, Kloner RA. Estradiol, administered acutely, protects ischemic myocardium in both female and male rabbits. JACC Feb, 1995; 189A.
289. Quinones MJ, Leor J, Kloner RA, Ito M, Patterson M, Witke WF, Kedes L. Immune-mediated response to adenovirus affects the expression of genes delivered to adult rat myocardium. JACC Feb. 1995; 323A.
290. Whittaker P, Kloner RA. Myocardial preconditioning by laser irradiation. JACC Feb, 1995; 355A.
291. Whittaker P, Kloner RA. Acute cardiac protection mediated by laser irradiation. Lasers in Surgery and Medicine Suppl 7 1995; page 11.
292. Leor J, Kloner RA. The January 17, 1994 Northridge Earthquake as a Trigger for Coronary Death. Journal of Investigative Medicine 1995; 43: (Suppl 2) 390A.
293. Alker KJ, Bellows SD, Kloner RA. Intermittent or Staged Reperfusion of Ischemic Myocardium Does Not Exacerbate Reperfusion Injury: Evidence Against Lethal Cell Reperfusion Injury in the Rabbit. Journal of Investigative Medicine 1995; 43:(Suppl 2) 312A.
294. Bellows SD, Hale SL, Kloner RA. An Acute Dose of Ethanol Reduces Infarct Size in the Ischemic Rabbit Model. Journal of Investigative Medicine 1995; 43:(Suppl 2) 321A.
295. Leor J, Patterson M, Quinones MJ, Kedes L, Kloner RA. Successful transplantation of fetal cardiomyoblasts into the infarcted myocardium of rat: A potential method for repair of infarcted myocardium. Circulation 92 (Suppl I); 1995; I-50.
296. Leor J, Kloner RA. Scared to death? The occurrence of sudden cardiac death during the 1994 Northridge Earthquake. Circulation 92 (Suppl I); 1995; I-96.
297. Simkhovich BZ, Przyklenk K, Hale SL, Kloner RA. Subcellular distribution of protein kinase C is not altered by brief preconditioning ischemia in rabbit myocardium. Circulation 92 (Suppl I); 1995; I-137.
298. Przyklenk K, Zhao L, Kloner RA, Elliott GT. Monophosphoryl Lipid A (MLA) is a "Preconditioning mimetic" in the canine model. Circulation 92 (Suppl I); 1995; I-388.
299. Przyklenk K, Zhao L, Kloner RA, Elliott GT. Preconditioning preserves 5' nucleotidase activity and reduces infarct size: cause-and-effect or parallel observations? Circulation 92 (Suppl I); 1995; I-390.
300. Birnbaum Y, Davis V, Sclarovsky S, Kloner RA. Distortion of the terminal portion of the QRS on admission in acute myocardial infarction: correlation with infarct size and long term prognosis in TIMI-4. Circulation 92 (Suppl I); 1995; I-540.
301. Allen J, Cox T, Kloner RA. Myocardial stunning following exercise testing in man: Early time course. Circulation 92 (Suppl I); 1995; I-551.
302. Nishimoto Y, Firth BR, Kloner RA, Leor J, Lerman RD, Bhandari AK, Cannom DS. The 1994 Northridge earthquake triggered shocks from implantable cardioverter defibrillators. Circulation 92 (Suppl I); 1995; I-606.
303. Whittaker P, Kloner RA. Excimer laser channels protect against myocardial ischemia. J. Am. Coll. Cardiol. 1996; 27 (Suppl A) 13A.
304. Kloner RA, Vetrovec G. Long acting calcium channel blockers nifedipine GITS and amlodipine in hypertension - Rate of myocardial infarction. J. Am. Coll. Cardiol. 1996; 27 (Suppl A) 177A.
305. Przyklenk K, Zhao L, Kloner RA, Elliott GT. Preconditioning preserves sarcoplasmic reticular function. J. Am. Coll. Cardiol. 1996; 27 (Suppl A) 183A.
306. Leor J, Quinones MJ, Patterson M, Kedes L, Kloner RA. Feasibility, timing, and location of adenovirus-mediated gene transfer into myocardial infarction. J. Am. Coll. Cardio. 1996; 27(Suppl A) 289A.
307. Przyklenk K, Hata K, Kloner RA. Brief intracoronary calcium infusion "preconditions" canine myocardium. J. Am. Coll. Cardiol. 1996; 27 (Suppl A) 292A.
308. Kloner RA. Treating hypertension in the cardiac patient. American J. Hypertension 1996; 9:198A.
309. Kloner RA, Vetrovec G, Materson BJ, Levenstein M. Cardiovascular safety of dihydropyridines: A hard look at real data. American J. Hypertension 1996; 9:199A.
310. Birnbaum Y, Kloner RA, Sclarovsky S, Cannon CP, McCabe CH, Davis V, Braunwald E. Distortion of the terminal portion of the QRS on admission in acute myocardial infarction: correlation with infarct size and long-term prognosis in TIMI-4. Israel J Medical Sciences. 1996; 32 (Supplement) S8.
311. Leor J, Poole WK, Kloner RA. The Northridge earthquake as a trigger for sudden cardiac death. Israel J Medical Sciences 1996; 32 (Supplement) S26.
312. Leor J, Patterson M, Quinones MJ, Kedes LH, Kloner RA. Successful transplantation of fetal cardiomyocytes into the infarcted myocardium of rat: A potential method for repair of infarcted myocardium. Israel J. Medical Sciences 1996; 32(Supplement) S27.
313. Leor J, Quinones MJ, Patterson M, Kedes L, Kloner RA. Feasibility, timing, and location of adenovirus-mediated gene transfer into myocardial infarction. Israel J. M Medical Sciences 1996; 32 (Supplement) S27.
314. Przyklenk K, Hata K, Kloner RA. The Na+-H+ exchanges inhibitor dimethylamiloride blocks preconditioning in the canine model. European Heart Journal 1996; 17(Abstract Supplement) 258.
315. Leor J, Patterson M, Quinones MJ, Kedes LH, Kloner RA. Successful transplantation of fetal cardiomyocytes into the infarcted myocardium of rat: a potential method for repair of infarcted myocardium. European Heart Journal 1996; 17 (Abstract Supplement) 268.
316. Leor J, Quinones MJ, Patterson M, Kedes L, Kloner RA. Feasibility, timing, and location of adenovirus-mediated gene transfer into myocardial infarction. European Heart Journal 1996; 17 (Abstract Supplement) 269.
317. Przyklenk K, Hata K, Kloner RA. The Na+-H+ exchange inhibitor dimethylamiloride blocks preconditioning in the canine model. Circulation 1996; 94 (Suppl I) I-424.
318. Birnbaum Y, Kloner RA. The effect of CY 1503 on infarct size and "no-reflow" in the rabbit model of acute myocardial infarction/reperfusion. Circulation 1996; 94 (Suppl I); I-486.
319. Przyklenk K, Hata K, Zhao L, Kloner RA, Elliott GT. Preconditioning does not depend upon enhanced 5' nucleotidase activity or increased adenosine levels during sustained coronary occlusion. Circulation 1996; 94 (Suppl I); I-550.
320. Hata K, Kloner RA, Przyklenk K. Brief antecedent ischemia attenuates platelet-mediated thrombosis in damaged and stenotic canine coronary arteries. Circulation 1996; 94 (Suppl I); I-588.
321. Hale SL, Kloner RA. Topical regional cooling of the heart profoundly reduces myocardial infarct size in rabbits. Circulation 1996; 94 (Suppl I); I-607.
322. Kloner RA, Shook T, Antman EM, Cannon CP, Przyklenk K, McCabe CH, Braunwald E, TIMI 9 Investigators. A prospective analysis on the potential preconditioning effect of preinfarct angina in TIMI 9. Circulation 1996; 94 (Suppl I); I-611.
323. Simkhovich BZ, Przyklenk K, Kloner RA. Time course of PKC translocation in ischemic rabbit heart. Circulation 1996; 94 (Suppl I); I-660.
324. Kloner RA, Leor J, Chen H, Giangreco CA, Poole WK, Perritt RL. A population-based analysis of the effect of the Northridge Earthquake on cardiac events among 19,617 deaths in Los Angeles County, California. Circulation 1996; 94 (Suppl I); I-711.
325. Cox TA, Zhang HP, Kloner RA, Allen JW. Does the severity of transmural ischemia affect recovery? J. of Investigative Medicine 1997; 45:163A.
326. Hata K, Kloner RA, Przyklenk K. The benefits of brief antecedent ischemia on platelet-mediated thrombosis are mimicked by brief intracoronary adenosine infusion. J. Am. Coll. Cardiol. 1997; 29 (Suppl A) 179A.
327. Birnbaum Y, Kloner RA. Ischemic preconditioning at a distance: Reduction of myocardial infarct size by partial reduction of blood supply combined with pacing of the gastronemius muscle. J. Am. Coll. Cardiol. 1997; 29 (Suppl A) 360A.
328. Bauer B, Simkhovich BZ, Kloner RA, Przyklenk K. The second messenger inositol (1,4,5)-trisphosphate mediates infarct size reduction with preconditioning in isolated rabbit heart. J. Am. Coll. Cardiol. 1997; 29 (Suppl A) 360A.
329. Simkhovich BZ, Kloner RA, Przyklenk K. Preconditioning alters tissue levels of the second messenger inositol trisphosphate in rabbit heart. Circulation 1997; 96 (Suppl I); I-575.
330. Dave RH, Hale SL, Kloner RA. Closed circuit, hypothermic, pericardioperfusion: A potential cardioprotection technique for minimally invasive cardiac surgery. Circulation 1997; 96 (Suppl I); I-742.
331. Hata K, Kloner RA, Przyklenk K. Brief myocardial ischemia attenuates platelet aggregation in remote, damaged, and stenotic rabbit carotid arteries. J. Am. Coll. Cardiol. 1998; 31 (Suppl A) 168A.
332. Schwarz ER, Speakman MT, Kloner RA. A novel technique of plication without resection for treating infarct expansion and remodeling. Circ. 1998; 98 (Suppl 1): 1-418.
333. Schwarz ER, Speakman MT, Patterson M, Hale SL, Kedes L, Kloner RA. Effect of intramyocardial injection of DNA expressing vascular endothelial growth factor in myocardial infarct tissue in the rat heart-angiogenesis and angioma formation. Circ. 1998; 98 (Suppl 1):I-456.
334. Hale SL, Kloner RA. Extending the window of protection of ischemic preconditioning to include prolonged coronary artery occlusion. Circ. 1998; 98 (Suppl 1) I-485.
335. Kloner RA, Poole K, Perritt R. When throughout the year is coronary death most likely to occur? A twelve year population based analysis of over 220,000 cases. Circ. 1998; 98 (Suppl 1) I-764.
336. Gysembergh A, Kloner RA, Przyklenk K. Inositol triphosphate – induced calcium release during ischemia contributes to myocardial necrosis in rabbit heart. JACC Suppl A, February 1999; 33:358A.
337. Kloner RA, Brown M and the Sildenafil Study Group. Safety of Sildenafil Citrate in men with erectile dysfunction taking multiple antihypertensive agents. Am J. Hypertension 1999; 12:37A.
338. Simkhovich BZ, Abdishoo S, Hale SL, Poizat C, Kedes LH, Kloner RA. Changes in gene expressiion in the ischemically preconditioned rabbit heart: Gene discovery array study. Circulation 1999: 100 (Suppl I) I-56.
339. Poizat C, Sartorelli V, Chung G, Dow J, Kloner RA, Kedes LH. Inhibition of pivotal cardiac transcription factors in doxorubicin-induced cardiomyopathy. Circulation 1999; 100 (Suppl 1) I-213.
340. Gysembergh A, Lemaire S, Sportouch C, Piot C, Richard S, Kloner RA, Przyklenk K. Inositol trisphosphate signaling “preconditions” rabbit heart: Role of intercalated discs? Circulation 1999 (Suppl 1) 100:I-491.
341. Patterson M, Kopyov O, Kloner RA. Basic fibroblast growth factor and differentiation of fetal cardiac myocytes. A potential improvement for fetal cell transplant therapy. Circulation 1999; (Suppl 1) 100:I-164.
342. Kloner RA, Chen H. Death rates from heart disease in Los Angeles County (1987 – 1997): Reductions in White and African Americans but increases in Hispanics and Asian/Pacific Islanders. J. Am. Coll Cardiol. 2000 35 (Suppl A) 219A.
343. Hale SL, Kloner RA. Apex to base position of an infarct is a major determinant of its size in relation to the risk zone. J. am. Coll. Cardiol. 2000 35 (Suppl A) 378.
344. Kloner RA, Das S, Poole WK, Muller J, Cannon CP, Braunwald E. Seasonal variation of myocardial infarct size in humans. J. Am. Coll. Cardiol. 2000 35 (Suppl A) 389A.
345. Schwarz ER, Hale SL, Kloner RA. Do transplanted cardiomyoctyes augment global left ventricular function in infarcted rat heat? J. Am. Coll. Cardiol. 2000 35 (Suppl A) 394A.
346. Müller-Ehmsen J, Dow JS, Kloner RA, Kedes LH. Cardiomyocyte transplantation: a PCR based method for the quantification of grafted cell survival. The FASEB Journal 2000; 14 (4):A158.
347. Kloner RA, Weinberger MH, Poole JT, Chryant SG, Harris SM, Prasad R, Michelson EL for the CASTLE Study Investigators. Comparison of the efficacy and tolerability of candesartan cilexetil and amlodipine in patients with mild hypertension (CASTLE Study) Am. J. Hypertension 2000; 13 (No. 4, Part 2) 133A-134A..
348. Phillips R, Kloner RA, Weinberger MH, Grimm RH. Amlodipine vs Losartan in the treatment of mild to moderately severe hypertension. Am. J. Hypertension 2000; 13 (No 4, Part 2) 124A-125A.
349. Whittaker P, Muller-Ehmsen J, Dow JS, Kedes LH, Kloner RA. Structural development of neonatal myocytes implanted into adult myocardium. Circulation 2000; 102 (Suppl II); II-201.
350. Gysembergh A, Kloner RA, Przyklenk K. P38 mitogen-activated protein kinase activity is not increased in preconditioned versus control heart. Circulation 2000; 102 (Suppl II); II-211.
351. Przyklenk K, Kloner RA. Viagra does not exacerbate ischemia, but renders platelets refractory to the inhibitory effects of adenosine. Circulation 2000; 102 (Suppl II); II-254.
352. Muller-Ehmsen J, Dow JS, Long TI, Laird PW, Kedes LH Kloner RA. Long-term impact of grafted neonatal cardiomyocytes on cardiac function of rats with myocardial infarction as assessed by echocardiography. Circulation 2000; 102 (Suppl II); II-682.
353. Muller-Ehmsen J, Dow JS, Sakoda T, Long TI, Laird PW, Kloner RA, Kedes LH. Quantitative analysis of the survival of neonatal cardiomyocytes after grafting into healthy rat left ventricle using fluorescence based real-time TaqMan PCR. Circulation 2000; 102 (Suppl II); II-651.
354. Kavanagh GJ, Whittaker P, Prejean CA, Firth BR, Kloner RA, Kay GL. Excimer laser transmyocardial revascularization: dissociation between improvement in angina and regional myocardial perfusion. Circulation 2000; 102 (Suppl II); II-736.
355. Hale SL, Kloner RA. Elevated body temperature during acute myocardial ischemia exacerbates necrosis. J. Am Coll Cardiol. 2001; 37 (Suppl A), 374A.
356. Etzion S, Barbash IM, Feinberg M, Kloner RA, Kedes L, Leor J. Genetically modified fibroblasts obtained from the infarcted myocardium as donor cells for transplantation. European Heart J. Vol 22, abstr. Suppl. Sept. 2001; page 489.
357. Etzion S, Barbash I, Feinberg MS, Ilia R, Kloner RA, Kedes L. Cellular cardiomyoplasty of cardiac scar fibroblasts by adenoviral delivery of Myo D Ex Vivo: A new unlimited source of cells for transplantation. Circulation 2001; 104 (Suppl II): II-556.
358. Simkhovich BZ, Marjoram P, Dow J, Kedes L, Kloner RA. A brief episode of myocardial ischemia in the rat turns on novel sets of genes. J. Am Coll Cardiol 2002; 39 (Suppl A):283A.
359. Reffelmann T, Kloner RA. Rapid expansion of anatomical no reflow during reperfusion in the rabbit. J. Am Coll Cardiol 2002; 39 (Suppl A):324A.
360. Kloner RA, Poole K, Shook T, Przyklenk K, Perritt K. Old age and myocardial infarct size in the reperfusion era. J. Am Coll Cardiol 2002; 39 (Suppl A): 302A.
361. Kloner RA, Emmick J, Bedding A, Humen D. Pharmacodynamic interactions between tadalafil and nitrates. J. Am Coll Cardiol 2002; 39 (Suppl A): 291A.
362. Muller-Ehmsen J, Peterson KL, Kedes L, Whittaker P, Dow JS, Kloner RA. Long-term beneficial effects of neonatal cardiomyocytes on left ventricular ejection fraction, regional wall motion, and scar thickness after transplantation into infarcted rat hearts. J. Am Coll Cardiol 2002; 39 (Suppl A): 169A.
363. Ross A, Gibbons R, Kloner RA, Marder VJ, Stone GW. Alexander RW. Acute myocardial infarction study of adenosine (AMISTAD II). J Am Coll Cardiol 2002; 39 (Suppl A): 338A.
364. Kloner RA, Watkins V, Costigan T, Bedding A, Mitchell M, Emmick J. Cardiovascular profile of tadalafil, a new PDE 5 inhibitor. The Journal of Urology 2002; No. 4, 167 (Supplement); 176.
365. Kloner RA, Mitchell M, Bedding A, Emmick J. Pharmacodynamic interactions between tadalafil and nitrates compared with sildenafil. The Journal of Urology 2002; No. 4, 167 (Supplement); 176-177.
366. Hutter AM, Kloner RA, Watkins V, Costigan T, Bedding A, Mitchell MI, Emmick JT. Blood pressure and cardiovascular effects of tadalafil, a new PDE5 inhibitor. Am. J. Hypertension 2002; 15 (No. 4, Part 2), 140A.
367. Müller-Ehmsen J, Peterson KL, Kedes L, Whittaker P, Dow JS, Kloner RA. Beneficial effects of neonatal cardiomyocytes on left ventricular ejection fraction and scar thickness six months after transplantation into infarcted rat hearts. Eur Heart J. 2002; 23 (Suppl): 16.
368. Kloner RA, Mohan P, Norenberg C, Pomerantz K, Segenson T, Glasser SP. Cardiovascular safety of vardenafil, a potent, highly selective PDE5 inhibitor in patients with erectile dysfunction: an analysis of five - controlled clinical trials. Pharmaco Therapy 2002; 22:1371.
369. Kloner RA, Watkins V, Costigan T, Bedding A, Mitchell M, Emmick J. Cardiovascular profile of tadalafil, a new PDE5 inhibitor. Int. J. Impotence Research, Suppl. 2002; S31.
370. Patterson D, MacDonald TM, Effron MB, Emmick JT, Mitchell M, Bedding A, Kloner RA. Tadalafil does not affect time to ischemia during exercise stress testing in patients with coronary artery disease. Int. J. Impotence Research, Suppl 2002; S102.
371. Kloner RA, Emmick J, Bedding A, Humen D. Pharmacodynamic interactions between tadalafil and nitrates. Int. J. Impotence Research. Suppl. 2002; S29.
372. Kloner RA, Yao M, Peterson KL, Hale SL, Dow J, Kedes L. Rebuilding the heart: the long term outcome of fetal cell transplantation on post-infarct left ventricular remodeling. Circulation (Suppl II) 2002; 106:II-132.
373. Przyklenk K, Li G, Simkhovich BZ, Kloner RA. Mechanism of preconditioning are age - related: protein kinase C-ε plays a role in adult, but not old, rabbit. Circulation (Suppl II) 2002; 106:II-148.
374. Patterson D, MacDonald TM, Effron MB, Emmick JT, Mitchell MI, Wood E, Kloner RA. Tadalafil does not affect time to ischemia during exercise stress testing in patients with coronary artery disease. Circulation (Suppl II) 2002; 106:II-330.
375. Kloner RA, Mohan, P, Segerson T, Thibonnier M, Norenberg C, Padma-Nathan H. Cardiovascular safety of vardenafil in patients receiving antihypertensive medications: A post-hoc analysis of five placebo-controlled clinical trials. J Am Coll Cardiol 2003; 41 (Suppl A):276A-277A.
376. Reffelmann T, Kloner RA. Powerful microvascular and myocardial protection by Na+/H+ -exchange inhibition an ischemic preconditioning: evidence for a causal link in the rabbit. J Am Coll Cardiol 2003; 41 (Suppl A):373A.
377. Hale SL, Dae MW, Kloner RA. Marked reduction in no-reflow with late initiation of hypothermia in a rabbit myocardial infarct model. J Am Coll Cardiol 2003; 41 (Suppl A) 381A.
378. Reffelmann T, Kloner RA. Can anatomic no-reflow be prevented by pharmacologic treatment with adenosine and verapamil? J Am Coll Cardiol 2003; 41 (Suppl A) 401A.
379. Kloner RA, Müller-Ehmsen J, Yao M, Reffelmann T, Hale SL, Dow J, Simkhovich B, Kedes L. Cellular cardiomyoplasty. J. Mol and Cellular Cardiology 2003; 35:A4.
380. Simkhovich B, Marjoran P, Poizat C, Kedes LH, Kloner RA. Differential changes in gene expression in young and old rat hearts following ischemia/reperfusion. J. Mol. and Cellular Cardiology 2003; 35:A26.
381. Chi JS, Obed E, Matthews RV, Burstein S, Mayeda G. Kloner RA, Shook TL. Percutaneous manangement keeps hemodialysis vascular assess grafts functional but multiple interventions are usually required. Am. J. Cardiol.; TCT Abstracts, 2003, September 15 ­ 17: 147 L. (Suppl Vol. 92).
382. Jackson G, Kloner RA, Emmick JT, Mitchell MI, Bedding A, Pereira A. Interaction between tadalafil and two alpha blockers: doxazosin and tamsulosin. Int J. Impot Res 2003; 15(Suppl 6):S60.
383. Jackson G, Kloner RA, Hutter AM, Emmick JT, Mitchell MI, Denne J. Interaction with nitrates no longer evident 48 hours after dosing of tadalafil. Int. J. Impot Res 2003; 15(Suppl 6):S20.
384. Dai W, Hale SL, Kloner RA. Survival, differentiation, and contractility of immature cardiac cells implanted into the outer wall of aorta in rats as a step in the development of an auxiliary circulatory pump. J. Am. Coll Cardiol 2004; 43 (Suppl A):236A.
385. Simkhovich BZ, Hale SL, Kloner RA. Mild local hypothermia preserves high energy phosphate metabolism during regional ischemia. J. Am. Coll Cardiol 2004; 43 (Suppl A):256A-257A.
386. Kloner RA, Chi JS, Poole WK, Walton JD, Kandefer S. Increased cardiovascular mortality with the turn of the millennium. J. Am Coll Cardiol 2004; 43 (Suppl A):260A.
387. Sesti C, Hale SL, Dai W, Wold LE, Dow JS, Simkhovich BZ, Kloner RA. Stem cells for repair of infarcted myocardium? NHLBI Stem Cell RFA Grantees Meeting, Abstract Book 2004.
388. Kloner RA, Jackson G, Emmick JT, Mitchell MI, Bedding A, Warner MR, Pereira A. Interaction between the phosphodiesterase 5 inhibitor, tadalafil, and the two alpha-blockers: doxazosin and tamsulosin. J. of Urology Vol 171, No 4, Supplement, Monday May 10, 2004; page 315. Abstract # 1195.
389. Dai W, Hale SL, Martin BJ, Kuang J-Q, Kloner RA. Survival and differentiation of allogenic mesenchymal stem cells in myocardial infarction in rats. Presented at the National Heart, Lung, and Blood Institute Symposium on Cardiovascular Regenerative Medicine. Abstract Booklet, September 13 ­ 14, 2004, NIH, Bethesda, MD.
390. Dai W, Hale SL, Kloner RA. Morphological development and contractile ability of transplanted neonatal cardiac cells within the wall of the aorta in rats. Presented at the National Heart, Lung, and Blood Institute Symposium on Cardiovascular Regenerative Medicine. Abstract Booklet, September 13 ­ 14, 2004, NIH, Bethesda, MD.
391. Wold LE, Kleinman MT, Dow JS, Siouta C, Kloner RA. Ultra ­ fine particles isolated from ambient air induce direct cardiovascular effects without having to be inhaled. Presented at the 2004 Symposium “Pollutants and Heart Disease.” University of Louisville, Kentucky October 16 ­ 17, 2004.
392. Kloner RA, Dai W. Biologic ventricular assist device in Research in innovative tissue engineering grantees meeting. Program book. Presented at NHLBI meeting September 9 ­ 10, 2004, Bethesda, MD.
393. Dai W, Hale SL, Kloner RA. Neonatal cardiomyocytes do no require a cardiac milieu to establish contractile units. J. Am. Coll Cardiol 2005; 45 (Suppl A):175A
394. Dai W, Hale SL, Martin BJ, Kuang JQ, Kloner RA. Improvement of left ventricular function by intramuscular allogeneic mesenchymal stem cells transplantation in postinfarcted rat myocardium may be transient. J. Am. Coll Cardiol 2005; 45 (Suppl A):227A.
395. Dai W, Hale SL, Kloner RA. Development of the first spontaneously beating vein. J. Am Coll Cardiol 2005; 45 (Suppl A):412A.
396. Kloner RA. Cellular Therapy for Heart Failure. In Program Workbook for New Frontiers in Genomics and Cardiovascular Disease. Presented April 8 ­ 9, 2005, Philadelphia, pages 178-179.
397. Kloner RA. Cell Therapy for the Treatment of Myocardial Infarction. In Stem Cells, Research and Therapeutics; April 11 ­ 12, 2005, San Diego, CA. GTCbio Abstract Book, page 35.
398. Sesti C, Hale SL, Lutzko C, Kloner RA. Granulocyte colony ­ stimulating factor and stem cell factor improve contractile reserve of the infarcted left ventricle independent of restoring muscle mass. In Stem Cells, Research and Therapeutics; April 11 ­ 12, 2005, San Diego, CA. GTCbio Abstract Book, page 155.
399. Dai W, Hale SL, Martin BJ, Kuang J-Q, Wold LE, Simkhovich BZ, Kloner RA. Long ­ term survival, differentiation, and “Homing” of allogeneic mesenchymal stem cells in myocardial infarction in rats. In Stem Cells, Research and Therapeutics; April 11 ­ 12. 2005, San Diego, CA. GTCbio Abstract Book, page 156.
400. Dow J, Simkhovich BZ, Kedes L, Kloner RA. Washout of transplanted cells from the heart: A potential new hurdle for cell transplantation therapy. In Stem Cells, Research and Therapeutics; April 11 ­ 12, 2005, San Diego, CA. GTCbio Abstract Book, pages 156-157.
401. Hale SL, Sesti C, Kloner RA. Erythropoietin reduces left ventricular remodeling and improves cardiac function after myocardial infarction, independent of cell replacement in the scar. In Stem Cells, Research and Therapeutics; April 11 ­ 12, 2005, San Diego, CA. GTCbio Abstract Book page 194.
402. Papademetriou V, Hainer JW, Sugg J, and ATTACH Investigators (Dr. Kloner was an ATTACH Investigator). Combination of Toprol-XL and hydrochlorothiazide: Results of a Factorial Clinical Trial. Presented at the American Society of Hypertension in San Francisco, May 16, 2005. Am. J. Hypertension 2005 May; 18 (5 Pt. 2): 91A.
403. Bai Y, Williams T, Dow J, Kloner RA, Kedes L, Poizat C. Role of nuclear calcium/calmodulin ­ dependent protein kinase II δβ in doxorubicin ­ induced cardiomyopathy. (presentation at 2nd Annual Symposium of Basic Science Council of the American Heart Association). Circ. Res (online edition) July 22;Vol 97; 2005, e9-e50.
404. Sesti C, Hale SL, Lutzko C, Kloner RA. Granulocyte colony-stimulating factor and stem cell factor improve contractile reserve of the infarcted left ventricle independent of restoring muscle mass. Abstract Book of the 2005 Young Investigators Forum of the American Heart Association Western States Affiliate at University of California, Irvine. September 30, 2005; page 39.
405. Wold LE, Simkhovich BZ, Kleinman MT, Nordlie MA, Dow JS, Sioutas C, Kloner RA. Ultra-fine particles isolated from ambient air and diesel fuel have direct cardiovascular mechanisms independent of pulmonary inflammation. Abstract Book of the 2005 Young Investigators Forum of the American Heart Association Western States Affiliate at University of California, Irvine. September 30, 2005; page 62.
406. Dai W, Wold LE, Hale SL, Dow JS, Kloner RA. Mesenchymal stem cells remain in the infracted heart but do not promote long-term functional improvement of the left ventricle. Abstract Book of the 2005 Young Investigators Forum of the American Heart Association Western States Affiliate at University of California, Irvine. September 30, 2005; page 76.
407. Sesti C, Simkhovich BZ, Kalvinsh I, Kloner RA. Mildronate, a new fatty acid oxidation inhibitor and anti-anginal agent, reduces myocardial infarct size independent of hemodynamics. Circulation 2005 (Suppl II); 112:II-133.
408. Kloner RA, Dow J, Bhandari A. Postconditioning markedly attenuates ventricular arrhythmias following ischemia/reperfusion independent of a mitochondrial KATP channel mechanism. Circulation 2005 (Suppl II); 112:II-1108-II-1109.
409. Jackson G, Kloner RA, Hutter A, Mittleman MA, Chan M, Warner MR, Costigan TM, Vail GM. Cardiovascular Safety Update of Tadalafil: Retrospective Data Analysis from Placebo-Controlled and Open-Label Clinical Trials of Tadalafil Comparing as Needed Dosing, 3 Times Per Week Dosing, and Once a Day Dosing. J Sex Med 2006; 3 (Suppl 3):213.
410. Hale SL, Leeka JA, Kloner RA. Better ventricular function and reduced necrosis after myocardial ischemia/reperfusion in rabbits treated with ranolazine, an inhibitor of the late sodium current. J. Am Coll Cardiol 2006; 47 (Suppl A); 169A.
411. Sesti C, Florio V, Kloner RA. The long acting phosphodiesterase-5 inhibitor tadalafil reduces myocardial infarct size. J. Am Coll Cardiol 2006; 47 (Suppl A); 170A.
412. Wold LE, Simkhovich BZ, Nordlie MA, Kleinman MT, Sioutas C, Kloner RA. Direct and acute cardiotoxicity of ultrafine air pollutants. J. Am Coll Cardiol 2006; 47 (Suppl A); 84A.
413. Dai W, Wold LE, Hale SL, Kloner RA. Mesenchymal stem cells improve cardiac function in a rat model of myocardial infarction through a mechanism independent of increasing muscle mass or limiting myocardial infarct size. J. Am Coll Cardiol 2006; 47 (Supp A); 191A.
414. Dai W, Wold LE, Dow JS, Kloner RA. Collagen implantation as an internal support to prevent eccentric hypertrophy and preserve cardiac function after myocardial infarction in rats. J Am Col Cardiol 2006; 47 (Suppl A); 191A.
415. Kloner RA, Gibbons RJ, Ross AM, Alexander RW, Forman MB, Stone GW. Impact of time to presentation and reperfusion modality on the efficacy of adenosine during reperfusion therapy for acute myocardial infarction: The AMISTAD-2 Trial. J. Am Col Cardiol 2006; 47 (Supp A); 175A.
416. Kloner RA, Dai W, Hale SH. Mesenchymal stem cells for myocardial infarction. Abstract Book. Stem Cell RFA Grantees Meeting. April 26-28, 2006. NHLBI. Rockville, MD.
417. Kloner RA, Neutel JM, Roth EM, Weiss RJ, Weinberger MH, Thakker KM, Schwartz B, Sun W, Gregg AM for the Trial Investigators. Addition of amlodipine to the antihypertensive regimen of diabetic hypertensives initiated with quinapril or losartan monotherapy more than doubles blood pressure goal attainment: Results from the Amlodipine Diabetic Hypertension Efficacy Response Evaluation Trial. J. Clinical Hypertension 2006; 8:455.
418. Kloner RA. Ischemia/Myocardium Molecular View. Presented at The Role of Air Pollutants in Cardiovascular Disease. U.S. EPA/NHLBI/NIEHS. Research Triangle Park, North Carolina, October 12-13, 2006.
419. Simkhovich BZ, Kleinman MT, Wold LE, Kloner RA. Direct and acute cardiotoxicity of ultrafine air pollutants in Langendorff - perfused young and old rat hearts. Workshop Abstract Book. The Role of Air Pollutants in Cardiovascular Disease, October 12-13, 2006, Research Triangle Park, North Carolina, page 35.
420. Broderick GA, Costabile RA, Kloner RA, Rosen RC, Sadovsky R. Evolving strategies in ED management. Focus on a novel dosing regimen. J. Sex Med 2007; 4 (Suppl 1):53-58.
421. Hale SL, Dow JS, Dai W, Kloner RA. Homing of mesenchymal stem cells following intravenous injection: The wrong approach for cell delivery to infarcted myocardium? A quantitative assessment using nanoparticle labeling. Circulation (Supplement II) 2006; 114: II-79.
422. Dow J, Kloner RA. Postconditioning does not reduce myocardial infarct size in an in-vivo regional ischemia model. Circulation (Supplement II) 2006; 114:II-272.
423. Hale SL, Kloner RA. Evidence that the anti-anginal agent and inhibitor of the late sodium current, ranolazine, improves post-ischemic stunned myocardium in the rabbit. Circulation (Supplement II) 2006; 114; II-441.
424. Dai W, Kay GL, Jyrala AJ, Kloner RA. Direct collagen injection to thicken the infarct scar: collagen density determines angiogenesis. J. Am Coll Cardiol 2007; 49 (Supplement A): 185A.
425. Dai W, Field LJ, Hale SL, Zweigerdt R, Graichen RE, Kay GL, Jyrala AJ, Davidson B, Pera M, Kloner RA. Survival and maturation of human embryonic stem cell-derived cardiomyocytes implanted into rat hearts exposed to ischemia. J. Am Coll Cardiol 2007; 49 (Supplement A); 233A.
426. Simkhovich BZ, Kleinman MT, Kloner RA. Young hearts are as susceptible as old hearts to the direct and acute cardiotoxic effects of ultrafine air pollutants. Experimental Biology 2007: Late-Breaking Abstracts LB491; page LB105.
427. Hwang H, Kleinman MT, Simkhovich BZ, Kloner RA. Direct and acute cardiotoxic effects of ultrafine air pollutants in spontaneously hypertensive rats (SHR) and Wistar-Kyoto rats (WKY). Experimental Biology 2007: Late-Breaking Abstracts LB493; page LB105.
428. Hwang H, Simkhovich BZ, Dai W, Kleinman MT, Poole WK, Kloner RA. Direct and acute cardiotoxicity of ultrafine particles (UFP) in healthy and diseased hearts. American Heart Association. Young Investigators Forum 2007; La Jolla, CA, September 28, 2007, abstract book P5.
429. Dai W, Hale S, Kloner RA. The delivery vehicle influences the efficiency of transplanted mesenchymal stem cells’ effect on functional improvement in a rat myocardial infarction model. In Abstract Book for National Heart Lung and Blood Institute, Symposium in Cardiovascular Regenerative Medicine, October 1 ­ 2, 2007, Natcher Conference Center, NIH, Bethesda, MD, pages 39 ­ 40.
430. Dai W, Field L, Rubart M, Reuter S, Hale SL, Zweigerdt R, Graichen RE, Kay GL, Jyrala AJ, Colman A, Davidson BP, Pera M, Kloner RA. Transplanted human embryonic stem cell-derived cardiomyocytes from grafts in nude rat hearts exposed to ischemia/reperfusion. In Abstract Book for National Heart Lung and Blood Institute Symposium on Cardiovascular Regenerative Medicine, October 1 ­ 2, 2007, Natcher Conference Center, NIH, Bethesda, MD, page 40.
431. Hale SL, Dai W, Dow JS, Kloner RA. The transmigrating stem cell: Relocation of stem cells injected as therapy for myocardial infarction. In Abstract Book for National Heart Lung and Blood Institute Symposium on Cardiovascular Regenerative Medicine, October 1 ­ 2, 2007, Natcher Conference Center, NIH, Bethesda, MD, pages 42-43.
432. Abdalrahman I, Dharmashankar K, Rezkalla SH, Kloner RA. Incidence, outcome and treatment of no reflow phenomenon in patients with ST segment elevation myocardial infarction. Am. J. Cardiology 2007; (Suppl. Transcatheter Cardiovascular Therapeutics; Abstracts October 20 ­ 25) 100:183L
433. Yu N, Ai L, Rouhanizadeh M, Kloner RA, Kim ES, Hsiai TK. Flexible shear stress sensor for in vivo cardiovascular testing. Conference proceedings: Solid ­ State Sensors, Actuators and Microsystems Workshop. Hilton Head, South Carolina, 2008.
434. Dow J, Bhandari A, Kloner RA. Postconditioning markedly reduces reperfusion ­ induced ventricular arrhythmias ­ even in the senescent heart. J. Am Coll Cardiol 2008; 51 (Suppl A); A181.
435. Hale SL, Kloner RA. Ranolazine’s mechanism of action for reducing myocardial infarct size is independent of changes in coronary collateral blood flow. J. Am Col Cardiol 2008; 51 (Suppl A); A182.
436. Hwang H, Simkhovich BZ, Kleinman MT, Kloner RA. The direct toxic effect of ultrafine particles in coronary flow: The importance of the hydroxyl radical. J. Am Coll Cardiol 2008; 51 (Suppl A); A303.
437. Dharmashanker KC, Abdalrahman IB, Raza Q, Berg RL, Rezkalla SH, Kloner RA. The gender difference in no reflow phenomenon in patients with ST segments elevation acute myocardial infarction. J. Am Coll Cardiol 2008; 51 (Suppl B), B61-B62.
438. Hwang H, Simkhovich BZ, Dai W, Kleinman MT, Poole WK, Kloner RA. Direct and acute cardiotoxicity of ultrafine particles in healthy and diseased hearts. Presented as Late Breaking Abstract. The FASEB Journal 2008; 22:1678.
439. Hwang H, Simkhovich B, Kleinman M, Kloner R. Cardiovascular effects of ultrafine particles (UFP) are attenuated by a hydroxyl radical scavenger. Abstract book of the National Institute of Environmental Health Sciences ­ US EPA RFA Grantees Meeting. Current Understanding of Air Pollution Effects and Cardiovascular Disease. September 3, 2008, NIEHS, Research Triangle Park, North Carolina.
440. Simkhovich B, Kleinman M, Kloner R. Direct exposure to ultrafine particles (UFP) adversely affects cardiac function in perfused hearts from young and old rats to a similar degree. Abstract book of the National Institute of Environmental Health Sciences ­ US EPA RFA Grantees Meeting. Current Understanding of Air Pollution Effects and Cardiovascular Disease. September 3, 2008, NIEHS, Research Triangle Park, North Carolina.
441. Kleinman MT, Simkhovich BZ, Gookin G, Salazar K, Willett P, Kloner RA. Acute and sub-chronic cardiotoxic effects of inhaled ultrafine particles in spontaneously hypertensive rats and Wistar-Kyoto rats. Abstract book of the National Institute of Environmental Health Sciences ­ US EPA RFA Grantees Meeting. Current Understanding of Air Pollution Effects and Cardiovascular Disease. September 3, 2008, NIEHS, Research Triangle Park, North Carolina.
442. Hwang H, Arcidi JM, Hale SL, Simkhovich BZ, Belardinelli L, Dhalla A, Shryock J, Kloner RA. Ranolazine, a late sodium current inhibitor, as an adjunct to cardioplegia further reduces contracture during ischemia and reperfusion. Circulation, 2008; 118 (Supplement 2); S705.
443. Simkhovich BS, Mehrian-Shai R, Hsu N, Lin SM, Feng G, Kleinman MT, Kloner RA. Cardiac pro-oxidant gene expression patterns are altered by chronic exposure to particulate air pollutants. J. Am Coll Cardiol 2009; 53 (Suppl A); A145.
444. Simkhovich BZ, Gookin G, Meacher D, Willert P, Kleinman MT, Kloner RA. Pathologic changes to the heart induced by chronic exposure to air pollutants generated in traffic and the wildfires of Southern California in October 2007. J. Am Coll Cardiol 2009; 53 (Suppl A); A167.
445. Dow J, Hale S, Shryock J, Belardinelli L, Dhalla A, Bhandari A, Kloner RA. Ranolazine, a late sodium current inhibitor, markedly reduces ventricular arrhythmias in a model of coronary occlusion/reperfusion. J. Am Coll Cardiol 2009 53 (Suppl A); A198.
446. Dai, W, Hale SL, Kay, GL, Jyrala AJ, Kloner RA. Collagen matrix as a delivery vehicle prevents injected stem cells from migrating out of infarcted myocardium to remote organs in a rat myocardial infarction model. J. Am Coll Cardiol 2009; 53 (Suppl A); A314.
447. Dow J, Bhandari A, Kloner RA. Ischemic postconditioning is a powerful antiarrhythmic therapy with a mechanism that is independent of previous standard mechanisms associated with the cardioprotective effects of pre and postconditioning. J. Am Coll Cardiol 2009; 53 (Suppl A);
448. Kloner RA, McDonald S, Leeka J, Poole WK. A comparison of cardiovascular death rates in the same city during a losing versus winning Super Bowl Championship. J. Am Coll Cardiol 2009; 53 (Suppl A); A317.
449. Kloner RA. Comparative Aspects of ES, MSC, BMSC for Cardiac Repair (on CD of abstracts, under Kloner, Speakers Biography Section). Abstract for 5th Annual Modern Drug Discovery and Development Summit. Oct. 14-16, 2009, San Diego.
450. Kloner RA, Dow J, Bhandari A, Dhalla A, Shryock J, Belardinelli L. Ranolazine is a potent antiarrhythmic agent that reduces ventricular arrhythmias by inhibition of the late sodium channel. Circulation 2009; 120 (Suppl 2); S692.
451. Hwang H, Sasaki T, Kahn M, Kloner RA. Inhibition of β-catenin/cyclic AMP Response Element-binding Protein-binding Protein Interaction by ICG-001-Improves Contractile Function in Chronically Infarcted Rat Myocardium. The FASEB Journal 2010; 24:1058.12
452. Hwang H, Hale SL, Kloner RA. Effects of Zoledronate in the Repair of Chronically Infarcted Rat Myocardium. The FASEB Journal 2010; 24:787.3.
453. Hwang H, Kloner RA. The combined administration of multiple soluble factors in the repair of chronically infarcted rat myocardium. The FASEB Journal 2010; 24:1010.3
454. Kloner RA. State of Science of Cardioprotection: Challenges and Opportunities. Presented at New Horizons in Cardioprotection Workshop, Sponsored by the National Heart, Lung, and Blood Institute. National Institutes of Health, Rockville, MD September 20 ­ 21, 2010 (abstract on CD of meeting).
455. Kloner RA. No Reflow Phenomenon: Maintaining Vascular Integrity. Presented at New Horizons in Cardioprotection Workshop, Sponsored by The National Heart, Lung, and Blood Institute, National Institutes of Health, Rockville, MD September 20 ­ 21, 2010 (abstract on CD of meeting).
456. Simhhovich BZ, Mehriam-Shai R, Meacher P, Gookin G, Hsu Y-H, Lin S, Feng G, Kleinman MT, Kloner RA. Oxidative stress in the heart correlates with changes in cardiac gene expression patterns in rats chronically exposed to ambient air pollutants. Circulation, 23 November 2010; 122 (Issue 21 Suppl):A11199.
457. Kearns-Jonker M, Dai W, Gunthart M, Girish N, Pera M, Mummery C, Kloner RA. Genetically engineered mesechymal stem cells confer beneficial effects on both cotransplanted human embryonic stem cell derived cardiomyocytes as well as the recipient heart. Circulation, 23 November 2010; 122 (Issue 21 Suppl):A14863.
458. Kloner RA, Dow J, Bhandari A. First direct comparison of the late sodium current blocker ranolazine to established antiarrhythmic agents in an ischemia/reperfusion model. Circulation, 23 November 2010; 122 (Issue 21 Suppl):A12110.
459. Dai W, Kearns-Jonker M, Gerczuk P, Gunthart M, Girish N, Pera M, Mummery C, Kloner RA. The effect of co-transplantation of human embryonic stem cell-derived cardiomyocytes and mesenchymal stem cells on ventricular function and remodeling after myocardial infarction in nude rats. Circ. Res., 2011; 109 (12 Supplement):AP028.
460. Hale SL, Dai W, Kloner RA. A novel mitochondrial permeability transition pore inhibitor, Bendavia, reduces microvascular obstruction (no-reflow) due to myocardial ischemia/reperfusion injury in the rabbit. Circ. Res., 2011; 109 (12 Supplement):AP169.
461. Kloner RA, Hale SL, Gorman RC, Shuto T, Koomalsingh KJ, Gorman JH, Sloan RC, Frasier CR, Kypson AP, Brown DA. Bendavia, a novel mitorchondrial-targeted cytoprotective compound reduces ischemia/reperfusion injury: Experience in 3 independent laboratories. Circulation, 2011; 124 (Supplement 21):A9581.
462. Dow J, Simkhovich BZ, Bhandari A, Kloner RA. Remote preconditioning has a powerful antiarrhythmic effect independent of the reperfusion injury salvage kinase pathways. Circulation, 2011; 124(Supplement 21):A9583.
463. Schwartz BG, McDonald S, Poole WK, Kloner RA. The effect of the stock market crash and seasons on death and ischemic heart disease death in Los Angeles County. Circulation, 2011; 124(Supplement 21):A13300.
464. Dow JS, Painovich J, Hale SL, Longhurst JC, Tjen-A-Looi S, and Kloner RA. Effects of commonly used Chinese herbal medicines and electroacupuncture on experimental myocardial infarct size. FASEB J, March 29, 2012 26:1136.4.
465. Simkhovich BZ, Dow J, Kloner RA. Anti-arrhythmic effect of remote ischemic preconditioning is accompanied by changes in the salvage kinases in the rat heart non-ischemic area. FASEB J, March 29, 2012 26:1136.2.
466. Dai W, Gerczuk P, Yuanyuan Z, Kay GL, Jyrala AJ, and Kloner RA. Intramyocardial injection of heart tissue-derived extracellular matrix improves cardiac function in a rat myocardial infarction model. FASEB J, March 29, 2012 26:905.23.
467. Hale SL and Kloner RA. Hypothermia protects against myocardial microvascular damage (no-reflow) even when initiated after coronary artery reperfusion. FASEB J, March 29, 2012 26:857.2.
468. Gerczuk PZ, Breckenridge DG, Liles JT, Shryock JC, Belardinelli L, Kloner RA, and Dai W. An apoptosis signal-regulating kinase 1 inhibitor reduces cardiomyocyte apoptosis and infarct size in a rat ischemia-reperfusion model. FASEB J, March 29, 2012 26:1114.6.
469. Simkhovich BZ, Kleinman MT, Kloner RA, PL1:Air pollution and heart disease – from genetic changes to pharmacologic interventions. International Conference in Pharmacology. Targeting cellular regulatory systems. April 20-21, 2012, Riga, Latvia. Abstract Book, page 11.
470. Zhiroff K, Marrero EP, Kloner RA, Burstein S, Mayeda G, Economides C. Long-term patency of failed hemodialysis AV access after endovascular revascularization. Catherization and Cardiovascular Intervention, 2012: 79, Issue S1: pages S39-S40.
471. Dai W, Gerczuk PZ, Zhang Y, Smith L, Kopyov O, Kay GL, Jyrala AJ, Kloner RA. Extracellular matrix implantation prevents left ventricular paradoxical systolic bulging and postinfarction remodeling in rats independent of cardiac stem cell recruitment. Circulation, 2012;126:A11718.
472. Brown DA, Hale SL, Del Rio CL, Hamlin RL, Yueyama Y, Kijtawornrat A, Yeh ST, Frasier CR, Stewart LM, Patel HD, Collins MC, Muller-Borer BJ, Shaikh SR, Harris M, Fisher-Wellman KH, Neufer PD, Kloner RA. Bendavia, a mitochondria-targeting peptide, reduces reperfusion injury and reactive oxygen species levels through a mechanism independent of direct oxygen radical scavenging: A multicenter study. Circulation, 2012;1126:A10740.
473. Dai W, Kopyov O, Kloner RA. Chondro-osteogenic mass formation postinfarction is a natural part of the necrotic process and is independent of stem cell implantation. Circulation, 2012;126:A11711.
474. Dai W, Kloner RA. The effect of cell therapy versus noncellular biomaterial implantation on cardiac structure and function following myocardial infarction. Circulation, 2012;126:A11715.
475. Schwartz BG, Kloner RA. Seasonal variation in cardiac death rates is uniform across different climates. Circulation, 2012;126:A11723.
476. Schwartz BG, Franklin M, Kloner RA. Temperature and respiratory infection influence seasonal variation in total and ischemic heart disease death rates. Circulation, 2012;126:A17275.
477. Hale SL, Kloner RA. Delayed hypothermia reduces the no-reflow phenomenon independently of effect on infarct size: Evidence that microvascular damage represents true reperfusion injury. Circulation, 2012;126:A11263.
478. Brown DA, Patel HA, Moukdar F, Shaikh SR, Harris M, Fisher-Wellman K, Neufer PD, Hale SL, Dai W, Kloner RA. Preserving mitochondrial function during acute coronary syndromes with the mitochondria-targeting peptide Bendavia. Accepted for the United Mitochondrial Diseases Foundation (UMDF) Mitochondrial Medicine 2013: Newport Beach, CA. June 12-15, UMD Abstract Booklet 2013. Mitochondrion; 2013;13:923.
479. Shi J, Dai W, Hale SL, Kloner RA. Chronic Bendavia (a mitochondrial – targeting peptide) restores mitochondrial related gene expression in the noninfarcted border zone of infarcted hearts. Circulation. 2013;128:A12105.
480. Shi J, Dai W, Hale SL, Kloner RA. A mitochondrial-targeting peptide (Bendavia) regulates matrix metalloproteinase expression and preserves SERCA2a pump level in the noninfarcted border zone of infarcted hearts. Circulation. 2013;128:A13175.
481. Dow J, Herring M, Bhandari A, Kloner R. Acute testosterone infusion does not exacerbate arrhythmias in the rat model of ischemia/reperfusion (547.15). FASEB J, April 2014;28:547.15.
482. Sachdeva J, Dai W, Kloner R. Structural and functional assessment of an experimental model of takotsubo cardiomyopathy (648.8). FASEB J, April 2014;28:648.8.
483. Herring M, Dai W, Hale S, Kloner R. Rapid induction of hypothermia by the Thermosuit system profoundly reduces infarct size and anatomic zone of no-reflow following ischemia/reperfusion in rabbit and rat hearts (547.12). FASEB J, April 2014;28:574.12.
484. Dai W, Shi J, Hale S, Kloner R. Chronic Bendavia therapy improves post-infarction cardiac function and prevents adverse left ventricular remodeling in rats (652.8). FASEB J, April 2014;28:652.8.
485. Dow J, Simkhovich B, Hale S, Kay G, Kloner R. Capsaicin-induced cardioprotection is driven by its hypothermic effect (1154.1). FASEB J, April 2014;28:1154.1.
486. Shi J, Dai W, Hale S, Kloner R. A mitochondrial-targeting peptide (Bendavia) decreases apoptosis and suppresses cardiac fibrosis in the noninfarcted border zone of infarcted hearts (1154.3). FASEB J, April 2014;28:1154.3.
487. Pasha E, Kraus A, Machin DR, Alkatan M, Kloner R, Tanaka H. Effects of unilateral remote ischemic preconditioning on anaerobic exercise performance in recreationally active adults. Medicine and Science in Sports and Exercise. 2014;Vol 46, No. 5 Supplement; S149; Abstract #733.
488. Kraus A, Pasha E, Machin DR, Alkatan M, Kloner RA, Tanaka H. Bilateral upper limb remote ischemic preconditioning improves peak anaerobic power in recreationally active adults. Medicine and Science in Sports and Exercise. 2014;Vol 46, No. 5 Supplement; S687; Abstract #3347
489. Oskui PM, Kloner RA, Burstein S, Zhiroff K, Kartub BR, Hale S, Mayeda GS. The safety and efficacy of peripheral vascular procedures performed in the outpatient setting. Presented at OEIS Meeting (Outpatient Endovascular and Interventional Society), Austin, TX; May 17, 2014.
490. Kloner RA, Dai W, Hale SL, Shi J, Brown D. The effect of Bendavia on ischemia/reperfusion injury, left ventricular remodeling and dysfunction. The Journal of Heart Disease. 2014;11:51 (Abstract 203).
491. Shi J, Dai W, Hale SL, Kloner RA. A mitochondrial-targeting peptide (Bendavia) regulates glucose and fatty acid oxidation related gene expression and prevents myocardial hypertrophy in the non-infarcted border zone of infarcted hearts. Abstract #19071 presented at Scientific Sessions of the American Heart Association, Chicago, Ill. Nov. 15-19, 2014; Circulation 2014; 130: A19071.
492. Dai W, Herring MJ, Hale SL, Kloner RA. Transient hypothermia during the acute phase of myocardial infarction dramatically reduces scar size, prevents left ventricular dilation and remodeling, and preserves cardiac function. Abstract #158. Presented at ReSS as part of the Scientific Sessions of the American Heart Association (Best Original Resuscitation Science Poster Session) Chicago, Ill. Nov. 15, 2014; Circulation 2014; 130: A158.
493. Kloner RA. Stroke: A Primer. Abstract booklet for Huntington Medical Research Institute presents Brain Day. Presentation on March 28, 2015, Pasadena, CA.
494. Kloner RA, Dai W. Use of neonatal cardiomyocyte transplants into the aorta and vena cava as biologic pumps. Tissue Engineering; Part A, Volume 21, Supplement 1, 2015: page S-78.
495. Daaboul Y, Korjian S, Weaver WD, Kloner R, Giugliano R, Carr J, Neal BJ, Chi G, Cochet M, Goodell L, Michalak N, Rusowicz-Orazem L, Alkathery T, Allaham H, Shakil M, Szlosek D, Gibson CM. The association between left ventricular mass and measures of infarct size in anterior ST-Segment elevation myocardial infarction: insights from the EMBRACE STEMI Clinical trial. J Am Coll Cardiol 2016; 67: (13\_S): 495-495. Doi: 10.1016/S0735-1097(16)30496-X
496. Dai W, Cheung E, Allmeann RJ, Brown DA, Kloner RA. Cardioprotective effects of mitochnodria-targeted peptide SS-20 in two different models of rat ischemia/reperfusion. FASEB J April 2016 30: 1201.13
497. Shi J, Dai W, Kloner RA. Therapeutic hypothermia reduces the inflammatory response following ischemia/reperfusion injury in rat hearts. FASEB J April 2016 30: 1277-1.
498. Kloner RA. Attempts to reduce various forms of myocardial ischemia/reperfusion injury. From Programme and Abstract Book of The ParadOx Workshop. The oxygen paradox and the French paradox in ageing and disease. Hosted by the Good Samaritan Hospital of Los Angeles, the Leonard Davis School of Gerontology of the University of Southern Califroania, and the USC Free Radical Institute, and the Univeristy Pierre and Maire Curie, and Sorbonne University of Paris. Los Angeles, Oct 13-16, 2016.
499. Dai W, Kloner RA. Preservation of cardiac structure and function compared to brain in a rat hemorrhagic shock model. Presentation at the American Heart Assoc Scientific Sessions, Resuscitation Science Symposium Nov 12-16, 2016 New Orleans, Louisiana ; Circulation. 2016; 134: A12591.
500. Dai W, Kloner RA. Delayed therapeutic hypothermia protects against the myocardial no-reflow phenomenon independent of infarct size in a rat ischemia/reperfusion model. Presentation at the American Heart Assoc Scientific Sessions, Resuscitation Science Symposium,. Nov 12-16, 2016; New Orleans, Louisiana; Circulation. 2016; 134; A12589.
501. Pahlevan NM, Rinderknecht D, Tavallali P, Razavi M, Tran TT, Fong M, Kloner RA, Csete M, Gharib M. A new noninvasiec iphone application to monitor left ventricular ejection fraction in heart failure patients. Presentation at the American Heart Assoc Scientific Sessions, Nov, 12-16, 2016, New Orleans, Louisiana; Circulation. 2016; 134: A17227.
502. Korjian S, Daaboul Y, Kloner RA, Giugliano RP, Weaver WD, Carr J, Michalak N, Chi G, Villarreal M, Gallo A, Jain P, Szlosek D, Rusowicz-Orazem L, Gibson CM. The relationship between patency of the culprit artery on admission and electrolyte changes in anterior STEMI-Analysis from the EMBRACE STEMI clinical trial. Presentation at the American Heart Assoc Scientific Sessions, Nov 12-16, 2016, New Orleans, Louisiana; Circulation. 2016; 134: A18092.
503. Dai W, Hale S, Kloner RA. Uncoupling the reductions in microvascular no-reflow from reduction in myocardial infarct size; Therapeutic implications. Journal of Critical Care 2017; 38: 362. Abstracts from the 15th International Conference on Complex Acute Illness ( ICCAI); Society of complex illnesses. Caltech, Pasadena, CA, Aug 2016. http://dx.doi.org/10.1016/j.jcrc2016.11.013
504. Shi J, Dai W, Kloner RA. A mitochondrial targeting peptide ( elamipretide) prevents myocardial matrix remodling in the infarcted zone of infarcted heart. Journal of Criticial Care 2017; 38: 363. Abstracts from the 15th International Conference on Complex Acute Illness ( ICCAI); Caltech, Pasadena, CA Aug 2016. <http://dx.doi.org/10.1016/j.jcrc.2016.11.015>
505. Kloner RA. Remote ischemic preconditioning. From Bench to Bedside. In Abstract Book of the 16th Annual International Dose-Response Conference. Preconditioning: In Biology and Medicine. Mechanisms and Translational Research. Page 6; April 18-19, 2017. U of Massachusettes, Amherst, MA.
506. Dai W, Carreno J, Shi J, Hale S, Kloner RA. Characterization of myocardial infarct and no-reflow Size in Zucker Diabetic Fatty Rat myocardial ischemia/reperfusion model. Circulation. 2017; 136: A16834.
507. Shi J, Dai W, Carreno J, Hale SL, Kloner RA. Blood-based biomarkers as early predictors of long term outcome in an experimental model of hemorrhagic shock. Circulation. 2017; 136: A14974.
508. Kloner RA, Coleman G, Yuan J, Conrad A, Pergola PE. Effect of patiromer in hyperkalemic patients with or without RAASi. Circulation. 2017; 136: A14680.
509. Dai W, Shi J, Carreno J, Hale S, Kloner RA. Relationship between survival and duration of hypotension in rat fixed pressure hemorrhagic shock model: The first critical 30 minutes. Circulation. 2017; 136: A16717.
510. Dai W, Shi J, Hale S, Csete M, Carreno J, Kloner RA. Protective effect of isoflurane in an experimental model of hemorrhagic shock. Circulation. 2017; 136: A16646.
511. Shi J, Dai W, Carreno J, Hale SL, Kloner RA. Blood-based biomarkers as early predictors of mortality in experimental hemorrhagic shock. FASEB Journal. 2018; 32: Issue 1\_supplement; Abstract 575.4.
512. Dai W, Shi J, Carreno J, Hale S, Kloner RA. Remote limb ischemic preconditioning improves post-resuscitation long term survival in a rat fixed pressure hemorrhagic shock model. FASEB Journal. 2018; 32: Issue 1\_supplement; Abstract 575.3.
513. Mogadam E, King K, Kloner R, Shriner K, Chu K, Royal D. Lower nadir CD4-T-cell count is a strong predictor of endothelial dysfunction in HIV-infected patients. Accepted for presentation a the the Basic Cardiovascular Sciences 2018 Scientific Sessions. July 30-Aug 2, 2018, San Antonio, Texas. Circ Res 123 (Suppl-1), Aug 2018, Abstract 513. https://doi.org/10.1161/res.123.suppl-1.513.
514. Pahlevan NM, Dai W, Kloner RA. Noninvasive and instantaneous diagnostics of acute myocardial infarction. Circ. 2018; 138: A15311.
515. Dai W, Shi J, Carreno J, Hale SL, Kloner RA. Remote limb ischemic preconditioning improves short and long term survival and maintains intravascular blood volume during resuscitation of hemorrhagic shock. Circ. 2018; 138: A186.
516. Dai W, Shi J, Carreno J, Hale SL, Kloner RA. Effects of anesthetic agents on the hemodynamic stabilization and long term survival in an experimental model of hemorrhagic shock. Circ. 2018; 138: A187.
517. Shi J, Dai W, Carreno J, Hale SL, Kloner RA. Effects of anesthetic agents on blood parameters in rats with hemorrhagic shock. Circ. 2018; 138: A191.
518. Johnson R, Kwang D, Kloner R, Fonteh AN, Kleinman MT, Harrington MG, Arakaki X. Cerebro-cardiovascular relationships during working memory testing are different in cognitively healthy individuals with abnormal CSF amyloid/tau. Presented at the Alzheimer’s Association International Conference, poster P3-077 on July 16, 2019, Los Angeles, CA. Alzheimer’s and Dementia; July 2019; Vol 15; Issue 7S; Part\_18 Supplement, Page P955.
519. Rashid A, Dai W, Kloner RA, Pahlevan N. A hybrid artificial intelligence-intrinsic frequency method for instantaneous detection of acute myocardial infarction. Circulation. 2019; Vol 140; Issue Suppl 1: A12573
520. Dai W, Shi J, Carreno J, Kloner RA. Therapeutic hypothermia alone and in combination with preconditioning improves long term survival during resuscitation of hemorrhagic shock. Circulation. 2019; Vol 140; Issue Suppl 2; 140: A216.
521. Dai W, Shi J, Carreno J, Kleinman MT, Herman DA, Johnson RM, Renush S, Hasen I, Kloner RA. Effects of chronic electronic cigarette vapor exposure on cardiac function in a rat experimental myocardial infarction-reperfusion model. Circulation 2019; Vol 140. Issue Suppl 1: A11701.
522. Shi J, Dai W, Carreno J, Hale SL, Kloner RA. Effects of therapeutic hypothermia on blood parameters in rats with acute hemorrhagic shock. Circulation 2019; Vol 140. Issue Suppl 2; A120.
523. Shi J, Dai W, Carreno J, Hale SL, Kloner RA. Therapeutic hypothermia alone and combination with preconditioning blunt inflammation in experimental hemorrhagic shock. Circulation 2019; Vol 140; Issue Suppl 2; A218.
524. Dai W, Zhao L, Carreno J, Kleinman M, Kloner RA. Effects of nicotine on myocardial infarction and no reflow size in a rat experimental model of coronary artery occlusion/reperfusion. Presented at Oct 2019 NIH Tobacco Regulatory Science Meeting, Bethesda, MD. Program Book. Poster Session 1; Board #22, Page 29, 2019.
525. Shi J, Dai W, Carreno J, Kloner RA. Neuroprotection of remote ischemic preconditioning and hypothermia in a model of hemorrhagic shock induced brain injury. Circulation 2019; 140 (25), 17 Dec ; pages e965-e1011.
526. Zhao L, Dai W, Carreno J, Shi J, Kleinman M, Kloner RA. Acute administration of nicotine induces transient elevation of blood pressure and increases myocardial infarct size in an acute myocardial ischemia/repefusion rat model. Circulation 2020, Vol. 142, Issue Suppl\_3, Abstract 13788.
527. Dai W, Shi J, Carreno J, Zhao L, Kleinman MT, Herman DA, Johnson RM, Renush S, Hasen I, Tang A, Kloner RA. Effects of chronic electronic cigarette vapor exposures on the cardiovascular function in rats. Circulation 2020, Vol 142, Issue Suppl\_3; Abstract 13868.
528. Dai W, Shi J, Carreno J, Zhao L, Kleinman MT, Herman DA, Johnson RM, Renush S, Hasen I, Ting A. Chronic electronic cigarette vapor exposure leads to impaired cardiac function in experimental rat myocardial ischemia/reperfusion model. Circulation 2020, Vol.142, Issue Suppl\_3, Abstract 13764.
529. Shi J, Kleinman MT, Arechavala RJ, Herman D, Hasen I, Ting A, Dai W, Carreno J, Chavez J, Zhao L, Kloner RA. Inflammatory changes in the lungs of rats exposed to e-cigarettes without marijuana, vitamin E oil, or nicotine. Circulation 2020, Vol 142, Issue Suppl\_3, Abstract 13869.
530. Dai W, LeGrand B, Boucard A, Carreno J, Zhao L, Kloner RA. Effects of Op2113 on myocardial infarct size and no reflow in a rat myocardial ischemia/reperfusion model. Circulation 2020, Vol. 142, Issue Suppl\_ 3, Abstract 13780.
531. Alavi R, Dai W, Kloner RA, Pahleven NM. A hybrid artificial intelligence-intrinsic frequency method for instantaneous determination of myocardial infarct size. Circulation 2020, Vol. 142, Issue Suppl\_3, Abstract 15899.
532. Arechavala RJ, Kloner R, Hung S-M, Harrington MG, Arakaki X, Kleinman MT. Heart rate variability changes during task shifting testing in pre-symptomatic Alzheimer’s disease. Alzheimer’s and Dementia; Vol 16; Issue S5; First published 07 Dec 2020.
533. Arakaki X, Hung S-M, Wei K, Tran T, Arechavala RJ, Kleinman MT, Kloner R, Fonteh AN, King K, Harrington MG. A study of alpha desynchronization , heart rate, and MRI during stroop testing unmasks pre-symptomatic Alzheimer’s Disease. Alzheimer’s and Dementia; Vol 16; Issue S5; First published : 07 Dec 2020.
534. Rochart R, Lin Q, Doyle JC, Arechavala RJ, Kloner R, Kleinman MT, Harrington MG, Arakaki X. Heart rate and blood pressure decreases after a motor task in pre-symptomatic AD. Alzheimer’s and Dementia; Vol 16; Issue S5; First published 07 Dec 2020.
535. Dai W, Zhao L, Shi J, Carreno J, Kleinman M, Herman D, Arechavala R, Renusch S, Hasen I, Ting A, Kloner RA. Effects of chronic electronic cigarette vapor exposure and standard cigarette smoke on myocardial infarction and no-reflow in a rat model. The FASEB Journal, Vol 35, Issue S1, May 14, 2021. Experimental Biology 2021 Meeting Abstracts. Physilogy.
536. Alavi R, Dai W, Kloner RA, Pahlevan NM. A physics-based machine learning approach for instantaneous classification of myocardial infarct size. Circulation 2021, Vol 144, Issue Suppl\_1/16 November. Abstract 12098.
537. Alavi R, Dai W, Arechavala RJ, Kleinman MT, Kloner RA, Pahlevan NM. Nicotine delivered by electronic cigarette vapor or standard cigarettes adversely affects left ventricular systolic function measured by cardiovascular intrinsic frequency in rats. Circulation 2021, Vol 144, Issue Suppl\_1/ 16 November. Abstract 13745.
538. Kloner RA, Kostis JB, Qiu C, Gupta A, McGraw T. Clinical safety of tadalafil in patients receiving concomitant antihypertensice medication. Circulation 2021, Vol 144, Issue Suppl\_1/ 16 November. Abstract 10964.
539. Shi J, Dai W, Chavez JN, Carreno J, Zhao L, Kleinman MT, Arechavala RJ, Hasen I, Ting A, Bliss B, Monterrosa Mena JE, Kloner RA. One acute exposure to e-cigarette smoke using various heating elements and power levels induces pulmonary inflammation. Circulation 2021, Vol 144, Issue Suppl\_1/16 November. Abstract 10299.
540. Monterrosa Mena JE, Hsu H-W, Arechavala RJ, Hasen I, Ting A, Bliss B, Shi J, Dai W, Chavez J N, Carreno J, Zhao L, Kloner RA, Kleinman MT. Inflammatory gene expressión changes and immune system depression in rats exposed to a single 4-hr exposure to electronic cigarette vapor. Circulation 2021, Vol 144, Issue Suppl\_1/16 November. Abstract 12450.
541. Arechavala RJ, Liu A, Rochart R, Kloner R, Fonteh AN, Kleinman MT, Harrington MG, Arakaki X. Task switching challenge to reveal abnormal brain-heart signatures in cognitively healthy individuals with abnormal CSF amyloid/tau. Alzheimer’s and Dementia ; Vol 17; Issue S5 First published: 31 Dec 2021.
542. Xianghong Arakaki, David Buennagel, Anne Nolty, Mitchell Spezzaferri, Caleb Sin, Shant Rising, Helena Chui, Alfred N. Fonteh, Robert A. Kloner. Triglyceride and VLDL cholesterol are lower in cognitively healthy individuals with Amyloid pathologies than those without. Alzheimer’s association, Alzheimer's Association International Conference (AAIC): Poster #64860, San Diego, CA, July 31-Aug 4, 2022; Alzheimer’s and Dementia. Vol 18; Issue S3. First Published: 20 Dec 2022.
543. Xianghong Arakaki, Elizabeth Hok Yee Choy, Rebecca Johnson Arechavala, Anne Nolty, Mitchell Spezzaferri, Caleb Sin, Shant Rising, David Buennagel, Cathleen Molloy, Alfred N. Fonteh, Robert A. Kloner, Michael T. Kleinman. Resting heart rate (variability) predicts cognitive function and suggests different heart-brain connections in cognitively healthy individuals with abnormal CSF amyloid/tau. Alzheimer’s association, Alzheimer's Association International Conference (AAIC): Poster #64297, San Diego, CA, July 31-Aug 4, 2022; Alzheimer’s and Dementia; Vol 18; Issue S5; First published: 20 Dec 2022.
544. Xianghong Arakaki, Ryan Butler, Jimmy J. Kang, Thomas Macias, Helena Chui, Anne Nolty, Mitchell Spezzaferri, Caleb Sin, Shant Rising, Cathleen Molloy, Robert A. Kloner, Alfred N. Fonteh. MRI norm percentile in age-related atrophy starts from MCI stage. Alzheimer's Association International Conference (AAIC): Poster #64364, San Diego, CA, July 31-Aug 4, 2022; Alzheimer’s and Dementia ; Vol 18; Issue S5. First published: 20 Dec 2022.
545. Xia, C, Pogoda, J.M., Hubble, V.B., Rogando, A., Kloner, R.A., Fonteh, A.N., Arakaki, X. Sex differences in behavioral reaction in a rodent model of acute migraine. Headache. Volume 62, Issue S1. P-05. Special Issue: American Headache Society 64th Annual Scientific Meeting. June 9-12, 2022. Denver, Colorado.
546. Humayun A, Singh SG, Gray A, Jonhson D, Nair A, Stinson C, Dean T, Chen Q, Barsotti R, Young L, Dai W, Kloner RA. Naltrindole pretreatment exhibits robust cardioprotection in an acute in vivo model of ischemia/reperfusion. Presentation at EB 2022, Philadelphia, April 2-5, 2022. R5461. FASEB J. 2022 May;36 Suppl 1. doi: 10.1096/fasebj.2022.36.S1.R5461.PMID: 35553163
547. Humayun A, Singh SG, Gray A, Tanoh DB, Taylor G, Thomas L, Johnson D, Nair A, Stinson C, Dean TC, Chen Q, Barsotti R, Young L, Dai W, Kloner RA. Naltrindole pretreatment exhibits potent cardioprotection in both ex vivo and in vivo models of ischemia/reperfusion injury. Accepted Cardio Forum 2022. 2nd Virtual Global Summit. May 16,17 2022.
548. Kloner RA, Stanek E, Crowe CL, Singhal M, Pepe RS, Bradsher J, Rosen R. The Effect Of Phosphodiesterase-5 Inhibitors On Major Adverse Cardiovascular Events And Mortality In A Large Cohort Of Men With Erectile Dysfunction From A Nationwide Insurance Database: A Retrospective Study Circulation: Cardiovascular Quality and OutcomesVolume 15, Issue Suppl\_1 1 May 2022. Abstract 195.
549. Cynthia T. Clague PhD, Cattleya Ounekeo BS/MBA, Dale M. Groth BS/SRS, William Van Alstine DVM/PhD/ DACVP, Panapat Uawithya MD, PhD Deepak Bhatt MD/MPH, Paul Iaizzo PhD, Robert Kloner MD/PhD, Kroekkiat Chinda DVM/PhD, Satit Janwanishstaporn MD, Pramote Hochareon MD,Significant Infarct Size Reduction Through Isolated Coronary Sinus Retroperfusion Cooling: A Pilot Preclinical Study in a Reperfusion Delay Model. TCT 2022 Abstract #49; J Am Coll Cardiol. 2022 Sep, 80 (12\_Supplement) B20.
550. Alavi R, Dai W, Kloner RA, Pahlevan N. Noninvasive and instantaneous detection of myocardial ischemia from a single carotid waveform using a physics-based machine learing methodology. Accepted for presentation at the American College of Cardiology meetings, New Orleans, Louisiana, March 2023. Abstract in press JACC, 2023. Accepted for Young Investigators Comptetion. J Am Coll Cardiol 2023. March , Vol 81; Issue No. 8- Supplement. pp 4012.
551. Kloner RA, Kleinman MT. One acute exposure to e-cigarette smoking using various heating elements and power levels induces pulmonary inflammation. Abstract ( EVALI Supplement Webinar Presentation Guide. NIH. Pages 21-23, Oct 2022) and presentation at NIH EVALI Supplement Webinar. 10/28/22. Bethesda, MD.
552. Alavi R, Dai W, Arechavala RJ, Kleinman MT, Kloner RA, Pahlevan NM. Detection of the effect of nicotine delivered by e-cigarettes or standard cigarettes on cardiovascular system from a carotid waveform using a physics-based machine learning approach. Circulation . 2022; 146, Issue Suppl\_1:A12922.
553. Dai W, Brown DA, Kloner RA. Effects of SBT-255 on myocardial infarct size and no reflow in a rat myocardial ischemia/reperfusion model. Circulation 2022; 146, Issue Suppl\_1; A13279.
554. Dai W, Shi J, Zhao L, Carreno J, Kleinman MT, Herman D, Arechavala RJ, Renusch S, Hasen I, Ting A, Kloner RA. Differences in infarct size and no-relfow by sex in young adult rats in an electronic cigarette exposure study. Circulation 2022; 146, Issue Suppl\_1; A13315.
555. Dai W, Shi J, Zhao L, Carreno J, Kleinman MT, Herman D, Arechavala RJ, Renusch S, Hasen I, Ting A, Kloner RA. Impact of chronic electronic cigarette vapor exposure on the recovery of cardiovascular function in experimental rat myocardial ischemia/reperfusion model. Circulation 2022; 146; Suppl\_1; A 13324.
556. Humayan A, Singh S, Gray A, Johnson D, Dean T, Chen Q, Barsotti R, Young L, Dai W, Kloner R. Naltrindole pretreatment elecits potent doses dependent effects on reducing infarct size during ischemia reperfusion in-vivo. Accepted for the Am Physiology Summit, Long Beach, CA. April, 2023.
557. McVary KT, Daluwatte C, Kloner RA, Montmerle M, Rollot M, Guilmin P, Blanchon M, Lambertl N, Esnautl C, Steward A, McGraw T. Cluster algorithm for credible subgroup identification in patients with erectile dysfunction receiving tadalafil: A real world data study. Accepted for presentation to ISPOR 2023. Boston, MA. May 7-10, 2023.
558. Cathleen Molloy, Elizabeth Choy, Abdulhakim Al-Ezzi, David Buennagel, Shelly aguda, Anne Nolty, Mitchell Spezzaferri, Caleb Sin, Shant Rising, Alfred N. Fonteh, Yafa Minazad, Michael Klainman, Robert A. Kloner, Xianghong Arakaki. Correlation between heartrate and alpha Event-Related Desynchronization reveals cognitively healthy individuals with pathological CSF amyloid/tau during a Stroop task. AAIC 2023; Alzheimer’s and Dementia; Vol 19; Issue S15; First published: 25 Dec 2023.
559. Shant Rising, Rachel Woo, Anne Nolty, Helena Chui, Ryan Butler, Jimmy Kang, Mitchell Spezzaferri, Caleb Sin, David Buennagel, Shelly Aguda, Yafa Minazad, Sung Kim, Robert Kloner, Alfred Fonteh, Xianghong Arakaki. Larger hippocampal and temporal lobe volume may associate with early rapid forgetting in cognitively healthy individuals with a predisposition to Alzheimer’s disease. AAIC 2023; Alzheimer’s and Dementia; Vol 19; Issue S18. First published 25 Dec 2023.
560. Alfred N. Fonteh, Salvador Maldonado, David Buennagel, Ryan Butler, Jimmy Kang, Thomas Macias, Caleb Sin, Mitchel Spezzaferri, Shant Rising, Anne Nolty, Helena Chui, Yafa Minazah, Robert Kloner, Xianghong Arakaki. Association of urine dicarboxylic acid levels with intracranial volume–normalized brain regions and with white matter hypo-intensities. AAIC 2023; Alzheimer’s and Dementia; Vol 19; Issue S16. First published: 25 Dec 2023.
561. Alfred N. Fonteh, Xiaomeng Wu, Natalie Astraea, Tamara Ellenberger, Caleb Sin, Mitchel Spezzaferri, Shant Rising, Anne Nolty, Helena Chui, Yafa Minazah, Robert Kloner, Xianghong Arakaki. Amyloid ratios in plasma and CSF are biomarkers of pre-symptomatic Alzheimer’s disease. AAIC 2023; Alzheimer’s and Dementia ; Vol 19; Issue S14; First published: 25 Dec 2023.
562. Sara W Adams, Amir-Vala Tavakoli, Cathleen Molloy, Daw-An Wu, PhD, Shao-Min (Sean) Hung, PhD, Yafa Minazad, DO, MMM, Robert A Kloner, MD, PhD, Shinsuke Shimojo, PhD and Xianghong Arakaki, MD, PhD. Saccadic latency differences in preclinical Alzheimer’s disease. AAIC 2023; Alzheimer’s and Dementia; Vol 19; Issue S18. First published: 25 Dec 2023.
563. Phonemic Fluency and Brain Volumetrics Distinguish Cognitively Healthy Adults with Predisposition to Alzheimer’s Disease. Rachel Woo, Shant Rising, Sung Kim, Anne Nolty, Xianghong Arakaki, Robert Kloner. Presented for American Academy of Clinical *Neuropsychology (AACN), Washington DC.2023*
564. [Choriocapillaris Flow Deficits Analysis as Biomarker in Early Alzheimer’s stages](https://iovs.arvojournals.org/article.aspx?articleid=2790567). Giulia Corradetti, Deniz Oncel, Shin Kadomoto, David Buennagel, Xianghong Arakaki, Alfred N Fonteh, Shelly Aguda, Robert A Kloner, SriniVas R Sadda, Alfredo A Sadun, Jane W Chan. Investigative Ophthalmology & Visual Science. 64 (8): 2533-2533. 2023.
565. Inner Retinal Optical Coherence Tomography Angiography Metrics in Pre-Alzheimer’s Disease. [Jane W. Chan](https://iovs.arvojournals.org/solr/searchresults.aspx?author=Jane+W.+Chan); [Giulia Corradetti](https://iovs.arvojournals.org/solr/searchresults.aspx?author=Giulia+Corradetti); [Deniz Oncel](https://iovs.arvojournals.org/solr/searchresults.aspx?author=Deniz+Oncel); [Shin Kadomoto](https://iovs.arvojournals.org/solr/searchresults.aspx?author=Shin+Kadomoto); [David Buennagel](https://iovs.arvojournals.org/solr/searchresults.aspx?author=David+Buennagel); [Xianghong Arakaki](https://iovs.arvojournals.org/solr/searchresults.aspx?author=Xianghong+Arakaki); [Alfred N Fonteh](https://iovs.arvojournals.org/solr/searchresults.aspx?author=Alfred+N+Fonteh); [Shelly Aguda](https://iovs.arvojournals.org/solr/searchresults.aspx?author=Shelly+Aguda); [Robert A Kloner](https://iovs.arvojournals.org/solr/searchresults.aspx?author=Robert+A+Kloner); [SriniVas R Sadda](https://iovs.arvojournals.org/solr/searchresults.aspx?author=SriniVas+R+Sadda); [Alfredo A. Sadun](https://iovs.arvojournals.org/solr/searchresults.aspx?author=Alfredo+A.+Sadun). Investigative Ophthalmology & Visual Science. 64 (8): 2533-2533. 2023.
566. Age-Related Changes in Sodium Concentrations in Cerebrospinal Fluid, Plasma, and Brain Regions: Implications for Brain Function and Hypertension Risk. Chenchen Xia, Wangde Dai, Xiaomeng Wu, Nathan F. Dalleska, Natalie Astraea, Alfred N. Fonteh, Anju Vasudevan, Robert A. Kloner, Xianghong Arakaki. Accepted for Society for Neuroscience SfN2023. Washington DC. 2023.
567. Altered Brain Connectivity during Resting-State as Electrophysiological Signatures in Cognitively Healthy Individuals with Pathological CSF Amyloid/tau. Abdulhakim Al-Ezzi, Cathleen Molloy, David Buennagel, Alfred N Fonteh, Ryan Butler, Jimmy J Kang, Rebecca J Arechavala, Michael Kleinman, Robert A Kloner, Xianghong Arakaki. Accepted for Society for Neuroscience SfN2023. Washington DC. 2023.
568. Dai W, Shi J, Carreno J, Kleinman MT, Herman D, Johnson R, Renusch S, Hasen I, Ting A, Kloner RA.The effect of electronic cigarette exposure on flow mediated vasodilation and LV remodeling in a chronic myocardial infarction model. Circulation. Vol 148; Issue Suppl \_1/7 November 2023. Abstract 13361.
569. Shi J, Dai W, Carreno J, Kleinman MT, Herma D, Johnson R, Renusch S, Hasen I, Ting A, Kloner RA. The effect of electronic cigarette exposure with nicotine on expression of inflammatory genes and blood parameters in a chronic myocardial infarction model. Circulation; Vol 148; Issue Suppl\_1/7 November 2023. Abstract 14730.
570. Dai W, Shi J, Carreno J, Kleinman MT, Herman D, Johnson R, Renusch S, Hasen IA, Ting A, Kloner RA. The effect of chronic standard cigarette smoke exposure compared to chronic electronic cigarette exposure with or without nicotine on blood pressure. Circulation; Vol 148; Issue Suppl \_1/7 November 2023; Abstract 13349.
571. Clair L, Ramsarran J, Tanoh DB, Humayun A, Melnik J, Dean T, Chen Q, Barsotti R, Young L, Dai W, Kloner RA. Naltrindole mitigates rigor during myocardial ischemia by a novel mechanism and shows translational cardioprotection in myocardial ischemia-reperfusion injury models. Circulation; Vol 148; Issue Suppl\_1/7 November 2023. Abstract 17814.
572. Alavi R, Dai W, Kloner RA, Pahlevan NM. Systems hemodynamics approach for evaluating myocardial risk zone from carotid pressure waveforms in coronary occlusion/reperfusion rat models. Bulletin of the American Physical Society. Presented at the 76th annual meeting of the division of fluid mechanics. Nov 19-21, 2023. Washington, DC. Abstract: L06.00002.
573. Pahlevan NM, Alavi R, Dai W, Kloner RA. Assessment of hemodynamic changes during acute myocardial ischemia and infarction using intrinsic frequency method. Bulletin of the American Physical Society. Presented at the 76th annual meeting of the division of fluid mechanics. Nov 19-21, 2023. Washington, DC. Abstract: L10.00002.
574. Alavi R, Mazandarani SP, Dai W, Arechavala R, Herman D, Kleinman M, Kloner RA, Pahlevan NM. Detection of adverse effects of chronic e-cigarette and standard cigarette on ventricular and arterial functions in rats using intrinsic frequency of carotid pressure waveforms. J Am Coll Cardiol 2024. Apr, 83 (13\_Supplement) 1809.

**ELECTED INVITED LECTURES – Since 1985**

December 5, 1984 The Stunned Myocardium. Medical Grand Rounds, Harper Hospital, Detroit MI.

February 5, 1985 Myocardial Infarct Size Reduction. Cardiology Conference, Harper Hospital, Detroit, MI.

February 27, 1985 New vs. Old Therapy for Congestive Heart Failure. Cardiology Update, St. John Hospital, Detroit MI.

March 7, 1985 Basic Science of Myocardial Ischemia. Cardiology Conference, Harper Hospital, Detroit, MI.

March 8, 1985 The Stunned Myocardium. Cardiology Grand Grounds, Henry Ford Hospital, Detroit, MI.

March 13, 1985 Experimental Myocardial Infarction. Co-Chairman. Experimental Myocardial Infarction. Modification of Injury II. College of Cardiology, Anaheim, CA.

March 20, 1985 Clinical and Experimental Interventions to Reduce Infarct Size. Critical Care Medicine Update, 1985, Johns Hopkins University School of Medicine, Baltimore MD.

March 27, 1985 Common Problems in Cardiology: New Approaches to Old Disease. Workshops in Internal Medicine, Wayne State University School of Medicine, Detroit, MI.

April 4, 1985 Basic Science of Myocardial Ischemia ­ Part 2. Cardiology Conference, Harper Hospital, Detroit, MI.

April 24, 1985 Stunned Myocardium. Cardiology Seminar Conference, Sinai Hospital, Detroit, MI.

April 30, 1985 Chronic Ischemic Heart Disease; Pulmonary Heart Disease, Congenital Heart Disease. Internal Medicine Board Review Course Harper Hospital, Detroit, MI.

May 3, 1985 Stunned Myocardium. Detroit Heart Club, Harper Hospital, Detroit, MI.

May 31, 1985 New versus Old Therapy for Congestive Heart Failure. Guest Lecturer, Flint Osteopathic Hospital, Flint, MI.

June 6, 1985 Treatment of Congestive Heart Failure. Critical Care Case Conference, Detroit Receiving Hospital, Detroit, MI.

August 8, 1985 Acute Myocardial Infarction and Beta Blockade. Cardiology Conference, Hutzel Hospital, Detroit, MI.

August 8, 1985 Therapy for Acute Myocardial Infarction. Housestaff Conference, Harper Hospital, Detroit, MI.

September 13, 1985 The Status of Myocardial Infarct Size Reduction, 1985. Cardiology Rounds, Henry Ford Hospital, Detroit, MI.

October 1, 1985 Acute Myocardial Infarction: Emerging Concepts of Pathogenesis and Treatment, and The No Reflow Phenomenon and the Stunned Myocardium. Graduate Hospital Research Symposium, Graduate Hospital and University of Pennsylvania School of Medicine, Philadelphia, PA.

October 10, 1985 Report from the Experimental Myocardial Ischemia Laboratory. Cardiology Research Conference, Harper Hospital, Detroit, MI.

October 31, 1985 Mechanisms of the Stunned Myocardium. Harvard Ischemia SCOR Research Meeting, Massachusetts General Hospital, Boston, MA.

November 1, 1985 Angina Pectoris. Oakwood Hospital, Dearborn MI.

November 6, 1985 Intermittent Coronary Reperfusion Does Not Reduce Anatomic Infarct Size. American Federation for Clinical Research, Central Meetings, Chicago, IL.

November 11, 1985 Stunned Myocardium. Cardiovascular Conference, Annual Scientific Sessions of the American Heart Association, Washington, DC.

November 22, 1985 ECG and Systemic Disease. ECG Mini-course, Harper Hospital, Detroit, MI.

January 6, 1986 Angina Pectoris. Bi-County Hospital, Warren, MI.

January 7, 1986 Beta Blockers in Angina and Myocardial Infarction. Cottage Hospital, Grosse Pointe, MI.

January 9, 1986 Stunned Myocardium. Department of Physiology, University of South Alabama, Mobile, AL.

January 30, 1986 Angina Pectoris. Riverside Hospital, Trenton, MI.

February 1, 1986 Role of Vasodilators in Acute Illness. St. Mary’s Hospital, Livonia, MI.

February 5, 1986 Experimental Myocardial Ischemia. Department of Pathology Conference, Wayne State University, Detroit MI.

February 14, 1986 Ischemia and Infarction. ECG Mini-Course, Harper Hospital, Detroit, MI.

February 18, 1986 The Healing Phase of Infarction and Stunned Myocardium and Free Radicals. Cardiology Seminars, The University of Michigan Medical Center, Ann Arbor, MI.

February 20, 1986 The Healing Phase of Acute Myocardium Infarction. Cardiology Grand Rounds, Harper Hospital, Detroit, MI.

February 28, 1986 The Treatment of Congestive Heart Failure. Mt. Carmel Mercy Hospital, Detroit, MI.

March 14, 1986 The Stunned Myocardium. Pharmacology Conference, Wayne State University, Detroit, MI.

March 26, 1986 Stunned Myocardium and the Window of Opportunity. Workshops in Internal Medicine, Wayne State University School of Medicine, Detroit, MI.

March 27, 1986 Patient Management Seminar. Year III Cardiology Course, Patient Management Seminar, Wayne State University School of Medicine, Detroit, MI.

April 17, 1986 Management of Congestive Heart Failure. Lansing General Hospital, Lansing, MI.

April 23, 1986 Angina Pectoris. Medical Grand Rounds, William Beaumont Hospital, Royal Oak, MI.

April 24, 1986 Research Aspects of Heart Attack. Staff Meeting, American Heart Association of Michigan, Plymouth, MI.

April 25, 1986 Ischemia and Infarction. ECG Minicourse, Harper Hospital, Detroit, MI.

May 6, 1986 Chronic CAD and Pulmonary and Congenital Heart Disease. Board Review Course, Harper Hospital, Detroit, MI.

May 16, 1986 Mixed Angina. Continuing Medical Education Program, North Detroit General Hospital, Detroit, MI.

June 24, 1986 Angina Pectoris. Lynne Hospital, Lincoln Park, MI.

July 10, 1986 Treatment of Heart Failure. Medical Grand Rounds, Allen Park Veterans Administration Hospital, Allen Park, MI.

July 29, 1986 Acute Myocardial Infarction. Intern Emergency Lecture, Harper Hospital, Detroit, MI.

August 28, 1986 Refractory Congestive Heart Failure. Toledo Hospital, Toledo, OH.

September 9, 1986 Hypertension. Troy Beaumont Hospital, Troy, MI.

September 11, 1986 Effects of Calcium Antagonists on Infarcting Myocardium. Calcium Antagonist: Emerging Clinical Opportunities - A World-wide Perspective (An international symposium sponsored by Harvard Medical School, Boston MA).

September 16, 1986 New vs. Old Therapy for Congestive Heart Failure. Flint Osteopathic Hospital, Flint, MI.

September 19, 1986 The Effect of Calcium Blockers on Experimental Myocardial Ischemia. Research Conference, Cardiology Division, Harper Hospital, Detroit, MI.

October 7, 1986 Angina Pectoris. Mt. Carmel Mercy Hospital, Detroit, MI.

October 16, 1986 The Effect of Calcium Blockers on Stunned Myocardium. Harvard Ischemia SCOR Annual Scientific Session, Massachusetts General Hospital, Boston, MA.

October 23, 1986 ACE Inhibition in Mild and Moderate Hypertension. Riverside Hospital, Toledo, OH

November 6, 1986 Angina Pectoris. South Bend Memorial Hospital, South Bend, IN.

November 12, 1986 Angina Pectoris and Silent Myocardial Ischemia. St. Mary Hospital, Livonia, MI.

November 14, 1986 Stunned Myocardium. Medicine Today Update, Case Western Reserve University Hospitals at Cleveland, Cleveland, OH.

November 24, 1986 Stunned Myocardium. Cardiology Conference, Visiting Professor, University of Cincinnati, OH.

December 15, 1986 Angina Pectoris. Riverside Hospital, Trenton, MI

January 12, 1987 Mixed Angina and Silent Ischemia. Troy Beaumont Hospital, Troy, MI.

January 15, 1987 Angina Pectoris. Guest Lecturer, Metropolitan Hospital, Detroit MI.

January 16, 1987 Ischemia and Infarction. ECG Minicourse, Harper Hospital, Detroit, MI.

January 22, 1987 Myocardial Ischemia and Calcium Channel Blockers. Bi-County Community Hospital, Warren, MI.

January 26, 1987 Heart Failure-Ace Inhibition. Visiting Professor, Conemaugh Valley Memorial Hospital, Johnstown, PA.

 Management of Hypertension. Visiting Professor, Conemaugh Valley Memorial Hospital, Johnstown, PA.

 Management of Congestive Heart Failure. Visiting Professor, Conemaugh Valley Memorial Hospital, Johnstown, PA.

January 29, 1987 Pathophysiology of Coronary Artery Disease. Physician Assistant Cardiology Course. Harper Hospital, Detroit, MI.

February 4, 1987 Ischemic Burden. Cardiology Lecture Series, Botsford Hospital, Farmington Hills, MI.

February 12, 1987 Angina/Silent Ischemia. Postgraduate Course, Garden City Hospital, Garden City, MI.

March 10, 1987 Stunned Myocardium, Pathogenesis and Clinical Importance. Case Presentation—Dyspnea and Chest Discomfort in a Young Patient Post MI and Ventricular Aneurysmectomy. Chairman and Lecturer, Fireside Panel Program, American College of Cardiology 36th Annual Scientific Sessions, New Orleans, LA.

March 12, 1987 Treatment of Angina, Silent Ischemia; the role of Calcium Channel Blockers. Guest Lecturer, Detroit Osteopathic Hospital, Highland Park, MI.

March 16, 1987 Congestive Heart Failure. Guest Lecturer, Detroit Osteopathic Hospital, Highland Park, MI.

March 20, 1987 Silent Myocardial Ischemia. Grand Rounds, Fairview Hospital, Westlake, OH.

March 24, 1987 Treatment of Congestive Heart Failure. Medical Grand Rounds, Saint John Hospital,

Detroit, MI.

March 26, 1987 Acute Interventions in the Management of Myocardial Infarction. Spring Refresher and Board Examination Review Course, University of Michigan Medical School, Ann Arbor, MI.

 New Treatments for Heart Failure. Spring Refresher and Board Examination Review Course, University of Michigan Medical School, Ann Arbor, MI.

March 30, 1987 Role of Oxygen-free Radicals in Myocardial Ischemia and Infarction. Chairman and Lecturer, American Physiological Society Annual Meeting, Washington, DC.

 Introduction: Myocardial Ischemia and Coronary Reperfusion. Chairman and Lecturer, American Physiological Society Annual Meeting, Washington, DC.

April 1, 1987 The No-Reflow Phenomenon Following Acute Myocardial Infarction. Guest Lecturer, Federation of American Societies for Experimental Biology, Washington DC.

April 4, 1987 Pathophysiology of Coronary Artery Disease. Symposium, St. Mary Hospital, Livonia, MI.

April 7, 1987 Patient Management. Patient Management Seminar, Harper Hospital, Detroit, MI.

April 10, 1987 Ischemia and Infarction. ECG Minicourse, Harper Hospital, Detroit, MI.

April 16, 1987 Esmolol (Brevibloc) - Ultrashort acting Beta Blockade. Cardiology Grand Rounds, Harper Hospital, Detroit, MI.

April 25, 1987 Stunned Myocardium. Medical Research Seminar and Visiting Professor to Cardiology Division, Vanderbilt University School of Medicine, Nashville, TN.

April 28, 1987 Chronic Ischemic Heart Disease, Pulmonary/Congenital Heart Disease. Board Review Course in Internal Medicine, Wayne State University, Detroit, MI.

May 3, 1987 Co-Chairman. Cardiovascular VII, AAP/ASCI/AFCR National Meeting, San Diego, CA.

October 7, 1987 Salvage of Ischemic Myocardium. Grand Rounds, Harper and Grace Hospitals, Detroit, MI.

October 8, 1987 Salvage of Ischemic Myocardium. Grand Rounds, Hutzel Hospital, Detroit, MI.

October 17, 1987 The Effects of Calcium Antagonists in Acute Myocardial Infarction versus Clinical Impressions. Symposium, Royal College of Surgeons, Dublin, Ireland.

October 30, 1987 The Stunned and Hibernating Myocardium. Medical Staff Conference, Bergen Mercy Hospital, Omaha, NE.

November 3, 1987 Myocardial Stunning and Ischemia. Medical Department Meeting, Beyer Memorial Hospital, Ypsilanti, MI.

November 17, 1987 Reperfusion Injury by Oxygen-Derived Free Radicals: A flow-Dependent Phenomenon. Co-Chairman of Session; 69th Scientific Sessions, American Heart Association, Anaheim, CA.

December 2, 1987 Myocardial Consequences of Brief Periods of Ischemia and Stunned Myocardium. Course Co-Director, Mini-symposium, Wayne State University School of Medicine, Fairlane Manor, Dearborn, MI.

December 8, 1987 Myocardial Stunning and Ischemia. Internal Medicine Conference, Pontiac General Hospital, Pontiac, MI.

December 10, 1987 The Stunned Myocardium. Critical Care Conference, Detroit Receiving Hospital, Detroit, MI.

December 11, 1987 Pathophysiology of Cardiovascular Disease in Aging. Symposium, Wayne State University School of Medicine, Hyatt Regency Hotel, Dearborn, MI.

December 14, 1987 The Stunned Myocardium ­ The Pathophysiology of the Failing Ischemic Heart. 41st Postgraduate Assembly in Anesthesiology, New York, NY.

January 7, 1988 Acute Myocardial Infarction and Stunned Myocardium. Guest Lecturer, Riverside Hospital, Toledo, OH.

January 12, 1988 Myocardial Stunning: Basic and Clinical Insights. Cardiology Grand Rounds, University of Alabama at Birmingham, Birmingham, AL.

January 22, 1988 Ischemia and Infarction. ECG Minicourse, Harper Hospital, Detroit, MI.

January 26, 1988 Stunned Myocardium. Cardiology Lecture Series, Botsford General Hospital, Farmington Hills, MI.

February 6, 1988 Stunned Myocardium, Effects of Calcium Blockers. American Heart Association Cardiology Update 1988, Bowling Green, KY.

February 9, 1988 Stunned Myocardium. CME Program, St. Mary’s Medical Center, Knoxville, IN.

February 16, 1988 Myocardial Stunning and Ischemia. Guest Lecturer, Mt. Clemens General Hospital, Mount Clemens, MI.

February 24, 1988 Reperfusion Phenomenon. Cardiology Conference, Strong Memorial Hospital, University of Rochester Medical Center, Rochester, NY.

February 27, 1988 Cardioprotective Effect of ACE Inhibitor Therapy. Symposium on New Developments in Cardiovascular Disease for Primary Care Physicians, Newport Beach, CA.

March 10, 1988 Cardiovascular Lecture. Detroit Osteopathic Hospital, Highland Park, MI.

March 15, 1988 Update on Beta Blockers. Cardiology Lecture Series, Botsford General Hospital, Farmington Hills, MI.

March 18, 1988 Ischemic Cascade. Guest Lecturer, Staff Conference Veterans Administration Hospital, Canandaigua, NY.

March 19, 1988 Cardiovascular Lecture. Guest Lecturer, Sheehan Memorial Hospital, Buffalo, NY.

March 26, 1988 Recent Advances in Myocardial Stunning: An Introduction to Therapeutic Considerations. Symposium Speaker, American College of Cardiology Annual Meeting, Atlanta, GA.

April 15, 1988 Stunned Myocardium: An Update. Symposium Speaker, Montefiore Medical Center and Albert Einstein College of Medicine, Sponsors/St. George, Bermuda.

April 19, 1988 Chronic Ischemic Heart Disease: Pulmonary/Congenital Heart Disease. Comprehensive Review of Internal Medicine, Harper Hospital, Detroit, MI.

May 2, 1988 Clinical Perspectives in the Stunned and Hibernating Myocardium. Guest Lecturer, Veterans Administration West Los Angeles Hospital and UCLA, Los Angeles, CA.

May 6, 1988 Silent Ischemia, Current Concepts. Visiting Professor Rounds, Hartford Hospital, Hartford, CT.

May 9, 1988 Recent Advances in the Stunned Myocardium. Annual Cardiac Teaching Day, Millard Fillmore Hospital, Buffalo, NY.

May 13, 1988 Reperfusion Phenomenon. Symposium Speaker, Eli Lilly and Company, Indianapolis, IN.

May 23, 1988 Healing Phase of Myocardial Infarction. Cardiology Conference, Boston University Medical Center, Boston, MA.

May 24, 1988 Stunned Myocardium. Guest Lecturer, Tuffs New England Medical Center/Boston, Boston, MA

May 25, 1988 The Stunned Myocardium: Reversible Post-Ischemic Ventricular Dysfunction

Following Coronary Occlusion. Guest Lecturer, Continuing Medical Education Symposium, Wayne State University School of Medicine, Detroit, MI.

May 26, 1988 Protection of Ischemic Myocardium. Cardiology Grand Rounds, Baylor College of Medicine, Houston, TX.

June 4, 1988 Cocaine and Heart Attacks. Guest Panelist, “Health Matters,” WTVS Channel 56, Detroit, MI.

June 14, 1988 The Stunned Myocardium. Cardiology Grand Rounds: Metropolitan Hospital, New York, NY; Montefiore Hospital, NY; Harlem Hospital, New York, NY. Medical Grand Rounds, Mt. Sinai Medical Center, New York, NY. Guest Lecturer, Albert Einstein Medical Center, New York, NY.

June 21, 1988 The Stunned Myocardium. Guest Lecturer, Horton Memorial Hospital, Middletown, NY.

August 7-11, 1988 Lecture: “Free radical scavengers and preservation of myocardial structure and function.” XIIth Meeting of the International Society on Oxygen Transport to the Tissue, Ottawa, Canada.

October 2-5, 1988 Lecture: “Free radical scavengers.” Fosinopril and Zofenopril Worldwide Investigators Symposium. Southampton, Bermuda.

October 5, 1988 Lecture: “Stunned Myocardium.” Louisiana State University Medical Center, New Orleans, LA.

October 5, 1988 XVIIIth Annual Dialogue “The Stunned Myocardium: Heart Muscle Weakness and Recovery Following Ischemia.” 40th Annual AAFP Scientific Assembly. New Orleans, LA.

October 22, 1988 Myocardial Stunning: Pathophysiology and Clinical Implications. Symposium: Newer Aspects of Ischemic Heart Disease, St. George, Bermuda.

October 25, 1988 The Stunned Myocardium. Medical Grand Rounds. University of Cincinnati Medical School.

November 3, 1988 Coronary Ischemic Mechanisms: Current Concepts. Cardiology Update 1988. Sisters of Charity Hospital and State University of New York at Buffalo.

November 13, 1988 Free Radicals and Reperfusion Induced Myocardial Injury. Satellite Symposium to AHA. Cardioprotective Effects of Angiotensin Converting Enzyme Inhibition, Washington DC.

November 26, 1988 Free Radical Scavenging. 2nd Canadian Update on ACE - Inhibition, Nassau, Bahamas.

December 13, 1988 Reperfusion Injury and the Effect of TPA on Infarct Size and Myocardial Hemorrhage. Seminar at Genentech Inc. South San Francisco, CA.

December 14, 1988 The Role of Free Radicals in Reperfusion Induced Myocardial Injury. Dean’s Interdepartmental Conference. Department of Medicine U.C. Davis and Martinez VA Medical Center, Martinez, CA.

January 8, 1989 Plenary Lecture. Reperfusion Injury: Pathophysiology and Implications. Symposium. Frontiers of Cardiovascular Therapy and Cardiac Protection: Resolved and Unresolved Issues. Antigua.

January 31, 1989 Stunned Myocardium. University of Maryland Medical Grand Rounds, Baltimore, MD.

February 1, 1989 Stunned Myocardium. Johns Hopkins Hospital. Cardiology Grand Rounds, Baltimore, MD.

February 10, 1989 Post-MI-Acute and Long-Term Management. Huntington Hospital, Pasadena, CA.

February 20, 1989 Post-Ischemic Myocardial Stunning. Cardiology Research in Progress Meeting. LAC Harbor UCLA Medical Center, Los Angeles, CA.

March 15, 1989 Stunned and Hibernating Myocardium. Visiting Professor Luncheon. Loma Linda University, CA.

March 18, 1989 Management of Coronary Heart Disease: Direction for 1989 and Predictions for the 1990’s. Satellite Symposium ACC. Anaheim, CA.

March 28, 1989 Stunned Myocardium. Cardiology Research Conference, University of Colorado, Denver, CO.

April 11, 1989 Stunned and Hibernating Myocardium. Research Seminars in Cardiovascular Nuclear Medicine, UCLA. Los Angeles, CA.

April 18, 1989 Cardiogenic Shock ­ Stunned Myocardium. Research Lecture, UCLA. Los Angeles, CA.

April 25, 1989 The Stunned Myocardium. The Bellet Lecture. Temple University School of Medicine. Philadelphia, PA.

May 9, 1989 Stunned Myocardium. Cardiology Grand Rounds. Medical College of Virginia. Richmond, VA.

May 10, 1989 New Concepts of Reperfusion Injury. Cardiology Grand Rounds. Massachusetts General Hospital. Boston, MA.

May 11, 1989 Stunned Myocardium. Medical Grand Rounds. Massachusetts General Hospital. Boston, MA.

 Stunned Myocardium. Cardiology Grand Rounds. Brigham and Women’s Hospital. Boston, MA.

May 17, 1989 Effects of Calcium Channel Antagonists on Brief and Prolonged Coronary Artery Occlusion/Reperfusion. XIII Congress of the International Society for Heart Research. Ann Arbor, MI.

May 24, 1989 Myocardial Stunning. Cardiac Catheterization Conference. Hospital of the University of Pennsylvania, PA. Philadelphia, PA.

May 31, 1989 The Stunned Myocardium. Medical Grand Rounds. University California San Diego. San Diego, CA.

 Adjuvant Therapy for Coronary Reperfusion. Cardiology Conference, San Diego VA and UCSD. San Diego, CA.

June 6, 1989 Stunned Myocardium. Duke University Multi-Specialty Conference. Raleigh Durham, NC.

June 20, 1989 The Stunned Myocardium: Clinical Prospective. Cardiology Grand Rounds, Cedars Sinai Medical Center. Los Angeles, CA.

June 30, 1989 Hypertension and Lipid Evaluation. Hollywood Presbyterian Hospital. Los Angeles, CA.

July 26, 1989 Reperfusion Injury of the Myocardium. University CA Davis VAMC. Martinez, CA.

August 2, 1989 The Stunned Myocardium. Medical Grand Rounds. The University of Oklahoma Tulsa, OK.

September 13, 1989 Therapeutic Modalities of Myocardial Stunning. Scripps Memorial Hospital. La Jolla, CA.

October 24, 1989 Reperfusion-induced myocardial injury and free-radicals. Satellite Symposium of the Annual Meeting of the Canadian Cardiovascular Society. “New Directions in Cardiac Interventions. Vancouver, British Columbia.

October 31, 1989 Stunned and Hibernating Myocardium. Cardiology Grand Rounds. The Presbyterian Hospital ­ Columbia University. New York, NY.

 Adjuvant Therapy for Myocardial Infarction. Cardiology Rounds. Montefiore Hospital. New York, NY.

November 2, 1989 Stunned Myocardium. Cardiology Rounds. Bellevue Hospital. New York, NY.

November 12, 1989 Predictions for the 1990’s. Satellite Symposium AHA. Management of Coronary Heart Disease: Direction for 1989; Predictions for the 1990’s. New Orleans, LA.

November 12, 1989 Cardioprotection: How Far Have We Come? Satellite Symposium AHA. The Ischemic Myocardium. New Directions in Evaluation and Management.

November 15, 1989 Influx of neutrophils into the walls of large epicardial coronary arteries. Lecture at American Heart Association Annual Meeting. New Orleans, LA.

December 11, 1989 Approaches to Reperfusion Injury. Cardiology Grand Rounds. William Beaumont Hospital. Royal Oaks, MI.

January 9, 1990 Adjuvant Therapy of Myocardial Infarction and the Role of Oxygen Radicals. Medical Grand Rounds. New England Deaconess Hospital. Boston, MA.

February 21, 1990 The Stunned and Hibernating Myocardium. Western Heart Institute. St. Mary’s Hospital and Medical Center. San Francisco, CA.

March 1-4, 1990 Silent Ischemia. Detection and Management. Advances in Cardiology. 8th Annual Winter Symposium. Breckenridge, CO.

Clinical Management. Decisions Following Acute MI. Porter Memorial Hospital.

March 19, 1990 New Aspects of Reperfusion. Co-Chairman of Session. American College of Cardiology (ACC) Annual Meeting. New Orleans, LA.

March 21, 1990 Myocardial Stunning Following Exercise Treadmill Testing in Man. Lecture ­ ACC Annual Meeting. New Orleans, LA.

March 28, 1990 Post-ischemic ventricular dysfunction. Cardiology Sub-Specialty Lecture. UC Irvine. Orange, CA.

May 7, 1990 Stunned and Hibernating Myocardium. University of Minnesota. Clinical Cardiology Lecture. Minneapolis, MN.

May 8, 1990 The Stunned Myocardium. Mayo Clinic. Department of Cardiology. Rochester, MN.

May 26, 1990 Adjuvant Therapy for MI. Kaiser Permanente Sunset Symposium. Los Angeles, CA.

June 1­2, 1990 Cardioprotection Redefined for the 1990’s. Symposium: New Directions in Clinical Cardiology for the 1990’s. Newport Beach, CA.

June 6, 1990 Stunned Myocardium. Cardiology Grand Rounds UCSF. San Francisco, CA.

June 8, 1990 The Management of Patients After Thrombolysis: Role of Pharmacologic Interventions; Role of ACE ­ Inhibitors in Ventricular Remodeling. Post Ischemic left ventricular dysfunction: The Stunned Myocardium. American College of Cardiology. Second Annual Cardiovascular Conference at Lake Tahoe. UCSF ­ Fresno, CA.

June 9, 1990 The Effect of Degrees of Vascular Occlusion on Myocardial Function. Symposium: The Coronary Vasculature: Scientific Theories and Therapeutic Considerations: Vascular Reactivity and Ischemic Syndromes. Monterey, CA.

September 6, 1990 Stunned Myocardium. Allegheny General Hospital. Cardiology Grand Rounds. Pittsburgh, PA.

September 9-14, 1990 Principles Underlying Salvage of Ischemic Myocardium and Reperfusion: Effect of Drug Therapy. XVIIIth International Congress of the International Academy of Pathology ­ Buenos Aires, 1990 sponsored Duke University Medical Center.

October 1, 1990 The Stunned Myocardium. USC/Community Hospital Network Panorama Community Hospital Symposium “Medicine 1990” Los Angeles, CA.

October 5, 1990 Medical Management of Patients Following Thrombolytic Therapy. Symposium: Cardiology Update ­ Alta Bates ­ Herrick Hospital, Berkeley, CA.

October 16, 1990 Stunned Myocardium. Cardiology Conference. Northwestern U. Medical School, Chicago, IL.

October 16, 1990 Stunned Myocardium: Experimental and Clinical Observations. Douglas Boyd Memorial Lecture. Highland Park Hospital, Highland Park, IL.

October 23, 1990 Approach to Treatment of Cocaine-Induced Cardiac Toxicity. American College of Chest Physicians (ACCP) 56th Annua1 Scientific Assembly Symposium, Toronto, Canada.

October 24, 1990 Effects of Cocaine on Cardiovascular Dynamics and Myocardial Blood Flow. ACCP Symposium, Toronto, Canada.

 Pathophysiology of Myocardial Stunning. ACCP Colloquium.

November 6, 1990 Medical Management of Coronary Artery Disease. UCLA Family Medicine Grand Rounds, Los Angeles, CA.

November 15, 1990 Experimental Myocardial Ischemia/Infarction: Role of Free Radicals. Co-Chair Session. American Heart Association, Annual Scientific Sessions. Dallas, TX.

November 15, 1990 Effect of neutrophil infiltration into large coronary arteries after reperfusion. Presentation. American Heart Association. Annual Scientific Sessions. Dallas, TX.

December 6, 1990 Stunned and Hibernating Myocardium. Creighton University, Omaha, NE.

December 7, 1990 Myocardial Stunning and Hibernating. University of Nebraska Medical Center, Omaha, NE.

December 10, 1990 The Stunned Myocardium. West LA VA Medical Center Cardiology Lecture.

January 8, 1991 Cocaine Cardiotoxicity. University Hospital. University of Colorado, Denver, CO.

January 16, 1991 Stunned Myocardium. Loma Linda University, CA.

February 13, 1991 The Alteration in the Natural History of Viral Myocarditis by ACE Inhibitors. Children’s Hospital of Los Angeles Cardiology Conference.

February 15, 1991 Postischemic LV Dysfunction ­ Stunned Myocardium. Cleveland Clinic Foundation Cardiology Grand Rounds, Cleveland, OH.

February 22, 1991 Review of Anticoagulants in Non-Valvular Atrial Fibrillation and Their Role in Myocardial Infarction. St. Jude Medical Center, Orange County, CA.

March 11, 1991 Cardioprotection with calcium channel blockers. University Medical Center of Southern Las Vegas, Nevada Medical Conference, Las Vegas, NV.

April 1, 1991 Cardiac Effects of Calcium Channel Blockers. Forum on Cardiovascular Therapy Symposium, Miami, FL.

April 2, 1991 Cocaine Cardiotoxicity. University of Miami Medical School ­ Visiting Professor, VAH Morning Report.

May 2, 1991 Stunned Myocardium. Buffalo General Hospital, State University of New York at Buffalo.

May 11, 1991 Role of the microcirculation during ischemia and reperfusion. An International Forum on Reperfusion Injury ­ The Brocket Symposium ­ England.

May 14, 1991 The Stunned and Hibernating Myocardium. University College Hospital, London, England.

May 23, 1991 The Stunned Myocardium. The John C. Wilson Jr. Memorial Lecture. Good Samaritan Hospital, Los Angeles, CA.

May 30, 1991 How to Write and Publish a Research Paper, and Cocaine and the Heart. The Cleveland Clinic Foundation. Department of Cardiology Visiting Professor. Cleveland, OH.

June 1, 1991 Cocaine Cardiotoxicity. Course Director ­ Advances in Cardiology, Symposium. The Heart Institute of the Good Samaritan, Los Angeles, CA.

 Summary of Research Advances at the Heart Institute. Course Director ­ Advances in Cardiology, Symposium. The Heart Institute of the Good Samaritan, Los Angeles, CA.

July 29, 1991 Cardio-protection with calcium channel blockers. National Medical Association 96th Annual Convention, Indianapolis, IN.

August 2, 1991 Controlling regression of left ventricular hypertrophy. Symposium: The Heart Institute. St. Vincent Hospital. Portland, Oregon “Thirty Something: at the heart of it.”

 Cocaine Cardiotoxicity. Symposium: The Heart Institute. St. Vincent Hospital. Portland, Oregon “Thirty Something: at the heart of it.”

August 22, 1991 Stunned Myocardium. Long Beach Memorial Hospital. University of California Irvine. Grand Rounds.

August 24, 1991 Medical Therapy of Cardiac Ischemia. San Diego State University CME Symposium “Cardiology for the Family Physician and Internist”

 The Acute MI: Thrombolytics and Other Interventions in Primary Care. San Diego State University CME Symposium “Cardiology for the Family Physician and Internist”

August 28, 1991 Effect of Cocaine on the Heart. Cook County Hospital, Department of Emergency Medicine, Chicago, IN.

August 29, 1991 Stunned Myocardium. University of Illinois, Department of Medicine Grand Rounds.

August 30, 1991 Stunned and Hibernating Myocardium. University of Chicago, Cardiology Research Conference, Chicago, IN.

September 10, 1991 Stunned Myocardium. Cardiology Lecture. University of Maryland, Baltimore, MD.

September 14, 1991 Silent Ischemia and Angina. Forum on Cardiovascular Therapy. Symposium. Coalinga, CA.

September 26, 1991 Clinical Applicability and Limitations of Animal Models in Assessing Progression of Myocardial Necrosis and Reperfusion After Coronary Occlusion. Symposium: Pharmacologic and Mechanical Interventions in Ischemic Heart Disease. The New York Cardiological Society. New York, NY.

 Modification of Reperfusion Injury, Myocardial Stunning, and Infarct Expansion in the Experimental Animal. Symposium: Pharmacologic and Mechanical Interventions in Ischemic Heart Disease. The New York Cardiological Society. New York, NY.

October 21, 1991 Stunned and Hibernating Myocardium. The Queen’s Medical Center Heart Institute, 2nd Annual Cardiology Hawaii Symposium, Honolulu, HI.

October 25, 1991 Stunned and Hibernating Myocardium. Queen’s University of Hawaii Medical Staff Conference.

November 5, 1991 Topics in Angina. Kansas City Cardiology Round Table. University of Kansas Medical Center, Grand Rounds. Kansas City, KS.

 Cardiovascular Protection with Calcium Channel Blockers. Kansas City Cardiology Round Table. University of Kansas Medical Center, Grand Rounds. Kansas City, KS.

November 21, 1991 Cocaine and the Heart. Sutter Hospital, Sacramento, CA.

December 5, 1991 Research on Reperfusion/Reperfusion/ Injury. Loyola University Medical Center Cardiology Lecture.

December 20, 1991 Basic Science Conference. Texas Heart Institute and St. Lukes Episcopal Hospital. Cardiology Grand Rounds, Houston, TX.

 Circadian Variation in Heart Disease. Texas Heart Institute and St. Lukes Episcopal Hospital. Cardiology Grand Rounds, Houston, TX.

January 6, 1992 Cardiotoxicity of Cocaine. UCLA Core Curriculum in Cardiology. Los Angeles, CA.

January 31, 1992 Mechanisms of Regression of Left Ventricular Hypertrophy. USC Division of Diabetes, Hypertension and Nutrition, Grand Rounds, Los Angeles, CA.

February 5, 1992 Current Research and Concepts in Cardiology. Wilford Hall. San Antonio, TX.

February 25, 1992 Mechanisms of CAD. Emmanuel Hospital. Portland, OR.

February 26, 1992 Regression of Left Ventricular Hypertrophy in the HTN Patient. VAMC. Oregon Health Sciences University. Portland, OR.

March 25, 1992 Reperfusion, reperfusion injury. Stanford University. Cardiology Research Conference. Stanford, CA.

April 14, 1992 Reperfusion injury ­ does it exist in man? American College of Cardiology Annual Scientific Session. Meet the Experts Session. Dallas, TX.

May 13, 1992 Cocaine Cardiotoxicity. USC. Medical Grand Rounds. Los Angeles, CA.

May 22, 1992 Microvascular injury following ischemia-reperfusion. A.N. Richards Symposium on Reperfusion Injury. Physiological Society of Philadelphia and Thomas Jefferson University. King of Prussia, PA.

June 11, 1992 Reperfusion injury: cause, clinical significance, and role of pharmacotherapy. Recent Advances in Cardiovascular Therapeutics. American College of Cardiology. Tufts University School of Medicine. Boston, MA.

 Diagnosis and management of “stunned” vs. “hibernating myocardium:” implications for therapy. Recent Advances in Cardiovascular Therapeutics. American College of Cardiology. Tufts University School of Medicine. Boston, MA.

June 26, 1992 Diastolic dysfunction of the heart. State University New York at Buffalo, Erie County Medical Center, Department of Medicine, Buffalo, NY.

July 16, 1992 Research and Clinical Aspects of Myocardial Reperfusion Injury. Mid-America Heart Institute. Kansas City, MO.

August 5, 1992 The Stunned Myocardium. University of Utah Medical Center. Department of Internal Medicine Grand Rounds. Salt Lake City, UT.

August 24, 1992 Stunned Myocardium. Mayo Clinic, Scottsdale. Scottsdale, AZ.

September 17, 1992 Stunned Myocardium. Cardiology Grand Rounds. Beth Israel Hospital. Boston, MA.

September 17, 1992 Does reperfusion injury occur in Man? Cardiology Grand Rounds. Brigham and Women’s Hospital, Harvard Medical School. Boston, MA

September 19, 1992 Left ventricular hypertrophy as a risk factor. Course Director. Advances in Cardiology, 1992. Good Samaritan Hospital. Los Angeles, CA.

October 10, 1992 Myocardial Hibernation. The Hanbury Manor Workshop. University College Hospital. London, England.

October 19, 1992 Reperfusion injury. Strong Memorial Hospital. University of Rochester, Department of Cardiology. Rochester, NY.

October 25, 1992 The issue of reperfusion injury. Chair: “Current Issues in Ischemia Reperfusion Injury.” 58th Annual International Scientific Assembly of the American College of Chest Physicians. Chicago, IL.

November 7, 1992 Hypertension and End-Organ Damage. Primary Care Cardiology Update. The St. Joseph Healthcare System. St. Joseph Medical Center. Albuquerque, NM.

 CHF with Normal Systolic Function. Primary Care Cardiology Update. The St. Joseph Healthcare System. St. Joseph Medical Center. Albuquerque, NM.

January 5, 1993 Cocaine Cardiotoxicity. Sepulveda VA UCLA. Los Angeles, CA.

February 8, 1993 Circadian Rhythms: Cardiovascular Events. Good Samaritan Hospital. Los Angeles, CA.

February 15, 1993 Cocaine-related sudden death. The cardiologist’s perspective. American Academy of Forensic Science. 1993 Annual Meeting-Boston, MA.

February 19, 1993 Limiting Infarct Size. Oklahoma Heart Center. Baptist Medical Center of Oklahoma. Oklahoma City, OK.

March 8-10, 1993 Medical Grand Rounds “Unstable Angina.” Visiting Professor. University College London Medical School. London, England.

 Reperfusion Injury in Man: Following: experimental confusion, is there clinical reality? Visiting Professor. University College London Medical School. London, England.

March 13, 1993 New Approaches to Treating Hypertension: Are we Missing Something? Symposium: Is comprehensive cardiovascular care possible? Satellite Symposium, American College of Cardiology, 1993. Anaheim, CA.

March 15, 1993 Co-chair. Adenosine and Mechanisms of Preconditioning. American College of Cardiology. 1993 Annual Meeting Anaheim, CA.

March 16, 1993 Chairman. Chemical Abuse and the Cardiovascular System. American College of Cardiology. 1993 Annual Meeting. Anaheim, CA.

March 19, 1993 Cardiovascular Applications of Fluorocarbons. Fifth International Symposium on Blood Substitutes. San Diego, CA.

March 30, 1993 Reperfusion Injury. University of Pennsylvania. Cardiology Seminar, Philadelphia, PA.

March 30, 1993 Stunned and Hibernating Myocardium. Lankenau Medical Center. Philadelphia, PA.

April 3, 1993 The Stunned and Hibernating Myocardium. The Prevention and Treatment of Cardiovascular Disease. American Heart Association, Dakota Affiliate, University of North Dakota School of Medicine. Bismarck, ND.

May 19, 1993 Treating the Broad Hypertension Population: Age, Gender and Race Differences. The American Society of Hypertension, Annual Meeting. New York, NY.

June 23, 1993 Reperfusion Injury. Department of Cardiology Grand Rounds. University California, San Diego. San Diego, CA.

June 25, 1993 Cocaine Cardiotoxicity. Division of Cardiology. UCLA, Los Angeles, CA.

June 28, 1993 Does reperfusion injury occur in man? University of Michigan, Cardiology Division. Ann Arbor, MI.

June 29, 1993 The Effect of Treating Hypertension. Wayne State University, Cardiology Division. Detroit, MI.

September 10, 1993 Stunned Myocardium: Clinical Relevance. 1993 Workshop: Frontiers in Perioperative Myocardial Management. Coronado, CA.

September 18, 1993 Effect of treating hypertension on cardiovascular morbidity and mortality. Course Director. Symposium: Advances in Cardiology 1993. Good Samaritan Hospital, Los Angeles, CA.

September 30, 1993 Stunned Myocardium. Cardiology Conference. Buffalo General Hospital, Buffalo, NY.

November 7, 1993 What have recent trials taught us about individualized care in hypertension? Satellite Symposium: Controversies in Cardiovascular Therapy. Atlanta, GA.

November 7, 1993 The Preconditioning Phenomenon. Moderator: The Preconditioning Phenomenon. Postgraduate Seminar at the American Heart Association Annual Scientific Sessions, Atlanta, GA.

November 8, 1993 Previous angina alters in-hospital outcome in TIMI-4. American Heart Association, Annual Scientific Sessions, Atlanta, GA.

November 19, 1993 Gender and Age Specificity in Hypertension. Dialogue on Gender and Age Specificity in Hypertension and related problems. 31st Annual Scientific Meeting, The Ontario College of Family Physicians, Toronto, Ontario.

November 29, 1993 Circadian Variation in Myocardial Ischemia. Reperfusion Injury. Cardiology Cath Conference University Hospital, Syracuse, NY.

 Stunned and Hibernating Myocardium. Cardiac Society of Central New York, Syracuse, NY

December 6, 1993 The Stunned Myocardium: Experimental and Clinical Status. New Approaches to Myocardial Protection. A symposium to celebrate the 25th year of the founding of the University of Auckland School of Medicine, Auckland, New Zealand.

January 1, 1994 Circadian Patterns of Cardiovascular Disease. University California, Irvine. Cardiology Conference.

February 5, 1994 The treatment of hypertension: facts and fiction. Mercy General Hospital Sacramento.

Symposium “Cardiology 1994.”

February 8, 1994 Circadian Rhythms of Cardiovascular Disease. Roybal Comprehensive Health Center, Los Angeles, CA.

February 11, 1994 Stunned Myocardium: Pathophysiology and Clinical Implications. Grand Rounds at the University of Kansas Medical Center School of Medicine. Wichita, KS.

February 18, 1994 Cocaine cardiotoxicity. Hollywood Community Hospital.

February 19, 1994 Myocardial Remodeling Post Myocardial Infarction. USC Symposium: From ischemia to heart failure: management strategies. Pasadena, CA.

 Myocardial Stunning and Hibernation. USC Symposium: From ischemia to heart failure: management strategies. Pasadena, CA.

March 1, 1994 Introduction to concept of opening the closed coronary artery. Course Director. Good Samaritan Hospital. Symposium “Opening of the Closed Coronary Artery.” Los Angeles, CA.

March 8, 1994 Circadian rhythm of cardiovascular events. Stanford University Medical Center. Core Curriculum Lecture for Medicine Residents. Stanford, CA.

March 15, 1994 Co-chairman. Modification of Myocardial Injury. American College of Cardiology. 43rd Annual Scientific Sessions. Atlanta, GA.

March 17, 1994 Reperfusion injury and ischemic preconditioning. Lahey Clinic ­ Cardiology Lectures. Boston, MA.

March 25-26, 1994 Myocardial flow and function: stunning, hibernation, and infarction. Assessment of Myocardial Viability Symposium. Ochsner Heart and Vascular Institute. New Orleans, LA.

 Treatment of myocardial stunning and hibernation. Assessment of Myocardial Viability Symposium. Ochsner Heart and Vascular Institute. New Orleans, LA.

April 13, 1994 Circadian Rhythm. King/Drew Medical Center. Family Practice Grand Rounds. Los Angeles, CA.

April 20, 1994 What have recent trials taught us about individualized care in hypertension? Satellite Symposium to American College of Physicians Ninth Scientific Meeting. “Talking the Long-Term View: Therapeutic issues and options in the management of angina and hypertension. Co-Chairman. Miami, FL.

April 26, 1994 Hypertension: Age, Gender, Racial Consideration. Emanuel Medical Center. Portland, OR.

May 1, 1994 Preconditioning. Cardiovascular Surgery Conference. Good Samaritan Hospital, Los Angeles, CA.

May 4, 1994 Stroke prevention in atrial fibrillation. USC Community Hospital Network/Cigna Healthcare. Huntington Beach, CA.

May 9, 1994 The Stunned and Hibernating Myocardium. Emory University, Cardiology Conference. Atlanta, GA.

May 17, 1994 The clinical importance of myocardial preconditioning. Annual Meeting of the British Cardiac Society. Torguay, England.

May 26, 1994 Hypertension: Aspects of age, gender, race. Henry Mayo Newhall Memorial Hospital. Valencia, CA.

May 31, 1994 Cocaine cardiotoxicity. Medical Grand Rounds. Harbor UCLA Medical Center. Torrance, CA.

June 17, 1994 Ischemic preconditioning. University of Washington. Cardiology Grand Rounds. Seattle, WA.

June 23, 1994 Preconditioning. Baylor University. Cardiology Grand Rounds. Houston, TX.

June 24, 1994 Preconditioning, stunned myocardium. Texas Heart Institute. St. Lukes Basic Science Conference. St. Lukes Cardiology. Grand Rounds. Houston, TX

July 11, 1994 Stunned myocardium. Albany Medical College. Cardiology Department.

July 20-23, 1994 Preconditioning ­ like phenomena and inadvertent preconditioning. International Society for Heart Research. 16th Annual Meeting. London, Ontario Canada.

August 12, 1994 Hypertension and the ACCT Trial. University of Chicago. Michael Reese Hospital. Chicago, IL.

August 29, 1994 Protection of ischemic myocardium with preconditioning and short-acting beta blocker. Marshfield Clinic. Marshfield, WI.

September 14, 1994 Stunned and hibernating myocardium. Krannert Institute of Cardiology. Indianapolis, IN.

September 21, 1994 An individual approach to the hypertensive patient: Insights from recent clinical trials. Symposium: Comprehensive Cardiovascular Care: Current Issues and Clinical Concepts. Sponsored by the Institute for Prevention of Cardiovascular Disease, Deaconess Hospital. Boston, MA.

October 6-8, 1994 Clinical evidence of preconditioning. European Society of Cardiology. Intrinsic Adaptive Mechanisms During Ischemia and Reperfusion. Nice, France.

October 25, 1994 Hypertension in patients at greater risks for renal complications: an individualized approach to therapy. National Kidney Foundation Symposium. Links between the kidney and cardiovascular disease: causes, consequences, and clinical implications. Orlando, FL.

October 28, 1994 Clinical aspects of preconditioning. Frontiers in Perioperative Myocardial Management. Global Educational Marketing. Montreal, Canada.

November 2, 1994 Stunned Myocardium. Howard University Hospital. Cardiology Rounds, Washington, D.C.

 Stunned Myocardium. George Washington University Medical Center. Cardiology Rounds. Washington, D.C.

 Stunned Myocardium. Georgetown University Hospital. Cardiology Rounds. Washington, D.C.

November 10, 1994 Medical Therapy of Angina and Circadian Rhythm. Northridge Medical Center. Northridge, CA.

November 17, 1994 Effect of amlodipine on ventricular mass in hypertensive patients: Aspects of age, gender, race. American Heart Association. 67th Scientific Sessions. Dallas, TX.

November 22, 1994 Preconditioning. Cardiovascular Society of Arizona. Phoenix, AZ.

November 28, 1994 Preconditioning Phenomenon. New England Deaconess Hospital & Harvard Medical School. Boston, MA.

 Hypertension: Aspects of age, gender, race. West Roxbury VA Medical Center. Medical Grand Rounds, Harvard Medical School, Boston, MA.

 Ischemic Preconditioning. New England Medical Center; Tufts University, Boston, MA. Seminar in Cardiovascular Physiology.

December 5, 1994 Stunned Myocardium. University of Utah ­ Lecture to residents. Salt Lake City, Utah.

January 6, 1995 Stunned Myocardium. UCI Medical Center, Orange, CA.

January 9, 1995 Triggers for Heart Disease: Effects of the 1994 Earthquake. Kaiser Permanente Medical Center, West Los Angeles, CA.

February 6, 1995 Ischemic Preconditioning. Kaiser Sunset Cath Laboratory Conference. Los Angeles, CA.

February 22, 1995 Hypertension. Arizona Heart Institute, Phoenix, AZ.

February 23, 1995 Hypertension. Mayo Clinic, Scottsdale, AZ.

February 24, 1995 Circulation Rhythm of Cardiovascular Disease. University of Arizona, Tucson, AZ.

March 2, 1995 Stunned Myocardium. Sepulveda VA, UCLA, Los Angeles, CA.

March 19, 1995 Women have a higher response rate than men to the antihypertensive calcium channel blocker amlodipine. American College of Cardiology 44th Annual Scientific Session, New Orleans, LA.

March 22, 1995 Co-Chair ­ Cardiovascular Toxicology. American College of Cardiology 44th Annual Scientific Session, New Orleans, LA.

March 22, 1995 Co-Chair ­ Preconditioning Symposium: Clinical evidence for preconditioning. American College of Cardiology 44th Annual Scientific Session, New Orleans, LA.

April 26, 1995 Stunned and Hibernating Myocardium. University of Iowa. Cardiology Grand Rounds, Iowa City, IA.

April 29, 1995 Cocaine and the Heart. 9th Annual Cardiopulmonary Update, Olean Medical Group and State University of New York at Buffalo, at Olean, NY.

May 7, 1995 Moderator, Poster Discussion, Cardiovascular: Ischemia/Infarction. The Clinical Research Meetings, San Diego, CA.

May 22, 1995 What is the clinical potential for ischemic preconditioning? International Society of Heart Research, Perdido Beach Resort, Orange Beach, AL.

May 31, 1995 The history of myocardial ischemia and reperfusion. History of Medicine Series, Good Samaritan Hospital, Los Angeles, CA.

June 26, 1995 Triggers of Cardiovascular Events. Hershey Medical Center. Pennsylvania State University, Hershey, PA.

July 10, 1995 Uses and Effects of Calcium Channel Blockers. Encino-Tarzana Regional Medical Center, Tarzana, CA.

July 28, 1995 Treatment of Hypertension: What the Recent Clinical Trials Tell Us. Manila Central University Medical Alumni Association of America, Scientific Seminars, Anaheim, CA.

August 15, 1995 Congestive Heart Failure. Colorado Chapter of The American College Cardiology, Denver, CO.

August 15, 1995 Circadian variation in myocardial variation. Rose Hospital, University of Colorado, Denver, CO.

September 20, 1995 Acute myocardial ischemic syndromes: Tips for the generalist. Crucial Issue for the Primary Care Physician, Maricopa Medical Center and Mayo Clinic Scottsdale, Scottsdale, AZ.

September 22, 1995 Practical approaches for long-term management of hypertension. Symposium: Cardiovascular Disease: The Critical Role of Family Physicians, Anaheim, CA.

October 25, 1995 Course Director: Lecturer: Preconditioning. New Syndromes and Phenomena in Cardiovascular Disease, Good Samaritan Hospital, Symposium, Los Angeles, CA.

October 27, 1995 Triggers of Cardiovascular Events. The Canadian Cardiovascular Society. Stratifying the Management of Angina. Toronto, Ontario.

November 4, 1995 Triggers of Cardiovascular Events: Lessons from the Northridge Earthquake. Kaiser Permanente Medical Group Cardiology Symposium, Santa Monica, CA.

November 11, 1995 Preconditioning in humans: Is there a therapeutic role? The Second International Satellite Symposium: Adenosine, Cardioprotection and Its Clinical Application. Long Beach, CA.

November 12, 1995 Revisiting BP Goals and Target ­ Organ Issues in Hypertension Patients. Symposium: Critical Issues, Control, Compliance, CHD Risk. Focus on Hypertension, Anaheim, CA.

November 14, 1995 Moderator: ATP-Dependent K+ Channels and Myocardial Protection. 68th Scientific Sessions, American Heart Association, Anaheim, CA.

November 27, 1995 Triggers of Cardiovascular Events. Marshfield Clinic, Grand Rounds, Marshfield, WI.

December 3, 1995 Hypertension: Aspects of Age, Gender, and Race. Common Office Problems in the Elderly, Symposium, Salinas, CA.

December 7, 1995 Triggers of Cardiovascular Events. Brigham & Women’s Hospital, Harvard Medical School Cardiology Grand Rounds, Boston, MA.

December 18, 1995 Reversible LV Dysfunction ­ Stunned and Hibernating myocardial states. West Los Angeles VAMC-UCLA/San Fernando Valley Cardiology Core Curriculum Lecture Series, Los Angeles, CA.

January 23, 1996 Circadian Rhythm in Cardiac Events. Cardiology Grand Rounds, Cedars Sinai Medical Center, Los Angeles, CA.

January 26, 1996 Triggers of Cardiovascular Events. Cardiology Grand Rounds, Johns Hopkins Hospital, Baltimore, MD.

February 7, 1996 Triggers of Cardiovascular Events. Cardiology Grand Rounds, U. San Diego, San Diego, San Diego, CA.

February 20, 1996 Cardiac Effects of Natural Disasters. The Annual Gordon Ira Lectureship. Mayo Clinic, Jacksonville, FL.

February 21, 1996 The Stunned Myocardium. Special Grand Rounds Mayo Clinic, Jacksonville, FL.

March 2, 1996 Hypertension – Aspects of Gender, Age, and Race. Symposium: Women and Heart Disease. Arizona Heart Institute Foundation, Phoenix, AZ.

March 6, 1996 Hypertension: Aspects of Age, Gender, Race and the Calcium Channel Blocker Controversy. Cardiology Conference, Good Samaritan Hospital, Los Angeles, CA.

March 8, 1996 Triggers of Cardiovascular Events. Cardiology Division. University of California at Irvine, Irvine, CA.

March 26, 1996 Long-acting Calcium Channel Blockers Nifedipine GITS and Amlodipine in Hypertension-Rate of Myocardial Infarction. American College of Cardiology 45th Annual Scientific Session. Orlando, FL.

April 2, 1996 Triggers of Cardiovascular Disease. Cardiology Grand Rounds, William Beaumont Hospital, Troy, MI.

May 7, 1996 Hypertension Therapy: Aspects of Age, Gender, Race. Cardiology Grand Rounds, University of Southern California, Los Angeles, CA.

May 15, 1996 Cardiovascular Safety of Dihydropyridines: A Hard Look at Real Data. Safety of Antihypertensive Therapies. A Series of Interactive Panels. American Society of Hypertension, New York, NY.

May 15, 1996 Treating Hypertension in the Cardiac Patient. Individualized Treatment of Hypertension in 1996. American Society of Hypertension. New York, NY.

May 24, 1996 Hypertension in Women. Symposium: Current Issues in Women’s Health Care, Wenatchee Valley Clinic Foundation, Winthrop, WA.

June 22, 1996 Implications to Clinical Practice: Myocardial Stunning, Myocardial Hibernation, Ischemic Preconditioning. Holy Cross Heart Center, Cardiovascular Symposium, Mission Hills, CA.

July 2-3, 1996 Co-Organizer. Moderator: Myocardial Preconditioning. Lecturer: Clinical Aspects of Preconditioning. The Medical and Cellular Implications of Myocardial Stunning, Hibernation, and Preconditioning. National Heart Lung and Blood Institute Workshop. Columbia, MD.

July 10, 1996 Triggers of Cardiovascular Disease. Noon Conference, Good Samaritan Hospital, Los Angeles, CA.

July 18, 1996 Triggers of Cardiovascular Disease. University Club, Duke University, Durham, NC.

July 27, 1996 Nifedipine in Ischemic Heart Disease. Cardiology and Heart Disease for the Primary Care Physician. 7th Annual Symposium of the California Heart Institute at Redding Medical Center, Olympic Valley, CA.

August 9, 1996 Stunned Myocardium. Department of Cardiology Grand Rounds, University of Florida at Gainesville, FL.

August 29, 1996 Clinical Aspects of Early and Delayed Myocardial Preconditioning. XVIIIth Congress of the European Society of Cardiology, Birmingham, United Kingdom.

September 11, 1996 Panel: Management of the Post-MI Patient. 64th Annual Fall Symposium of the American Heart Association. Greater Los Angeles Affiliate, Los Angeles, CA.

September 19, 1996 Ischemic Preconditioning. Cardiology Research Conference, Stanford University, Stanford, CA.

October 7, 1996 Experimental Models of Myocardial Ischemia and Infarction and Their Clinical Importance. XVIth Greater Boston Interventional Cardiology Forum. Acute Ischemic Syndromes. The TIMI Experience and Beyond-in honor of Eugene Braunwald, MD, Brigham and Women’s Hospital, Harvard Medical School, Boston MA.

October 29, 1996 Hypertension – Aspects of Age, Gender, and Race. Kings County Hospital and S.U.N.Y. Health Science Center, Brooklyn, NY.

November 13, 1996 A Population – Based Analysis of the Northridge Earthquake on Cardiac Events Among 19,617 Deaths in Los Angeles County, CA. American Heart Association, 69th Scientific Sessions, New Orleans, LA.

 A Prospective Analysis on the Potential Preconditioning Effect of Preinfarct Angina in TIMI 9. American Heart Association, 69th Scientific Sessions, New Orleans, LA.

January 7, 1997 Cocaine Cardiotoxicity. USC Division of Cardiology, Grand Rounds, Los Angeles, CA.

January 8, 1997 Stunned and Hibernating Myocardium. UCLA/VA Hospital, Wadsworth, Los Angeles, CA.

February 11, 1997 Illicit Drugs and the Athlete. Sudden Cardiac Death in the Athlete. Keystone, CO. A Futura Clinical Symposium.

February 16, 1997 Circadian Variation and Triggers of Cardiovascular Disease. Texas Academy of Family Physicians, San Antonio, TX.

March 3, 1997 Ischemic Preconditioning in the Heart. Cardiology Grand Rounds, Boston University Medical Center, Boston, MA.

March 5, 1997 Ischemic Preconditioning in the Heart. Maine Medical Center, Portland, ME.

March 15, 1997 Intrapericardial Hypothermia. The 2nd International Symposium on Intrapericardial Drug Delivery, Anaheim, CA.

March 15, 1997 Cause and effect: Which Patients are at Risk for Sexual Dysfunction. Sexual Dysfunction and Heart Disease: New Approaches, New Thinking, New Options, Anaheim, CA.

April 10, 1997 Triggers of Cardiovascular Events. University of Wisconsin Medical School, Madison, WI.

April 10, 1997 Hypertension: Age, Gender, Racial Considerations. Medical College of Wisconsin, Milwaukee, WI.

April 25, 1997 Triggers of Cardiovascular Disease. Harbor UCLA Cardiology Division, Torrance, CA.

May 3, 1997 Antihypertensive Treatment: Are Calcium Channel Blockers Safe? Advances in Clinical Cardiology, San Ramon, CA.

May 8, 1997 Myocardial Stunning and Hibernation. 33rd Annual Robert M. Jeresaty, MD, Cardiovascular Symposium, The Hoffman Heart Institute, Hartford, CT.

May 9, 1997 “Controversies” in Cardiology. Visiting Professor, Department of Cardiology, Cleveland Clinic, Cleveland, OH.

May 22, 1997 Sex and the Heart. USC Division of Cardiology, Research Seminar, Los Angeles, CA.

May 26, 1997 What to Consider When Choosing a Cardiovascular Agent. Building a Partnership for Cardiovascular Health: Help Your Patients Take Charge, Minneapolis, MN.

May 31, 1997 Calcium Channel Blockers in the Management of Hypertension: Facts, Controversies, Myths. High Desert, Cardiovascular Symposium 4, Lancaster, CA.

June 11, 1997 Acute Myocardial Infarction. Raising the Baseline. The Cardiology Update Series, Torrance, CA.

June 28, 1997 Management of the Patient with Heart Failure and Concomitant Disorders. Clinical Frontiers in Cardiology, Baltimore, MD.

July 12, 1997 Treatment of Hyperlipidemia. Hines VA Hospital, Loyola Medical School, Chicago, IL.

September 17-19, 1997 Myocardial Stunning and Hibernation. Visiting Professor of Medicine, Cardiology Division, Tufts University, Boston, MA.

 Effect of Cocaine on the Heart. Visiting Professor of Medicine, Cardiology Division, Tufts University, Boston, MA.

 Medical Grand Rounds: Triggers for Myocardial Infarction and Sudden Death. Visiting Professor of Medicine, Cardiology Division, Tufts University, Boston, MA.

September 20, 1997 Attempts to Regenerate Muscle Cells in Myocardial Infarcts. Targeting the Cardiovascular System: Biologics, Genes, and Pharmaceuticals in Diagnosis and Therapy. Northeastern University, Boston, MA.

October 15-17, 1997 Illicit Drug Use in the Athlete as a Contributor to Adverse Cardiac Events. International Summit on Diagnosis and Management of Hypertrophic Cardiomyopathy, Sudden Death and Athletes. Minneapolis Heart Institute Foundation, Minneapolis, MN.

November 19, 1997 The Link between Cardiovascular Disease and Male Erectile Dysfunction. Male Erectile Dysfunction and Cardiovascular Disease; New Clinical Strategies, Orlando, FL.

November 19, 1997 Evidence against PKC and Ecto-5’ nucleotidase. Controversies in Preconditioning, American Heart Association, Annual Scientific Sessions, Orlando, FL.

November 10, 1997 Moderator: Mechanisms of Ischemic Preconditioning. American Heart Association, Annual Scientific Sessions, Orlando, FL.

November 14, 1997 Ischemic Preconditioning. Bassett Hospital, Cooperstown, NY.

November 25, 1997 Hypertension: Aspects of Age, Gender, Race. University Hospital Clinic, Case Western Reserve, Cleveland, OH.

December 16, 1997 Triggers of Cardiovascular Disease. Harper Hospital, Wayne State University, Detroit, MI.

January 27, 1998 The Calcium Channel Blocker Controversy. Creighton University, St. Joe Hospital, Omaha, NE.

February 5, 1998 Gene and Cell Therapy of the Heart. Cardiology Research Conference, University of Southern California, Division of Cardiology, Los Angeles, CA.

February 25, 1998 Opportunities and Challenges for Protection of the Ischemic Myocardium in the Clinical Setting. Symposium: Vascular and Myocardial Aspects of Ischemic Heart Disease. American Heart Association, Incline Village, NV.

March 28, 1998 Intrapericardial Hypothermia as a Form of Cardioprotection. The 3rd International Symposium on Intrapericardial Drug Delivery, Atlanta, GA.

March 28, 1998 Program Chairman. Introduction and Cardiovascular Risk Factors as a Risk Factor for Erectile Dysfunction. Sexual Health and Heart: What are the Links (Satellite Symposium to the American College of Cardiology), Atlanta, GA.

March 31, 1998 Program Moderator: Basic Aspects of Acute Myocardial Infarction II. American College of Cardiology 47th Annual Scientific Session, Atlanta, GA.

April 4, 1998 Optimization of Antihypertensive Therapy in Older Patients with Concomitant Disease. Symposium: Comprehensive Cardiovascular Care for Older Hypertensive Patients. (Satellite Symposium of American College of Physicians), San Diego, CA.

April 13, 1998 Stunned and Hibernating Myocardium. Cardiology Lecture. Henry Ford Hospital, Detroit, MI.

April 25, 1998 Hypertension Therapy: Aspects of Age, Gender, Race. 12th Annual Cardiology Update. Olean Medical Group and Biomedical Sciences. State University of New York at Buffalo, Olean, NY.

May 5, 1998 Hypertension. UCLA Nursing School Course. N239A Biobehavioral Foundations of Acuity and Chronicity in Illness. Kathy Dracup, RN, D.NSc. Los Angeles, CA.

May 8, 1998 Stunning of the Myocardium. Cardiology Grand Rounds, Harbor UCLA, Torrance, CA.

May 8, 1998 Managing the Older Hypertensive Patient with Concomitant Conditions. Hypertension: Total Disease Management in the Older Patient. Satellite Symposium to the American Geriatric Society. Seattle, WA.

May 14, 1998 Stunned Myocardium. Internal Medicine Grand Rounds. UC Davis Medical Center, Sacramento, CA.

June 5, 1998 Attempts to regenerate muscle cells and new blood vessels in ischemic myocardium with gene therapy and cell therapy. Symposium: Angiogenesis and Direct Myocardial Revascularization. Cardiology Research Foundation. Washington Hospital Center. Chantilly, VA

June 11, 1998 Cardiovascular Risk Factors and Male Erectile Dysfunction: The Issue of Viagra. Medical Grand Rounds. Good Samaritan Hospital, Los Angeles, CA.

August 3, 1998 Cardiomyocytes as Donor Cells in a Model of Myocardial Infarction. NHLBI Workshop: Cell Transplantation: Future Therapy for Cardiovascular Disease, Columbia, MD.

August 10, 1998 An overview: Myocardial Preconditioning. International Society for Heart Research. XX Annual Meeting of the American Section, Ann Arbor, MI.

August 14, 1998 JNC VI and Systolic Hypertension. CME Lecture. Long Beach Comprehensive Health Center, Harbor/UCLA. Long Beach, CA.

September 12, 1998 Cardiovascular Risk Factors and Sexual Dysfunction. Clinical and Therapeutic Advances in the Treatment of Sexual Dysfunction: A Paradigm for Managed Care (Am. J. Managed Care). Chicago, IL.

September 17, 1998 Stunned and Hibernating Myocardium. Cardiology Lectures: Rhode Island Hospital, Brown University, Providence, RI.

 Ischemic Preconditioning. Cardiology Lectures: Rhode Island Hospital, Brown University, Providence, RI.

September 19, 1998 Sex and Heart Disease. Sierra Heart Institutes’ Ninth Annual Symposium “Trends in Cardiovascular Medicine: Cardiology for the Primary Physician.” Olympic Valley, CA.

September 29, 1998 Erectile Dysfunction and Viagra. Henry Ford Hospital, Detroit, MI, Cardiology Grand Rounds.

October 10, 1998 Attempts to regenerate myocytes and blood vessels in ischemic myocardium with gene therapy and cell implants. Transcatheter Cardiovascular Therapeutics – 10th Annual symposium. Washington DC.

October 12, 1998 Sildenafil nitrate interaction: mechanism, risks, and management strategies. Symposium: Pharmacologic therapy for erectile dysfunction. Satellite Symposium of the American College of Emergency Physicians. San Diego, CA.

October 20, 1998 Sex and heart disease. Family Practice Grand Rounds, Michael Reese Hospital, Chicago, IL.

November 7, 1998 New Approaches to Reducing Ischemic/Reperfusion Injury. Symposium: Biotechnology in Cardiovascular Medicine. Sponsored by Henry Ford Hospital, Dallas, TX.

November 8, 1998 Cardiovascular Risk Factors and Erectile dysfunction: What are the Links? Symposium: CVD and Sexual Health: What do Cardiologists need to Know? Satellite Symposium to the American Heart Association Annual Meeting, Dallas, TX.

November 10, 1998 Program Moderator. Ion Channels in Myocardial Ischemia. At 71st Scientific Session of the American Heart Association, Dallas, TX.

November 11, 1998 When Throughout the Year is Coronary Death Most Likely to Occur? Presentation at American Heart Association Scientific Sessions, Dallas, TX.

November 19, 1998 Mechanism-Based Treatment of Heart Failure: Current Status and Future Directions. Symposium: Heart Failure: New Pathophysiologic Concepts and Treatment Implications. Impact Communications, Beverly Hills, CA.

December 1-2, 1998 Comprehensive Hypertension Management in Older Patients. Symposium: Cardiovascular Disease in Older Patients. AM Medica/Johns Hopkins University. San Francisco and Los Angeles, CA.

December 9, 1998 Sex, the Heart and Male Erectile Dysfunction. St. Vincent Hospital, Portland OR. Medicine Grand Rounds.

December 21, 1998 Cocaine Cardiotoxicity. Cardiology Grand Rounds, Harbor UCLA, Torrance, CA.

January 12, 1999 Update on Viagra and the Heart. USC Division of Cardiology, Cardiology Grand Rounds, Los Angeles, CA.

February 16, 1999 Stunned Myocardium. UCI, Internal Medicine Grand Rounds, Irvine, CA.

February 20, 1999 Recent clinical trials in hypertension: Implications for management. Impact Communications Symposium “Hypertension in the Older Patient,” Pacific Palisades, CA.

March 5, 1999 Program Chairman Cardiovascular disease and the management of erectile dysfunction: What have we learned? Satellite symposium of the ACC sponsored by Johns Hopkins University School of Medicine. “Cardiovascular disease and sexual health: An expert’s dialogue,” New Orleans, LA.

March 26, 1999 Stunned and hibernating myocardium. Strong Memorial Hospital, Cardiology Lecture. Rochester, NY.

April 20, 1999 Diagnosis and treatment of hypertension. Guest Lecturer, UCLA School of Nursing, Los Angeles, CA.

April 22, 1999 New Antihypertensive Trials. Internal Medicine, Olive View – UCLA Medical Center, Sylmar, CA.

April 24, 1999 Triggers of Cardiovascular Disease. Annual Cardiology Update. Olean Medical Group, State University of New York at Buffalo, NY.

April 26, 1999 Ischemic preconditioning. University Hospital, State University of New York at Syracuse, NY. Cardiology lecture, medicine lecture.

 Hypertension. University Hospital, State University of New York at Syracuse, NY. Cardiology lecture, medicine lecture.

May 2, 1999 The Cardiologist’s Perspective of Sildenafil. Precautions for the use of sildenafil in cardiac patients. Society for the Study of Impotence, Annual Scientific Session, Dallas, TX.

May 21, 1999 Triggers of Cardiovascular events: Considerations for the elderly patient. Satellite Symposium of American Geriatrics Society Meeting, Philadelphia, PA. “Sexual Dysfunction in Elderly Patients. Clinical Considerations for Optimal Care.”

May 22, 1999 Safety of sildenafil citrate in men with erectile dysfunction taking multiple antihypertensive agents. American Society of Hypertension, Annual Scientific Meeting, New York, NY.

May 26, 1999 Triggers of cardiovascular disease. Cardiology Lecture, St. Louis University, St. Louis, MO.

June 4, 1999 Cardiovascular safety issue of management of erectile dysfunction. Symposium: Sexual Activity and Cardiac Risk. Robert Wood Johnson School of Medicine, Held at Princeton University, Princeton, NJ.

June 8, 1999 Use of Viagra in patients with Cardiovascular Disease. Cardiology Grand Rounds. Cedars-Sinai Medical Center, Los Angeles, CA.

June 10, 1999 Myocardial regeneration: An overview. Angiogenesis and Direct Myocardial Revascularization. Second Annual Symposium. Cardiovascular Research Foundation at the Washington Hospital Center, Washington, DC.

June 24, 1999 Stunned and hibernating myocardium. Cardiovascular Grand Rounds. St. Luke’s Hospital and the Mid America Heart Institute. Kansas City, MO.

July 17, 1999 Viagra: Risks and benefits for the Cardiac Patient. 10th Annual Symposium on Cardiovascular Disease and Internal Medicine sponsored by the California Heart Institute at Redding Medical Center. Berkeley, CA.

August 13, 1999 Participant, discussant. Tissue-genesis and Organogenesis Workshop. NIH, Bethesda, MD.

August 25, 1999 Recent Clinical Trials in Hypertension. Medical Grand Rounds, Loma Linda University, School of Medicine, Veterans Memorial Hospital. Loma Linda, CA.

September 13, 1999 New Research Projects. St. Elizabeth’s Medical Center, Vascular and Cardiology Dept. Boston, MA.

 Triggers of Cardiovascular Disease. St. Elizabeth’s Medical Center, Vascular and Cardiology Dept. Boston, MA.

September 14, 1999 Triggers of Cardiovascular Disease. Miriam Hospital, Brown University. Lecture to Internal Medicine.

September 15, 1999 Genetic and Cellular Approaches to Heal the Heart. Massachusetts General Hospital. Harvard Medical School, Cardiology Grand Rounds.

September 26, 1999 Cardiac Grafts: Functional Analysis. NHLBI Workshop. Heart Failure Research: New Approaches to Pathogenesis. San Francisco, CA.

October 6, 1999 Atherosclerosis: Expanding the spectrum of therapy. Mini Symposium: Atherosclerosis: Expanding the spectrum of therapy. Sponsored by Center for Healthcare Education. Beverly Hills, CA.

October 26, 1999 Sex and the Heart. Michael Reese Hospital. Lecture to Internal Medicine. Chicago, IL.

October 29-31, 1999 Sildenafil and the cardiac patient. Symposium: The pharmacologic management of male sexual dysfunction. Sponsored by Columbia University. Beverly Hills, CA.

 Practical aspects to using sildenafil workshop. Symposium: The pharmacologic management of male sexual dysfunction. Sponsored by Columbia University. Beverly Hills, CA.

November 2, 1999 Triggers of cardiovascular events. USC Division of Cardiology. Grand Rounds. Los Angeles, CA.

November 8, 1999 Program Co-Chair. The Safety of sildenafil citrate in the context of cardiovascular risk factors. Satellite Symposium to the AHA meetings. Sexual Health in Your CVD Patients. A Focus on Multi-Disciplinary Issues. Atlanta, GA.

November 10, 1999 Program Moderator. Role of KATP Channels in Preconditioning II 72nd Scientific Session of the American Heart Association. Atlanta, GA.

November 11, 1999 Recent clinical trials in hypertension. Medical Grand Rounds. Good Samaritan Hospital. Los Angeles, CA.

November 29, 1999 Sex and the Heart. Cardiology Grand Rounds. Harbor-UCLA. Torrance, CA.

February 6, 2000 Gene and Cell Therapy. University of Louisville, Cardiology Grand Rounds, Louisville, KY.

February 26, 2000 Hypertension. Florida Academy of Physician Assistants Symposium, Orlando FL.

March 7, 2000 CAD and erectile dysfunction. Hoag Hospital, Internal Medicine Conference, Newport Beach, CA.

March 10, 2000 Lecture: Conference goals. Program Co-Chair, “Sexual Health – Getting to the Heart of the Matter,” Satellite Symposium at the American College of Cardiology Annual Scientific Session, Anaheim, CA.

Lecture: PDE V Inhibition and endothelial function. Program Co-Chair, “Sexual Health – Getting to the Heart of the Matter,” Satellite Symposium at the American College of Cardiology Annual Scientific Session, Anaheim, CA.

Lecture: Panel discussion, closing remarks. Program Co-Chair, “Sexual Health – Getting to the Heart of the Matter,” Satellite Symposium at the American College of Cardiology Annual Scientific Session, Anaheim, CA.

March 14, 2000 Lecture: Erectile dysfunction and cardiac risk factors. Symposia 0626 at American College of Cardiology 49th Annual Scientific Session. “Sexual activity and the cardiovascular system,” Anaheim, CA.

Seasonal variation of myocardial infarct size in human. Presentations at American College of Cardiology 49th Annual Scientific Session, Anaheim, CA.

Death rates from heart disease in Los Angeles County (1987-1997). Presentations at American College of Cardiology 49th Annual Scientific Session, Anaheim, CA.

March 23, 2000 The triggers of cardiovascular disease. Medical Grand Rounds, University of Connecticut Health Center, Farmington, CT.

April 5, 2000 Lecture: New BP Targets and treatment goals in hypertension management. Cardiovascular Disease Update: New Concepts and Clinical Management Strategies. Co-Chair of Symposium. Satellite Symposium of Pri-Med West 2000 Meeting, Long Beach, CA.

April 6, 2000 Sex and the patient with cardiovascular risk factors. New Perspectives on Managing Erectile Dysfunction in Primary Care. Satellite Symposium of Pre-Med West 2000 Meeting, Long Beach, CA.

April 25, 2000 Hypertension. UCLA School of Nursing. Pathophysiology Course, Los Angeles, CA.

April 28, 2000 Erectile dysfunction, its cardiovascular connection and sildenafil. Cardiology Conference, Sharp Memorial Hospital. San Diego Cardiac Center, San Diego, CA.

May 13, 2000 Sex and ischemic heart disease. Symposium: Cardiology 2000. For primary care physicians. St. Mary Medical Center, Long Beach, CA.

May 26, 2000 Ischemic preconditioning. Cardiology Grand Rounds. Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.

May 29, 2000 Clinical challenges and treatment goals in hypertensive patients. Symposium: Cardiovascular Disease Update: Clinical applications of new concepts and treatment guidelines. Adjunct symposium at the American Academy of Physician Assistants Conference, Chicago, IL.

June 6, 2000 The management of erectile dysfunction in patients with cardiovascular concerns. Symposium: Optimizing the management of erectile dysfunction: An integrated approach, Los Angeles, CA.

June 9, 2000 Managing the hypertensive patient with multiple risk factors. Symposium: Rounds with experts. Case-based decision making in the treatment of hypertension, San Francisco, CA.

June 17, 2000 Invited Lectures: Gene and Cellular Therapy. American Section of the International Society for Heart Research, Louisville, KY.

Hypothermia and cardioprotection. American Section of the International Society for Heart Research, Louisville, KY.

August 22, 2000 Viagra (Sildenafil Citrate) Cardiovascular Experience. Symposium: Erectile Dysfunction, PDE5 Inhibition, and the Hypertensive Patient. Satellite Symposium of the 18th Scientific Meeting of the International Society of Hypertension. Chicago, IL.

September 21, 2000 Clinical challenges and new treatment goals for effective hypertension management in primary care. Cardiovascular Disease Update, Practical Strategies for Optimal Management of Multiple Risks. Satellite Symposium at the American Academy of Family Physicians annual meeting, Dallas, TX.

September 27, 2000 Sex and the Heart. Cardiology Grand Rounds, University of California at San Diego, San Diego, CA.

November 4, 2000 Cardiovascular Issues in ED Treatment and the treatment of ED in the CV Patient. Symposium: The Pharmacologic Management of Male Sexual Dysfunction, Beverly Hills, CA.

November 14, 2000 Co-Presenter (with Dr. Karin Przyklenk). Viagra does not exacerbate ischemia but renders platelets refractory to the inhibitory effects of adenosine. American Heart Association Scientific Sessions 2000, New Orleans, LA.

December 5, 2000 Gene and Cellular Therapy for the Heart. Cardiology Grand Rounds, University of Southern California, Los Angeles, CA.

December 6, 2000 Journal Club. Cardiology Journal Club, Tulane University, New Orleans, LA.

December 7, 2000 Myocardial Preconditioning. Cardiology Grand Rounds, Tulane University, New Orleans, LA.

 Viagra and CVD. San Antonio Cardiovascular Society and the American Heart Association Texas Affiliate, San Antonio, TX.

December 18, 2000 Erectile dysfunction and the cardiac connection. Internet Symposium: Chair, Future directions in the Management of Sexual Dysfunction for World Medical Leaders, New York, NY.

January 29, 2001 Stunned Myocardium. UC Irvine Cardiology Fellow’s Conference, Irvine, CA.

February 2, 2001 Sex and the Heart. Kaiser Permanente, Harbor City, CA.

February 13, 2001 Erectile Dysfunction. California Coalition of Nurse Practitioners, West Los Angeles, CA.

February 16, 2001 Hypertension Update for Front-Line Physicians: New Clinical Trials and Treatment Goals. Comprehensive Coverage of Cardiovascular Disease: Focus on Multiple-Risk Factor Management. Symposium held in conjunction with Pri-Med West 2001. Sponsored by Johns Hopkins, Long Beach, CA.

February 21, 2001 Erectile Dysfunction, Its Cardiovascular Connection, and Sildenafil. Stanford University Division of Endocrinology, Grand Rounds. Palo Alto, CA.

February 25, 2001 Expanding the Spectrum of Atherosclerosis. Adventist Health. San Joaquin Community Hospital. 1st Annual Cardiac Symposium. Bakersfield, CA.

March 8, 2001 Expanding the Spectrum of Atherosclerosis. Kern Medical Center/UCLA. Bakersfield, CA.

March 16, 2001 Course Director. Symposium in Association with the Annual Scientific Session of the American College of Cardiology: Sponsored by Keck School of Medicine USC. The Forgotten Question in CVD: Do Your Patients Have Erectile Dysfunction? Orlando, FL.

Presenter: Why Treat ED in Cardiac Patients? Symposium in Association with the Annual Scientific Session of the American College of Cardiology: Sponsored by Keck School of Medicine USC. The Forgotten Question in CVD: Do Your Patients Have Erectile Dysfunction? Orlando, FL.

March 20, 2001 Co-chair of Session, “Prediction of Viability in Chronic Coronary Disease.” American College of Cardiology. Orlando, FL.

 Presenter: Elevated body temperature during acute myocardial ischemia exacerbates necrosis. American College of Cardiology. Orlando, FL.

March 23, 2001 High Blood Pressure. Good Samaritan Hospital. Community Heart Update. Los Angeles, CA.

April 12, 2001 Expanding the Spectrum of Atherosclerosis. Rancho Los Amigos Medical Center. Downey, CA.

April 18, 2001 Molecular/Cellular Cardiology. USC Cardiology Research Conference. Los Angeles, CA.

April 21, 2001 Cardiovascular Safety of Drugs Used for Impotence. Symposium: Update in Cardiology 2001. Main Line Health Heart Center. Lankenau Hospital. Wynnewood, PA.

April 23, 2001 Expanding the Spectrum of Atherosclerosis. Creighton University Cardiology Grand Rounds. Omaha, NE.

April 25, 2001 Hypertension. University of Iowa. Cardiology Grand Rounds. Iowa City, IA.

April 30, 2001 Sex and the Heart. Chinese American Medical Association. Monterey Park, CA.

May 4, 2001 Cardiovascular Disease, What’s New? Gundersen Lutheran Medical Center. LaCrosse, WI.

May 10, 2001 Expanding the Spectrum of Atherosclerosis. Little Company of Mary Hospital. Torrance, CA.

May 14 2001 Atherosclerosis. Kansas University Medical Center, School of Medicine. Kansas City, MO.

May 15 2001 Atherosclerosis. Mid-America Cardiology, St. Luke’s Hospital. Kansas City, MO.

May 19, 2001 Blood Pressure and Beyond. Symposium: Challenge Facing the Primary Care Physician: Time to Treat or Refer. UC San Diego School of Medicine. San Diego, CA.

May 26, 2001 New Concepts and Clinical Challenges in Hypertensive Patients. Symposium: Cardiovascular Disease Update: Focus on Risk Factors and Their Effective Management. Adjunct Symposium at the American Academy of Physician Assistant’s Annual Conference. Sponsored by Johns Hopkins University. Anaheim, CA.

June 4, 2001 ED Update on New Therapies and Cardiovascular Safety. 2001 Annual Meeting of the American Urological Association. Course: Erectile Dysfunction. Update on New Therapies and Cardiovascular Safety. Anaheim, CA.

June 12, 2001 Management of ED in CV Patients. The Heart Institute of Spokane, Spokane, WA.

July 1, 2001 Program Co-Chair Managing the Multiple Risk Factor Patient: Focus on Hypertension and Hyperlipidemia. American Academy of Nurse Practitioners/Johns Hopkins. Orlando, FL.

July 7, 2001 Atherosclerosis/Chronic Coronary Artery Disease. USC Division of Cardiology CORE Curriculum Lecture. Los Angeles, CA.

July 8, 2001 Molecular and cellular approaches to repair the heart. International Society of Heart Research. Symposium: Heart Repair and Inflammation. Winnipeg, Manitoba, Canada.

September 11, 2001 Hypertension Therapy: Aspects of Age, Gender, Race. Regions Hospital. St. Paul, MN.

 Triggers of Coronary Artery Disease. Plummer House Mayo Clinic. Cardiovascular Division. Rochester, MN.

September 28, 2001 The importance of lipid therapy. CME Lecture. Good Samaritan Hospital. Los Angeles, CA.

October 5, 2001 New perspectives on the management of hypertension. The Heart Institute, Good Samaritan Hospital. 13th Annual Cardiovascular Nursing Symposium. Los Angeles, CA.

October 30, 2001 Hypertension Therapy. Cedars-Sinai Medical Center, Los Angeles, CA. Medicine Noon Conference.

November 2, 2001 Sildenafil’s cardiovascular safety profile: one less thing to worry about. Symposium: The Management of Male and Female Sexual Dysfunction. Sponsored by Columbia University. Beverly Hills, CA.

November 15, 2001 Hypertension therapy. Daniel Freeman Hospital, Inglewood, CA.

November 27, 2001 Update on erectile dysfunction and the cardiac connection. USC Division of Cardiology, Grand Rounds, Los Angeles, CA.

November 30, 2001 ED in the CV patient. Marshfield Clinic, Grand Rounds. Marshfield, WI.

The stunned myocardium. Marshfield Clinic, Grand Rounds. Marshfield, WI.

December 8, 2001 Cardiovascular Risk Evaluation. Symposium: Chronic Disease Management in Primary Care. Kansas City, MO.

January 14, 2002 Statins in Disease Progression. Cardiovascular Global Risk Management, Turnberry Isle Resort Club, Aventura, FL.

January 15, 2002 Sex and the Heart. Lafayette General Hospital, Lafayette, LA.

January 16, 2002 Sex and the Heart. Dauterive Hospital, New Iberia, LA.

March 15, 2002 Course Director and lecturer, “Managing Cardiac Patients with ED: New Data.” Symposium in Conjunction with ACC Sponsored by Keck School of Medicine at USC. Erectile Dysfunction: News for Cardiologists, Atlanta, GA.

March 16, 2002 Program Chairperson and lecturer, “Erectile Dysfunction Therapy: Further Cardiovascular Considerations.” Symposium in Conjunction with ACC sponsored by Annenberg Center for Health Sciences at Eisenhower. “Treating Erectile Dysfunction: Current Issues/Novel Therapeutic Options,” Atlanta, GA.

March 17, 2002 Presenter: Pharmacodynamic interactions between tadalafil and nitrates. American College of Cardiology Scientific Sessions, Atlanta, GA.

March 18, 2002 Presenter: “Old age and myocardial infarct size in the reperfusion era.” American College of Cardiology Scientific Sessions, Atlanta, GA.

March 21, 2002 Cell Transplantation Therapy – Cardiac Cath Conference. Virginia Commonwealth University, Richmond, VA, Visiting Professor.

Erectile Dysfunction and the Cardiovascular Link. Virginia Commonwealth University, Richmond, VA, Visiting Professor.

March 25, 2002 Systolic Hypertension in the Elderly. Chinese American Medical Association of Southern California, Los Angeles, CA.

April 3, 2002 “New Concepts and Clinical Challenges in Hypertensive Patients.” A symposium held in conjunction with Pri-Med West and sponsored by Johns Hopkins University School of Medicine.

April 9, 2002 Roundtable discussion of Cardiovascular Issues. Gunderson Lutheran Clinic, LaCrosse, WI.

April 10, 2002 Grand Rounds. Risk Factor Modification. Cardiology Grand Rounds, Winona Clinic, Winona, WI.

April 19-20, 2002 The Viagra Experience, Cardiology Data. ED Expert Series, The Clift House, San Francisco, CA.

April 29, 2002 Hypertension Therapy: Aspects of Age, Gender, and Race. Heart Group, Akron General, Cleveland, OH.

 Triggers of Cardiovascular Disease. Cleveland Clinic Foundation. Internal Medicine Noon Conference, Cleveland, OH.

April 29, 2002 Triggers of Cardiovascular Disease. Metrohealth Cardiology Grand Rounds, Case Western Reserve Medical Center, Cleveland, OH.

May 3, 2002 Hypertension in the Older Patient and Recent Clinical Trials. Queen of Angels – Hollywood Presbyterian Medical Center, Los Angeles, CA.

May 8, 2002 Introduction/Program Overview. New Therapies for Erectile Dysfunction: Expanded Opportunities for Successful Outcomes. Consortium for Improvement in Erectile Dysfunction, Marina Del Rey, CA. Sponsored by Annenberg Center for Health Sciences at Eisenhower.

Optimizing Clinical Management of Erectile Dysfunction: Use of Current and Novel Therapeutic Options. New Therapies for Erectile Dysfunction: Expanded Opportunities for Successful Outcomes. Consortium for Improvement in Erectile Dysfunction, Marina Del Rey, CA. Sponsored by Annenberg Center for Health Sciences at Eisenhower.

May 15, 2002 Hypertension in the Older Patient. Valley Hospital, Palmer, AK.

 Hypertension Therapy. Fairbanks Memorial Hospital, Fairbanks AK.

May 16, 2002 Hypertension Therapy. Alaska Native Medical Center Grand Rounds.

May 25, 2002 Systolic Blood Pressure and Cardiovascular Risk: A Comprehensive Management Plan for Front-Line Clinicians. Hypertension Update: New Targets and Treatment Strategies for Comprehensive Care. An Adjunct Symposium of the American Academy of Physician Assistant’s 30th Annual Physician Assistant Conference, Boston, MA. Sponsored by Johns Hopkins University School of Medicine.

May 27, 2002 Pharmacodynamic interactions between tadalafil and nitrates compared with sildenafil. American Urologic Association (AUA) Annual Meeting, Orlando, FL.

Cardiovascular profile of tadalafil, a new PDE5 inhibitor. American Urologic Association (AUA) Annual Meeting, Orlando, FL.

June 3, 2002 Hypertension. Los Angeles County Sheriff’s Department Medical Services/Professional Staff Association, Los Angeles, CA.

June 4, 2002 Novel Therapies for Erectile Dysfunction: Expanded Opportunities for Successful Outcomes. Consortium for Improved Erectile Function. Town Hall Forum Series, Regent Beverly Wilshire, Beverly Hills, CA.

June 6, 2002 Informal Case Studies on Hypertension and Dyslipidemia. St. Luke’s Hospital, Milwaukee, WI.

 Special Considerations in the Assessment and Management of Systolic Hypertension: Age, Gender, and Race. St. Luke’s Hospital, Milwaukee, WI, Grand Rounds.

June 7, 2002 Hypertension. Clinical Updates. Symposium: Clinical Cardiology for the New Millennium, St. Luke’s Medical Center. Milwaukee, WI.

June 10, 2002 Erectile Dysfunction and Cardiovascular Safety. Glendale Memorial Hospital and Health Center. Glendale, CA.

June 14, 2002 Erectile Dysfunction and the Heart. Huntington Hospital, Pasadena, CA.

June 22, 2002 Systolic Blood Pressure and Cardiovascular Risk: Update for Clinicians on the Front Line. Symposium held in conjunction with Pri Med Midwest. Sponsored by Johns Hopkins University School of Medicine, Current Concepts and Clinical Challenges in Hypertension Control, Convention Center, Rosemont, IL.

June 27, 2002 Cardiovascular Disease and Erectile Dysfunction. Asian American Medical Association, Empress Harbor Restaurant, Monterey Park, CA.

July 16, 2002 Cardiac Grafts – Functional Analysis. Heart Failure Research: New Approaches to Pathogenesis. National Heart, Lung, and Blood Institute. Bethesda, MD.

July 17, 2002 Global Cardiovascular Risk. Newark Beth Israel Medical Center, Cardiology Lecture. Newark, NJ.

July 18, 2002 Global Cardiovascular Risk. East Orange VA Hospital. East Orange, NJ.

July 27, 2002 Erectile dysfunction in the cardiac patient: how common and should we treat? Third International Conference on the Management of Erectile Dysfunction. Linking Pathophysiology and Therapeutic Response, McLean, VA.

August 6, 2002 Presentation from Breakout Session: Particulate Air Pollution and Myocardial Infarction. The Role of Environmental Agents in Cardiovascular Disease. National Institute of Environmental Sciences. Durham, NC.

August 9, 2002 Global cardiovascular risks. St. Joseph Heritage Healthcare. Fullerton, CA.

August 12, 2002 Hypertension therapy: Aspects of age, gender, race. St. Vincent’s Hospital, Hartford, CT.

 What practitioners need to know about patients with angina or hypertension and concomitant CHF. Baystate Medical Center, Springfield, MA.

August 13, 2002 Triggers of Cardiovascular Disease. University of Connecticut and St. Francis Hospital, Hartford, CT.

 Triggers of Cardiovascular Disease. Hartford Hospital, Cardiology Grand Rounds. Hartford, CT.

August 14, 2002 Early and Aggressive Statin Therapy. Danbury Hospital and Yale University School of Medicine, Grand Round. Danbury, CT.

August 24, 2002 Sex and the Heart: The Patient with Cardiovascular Disease – Who to treat and who to refer to a cardiologist. A symposium on the Management of Male Sexual Dysfunction and other Critical Issues in Men’s Health. Atlanta, GA.

September 27, 2002 Sex and the Heart: The Patient with Cardiovascular Disease – Who to treat and who to refer to a cardiologist. A symposium on the Management of Male Sexual Dysfunction and Other Critical Issues on Men’s Health. Chicago IL.

September 30, 2002 Erectile Dysfunction in the Cardiac Patient. University of Miami, Jackson Memorial Hospital, Department of Endocrinology. Miami, FL.

October 1, 2002 Sex and the Heart. University of Miami, Cardiology Grand Rounds, Jackson Memorial Hospital.

October 3, 2002 Therapies for Controlling Cholesterol. 14th Annual Cardiovascular Nursing Symposium, Heart Institute, Good Samaritan Hospital. Los Angeles, CA.

October 9, 2002 Intervention to Prevention: Evolving Atherosclerotic Management. Symposium: Intervention to Prevention: Evolving Atherosclerosis Management. Beverly Hills, CA. Sponsored by Academy for Healthcare Education and Brigham and Women’s Hospital.

October 11, 2002 Triggers of Cardiac Events. UC Davis, Cardiology Grand Rounds. Sacramento, CA.

October 12, 2002 How to Treat Hypertension in 2002. Cardiology 2002: An update on diagnosis and therapy. 70th Annual Fall Symposium of the American Heart Association - Western States Affiliate. Los Angeles, CA.

October 23, 2002 Stunned Myocardium. Boston Medical Center. Boston University Cardiology Grand Rounds. Boston, MA.

October 24, 2002 Cellular transplant therapy. Lahey Clinic Medical Center, Cardiology Grand Rounds. Burlington, MA.

October 25, 2002 Transplanted myocytes after myocardial infarction. The Cutting Edge – Cardiology for the Future. Symposium at Long Beach Memorial Medical Center. Long Beach, CA.

November 1, 2002 Sex and the Heart: The patient with cardiovascular disease – who to treat and who to refer to cardiologist. The Management of Male and Female Sexual Dysfunction. Beverly Hills, CA.

November 17, 2002 Program Chairperson. Symposium held in conjunction with AHA. Cardiovascular consideration in the management of erectile dysfunction: Clinical benefits of current and novel PDE5 inhibitors. Chicago, IL.

Introduction. Symposium held in conjunction with AHA. Cardiovascular consideration in the management of erectile dysfunction: Clinical benefits of current and novel PDE5 inhibitors. Chicago, IL.

 A review of current and novel PDE5 inhibitors: Clinical considerations of managing erectile dysfunction. Symposium held in conjunction with AHA. Cardiovascular consideration in the management of erectile dysfunction: Clinical benefits of current and novel PDE5 inhibitors. Chicago, IL.

November 17, 2002 Bench: Cooling to Preserve Myocardium at Risk. Symposium: Interventional Cardiology 2002: Bench to Bedside and Beyond. American Heart Association Scientific Sessions 2002. Chicago, IL.

November 17, 2002 Program Moderator. Emerging concepts of the consequences of Ischemia/Reperfusion.

Cardiac: Metabolism, Function, Ischemia. American Heart Association Scientific Sessions, 2002. Chicago, IL.

November 18, 2002 Rebuilding the Heart: Long term outcome of fetal cell transplantation on post infarct left ventricular remodeling. Presenter: Featured Research Session: Rebuilding the Myocardium – Stem Cell Therapy. American Heart Association Scientific Session, 2002. Chicago, IL.

November 20, 2002 Disasters – Natural and Man Made: Impact on CVD Risk. Plenary Session XII. Disasters, Stress, and Depression - Risk Factors for the New Millennium. American Heart Association Scientific Sessions 2002. Chicago, IL.

December 6, 2002 Cellular Transplant Therapy Discussion. Therapeutic Horizons in Heart Failure UCSD. The La Jolla-Rome-Yamaguchi Research Conferences on Cardiac Function. La Jolla, CA.

December 14, 2002 Sex and the Heart: The Patient with cardiovascular disease-Who to treat and who to refer to a cardiologist. The Management of Male Sexual Dysfunction. Dallas, TX.

January 10, 2003 Cardiovascular Risk and Disease with the Erectile Dysfunction Patient. Kaiser Permanente of San Diego, CA.

January 17, 2003 Treatment of Hyperlipidemia. St. Mary Medical Center Long Beach/UCLA.

January 25, 2003 Erectile Dysfunction in the Cardiac Patient. South Florida Medical Research Symposium. “Update on Women’s and Men’s Sexual Health.” Miami, FL.

January 30, 2003 Cell Therapy for Myocardial Infarction (Medical Grand Rounds). Visiting Professor, University of Texas, Medical Branch, Galveston, TX, Division of Cardiology.

 Stunned and Hibernating Myocardium (Cardiology Research Conference). Visiting Professor, University of Texas, Medical Branch, Galveston, TX, Division of Cardiology.

January 31, 2003 Cellular Therapy for Heart (Basic Science Conference). Texas Heart Institute, St. Lukes’ Hospital. Houston, TX.

Erectile Dysfunction, its Cardiovascular Connection, and Sildenafil (Cardiology Grand Rounds). Texas Heart Institute, St. Lukes’ Hospital. Houston, TX.

February 11, 2003 Systolic Hypertension (Medicine Grand Rounds). Beth Israel Hospital. New York City, NY.

February 13, 2003 Systolic Hypertenison (Medical Grand Rounds). SUNY Downstate Medical Center. Visiting Professor. Brooklyn, NY.

Ischemic Preconditioning (Cardiovascular Conference). SUNY Downstate Medical Center. Visiting Professor. Brooklyn, NY.

February 20, 2003 Stunned Myocardium. Loma Linda University, Cardiology Department. Loma Linda, CA.

February 27, 2003 Hypertension: New Clinical Trials. Anaheim General Hospital. CME Program. Anaheim, CA.

March 29, 2003 Cardiovascular effects of phosphodiesterase inhibitors. Simposio International SOCE SP/SBC. Chicago, IL.

March 31, 2003 Cardiovascular Safety of Vardenafil in Patients Receiving Antihypertensive Medications: A Post-Hoc Analysis of Five Placebo ­ Controlled Clinical Trials (presenter). American College of Cardiology. Chicago, IL.

April 1, 2003 Powerful microvascular and myocardial protection by Na+/H+ exchange inhibition and ischemic preconditioning ­ evidence for a casual link in the rabbit (presenter). American College of Cardiology. Chicago, IL.

April 2, 2003 Symposium: Erectile Dysfunction and the Heart: More than Meets the Eye. Sex, Erectile Dysfunction, and the Heart: Growing Problem ­ Separating the Myth from Reality (presenter). American College of Cardiology. Chicago, IL.

Can anatomic no ­ reflow be prevented by pharmacologic treatment with adenosine and verapamil? (Presenter). American College of Cardiology. Chicago, IL.

April 4, 2003 Treatment goals and practical strategies for hypertension. Control in patients with multiple risk factors. Pri-Med Satellite Symposium Cardiovascular Disease Update: Optimal Primary Care Management of Multiple Risk Factors. Sponsored by Johns Hopkins. Long Beach, CA.

April 8, 2003 “The ALLHAT Study” Endocrine Grand Rounds. Cedars-Sinai, Medical Center. Los Angeles, CA.

April 10, 2003 Erectile Dysfunction and Cardiovascular Disease (Grand Rounds). VA Sepulveda/UCLA. Los Angeles, CA.

April 25, 2003 Symposium: The Emerging Frontiers for Management of Erectile Dysfunction: Strategies for Patient Care on the Horizon. American Urological Association Annual Meeting. Chicago, IL.

Lecture: Favorable Safety Profile of PDE5 Inhibitors and Cardiovascular Clinical Considerations. American Urological Association Annual Meeting. Chicago, IL.

May 8, 2003 Hypertension Update. Northridge Hospital Medical Center. Van Nuys, CA.

May 16, 2003 Erectile Dysfunction and the Cardiac Connection. Grand Rounds. Good Samaritan Hospital. Los Angeles, CA.

May 26, 2003 Symposium: Cardiovascular Disease Update: New Concepts and Management Strategies for Clinicians on the Front Line. American Association of Physicians’ Assistants. Satellite Symposium. New Orleans, LA.

Lecture: The hypertensive patient with multiple risk factors: Practical approaches for comprehensive management. American Association of Physicians’ Assistants. Satellite Symposium. New Orleans, LA.

May 30, 2003 Erectile Dysfunction. San Joaquin Community Hospital, Cardiology Program Series. Bakersfield, CA.

June 28, 2003 Plenary Session I. Rebuilding myocardium in the infracted heart and proteomics of heart failure. XXV Annual Meeting of the International Society for Heart Research (ISHR) North American Section, Mystic, CT.

Lecture: Cellular Cardiomyoplasty. XXV Annual Meeting of the International Society for Heart Research (ISHR) North American Section, Mystic, CT.

August 1, 2003 Importance of Systolic Blood Pressure to Cardiovascular Outcomes. Frontiers in Hypertension Symposium. The George Washington University Medical Center. Washington, D.C.

September 12, 2003 Stunned and Hibernating Myocardium. Medical Grand Rounds. Queen’s Medical Center. Honolulu, HI.

September 23, 2003 Biologic Ventricular Assist Device. NIH, Research in Innovative Tissue Engineering Grantee Meeting. Rockville, MD.

October 10, 2003 Lipid Management. USC Department of Medicine. Core Curriculum Lecture. Los Angeles, CA.

October 13, 2003 ED in the Cardiovascular Patient. Cardiology Grand Rounds. Robert Wood Johnson Medical Center. New Brunswick, NJ.

October 21, 2003 Cellular Cardiomyoplasty. Cardiology Grand Rounds. USC Division of Cardiovascular Medicine. Los Angeles, CA.

October 23, 2003 From Evidence to Practice: Update in Hypertension, JNC7. Long Beach VA Hospital. Long Beach, CA.

November 1­2, 2003 Co-Chairman. The Leadership Conference on Sexual, Cardiovascular, and Metabolic Syndrome Related Therapeutics. Sponsored by USC. Beverly Hills, CA.

The cardiovascular profile of sildenafil and other PDE5 inhibitors. The Leadership Conference on Sexual, Cardiovascular, and Metabolic Syndrome Related Therapeutics. Sponsored by USC. Beverly Hills, CA.

Panel Discussant. The Leadership Conference on Sexual, Cardiovascular, and Metabolic Syndrome Related Therapeutics. Sponsored by USC. Beverly Hills, CA.

November 6, 2003 Update on Hypertension. JNC7 and Beyond. Medicine Conference. Ventura County Medical Center. Ventura, CA.

November 9, 2003 Novel PDE5 Inhibitors: Assessing Hemodynamic Effects and Safety Parameters. Satellite Symposium of the Scientific Sessions of the American Heart Association: Erectile Dysfunction and Cardiovascular Considerations: Managing Patients Effectively with PDE5 Inhibitors. Orlando, FL. Sponsored by Annenberg Center for Health Sciences.

November 9, 2003 Chairman. Satellite Symposium of the Scientific Sessions of the American Heart Association. PDE5 Inhibitors: Their Evolving Role in the Cardiovascular Arena. Sponsored by USC. Orlando, FL.

Introduction. Satellite Symposium of the Scientific Sessions of the American Heart Association. PDE5 Inhibitors: Their Evolving Role in the Cardiovascular Arena. Sponsored by USC. Orlando, FL.

PDE5 Inhibitors: Pharmacology and current utilization in the cardiovascular patient. Satellite Symposium of the Scientific Sessions of the American Heart Association. PDE5 Inhibitors: Their Evolving Role in the Cardiovascular Arena. Sponsored by USC. Orlando, FL.

Summary and concluding remarks. Satellite Symposium of the Scientific Sessions of the American Heart Association. PDE5 Inhibitors: Their Evolving Role in the Cardiovascular Arena. Sponsored by USC. Orlando, FL.

November 10, 2003 Special Sessions #3. New Approaches to Protecting Ischemic Myocardium. 2003 Scientific Sessions of the American Heart Association. Orlando, FL.

Lecture: Overview of Cardioprotection in Patients. 2003 Scientific Sessions of the American Heart Association. Orlando, FL.

November 12, 2003 Reducing Your Risk for Heart Disease. Good Samaritan Hospital. Presentation to Public.

January 7, 2004 Cellular Transplant Therapy for Heart Disease. Good Samaritan Hospital. Medical Grand Rounds. Los Angeles, CA.

January 16, 2004 Cell Transplant. Oregon Health Sciences University. Portland, OR. Lecture to Cardiology Fellows.

January 31, 2004 Erectile dysfunction and heart failure. University of Southern California. Heart Failure 2004. Annual Symposium. Los Angeles, CA.

February 10, 2004 Erectile dysfunction in the cardiac patient. Health Science Center. University of Virginia. Cardiology Grand Rounds. Charlottesville, VA.

February 12, 2004 Know your score in hypertension. Magic Johnson Foundation. Los Angeles, CA.

March 8, 2004 Presenter: Increased cardiovascular mortality with the turn of the millennium. American College of Cardiology, Annual Meetings. New Orleans, LA.

March 9, 2004 Co-Chair Symposium. The Infarct Artery is Open. Now What? American College of Cardiology, Annual Meetings. New Orleans, LA.

Co-Chair Symposium. Salvaging Ischemic Myocardial Damage. Lecture: The Conceptual Basis of Ischemic Cell Death. American College of Cardiology, Annual Meetings. New Orleans, LA.

April 29, 2004 Cellular and Gene Therapy for the Heart. Buffalo General Hospital. State University of New York at Buffalo Medical School. Medicine Grand Rounds. Buffalo, NY.

Global cardiovascular risk reduction. Erie County Medical Center. Buffalo, NY. Lecture to Department of Medicine.

May 3, 2004 Plenary Session: Update on Cellular Cardiomyoplasty and biologic LV Assist. International Society of Heart Research ­ American Section Annual Meeting. Cancun, Mexico.

May 10, 2004 Presenter: Interaction between the phosphodiesterase-5 inhibitor tadalafil and the alpha blockers doxazosin and tamsulosin. American Urologic Association Annual Meeting. San Francisco, CA.

May 12, 2004 New guidelines and clinical trial results: Insights and applications for the hypertensive patient with multiple risk factors. Cardiovascular disease update: New approaches for global risk management in primary care. Symposium sponsored by Johns Hopkins University School of Medicine in conjunction with PRI-MED West 2004 Conference. Anaheim, CA.

June 3, 2004 Medical Grand Rounds. Triggers of Myocardial Infarction. Annenberg Center for Health Sciences at Eisenhower. Rancho Mirage, CA.

June 11, 2004 Lecture: Cardiac safety and drug interaction effects. Second Princeton Consensus Conference on Sexual Dysfunction and Cardiac Risk. Princeton, NJ.

July 15, 2004 Erectile Dysfunction in the Cardiac Patient. UCLA Cardiology. Los Angeles, CA.

September 10, 2004 Implantation of neonatal cardiomyocytes into the aortic wall. NIH/NHLBI. RITE Grantee Meeting. Bethesda, MD.

October 1, 2004 Yes. Reperfusion injury is a well-established phenomenon and its prevention will save lives. Transcatheter Cardiovascular Therapeutics 2004. Washington, D.C.

Ischemic reperfusion injury. Identifying targets for prevention. Transcatheter Cardiovascular Therapeutics 2004. Washington, D.C.

Moderated Audience Questions and Answers. Acute Myocardial Infarction V. Novel pharmacologic, device, and cell-based approaches to enhance myocardial function and reduce mortality. Transcatheter Cardiovascular Therapeutics 2004. Washington, D.C.

November 6, 2004 Coronary Artery Disease: Discussion. 36th Bethesda Conference. “Recommendations for Determining Eligibility for Competition in Athletes with Cardiovascular Abnormalities?” New Orleans, LA.

November 7, 2004 Introductions and Welcome. Satellite Symposium of AHA meeting. Vascular Biology, Cardiovascular Disease and PDE5 Inhibitors from Endothelial Dysfunction to Pulmonary Hypertension. New Orleans, LA.

PDE5 Inhibitors and Coronary Artery Disease. Satellite Symposium of AHA meeting. Vascular Biology, Cardiovascular Disease and PDE5 Inhibitors from Endothelial Dysfunction to Pulmonary Hypertension. New Orleans, LA.

Questions and Answers Panel Discussion. Satellite Symposium of AHA meeting. Vascular Biology, Cardiovascular Disease and PDE5 Inhibitors from Endothelial Dysfunction to Pulmonary Hypertension. New Orleans, LA.

November 8, 2004 Balance and Imbalance of Regional Contractile Function and Blood Flow. American Heart Association Annual Scientific Sessions 2004. New Orleans, LA.

November 9, 2004 How to Treat Erectile Dysfunction in the Cardiac Patient. American Heart Association. Annual Scientific Sessions 2004. New Orleans, LA.

November 23, 2004 Stem Cell Transplantation. University of Southern California School of Engineering’s Department of Biomedical Engineering Seminar. Los Angeles, CA.

December 3, 2004 Panel B: Bone Marrow, Haematopoietic, Umbilical Cord and Mesenchymal Stem Cells. Joint UK/California Symposium: Stem Cells, Tissue Engineering, and Regenerative Medicine. Saban Research Institute, Childrens Hospital, Los Angeles, CA.

December 15, 2004 Cardioprotection. USC Research Conference. Division of Cardiovascular Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA.

January 6, 2005 Outcome studies in hypertension. USC Research Conference. Division of Cardiovascular Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA.

January 20, 2005 Program Chair. Symposium held in conjunction with Pri-Med 2005 Southwest Conference. Cardiovascular Disease Today. Houston, TX.

Lecturer: The polypharmacy paradigm: A comprehensive approach for our hypertensive patients with multiple risk factors. Symposium held in conjunction with Pri-Med 2005 Southwest Conference. Cardiovascular Disease Today. Houston, TX.

February 10, 2005 New Pharmacologic Therapies for Congestive Heart Failure. 43rd Annual Symposium on Critical Care, Trauma, and Emergency Medicine. Keck School of Medicine of USC and Institute of Critical Care Medicine, Las Vegas, NV.

Plenary Session: Stunned Myocardium and its Management. 43rd Annual Symposium on Critical Care, Trauma, and Emergency Medicine. Keck School of Medicine of USC and Institute of Critical Care Medicine, Las Vegas, NV.

February 11, 2005 Mini Course: Treating Erectile Dysfunction in the Coronary Patient. 43rd Annual Symposium on Critical Care, Trauma, and Emergency Medicine. Keck School of Medicine of USC and Institute of Critical Care Medicine, Las Vegas, NV.

Mini Course: Meet the Professor: Cardiology. 43rd Annual Symposium on Critical Care, Trauma, and Emergency Medicine. Keck School of Medicine of USC and Institute of Critical Care Medicine, Las Vegas, NV.

February 23, 2005 Stem Cells. USC Research Conference. Division of Cardiovascular Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA.

February 23, 2005 Stem Cells for Transplantation. 1EEE. Buena Ventura Engineering for Medicine and Biology. Cal Lutheran University. Thousand Oaks, CA.

March 7, 2005 Co-Chair Symposium. New Therapies as Adjuncts to Reperfusion. American College of Cardiology 54th Annual Scientific Sessions. Orlando, FL.

Abstract presentation: Improvement of left ventricular function by intramuscular allogeneic mesenchymal stem cells ­ transplantation in postinfarcted rat myocardium may be transient. American College of Cardiology 54th Annual Scientific Sessions. Orlando, FL.

April 9, 2005 Cellular therapy for Heart Failure: An Update. New Frontiers in Genomics and Cardiovascular Disease. Research and Education Foundation for Cardiovascular Disease. Chaired by Valentin Fuster. Philadelphia, PA.

April 11, 2005 Cell Therapy for Myocardial Infarction. Global Technology Community Bio.com Stem Cells Research and Therapeutics Meeting. San Diego, CA.

April 23, 2005 Erectile dysfunction in the cardiac patient. Sex and the Heart Symposium at the University of Texas Medical Branch. Galveston, TX.

April 27-29, 2005 Allogeneic mesenchymal stem cell transplantation in postinfarcted rat myocardium: short and long-term effects. Stem Cell RFA Grantees Meeting. National Institutes of Health. Bethesda, MD.

June 18-24, 2005 Cholesterol Management. Johns Hopkins CME at Sea ­ Alaska. Faculty. Sponsored by Johns Hopkins University School of Medicine, Baltimore, MD.

Hypertension ­ JNC7 and Beyond. Johns Hopkins CME at Sea ­ Alaska. Faculty. Sponsored by Johns Hopkins University School of Medicine, Baltimore, MD.

Case Studies. Johns Hopkins CME at Sea ­ Alaska. Faculty. Sponsored by Johns Hopkins University School of Medicine, Baltimore, MD.

Discussant. Johns Hopkins CME at Sea ­ Alaska. Faculty. Sponsored by Johns Hopkins University School of Medicine, Baltimore, MD.

July 18, 2005 Biologic Ventricular Assist Device. Research in Innovative Tissue Engineering Grantee Meeting. National Institutes of Health. Bethesda, MD.

August 6-12, 2005 Hypertension: 2005. 48th Annual USC Refresher Course in Medicine. Kapalua, Maui, HI.

Cardiology (Triggers of Cardiovascular Events). 48th Annual USC Refresher Course in Medicine. Kapalua, Maui, HI.

Congestive Heart Failure. 48th Annual USC Refresher Course in Medicine. Kapalua, Maui, HI.

Erectile Dysfunction. 48th Annual USC Refresher Course in Medicine. Kapalua, Maui, HI.

Hyperlipidemia: Current Management. 48th Annual USC Refresher Course in Medicine. Kapalua, Maui, HI.

Cardioprotection in Acute Myocardial Infarction. 48th Annual USC Refresher Course in Medicine. Kapalua, Maui, HI.

September 22, 2005 Stem Cell Research. Sutter Pacific Heart Center. Combined CV Services Division Meeting. Sausalito, CA.

September 26-27, 2005 PDE5 inhibitors and drug interactions: cardiac safety considerations. PDE5 Inhibition and HIV Risk. Current Concepts and Controversies. Bolger Center, Potomac, MD. Sponsored by Robert Wood Johnson Medical School, NIMH, NIDA, CDC.

October 7, 2005 Hypertension Update. Sharp Grossmont Hospital. La Mesa, CA.

October 11, 2005 Modifying the Risk Factors for Heart Disease. Good Samaritan Hospital. Los Angeles, CA.

October 18, 2005 Comparison of neonatal, fetal, and mesenchymal stem cells for replacement of infarcted myocardium. 17th Annual Transcatheter Cardiovascular Therapeutics. Washington, D.C.

Discussant: Molecular Cardiology II: Myocardial Regeneration and Repair. 17th Annual Transcatheter Cardiovascular Therapeutics. Washington, D.C.

October 19, 2005 Plenary Session 14: Late Breaking Clinical Trials III. Dynamic Commentary (on REVIVAL-2 Trial). 17th Annual Transcatheter Cardiovascular Therapeutics. Washington, D.C.

October 21, 2005 Moderator: Novel Approaches to Limit Infarct Size and Enhance Survival. 17th Annual Transcatheter Cardiovascular Therapeutics. Washington, D.C.

Featured Lecture: Reperfusion Injury: Definition, Pathophysiology, and Review of Animal and Human Studies. 17th Annual Transcatheter Cardiovascular Therapeutics. Washington, D.C.

Intravenous Adenosine: Should It be Used Now in All Patients with Anterior MI? 17th Annual Transcatheter Cardiovascular Therapeutics. Washington, D.C.

October 26, 2005 Adenosine for Myocardial Infarction. Research Conference, Division of Cardiovascular Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA.

October 27, 2005 Hypertension. JNC7 and Beyond. Kern Medical Center/UCLA. Bakersfield, CA.

November 11, 2005 Resuscitation Science Symposium: Abstract Presenter: Postconditioning markedly attenuates ventricular arrhythmias following ischemia/reperfusion independent of a mitochondrial KATP channel mechanism. Scientific Sessions of the American Heart Association 2005. Dallas, TX.

November 12, 2005 Moderator and Discussant: No Reflow in Acute Myocardial Infarction: From the Microcirculation to the Patients. Scientific Sessions of the American Heart Association 2005. Dallas, TX.

November 18, 2005 Sexual Health: The Big Picture. Voices and Choices: Perspective on ED Therapy. Symposium at The Sexual Medicine Society of North America Annual Meeting. New York, NY.

December 1, 2005 Know Your Score in Cardiovascular Risk. Know Your Score in Cardiovascular Risk. CME Program of Columbia University. Atlanta, GA.

December 9, 2005 Cell Therapy for Myocardial Infarction. Northwestern University, Feinberg School of Medicine, Cardiology Grand Rounds. Chicago, IL.

January 10, 2006 Management of Hypertension in 2006. Medical Staff Lecture, Providence Holy Cross Medical Center. Mission Hills, CA.

February 22, 2006 Update on stem cell therapy for the heart. USC Division of Cardiovascular Medicine, Research Conference. Los Angeles, CA.

February 24-26, 2006 Stem Cells for Cardiomyopathy: Are all stem cells created equal? New Directions in Cardiovascular Medicine: 2006. Los Angeles Cardiology Associates, Guidant. Rancho Mirage, CA.

March 12, 2006 Impact of time to presentation and reperfusion modality on the efficacy of adenosine during reperfusion therapy for acute myocardial infarction: The AMISTAD – 2 Trial. American College of Cardiology, Scientific Sessions. Atlanta, GA

March 13, 2006 Mesenchymal stem cells improve cardiac function in a rat model of myocardial infarction through a mechanism independent of increasing muscle mass or limiting myocardial infarct size. American College of Cardiology, Scientific Sessions. Atlanta, GA

March 24, 2006 Global risk factor management: focus on dyslipidemia. Medical Grand Rounds, Saint Francis Hospital. Memphis, TN.

April 1, 2006 Erectile dysfunction and hypertension. Sex and the Heart. The 2nd Annual Symposium, The University of Texas Medical Branch. Galveston, TX.

April 7, 2006 A new therapy for angina. Cardiology Conference, Sharp Memorial Hospital. San Diego, CA.

April 28, 2006 Mesenchymal stem cells for myocardial infarction. Stem Cell RFA, Grantees Meeting, NIH. Bethesda, MD.

May 16, 2006 Hypertension. Medical Grand Rounds, St. John’s Regional Medical Center. Oxnard, CA.

May 21, 2006 State-of-the-Art. Erectile dysfunction as a marker of cardiovascular disease. AUA (American Urological Association), 2006 Annual Meeting, Plenary Session. Atlanta, GA.

May 25, 2006 Hypertension. Anaheim General Hospital, CME Program. Anaheim, CA.

May 26, 2006 Understanding the ED treatment paradigm. Lectures to: Poway Scripps Internal Medicine and Scripps, Encinitas. San Diego, CA.

May 29, 2006 Hypertension and dyslipidemia: Taking aim at moving targets and increasing treatment adherence. Satellite Symposium. 34th Annual Physician Assistant Conference. San Francisco, CA. Looking Beyond Blood Pressure: Setting goals to improve cardiovascular disease outcomes.

June 15, 2006 “Ranolazine.” A new therapy for angina pectoris. Medical Grand Rounds, Long Beach Memorial Hospital. UC Irvine, Long Beach, CA.

July 26, 2006 New treatment for angina pectoris. Medical Grand Rounds, Good Samaritan Hospital. Los Angeles, CA.

August 7-11, 2006 Hypertension Update: The Latest in Drug Treatment. USC Refresher Course in Medicine. Ka’anapali, Maui, HI.

New Cardiovascular Risk Factors. USC Refresher Course in Medicine. Ka’anapali, Maui, HI.

New treatment for Myocardial Infarction and Angina. Adenosine, Ranolazine, and Cell Therapy. USC Refresher Course in Medicine. Ka’anapali, Maui, HI.

Erectile Dysfunction. USC Refresher Course in Medicine. Ka’anapali, Maui, HI.

LDL Cholesterol: How low should we go? And how do we get there? USC Refresher Course in Medicine. Ka’anapali, Maui, HI.

September 15, 2006 Dyslipidemia. Core Lecture to USC Residents, LAC/USC. Los Angeles, CA.

September 15, 2006 Contemporary management of myocardial ischemia. Hollywood Presbyterian Medical Center. Los Angeles, CA.

September 29, 2006 Preconditioning, Postconditioning, and Adenosine. The Fifth Annual Symposium. “The Cutting Edge ­ Cardiology for the Future.” Annual Symposium of Long Beach Memorial Hospital, and UCI.

October 5, 2006 New Pharmacologic therapies for angina pectoris. 17th Annual CV Nursing Symposium at Good Samaritan Hospital. Los Angeles, CA.

October 13, 2006 Ischemia/Myocardial Molecular View. The Risk of Air Pollutants in Cardiovascular Disease. Symposium of the U.S. Environmental Protection Agency, NHLBI and National Institute of Environmental Health Sciences. Research Triangle, N.C.

October 14, 2006 Stem Cell treatment for acute myocardial infarction. Sixth Annual Treatment of Cardiovascular Disease. The Latest Innovations. Sponsored by Hollywood Presbyterian Medical Center, Los Angeles, CA. Las Vegas NV.

October 24, 2006 Intravenous adenosine during primary PCI. Does it salvage myocardium, and if so, what does this teach us about reperfusion injury and postconditioning? Annual Transcatheter Cardiovascular Therapeutics Meeting, Washington DC.

Roundtable discussion and audience Q and A. Annual Transcatheter Cardiovascular Therapeutics Meeting, Washington DC.

October 25, 2006 The hope of cellular and noncellular therapy to rebuild an infarcted heart. Annual Transcatheter Cardiovascular Therapeutics Meeting, Washington DC.

Moderated discussion and audience Q and A. Annual Transcatheter Cardiovascular Therapeutics Meeting, Washington DC.

October 26, 2006 Mechanism of myocyte dysfunction, loss and repair: Is there evidence for significant turnover? Annual Transcatheter Cardiovascular Therapeutics Meeting, Washington DC.

Moderated discussion, panel discussion, Audience Q and A. Annual Transcatheter Cardiovascular Therapeutics Meeting, Washington DC.

November 3, 2006 Heart health and ED: Clarifying the connection, prescribing with prudence. Sexual Medicine Society of North America. Satellite Symposium: Evolving strategies in ED Management: Focus on a novel dosing regimen. Las Vegas, NV.

November 13, 2006 Evidence that the anti-anginal agent and inhibitor of the late sodium current, ranolazine, improves postischemic stunned myocardium in the rabbit. Laennec Clinical/Educator. Lecture and Heart Failure: Novel Therapeutics Session. Abstract Oral Sessions. Scientific Sessions of the American Heart Association 2006. Chicago, IL.

November 14, 2006 Discussant. APEX AMI Trial. Plenary Sessions. Late Breaking Clinical Trials II. Scientific Sessions of the American Heart Association 2006. Chicago, IL.

 How can we harness endogenous cardioprotection in clinical reperfusion? Cardiovascular Seminar. Endogenous protection of the heart from ischemia – reperfusion injury. Scientific Sessions of the American Heart Association 2006. Chicago, IL.

November 15, 2006 Postconditioning does not reduce myocardial infarct size in an in-vivo regional ischemia rodent model. Abstract Oral Sessions. Preconditioning and postconditioning to protect the heart. Scientific Sessions of the American Heart Association 2006. Chicago, IL.

February 1, 2007 Sex and the Heart. Erectile dysfunction as an early indicator of CAD. San Antonio Cardiovascular Society, Cardiovascular Division, University Texas Health Science Center, San Antonio, TX

February 14-15, 2007 Erectile Dysfunction in CVD Patients. Sixth Annual Cardiovascular Conference at Beaver Creek, Colorado. Beaumont Hospital, Duke University, University of Colorado, Miller School of Medicine. Miami, FL.

Environmental Triggers for AMI. Sixth Annual Cardiovascular Conference at Beaver Creek, Colorado. Beaumont Hospital, Duke University, University of Colorado, Miller School of Medicine. Miami, FL.

March 3-10, 2007 New Cardiovascular Risk Factors. 35th Annual Diagnostic and Therapeutic Skills in Internal Medicine, Mauna Kea, Island of Hawaii, University of Southern California. University of California, Irvine.

Hypertension Update: The Latest in Drug Treatment. 35th Annual Diagnostic and Therapeutic Skills in Internal Medicine, Mauna Kea, Island of Hawaii, University of Southern California. University of California, Irvine.

Management of Hyperlipidemia; 2007. 35th Annual Diagnostic and Therapeutic Skills in Internal Medicine, Mauna Kea, Island of Hawaii, University of Southern California. University of California, Irvine.

Seaside Chat: Cardiology. 35th Annual Diagnostic and Therapeutic Skills in Internal Medicine, Mauna Kea, Island of Hawaii, University of Southern California. University of California, Irvine.

Erectile Dysfunction: The Cardiologist’s Perspective. 35th Annual Diagnostic and Therapeutic Skills in Internal Medicine, Mauna Kea, Island of Hawaii, University of Southern California. University of California, Irvine.

New Treatments for Myocardial Infarction and Angina: Adenosine, Ranolazine, and Cell Therapy. 35th Annual Diagnostic and Therapeutic Skills in Internal Medicine, Mauna Kea, Island of Hawaii, University of Southern California. University of California, Irvine.

March 20, 2007 Tissue Stem Cells. USC INTD 650 Cell Biology and Medicine Course, USC. Los Angeles, CA.

March 22-23, 2007 The Application of Stem Cells in the Treatment of Myocardial Infarction. 3rd Annual Stem Cell Research and Therapeutics. GTC bio. La Jolla, CA.

Moderator: Session IV. Tissue Engineering and Regenerative Medicine. 3rd Annual Stem Cell Research and Therapeutics. GTC bio. La Jolla, CA.

March 26-27, 2007 Survival and maturation of human embryonic stem cell-derived cardiomyocytes implanted into rat hearts exposed to ischemia. 56th Annual Scientific Sessions of the American College of Cardiology. New Orleans, LA.

Resumption of Activity: Sex, Work, and Exercise. 56th Annual Scientific Sessions of the American College of Cardiology. New Orleans, LA.

Panelist: A case of illicit drug use leading to myocardial infarction: Cocaine ­ induced myocardial ischemia. 56th Annual Scientific Sessions of the American College of Cardiology. New Orleans, LA.

Natural and Unnatural Triggers of Myocardial Infarction. 56th Annual Scientific Sessions of the American College of Cardiology. New Orleans, LA.

March 31, 2007 New Advances in Medical Treatment of Heart Failure. Second Annual Boston Scientific Cardiovascular Updates 2007. Indian Wells, CA.

April 6, 2007 Triggers of Cardiovascular Events. Cardiology Conference. Baylor Hospital. Dallas, TX.

April 17, 2007 Hypertension and Dyslipidemia. Lecture to Medical Residents, Roger William Medical Center. Providence, RI.

April 18, 2007 Triggers of Cardiac Events. Rhode Island Hospital, Brown University. Providence, RI.

April 25, 2007 New Therapies for Angina Pectoris. Medical Grand Rounds, Good Samaritan Hospital. Los Angeles, CA.

April 26, 2007 Direct Renin Inhibition. UCLA Healthcare. Santa Monica, CA.

May 2, 2007 Stem Cell Therapy for the Heart. USC Cardiology, Research Lecture. Los Angeles, CA.

May 15, 2007 Contemporary Management of Myocardial Ischemia. Medical Grand Rounds, Banner Good Samaritan Medical Center. Phoenix, AZ.

May 21, 2007 The Transformation of Erectile Dysfunction into Male Sexual Health. American Urological Association. Course 64 PG. Anaheim, CA.

Erectile Dysfunction as a Marker of Cardiovascular Disease. American Urological Association. Course 64 PG. Anaheim, CA.

May 28, 2007 Partnership with Your Patient in Hypertension Control. Adjunct Symposium of the American Association of Physician’s Assistants. Philadelphia, PA.

Program Chair. Case Studies ­ Applying JNC7 Treatment Guidelines to Clinical Practice. Adjunct Symposium of the American Association of Physician’s Assistants. Philadelphia, PA.

July 10, 2007 Introduction to Research. University of Southern California, Department of Medicine, Division of Cardiovascular Medicine Research Conference. Los Angeles, CA.

July 11, 2007 Smoking Cessation. Medical Grand Rounds, Good Samaritan Hospital. Los Angeles, CA.

July 24, 2007 New Drugs in Hypertension. Medical Grand Rounds, Monterey Park Hospital, Monterey Park, CA.

August 1, 2007 Comparative Aspects of ES, MSC, and BMSC for Cardiac Repair. Fourth Annual Symposium of the American Heart Association Council on Basic Cardiovascular Sciences - Cardiovascular Repair and Regeneration: Structural and Molecular Approaches in the Cellular Era. Keystone Conference Center. Keystone, CO.

August 17, 2007 Cell Therapy for Myocardial Infarction. Cardiology Grand Rounds, UCLA. Los Angeles, CA.

September 8, 2007 The importance of aggressive blood pressure and lipid management in the diabetic patient. Third Annual Diabetes Symposium, St. Bernardine Medical Center. San Bernardino, CA.

September 18, 2007 Stress and Arrhythmia. 11th Annual Scientific Meeting. Heart Failure Society of America. Washington, D.C.

September 28, 2007 Myocardial ischemia redefined: Optimal Care in CAD. Centinela Hospital Medical Center, Medical Grand Rounds. Inglewood, CA.

October 6, 2007 Rebuilding a Broken Heart ­ The Role of Stem Cells. Seventh Annual Treatment of Cardiovascular Disease. Hollywood Heart and Vascular. Las Vegas, NV.

October 8, 2007 Cell Therapy for Myocardial Infarction. Tenth Annual Institute of Genetic Medicine Symposium at University of Southern California, Los Angeles, CA. “Urchins, Muscles and Genes.”

October 19, 2007 Myocardial Ischemia Redefined: Optimal Care in CAD: Stem Cell Therapy for Myocardial Ischemia/Infarction. University of California, Davis Medical Center, Cardiology Grand Rounds. Sacramento, CA.

October 21-23, 2007 Moderators: STEMI VI: Novel Strategies to Reduce Infarct Size and Improve Primary PCI Outcomes. Annual Transcatheter Cardiovascular Therapeutics. Washington, D.C.

Lecture: Systemic Review of Failed and Promising Adjunctive Pharmacologic Strategies to Reduce Infarct Size. Annual Transcatheter Cardiovascular Therapeutics. Washington, D.C.

Moderated Discussion and Questions and Answers. Panel Moderator. Annual Transcatheter Cardiovascular Therapeutics. Washington, D.C.

Moderator: Ischemic Heart Disease. Annual Transcatheter Cardiovascular Therapeutics. Washington, D.C.

Lecture: Experimental Study of Reperfusion Injury in Acute Myocardial Infarction: Past Lessons Learned and Future Prospects. Annual Transcatheter Cardiovascular Therapeutics. Washington, D.C.

Moderated Discussion and Questions and Answers. Panel Moderator. Annual Transcatheter Cardiovascular Therapeutics. Washington, D.C.

October 27, 2007 Triggers of Cardiovascular Events: Role of Circadian Rhythms. Recent Advances in Interventional Cardiology and Cardiac Electrophysiology. Medtronic. Los Angeles Cardiology Associates. Newport Beach, CA.

November 3, 2007 Sub-group Analysis of the AMISTAD 2 Adenosine Trial. Was It Really Negative? The Thirteenth International Symposium on Adenosine, Cardioprotection, and Its Clinical Application. Orlando, FL.

November 4, 2007 Management of Sexual Dysfunction in Patients with Heart Failure. American Heart Association Scientific Sessions, 2007. Orlando, FL.

November 14, 2007 Stem Cell Therapy for the Heart. Medical Grand Rounds, Good Samaritan Hospital. Los Angeles, CA.

February 1, 2008 Clinical Plenary Session 1: Cardiovascular Risk Assessment. The importance of microvascular damage and no reflow following reperfusion therapy for myocardial infarction. Society for Cardiovascular Magnetic Resonance. 11th Annual Scientific Sessions. Los Angeles, CA.

February 12, 2008 Survival and maturation of human embryonic stem cell-derived cardiomyocytes in rat hearts. Cardiovascular Revascularization Therapies 2008. Washington, DC.

March 24, 2008 Management of Hypertension. Pacific Alliance Medical Center. Los Angeles, CA.

March 30, 2008 Postconditioning markedly reduces reperfusion ­ induced ventricular arrhythmias ­ even in the senescent heart. American College of Cardiology 2008, Scientific Sessions. Chicago, IL.

April 1, 2008 Ischemia Symposium. Cardiac Repair with Stem Cells: A Status Report. American College of Cardiology 2008, Scientific Sessions. Chicago, IL.

Lecture: Promise of stem cells: Putting it in perspective with existing therapy. American College of Cardiology 2008, Scientific Sessions. Chicago, IL.

April 10, 2008 Update on Hypertension. Loma Linda University, Cardiovascular Conference. Loma Linda, CA.

April 16, 2008 Nebivolol: A novel beta blocker. LAC/USC Cardiology Conference. Los Angeles, CA.

May 6, 2008 A new treatment for hypertension. VA Long Beach, University California Irvine. Long Beach, CA.

May 16, 2008 Symposium: Translational Research in Cardiothoracic Surgery: A celebration of three decades of VA research by Shukri F. Khuri, M.D. VA Boston Healthcare System. Harvard Medical School and Boston University. VA Research Week. West Roxbury VA Hospital. West Roxbury, MA.

Invited Lecture: Human embryonic stem cells and non-cellular therapy in experimental models of myocardial ischemia ­ reperfusion and myocardial infarction. VA Boston Healthcare System. Harvard Medical School and Boston University. VA Research Week. West Roxbury VA Hospital. West Roxbury, MA.

June 28, 2008 Lecture: Cardioprotection by ranolazine. Symposium: Role of sodium and calcium overload in cellular dysfunction and cardiovascular disease: from pathophysiology to therapeutics. Hyatt Regency. Boston, MA.

July 9, 2008 New Drugs in Hypertension. JNC7 and Beyond. Good Samaritan Hospital, Medical Grand Rounds. Los Angeles, CA.

July 15, 2008 Myocardial Ischemia Redefined: Optimal Care in CAD. Centinela Hospital Medical Center. Inglewood, CA.

July 29, 2008 Hypertension Therapy: Importance of Treating Isolated Systolic Hypertension. Scripps Mercy Hospital. Medical Grand Rounds. San Diego, CA.

August 3-9, 2008 Management of Congestive Heart Failure. 51st Annual USC Refresher Course in Medicine. Maui, HI.

Case Studies on Hypertension. 51st Annual USC Refresher Course in Medicine. Maui, HI.

Management of Dyslipidemia. 51st Annual USC Refresher Course in Medicine. Maui, HI.

Current Management of Angina Pectoris. 51st Annual USC Refresher Course in Medicine. Maui, HI.

Triggers of Cardiovascular Events. 51st Annual USC Refresher Course in Medicine. Maui, HI.

September 8, 2008 Stem Cell Therapy in Models of Myocardial Infarction. Harbor UCLA Medical Center, Cardiology Grand Rounds. Torrance, CA.

September 11, 2008 Triggers of Cardiovascular Events. San Antonio Hospital, Medical Grand Rounds. Upland, CA.

October 4, 2008 Moderator; Course Director. Eighth Annual Treatment of Cardiovascular Disease Course. Present Strategies and Future Solutions. Las Vegas, NV.

Lecture: Triggers of Cardiovascular Events. Eighth Annual Treatment of Cardiovascular Disease Course. Present Strategies and Future Solutions. Las Vegas, NV.

October 10, 2008 Managing Hypertension in High Risk Patients. Fountain Valley Regional Hospital, CME Program. Fountain Valley, CA.

October 12-14, 2008 Lecture: Core Concepts: The Physiology of Stunned, Hibernating and Non-Viable Myocardium. Transcatheter Cardiovascular Therapeutics 2008. Washington D.C.

Lecture: ES-derived cells, Cardiac Progenitors: Tissue and cell preconditioning. Transcatheter Cardiovascular Therapeutics 2008. Washington D.C.

Moderated Discussion with Audience Q & A: Cell and Tissue Products: Balancing simplicity and effectiveness. Transcatheter Cardiovascular Therapeutics 2008. Washington D.C.

Lecture: Pre and Postconditioning Approaches to Reduce Angina and Improve LV Function. Transcatheter Cardiovascular Therapeutics 2008. Washington D.C.

Moderated Roundtable Discussion with Audience Q and A: Interventional Strategies and Adjunct Pharmacology in ACS and AMI. Transcatheter Cardiovascular Therapeutics 2008. Washington D.C.

Lecture: Novel approaches to reduce infarct size in the experimental setting. Transcatheter Cardiovascular Therapeutics 2008. Washington D.C.

Moderated Audience Q & A. Interventional Pathobiology: Insights and Clinical Implications. Transcatheter Cardiovascular Therapeutics 2008. Washington D.C.

October 24, 2008 New Advances in Stem Cell Therapy for Left Ventricular Dysfunction. 19th Annual Cardiovascular Nursing Symposium. Good Samaritan Hospital. Los Angeles, CA.

October 29, 2008 Stem Cells and the Heart. LAC/USC. Cardiology Lecture. Los Angeles, CA.

November 3, 2008 Stem Cell Therapy in the Treatment of MI. Albert Einstein Medical Center. Philadelphia, PA.

The Disease State of Hypertension. Research Conference and Cardiology Grand Rounds.

November 8, 2008 Organizing Committee: Lecture: Survival and Maturation of Human Embryonic Stem Cells for Ischemia/Reperfusion Injury and Hurdles to Overcome. The Fourteenth International Symposium on Cardioprotection and Its Clinical Application. Stem Cells, Autophagy, and Apoptosis. New Orleans, LA.

November 9, 2008 Moderator: Cardiovascular Seminar. Limiting Myocardial Infarct Size. American Heart Association Scientific Sessions, 2008. New Orleans, LA.

November 11, 2008 Cardiovascular Seminar. Issues and Challenges in the Management of Sexual Dysfunction. American Heart Association Scientific Sessions, 2008. New Orleans, LA.

Lecture: PDE5 Inhibitors: Are They Cardioprotective? American Heart Association Scientific Sessions, 2008. New Orleans, LA.

November 25, 2008 Triggers of Cardiovascular Events. The Criley Lecture. Department of Medicine Grand Rounds. Harbor UCLA Medical Center. Torrance, CA.

December 10, 2008 Treatment of Angina. LAC/USC. Cardiology Lecture. Los Angeles, CA.

February 5, 2009 Stem Cells for Repair of the Infarcted Heart. Scripps Green Hospital Cardiology Grand Rounds, La Jolla, CA.

February 6, 2009 Lecture: New Drugs in Hypertension. JNC7 and Beyond. Hollywood Presbyterian Medical Center. Los Angeles, CA.

Feb. 28-Mar. 7, 2009 Lecture 1: Management of Dyslipidemia. Keck School of Medicine of USC 37th Annual. Diagnostic and Therapeutic Skills in Internal Medicine. Island of Hawaii.

Lecture 2: Current Management of Angina Pectoris. Keck School of Medicine of USC 37th Annual. Diagnostic and Therapeutic Skills in Internal Medicine. Island of Hawaii.

Lecture 3: Hypertension Case Studies. Keck School of Medicine of USC 37th Annual. Diagnostic and Therapeutic Skills in Internal Medicine. Island of Hawaii.

Lecture 4: Management of Congestive Heart Failure. Keck School of Medicine of USC 37th Annual. Diagnostic and Therapeutic Skills in Internal Medicine. Island of Hawaii.

Lecture 5: Triggers of Cardiovascular Events. Keck School of Medicine of USC 37th Annual. Diagnostic and Therapeutic Skills in Internal Medicine. Island of Hawaii.

March 12, 2009 Lecture: Congestive Heart Failure. Promise Hospital of East Los Angeles. Paramount, CA.

March 28-30, 2009 Presentation: A Comparison of Cardiovascular Death Rates in the Same City during a Losing versus Winning Super Bowl Championship. 58th Annual Scientific Session of the American College of Cardiology. Orlando, FL.

Approaches to Help Your Patient Quit Smoking. (Satellite Meeting). 58th Annual Scientific Session of the American College of Cardiology. Orlando, FL.

April 4, 2009 Lecture: What’s New in Stem Cell Therapy for CAD and Heart Failure? Symposium: Recent Advances in Interventional Cardiology and Cardiac Electrophysiology. Newport Beach, CA. Sponsored by Los Angeles Cardiology Associates.

April 20, 2009 Lecture: Human embryonic stem cell therapy and noncellular therapy for myocardial infarction. Experimental Biology 2009 Meetings. Symposium: Translational Research: Innovative Approaches to Physiological Investigations. New Orleans, LA.

April 25-28, 2009 Important Safety Considerations for the Treatment of Cialis (Satellite Symposium). American Urologic Society Meeting. Chicago, IL.

May 11, 2009 Triggers of Cardiovascular Events. Noon Lecture. Verdugo Hills Hospital. Verdugo Hills, CA.

May 13, 2009 Case Studies in Hypertension. Noon Cardiology Lecture. Keck School of Medicine at University of Southern California. Los Angeles, CA.

July 8, 2009 Current Lipid Management Strategies. Medical Grand Rounds. Good Samaritan Hospital. Los Angeles, CA.

July 12, 2009 Research Process. Noon Cardiology Lecture. Keck School of Medicine at University of Southern California. Los Angeles, CA.

August 12, 2009 Cardioprotection: Studies using adjunctive therapy with reperfusion for myocardial infarction. Noon Cardiology Lecture. Keck School of Medicine at University of Southern California. Los Angeles, CA.

September 11, 2009 Opening Remarks. Symposium: The Role of Air Pollution In Heart Disease. The Heart Institute of Good Samaritan Hospital. Co-organizer with Dr. Boris Simkhovich.

Lecture: The Role of Air Pollution in Heart Disease: Introduction. Symposium: The Role of Air Pollution In Heart Disease. The Heart Institute of Good Samaritan Hospital. Co-organizer with Dr. Boris Simkhovich.

September 23-25, 2009 Lecture: Session VI. Miscellaneous Issues. Pathophysiology, prevention, and treatment of the no-reflow phenomenon. TCT 2009. Transcatheter Cardiovascular Therapeutics. San Francisco, CA.

Discussant. Session VI. Miscellaneous Issues. TCT 2009. Transcatheter Cardiovascular Therapeutics. San Francisco, CA.

Session III. End-stage, Structural Heart and Endovascular Intervention. Discussant. TCT 2009. Transcatheter Cardiovascular Therapeutics. San Francisco, CA.

Moderator: Session IV. Strategies to Reduce Infarct Size During Reperfusion Therapy. TCT 2009. Transcatheter Cardiovascular Therapeutics. San Francisco, CA.

Lecture: Session IV. Lethal reperfusion injury: What it is, and why have pharmacologic approaches failed again and again? TCT 2009. Transcatheter Cardiovascular Therapeutics. San Francisco, CA.

Lecture: Session IV. Postconditioning: Description, mechanisms, and randomized trial results. TCT 2009. Transcatheter Cardiovascular Therapeutics. San Francisco, CA.

Session IV. Strategies to Reduce Infarct size During Reperfusion Therapy. Discussant. TCT 2009. Transcatheter Cardiovascular Therapeutics. San Francisco, CA.

September 30, 2009 Triggers of Cardiovascular Events. Noon Cardiology Conference. Keck School of Medicine at University of Southern California. Los Angeles, CA.

October 2-3, 2009 To Drink or Not to Drink? That is the Question. 9th Annual Treatment of Cardiovascular Disease: Contemporary Issues and Updates, 2009. Sponsored by Hollywood Presbyterian Medical Center. Los Angeles, CA.

Pharmacological Treatment of CHF. 9th Annual Treatment of Cardiovascular Disease: Contemporary Issues and Updates, 2009. Sponsored by Hollywood Presbyterian Medical Center. Los Angeles, CA.

October 8, 2009 Ranexa, Efficacy and Safety in the Treatment of Chronic Angina. Loma Linda Medical Center. Cardiology Conference. Loma Linda, CA.

October 10, 2009 Controlling LDL Cholesterol. Symposium: Cardiology for the PCP Conference. Desert Medical Group/Oasis IPA. Palm Desert, CA.

October 14, 2009 Tissue Organ Stem Cells: Heart. Stem Cell Biology and Medical Course USC-INTD 650. Keck School of Medicine at University of Southern California. Los Angeles, CA.

October 16, 2009 Comparative aspects of ES, MSC, BMSC for Cardiac Repair. 2nd Advances in Stem Cell Discoveries Conference. GTCbio. San Diego, CA.

October 25, 2009 Stress and the Heart. Canadian Cardiovascular Congress. Joint CCS/ACC Symposium ­ The Brain and Heart Interactions. Edmonton, Canada.

November 3, 2009 Natural and Unnatural Triggers of Cardiovascular Events. Cardiology Grand Rounds. Cedars Sinai Medical Center. Los Angeles, CA.

November 4, 2009 Preconditioning and Postconditioning for Cardioprotection. Cardiology Conference. Keck School of Medicine at University of Southern California. Los Angeles, CA.

November 10, 2009 Ranexa, Efficacy and Safety in the Treatment of Chronic Angina. Noon. Cardiology Grand Rounds. St. Johns Cardiology Research Center at Harbor UCLA. Torrance, CA.

November 15-17, 2009 Moderator: Cardiovascular Seminar: Issues and Challenges in the Management of Sexual Dysfunction for Patients with Cardiac Disease. Scientific Sessions of the American Heart Association, 2009. Orlando, FL.

Lecturer: Which Cardiac Medications Interact with PDE5 Inhibitors? Scientific Sessions of the American Heart Association, 2009. Orlando, FL.

Moderator: Experimental Myocardial Infarction: Cell Therapy, Remodeling, Cardioprotection. Scientific Sessions of the American Heart Association, 2009. Orlando, FL.

Commentary: Experimental Myocardial Infarction: Cell Therapy, Remodeling, Cardioprotection. Scientific Sessions of the American Heart Association, 2009. Orlando, FL.

Lecture: Ranolazine is a potent antiarrhythmic agent that reduces ventricular arrhythmias by inhibition of the late sodium channel. Scientific Sessions of the American Heart Association, 2009. Orlando, FL.

Moderator and Co-organizer of Satellite Symposium (11/16/09): Ischemic Preconditioning: The Time has Come to Harness its Cardioprotective Powers in Patients. Lecture: Introduction and General Overview of Ischemic Conditioning (Pre-and Post-) Discussant. Scientific Sessions of the American Heart Association, 2009. Orlando, FL.

November 19-21, 2009 Lunch Symposium: Individualizing ED Treatment (Speaker, Discussant). Sexual Medicine Society of North America; Annual Meeting. San Diego, CA.

Lecture: ED and Cardiovascular Health: A Primer for the Clinician. Sexual Medicine Society of North America; Annual Meeting. San Diego, CA.

November 20, 2009 Ranexa, Efficacy and safety in the treatment of chronic angina. Lecture to Cardiology Division. San Diego, Sharp Memorial Hospital. San Diego, CA.

December 15, 2009 Cell Therapy for Myocardial Infarction. Clinical and Experimental Seminar Series. School of Pharmacy at University of Southern California. Los Angeles, CA.

December 16, 2009 Erectile Dysfunction and Cardiovascular Health. Noon Cardiology Conference. Keck School of Medicine at University of Southern California. Los Angeles, CA.

December 18, 2009 Ranolazine is a potent antiarrhythmic agent. Lecture at Cath Conference. Good Samaritan Hospital. Los Angeles, CA.

January 7, 2010 Management of patients with chronic angina. Annenberg Center for Health Sciences at Eisenhower Medical Center, Rancho Mirage, CA.

January 19, 2010 Progress and Promise in RAAS blockade. Marina del Rey Hospital, Marina del Rey, CA.

January 28, 2010 Late sodium channel blockade for cardioprotection. University of Southern California, Dept. of Medicine, Division of Cardiology. Los Angeles, CA.

February 8, 2010 Chronic Angina. Metro West Heart Center. Framingham, MA.

February 9, 2010 Chronic Angina. St. Vincent’s Hospital. Worcester, MA.

February 15, 2010 Clinical assessment for management of dyslipidemia. Fountain Valley Regional Hospital. Fountain Valley, CA.

February 24, 2010 Outcome studies of hypertension. University of Southern California. Dept. of Medicine. Division of Cardiovascular Medicine. Los Angeles, CA.

February 27, 2010 Late sodium channel blockade-a new therapeutic approach to treating Chronic Angina. Symposium: Recent Advances in the Management of Ischemic Heart Disease. The Heart Institute, Good Samaritan Hospital. Los Angeles, CA.

March 15, 2010 Symposium: Sex, the Heart and Erectile Dysfunction. American College of Cardiology. 59th Annual Scientific Session. Atlanta, GA.

- Co-Chair. American College of Cardiology. 59th Annual Scientific Session. Atlanta, GA.

- Lecture: PE5I’s Non-Erectile Dysfunction Rôle. American College of Cardiology. 59th Annual Scientific Session. Atlanta, GA.

- Poster Discussant Optimizing Stem Cell Therapy. American College of Cardiology. 59th Annual Scientific Session. Atlanta, GA.

March 31, 2010 Cardiovascular applications of the PDE5 Inhibitors. University of Southern California, Dept. of Medicine. Division of Cardiovascular Medicine. Los Angeles, CA.

April 16, 2010 The Risks of Smoking and Benefits of Quitting. Preventative Cardiologist Nurses Association Meeting. Schaumburg, IL.

May 3, 2010 Annual Models for Human Heart Stem Cell Therapy. Workshop on Annual Models for Human Stem Cell Therapy. The Jackson Laboratory. Bar Harbor, ME.

May 8, 2010 New Pharmacologic and Physiologic Approaches to Myocardial Protection, Salvage, and Recovery. The Society for Cardio-Vascular Angiography and Interventions. San Diego, CA.

May 12, 2010 Stable Ischemic Heart Disease. Hoag Memorial Hospital. Newport Beach, CA.

May 27, 2010 Managing Stable Ischemic Heart Disease. St. Vincent Medical Center. Los Angeles, CA.

June 29, 2010 Stable Ischemic Heart Disease. University of Miami, Cardiology Grand Rounds. Miami, FL.

July 14, 2010 Treatment of Chronic Angina. Long Beach Memorial Hospital. Long Beach, CA.

August 18, 2010 The No-reflow Phenomenon. University of Southern California, Dept. of Medicine, Division of Cardiology. Los Angeles, CA.

September 8, 2010 Management considerations in patients with stable ischemic heart disease. New and experimental antianginal agents. University of Southern California, Dept. of Medicine, Division of Cardiovascular Medicine. Los Angeles, CA.

September 16, 2010 Treatment of Chronic Angina. Long Beach VA Hospital/UC Irvine. Los Angeles, CA.

September 17, 2010 Erectile Dysfunction and CV Health. 21st Annual Cardiovascular Nursing Symposium. Good Samaritan Hospital. Los Angeles, CA.

September 20-21, 2010 Chairman. Lecture: State of Science of Cardioprotection: Challenges and Opportunities. NHLBI Workshop: New Horizons in Cardioprotection Workshop. Rockville, MD.

Lecture: No-Reflow Phenomenon: Maintaining Vascular Integrity. NHLBI Workshop: New Horizons in Cardioprotection Workshop. Rockville, MD.

September 22-23, 2010 Moderator: Session 1. New Perspectives on Stem Cells, Biologics, and Cardiovascular Disease. Transcatheter Cardiovascular Therapeutics 2010. Washington, D.C.

Lecture: Human Embryonic Stem Cells for Cardiac Regeneration. Transcatheter Cardiovascular Therapeutics 2010. Washington, D.C.

Lecture: Adenosine Regulating Agents for Cardioprotection. Transcatheter Cardiovascular Therapeutics 2010. Washington, D.C.

Discussant. Reperfusion Injury and Preconditioning Mechanisms. Transcatheter Cardiovascular Therapeutics 2010. Washington, D.C.

October 4, 2010 Cell Therapy for Myocardial Infarction. Keck School of Medicine at University of Southern California, Research Seminar Series. Los Angeles, CA.

October 11, 2010 Heart. Stem Cell Biology and Medicine INIP-650 (Course at USC, Los Angeles, CA)

October 13, 2010 Erectile Dysfunction and the Cardiovascular Connection. University of Southern California, Dept. of Medicine, Division of Cardiovascular Medicine. Los Angeles, CA.

October 29, 2010 The Risks of Smoking and the Benefits of Quitting. PRI MED, Mid Atlantic. Baltimore, MD.

November 8-10, 2010 Steering Committee, Writing Committee. Cardiometabolic Risks and Sexual Health – The Princeton III Conference. Miami Beach, FL.

Lecture: Hypertension and Lipids. Cardiometabolic Risks and Sexual Health – The Princeton III Conference. Miami Beach, FL.

Lecture (on behalf of Dr. Adolph Hutter): Difficult Cardiac Cases. Cardiometabolic Risks and Sexual Health – The Princeton III Conference. Miami Beach, FL.

Panel Discussant. Cardiometabolic Risks and Sexual Health – The Princeton III Conference. Miami Beach, FL.

November 15-17. 2010 Co-Moderator: Experimental Mycardial Infarction: Cells, Oxidant Stress and Remodeling. Scientific Sessions of the American Heart Association 2010. Chicago, IL.

Lecture: First Direct Comparison of the Late Sodium Current Blocker Ranolazine to Established Antiarrhythmics Agents in an Ischemia/Reperfusion Model. Scientific Sessions of the American Heart Association 2010. Chicago, IL.

December 8, 2010 Stem Cells for Treatment of Myocardial Infarction. University of Southern California, Dept. of Medicine, Division of Cardiovascular Medicine. Los Angeles, CA.

January 20-21, 2011 Moderator: Autologous Cell Products: Translational Directions. The Sixth International Conference on Cell Therapy for Cardiovascular Disease. New York Presbyterian Hospital, Columbia University, New York, NY.

Lecture: Comparison of different cell types for repair of myocardial infarction. The Sixth International Conference on Cell Therapy for Cardiovascular Disease. New York Presbyterian Hospital, Columbia University, New York, NY.

March 7-11, 2011 Update on new antihypertensive medicines: USC Diagnostic and Therapeutic Skills. HI.

Guidelines for the treatment of heart failure. USC Diagnostic and Therapeutic Skills. HI.

Roundtable discussion – cardiology. USC Diagnostic and Therapeutic Skills. HI.

Therapy for dyslipidemia. USC Diagnostic and Therapeutic Skills. HI.

Roundtable discussion - cardiology. USC Diagnostic and Therapeutic Skills. HI.

Managing chronic angina. USC Diagnostic and Therapeutic Skills. HI.

April 7, 2011 Grand Rounds Management of stable ischemic heart disease. Henry Mayo Newhall, Memorial Hospital. Valencia, CA.

April 30,2011 Lecture: A cardiologist’s perspective on smoking as a serious health concern. Primed. Updates for Cardiologist. Anaheim, CA.

Managing Stable Ischemic Heart Disease: Charting the Course. Primed. Updates for Cardiologist. Anaheim, CA.

May 10, 2011 Lecture: The Scientific Research Process: The good, the bad and the ugly! The Research Institute at Nationwide Children’s Hospital, Ohio State University, Columbus, OH.

May 15, 2011 Satellite Symposium: Heart of the matter: Hypogonadism. 2011 American Urologic Association Annual Meeting., Washington, DC.

Lecture: Testosterone and Cardiovascular Health: Safety of treatment for hypogonadism. 2011 American Urologic Association Annual Meeting., Washington, DC.

AUA Course #0281C Male Health. Hypertension-Dyslipidemia and Erectile Dysfunction. 2011 American Urologic Association Annual Meeting., Washington, DC.

May 25, 2011 Cardiology Grand Rounds. University of Louisville, Louisville, KY.

Distinguished Scientists Lecture Series. University of Louisville, Louisville, KY.

New Horizons in Cardioprotection. University of Louisville, Louisville, KY.

June 18, 2011 Lecture: Pharmacologic anti-anginal therapy: taking a closer look. Primed. Updates for Cardiologists, New York, NY.

July 12, 2011 Research Process. USC Research Conference.

August 6, 2011 Pharmacologic antianginal therapy: taking a closer look. Primed. Updates for Cardiologists, Baltimore, MD.

August 17, 2011 Cardioprotection. USC Research Conference. Los Angeles, CA.

September 7, 2011 New Antihypertensive Medications. Good Samaritan Hospital, Medical Grand Rounds. Los Angeles, CA.

September 22, 2011 Pharmacologic approach to chronic angina. Cardiology Grand Rounds, University Hospital, Case Western Reserve University, Cleveland, OH.

September 23, 2011 Grand Rounds: Erectile dysfunction and cardiovascular disease. The Cleveland Clinic, Heart and Vascular Institute. Cleveland, OH.

Research Conference: Controversies: New Horizons in Cardioprotection. The Cleveland Clinic, Heart and Vascular Institute. Cleveland, OH.

October 5, 2011 New Therapies for Managing Angina. USC Research Conference. Los Angeles, CA.

November 1, 2011 Lecture: New Horizons in Cardioprotection. USC School of Pharmacy. Los Angeles, CA.

November 7-10, 2011 Lecture: Induced pluri-potent cells and embryonic stem cells: Promises to keep? TCT 2011 (Transcatheter Cardiovascular Therapeutics). Moscone Center, San Francisco, CA.

Discussant: Clinical Directions: New Biologics, New Patients. TCT 2011 (Transcatheter Cardiovascular Therapeutics). Moscone Center, San Francisco, CA.

Lecture: Social stress-related triggers of acute myocardial infarction and sudden death: Examples and mechanisms. TCT 2011 (Transcatheter Cardiovascular Therapeutics). Moscone Center, San Francisco, CA.

Lecture: Reperfusion injury in 2011: Does it exist and what can we do about it? TCT 2011 (Transcatheter Cardiovascular Therapeutics). Moscone Center, San Francisco, CA.

Discussant: Approaches to reperfusion injury and enhancing myocardial recovery. TCT 2011 (Transcatheter Cardiovascular Therapeutics). Moscone Center, San Francisco, CA.

November 15, 2011 Moderator: Mechanisms of Ischemic Injury in the Heart. American Heart Association. Scientific Sessions 2011; Orlando, FL.

Lecture: Remote preconditioning has a powerful anti-arrhythmic effect independent of the reperfusion injury salvage kinase pathways. American Heart Association. Scientific Sessions 2011; Orlando, FL.

Lecture: Bendavia, a novel mitochondrial-targeted cytoprotective compound reduces ischemia/reperfusion injury: Experience in 3 independent laboratories. American Heart Association. Scientific Sessions 2011; Orlando, FL.

December 10, 2011 Pharmacologic antianginal therapy: Taking a closer look. PRIMED. Updates for Cardiologists; Miami, FL.

February 25, 2012 Triggers of cardiovascular events. Sharp Healthcare’s 2012 Cardiology Conference for Primary Care Clinicians, San Diego, CA.

April 3, 2012 Triggers of cardiac events. Cardiology Grand Rounds – University of Michigan, Ann Arbor, MI.

April 5, 2012 Triggers of cardiac events. Cardiology Grand Rounds - William Beaumont Hospital, Royal Oaks, MI.

April 18, 2012 Limiting infarct size. Washington Hospital Center – Teleconference. Washington DC.

April 21, 2012 Testosterone and cardiovascular disease. American Society of Andrology 37th Annual Conference. Tucson, AZ.

May 10, 2012 The continuum of stable ischemic heart disease. Henry Mayo Newhall Memorial Hospital; Seminar. Valencia, CA.

May 22, 2012 Update on cardioprotection. Cardiology Grand Rounds, Cedars-Sinai Medical Center, Los Angeles, CA.

July 23-27, 2012 Pharmacologic therapy for hypertension in 2012. USC Refresher Course in Medicine and Current Clinical Issues in Women’s Health. Maui, HI.

Chronic coronary artery disease: Case challenges. USC Refresher Course in Medicine and Current Clinical Issues in Women’s Health. Maui, HI.

Seaside chat – Cardiology. USC Refresher Course in Medicine and Current Clinical Issues in Women’s Health. Maui, HI.

Managing heart failure – Pharmacologic approach and the issue of when to revascularize the coronary patient. USC Refresher Course in Medicine and Current Clinical Issues in Women’s Health. Maui, HI.

Treatment of dyslipidemia: using evidence in making treatment choices. USC Refresher Course in Medicine and Current Clinical Issues in Women’s Health. Maui, HI.

Erectile dysfunction in patients with cardiac disease. USC Refresher Course in Medicine and Current Clinical Issues in Women’s Health. Maui, HI.

Cardiology in women: Emphasis on ischemic heart disease. USC Refresher Course in Medicine and Current Clinical Issues in Women’s Health. Maui, HI.

September 20, 2012 Erectile dysfunction and cardiovascular disease. USC School of Pharmacy. Noon Lecture, Los Angeles, CA.

September 28, 2012 Treatment of chronic ischemic heart disease: Therapies for chronic angina. Good Samaritan Hospital. 23rd Annual Cardiovascular Nursing Symposium. Los Angeles, CA.

September 29, 2012 Updates in medical therapy for CAD/IHD. Second Annual Philippine Medical Association of San Diego Symposium. Lakeside, CA.

October 10, 2012 The continuum of stable ischemic heart disease. Good Samaritan Hospital Medical Grand Rounds. Los Angeles, CA.

October 17, 2012 Research process. USC Cardiology. Research Lecture.

November 2, 2012 Co-chair, Co-organizer. The Cardioprotection Colloquium. UCLA, Los Angeles, CA.

Potential new therapies and status of clinical cardioprotection trials, 2012. The Cardioprotection Colloquium. UCLA, Los Angeles, CA.

Closing remarks. The Cardioprotection Colloquium. UCLA, Los Angeles, CA.

November 4-7, 2012 Inhibiton of phosphodiesterase type 5 by sildenafil and volume-overload heart failure. Scientific Sessions of the American Heart Association, 2012. Los Angeles, CA.

Extracellular matrix implantation prevents left ventricular paradoxical systolic bulging and postinfarction remodeling in rats independent of cardiac stem cell recruitment. Scientific Sessions of the American Heart Association, 2012. Los Angeles, CA.

Science of acute revascularization. Scientific Sessions of the American Heart Association, 2012. Los Angeles, CA.

The effect of cell therapy versus noncellular biomaterial implantation on cardiac structure and function following myocardial infarction. Scientific Sessions of the American Heart Association, 2012. Los Angeles, CA.

December 4, 2012 Optimal medical therapy for stable ischemic heart disease: Improving quality of life with antianginal therapy. American Society of Hospital Pharmacists. ASHP Annual Meeting: Traveling Optimal Pathways for Managing Stable Ischemic Heart Diseases. Las Vegas, NV.

December 17, 2012 Research Process. Harbor UCLA Cardiology Grand Rounds. Los Angeles, CA.

December 19, 2012 Extracellular matrix vs cell therapy. USC Cardiology – Research Lecture. Los Angeles, CA.

February 1, 2013 Diabetes and stable ischemic heart disease. Asian Physician Medical Group. Rosemead, CA.

February 20, 2013 Pharmacologic therapy for hypertension. USC Cardiovascular Division. Los Angeles, CA.

March 27, 2013 Women and stable ischemic heart disease. Asian Physician Medical Group. Fountain Valley, CA.

April 6, 2013 Stem cell therapy for heart failure: A status report. 17th Annual Heart Failure 2013. An Update on Therapy. Good Samaritan Hospital and the Heart Failure Society of America. Los Angeles, CA.

April 17, 2013 Oral antiplatelet therapy in ACS management. USC Cardiovascular Division. Los Angeles, CA.

April 20, 2013 Women and stable ischemic heart disease. Association of Black Women Physicians. Long Beach, CA.

April 30, 2013 Optimal medical therapy for stable Ischemic heart disease: Improving quality of life with antianginal therapy. Symposium: Improving Outcomes in Patients with Stable Ischemic Heart Disease. Pri-Med Cardiology Symposium. Anaheim, CA.

May 2, 2013 Oral antiplatelet therapy in ACS management. PCNA (Preventive Cardiovascular Nurses Association). Symposium: Oral Antiplatelet Therapies for Acute Coronary Syndromes and Best Practices in Secondary Prevention. Las Vegas, NV.

May 6, 2013 Debate: Are the Princeton 3 recommendations justified in the man with ED and no cardiovascular disease? American Society for Men’s Health. First Annual Spring Symposium. San Diego, CA.

June 6, 2013 Stem cell therapy for heart failure: A status report. Preventive and Consultative Heart Center of Excellence. Cedars-Sinai Medical Center. Los Angeles, CA.

June 8, 2013 Integrated treatment approach: Pharmacological treatment. Oregon Chapter of the American College of Cardiology Symposium: Rethinking Stable Ischemic Heart Disease, Assessment, Therapeutic Decision-Making, and New Standards for Optimal Care. Portland, OR.

June 19, 2013 Medical therapy of chronic stable angina. Update on ranolazine and the new ACC guidelines. USC Division of Cardiovascular Medicine. Los Angeles, CA.

July 2, 2013 Local planning committee. International Society of Heart Research. 21 World Congress. Symposium 15. Late Na+ Current as a Therapeutic Target. San Diego, CA.

The anti-anginal agent ranolazine is a potent anti-arrhythmic agent. International Society of Heart Research. 21 World Congress. Symposium 15. Late Na+ Current as a Therapeutic Target. San Diego, CA.

July 24, 2013 The effect of ranolazine on ventricular arrhythmias in an experimental model. USC Division of Cardiovascular Medicine. Los Angeles, CA.

August 21, 2013 Science of acute revascularization. USC Division of Cardiovascular Medicine. Los Angeles, CA.

September 1, 2013 Co-Chairperson. Targeting the mitochondria in cardio-renal disease: A novel therapy with Bendavia. European Society of Cardiology. Amsterdam, Netherlands.

September 20, 2013 Pharmacologic therapy for hypertension. Cardiovascular Nursing Symposium. Good Samaritan Hospital. Los Angeles, CA.

October 2, 2013 An update on cardioprotection. University of Minnesota. Cardiovascular Division. Robert J. Bache Visiting Lecture.

October 15, 2013 The antianginal agent ranolazine is a powerful antiarrhythmic. Los Angeles Area Cardiovascular Research Symposium and Research Award Reception. American Heart Association, Saban Research Institute. Los Angeles, CA.

October 29, 2013 Moderator: Strategies for cardiovascular repair: Stem cells and beyond, next generation biologics. TCT 2013 (Transcatheter Cardiovascular Therapeutics 2013). San Francisco, CA.

Lecture: Ranolazine, Bendavia and other unique pharmacologic agents. TCT 2013 (Transcatheter Cardiovascular Therapeutics 2013). San Francisco, CA.

Discussant: Emerging technologies and approaches to reduce infarct size in STEMI. TCT 2013 (Transcatheter Cardiovascular Therapeutics 2013). San Francisco, CA.

November 1, 2013 Pharmacists: A critical link in the continuum of care for patients with acute coronary syndrome. California Society of Health System Pharmacists. Anaheim, CA.

November 17, 2013 Poster Professor for Heart Failure: Pharmacologic therapy: Ischemia and Infarction. Scientific Sessions of the American Heart Association 2013. Dallas, TX.

November 17, 2013 Co-Chairman, Discussant. Lecture: Introduction to the concepts of ischemic conditioning. Satellite Scientific Focus Group Symposium: Ischemic Conditioning, Endothelial Function and Enhanced External Counterpulsation from Research Studies to Patient Care. Dallas, TX.

December 11, 2013 Helping manage stroke risk in patients with NVAF. PRIMED. Regional Conference. Los Angeles, CA.

March 11, 2014 Diabetes and stable ischemic heart disease. Family Choice Medical Group. Stanton, CA.

March 19, 2014 Stable Ischemic guidelines update. Asian Physician Medical Group. Fountain Valley, CA.

March 27, 2014 Seminar: Cell therapy for myocardial infarction. Brody School of Medicine. East Carolina University, Greenville, NC.

March 28, 2014 Cardiology grand rounds. Update on cardioprotection. Brody School of Medicine. East Carolina University, Greenville, NC.

March 31, 2014 Lectures: Ranolazine, Bendavia and other novel agents. American College of Cardiology 63rd Annual Scientific Session. Washington, DC.

Pre-and postconditioning: Core concepts and clinical studies. American College of Cardiology 63rd Annual Scientific Session. Washington, DC.

April 5, 2014 Session II: Moderator. 18th Annual Heart Failure 2014. An Update on Therapy. Los Angeles, CA.

April 7, 2014 Update on Cardioprotection. Huntington Research Medical Institute. Pasadena, CA.

April 16, 2014 Research process. USC, Cardiology Division, Los Angeles, CA.

April 30, 2014 Chair, cell therapy versus non-cellular therapy for myocardial repair. Discussant. Experimental Biology Meetings. San Diego, CA.

May 12, 2014 Hypothermia for reducing myocardial infarct size and the no-reflow phenomenon. International Society of Heart Research. American Section. Miami Beach, FL.

May 17, 2014 Cell Therapy for Myocardial Infarction. 16th Annual Cardiac Symposium. St. Bernardine Medical Center. San Bernardino, CA.

July 25-28, 2014 Lecture: The effect of Bendavia on ischemia/reperfusion injuries left ventricular remodeling and dysfunction. International Academy of Cardiology. Annual Scientific Sessions, 2014, 19th World Congress on Heart Disease. Boston, MA.

Co-Chair: PL10. Plenary Session. Cellular and molecular mechanisms of cardioprotection, cardiac regeneration and remodeling. International Academy of Cardiology. Annual Scientific Sessions, 2014, 19th World Congress on Heart Disease. Boston, MA.

August 15, 2014 Coming to grips with stable ischemic heart disease: Adopting new guidelines, absorbing new insights. Medical Grand Rounds. Texas Heart Institute, CHI St. Luke’s Health, Houston, TX.

September 26, 2014 Lecture: The complexities of stable ischemic heart disease and its treatment. North Carolina/South Carolina. ACC Chapter Meeting. Kiawah Island, SC.

October 27, 2014 Stable ischemic heart disease. USC Cardiology lecture. Los Angeles, CA.

November 13, 2014 Introduction to ECG and arrhythmias. Caltech – Course – Med E101. Pasadena, CA.

November 15-18, 2014 Poster Professor: Experimental myocardial Infarction. American Heart Association – Scientific Sessions 2014. Chicago, IL.

Lecture: Sexual dysfunction: Use of PDE5 inhibitors with nitrates. American Heart Association – Scientific Sessions 2014. Chicago, IL.

November 16, 2014 Co-Chair: Welcome and introductory remarks. Update on Clinical Application of Ischemic Conditioning. Chicago, IL.

March 6, 2015 Triggers of Cardiovascular Events. Huntington Memorial Hospital, Pasadena, CA.

March 25, 2015 Coming to grips with stable ischemic heart disease; adopting new guidelines; absorbing new insights. Medical Grand Rounds. Good Samaritan Hospital, Los Angeles, CA.

April 22, 2015 Stable ischemic heart disease; general medicine practices for healthcare providers. California Northstate University, Elk Grove, CA.

April 22, 2015 Adopting new guidelines, absorbing new insights. Coming to grips with stable ischemic heart disease. Valley Hospital Medical Center, Las Vegas, NV.

May 16, 2015 Testosterone therapy and the heart. American Society of Hypertension. Thirtieth Annual Scientific Meeting. NY, NY.

May 21, 2015 Translational efforts within cardiovascular research. Translational Medicine Symposium. Engineering the Future of Medicine. UC San Diego School of Medicine, San Diego, CA.

June 3, 2015 Advancing a partnership between patients, physicians, and the heart care team. Cardiology Napa Valley, 2015 Symposium. (Piedmont Heart Institute and Mount Sinai), Napa, CA. Best practices in SIHD management.

June 23, 2015 Triggers of cardiovascular events. Harbor UCLA Cardiology Grand Rounds, Torrance, CA.

June 30, 2015 Cell therapy for myocardial infarction. Huntington Medical Research Institutes/ Huntington Memorial Hospital, Pasadena, CA.

July 9, 2015 Research Process. Huntington Medical Research Institute, Pasadena, CA.

July 16, 2015 Epidemiology, pathophysiology and therapeutic targets in SIHD. California Northstate University, Elk Grove, CA.

August 5, 2015 Research Process. Keck School of Medicine at USC, LAC/USC Cardiology Lecture; Los Angeles, CA.

September 10, 2015 Use of neonatal cardiomyocyte transplants into the aorta and vena cava as biologic pumps. TERMIS World Congress, Boston, MA.

September 23, 2015 Biologic LV assist devices. Keck School of Medicine at USC; LAC/USC Cardiology Lecture. Los Angeles, CA.

October 1, 2015 Primer on Cardiac Phsyiology. Caltech Med E101; Caltech, Pasadena, CA.

October 11,2015 Moderator: Novel approaches to myocardial salvage. TCT 2015; San Francisco, CA.

October 12, 2015 Discussant: Session 1: Interventional heart failure: State of the art. TCT 2015; San Francisco, CA.

October 13, 2015 Introduction to ECG and arrhythmias. Caltech Med E101; Caltech, Pasadena, CA.

December 18, 2015 Best practices in SIHD management; Advancing a partnership between patients, physicians, and the heart care team. Satellite symposium at 32nd Annual Advances in Heart Disease, UCSF, Am Coll Cardiology; San Francisco, CA.

December 23, 2015 Remote ischemic preconditioning. USC, Division of Cardiology, noon lecture. Los Angeles, CA.

February 24, 2016 Management of stable ischemic heart disease. USC Division of Cardiology, noon lecture. Los Angeles, CA.

March 3, 2016 Cross talk: Straight to the Heart. With Dr. Marie Csete, Jones Coffee Roasters, Pasadena, CA.

April 2, 2016 Lecture: “Transforming the landscape of cardiology by targeting myocardial salvage.” American College of Cardiology Annual Scientific Session. Panelist: Myocardial Salvage: The next horizon in ACS therapy. Chicago, IL.

April 11, 2016 Core concepts: the physiology of stunned, hibernating, and nonviable myocardium. USC, Division of Cardiology, noon lecture. Los Angeles, CA.

May 12, 2016 Lecture: Novel approaches to cardiac assist devices. Caltech-HMRI/Doheney Eye Institute/JPL Collaborative Workshop; Caltech, Pasadena, CA: From the lab to the surgery room.

June 8, 2016 Erectile dysfunction and cardiovascular disease. USC, Division of Cardiology, noon lecture. Los Angeles, CA.

August 10-14, 2016 Discussion: Journal of Cardiovascular Pharmacology and Therapeutics. 15th International conference on complex acute illness; Caltech, Pasadena, CA.

Lecture: Applications of remote ischemic conditioning in medicine. 15th International conference on complex acute illness; Caltech, Pasadena, CA.

August 22, 2016 Lecture: Management considerations for patients with stable ischemic heart disease: Managing angina symptoms. McLaren Greater Lansing Cardiology Fellowship, Michigan State University.

August 26-28, 2016 Lecture: Erectile dysfunction, cardiovascular risk, and testosterone. National Lipid Association’s 2016 Fall Clinical Lipid Update. Amelia Island, FL.

September 29, 2016 AM lecture: Death must be near: the complicated relationship between angina and survival. USC Division of Cardiology. Los Angeles, CA.

October 13-16, 2016 Lecture: Attempts to reduce various forms of myocardial ischemia and reperfusion injury. The Paradox Workshop. The oxygen paradox and the French paradox in aging and disease. Hosted by Good Samaritan Hospital, Los Angeles, CA., USC, University Pierre and Marie Curie, and Sorbonne Universities of Paris.

October 18, 2016 Men’s Health Issues. Focus on Erectile dysfunction and cardiovascular disease connection. Research Lecture at Huntington Medical Research Institutes, Pasadena, CA.

November 14, 2016 Lecture: Death must be near: the complicated relationship between angina and survival. American Heart Association, Scientific Sessions, 2016. New Orleans, LA.

November 15, 2016 Lecture: Sexual Rehabilitation-Focused assessment of sexual function and dysfunction of cardiac patients. American Heart Association, Scientific Sessions, 2016. New Orleans, LA.

December 1, 2016 Sexual Rehabilitation – Focused assessment of sexual function and dysfunction of cardiac patients. USC, Division of Cardiology. Los Angeles, CA.

March 8, 2017 The Heart’s Impact on the Brain. Presented at Brain Day. Blaire Middle School, Pasadena, CA.

April 18, 2017 Remote ischemic preconditioning from bench to bedside. The 16th Annual International Conference on Dose-Response. U of Massachusetts, Amherst, MA.

May 12, 2017 Update on Cardioprotection. Lecture to Faraday, Inc. Seattle, WA.

May 18, 2017 Men’s Health Issues: Focus on Erectile Dysfunction and the Cardiovascular Connection. Penn Cardiology Grand Rounds. U of Penn. Pennsylvania, PA.

May 25, 2017 Why you should consider Science in Your Future. The 2nd Anniversary. The Mrs.Yun-Chung W. Chang. R.PH Memorial Scholarship Ceremony, The Athenaeum, Caltech, Pasadena, CA.

August 23, 2017 Remote Ischemic Preconditioning. Cardiology Division, Keck School of Medicine, University of Southern California. Los Angeles, CA.

November 13, 2017 Poster Professor. Novel insights into cardiac cell death. Scientific Sessions at the American Heart Association annual scientific sessions, Anaheim, CA.

Lecture: Triggers of Cardiovascular Events at SHAPE satellite symposium. Scientific Sessions at the American Heart Association annual scientific sessions, Anaheim, CA.

November 14, 2017 Presentation: Effect of patiromer in hyperkalemic patients with or without RAASi. Scientific Sessions at the American Heart Association annual scientific sessions, Anaheim, CA.

January 16, 2018 Research Conference: The Brain-Heart Connection. Stress as a trigger of cardiovascular events. Huntington Medical Research Institutes, Pasadena, CA.

March 8-9, 2018 Cardioprotection and mechanical circulatory support. 2018 A-CURE Faculty Meeting. Orlando, FL.

April 14, 2018 Welcome/Introduction. First Annual Halt HCC. Los Angeles Multi-Specialty Conference. Huntington Medical Research Institutes, Pasadena, CA.

May 15, 2018 Research Conference: No-reflow phenomenon. Huntington Medical Research Institutes, Pasadena, CA.

May 31, 2018 Vascular inflammation in atherosclerosis: Clinical implications. PriMed West. Anaheim, CA.

June 5, 2018 Be still my heart…but not too still! Food for thought. Lunch with a scientist. Huntington Medical Research Institute. Pasadena, CA.

June 14, 2018 No reflow phenomenon. Lecture to cardiology staff, fellows, residents. LAC/USC Keck School of Medicine at USC. Los Angeles, CA.

June 20, 2018 No reflow phenomenon. ARENA Pharmaceuticals. San Diego, CA

August 2, 2018 Cell therapy for myocardial infarction and LV assist device. Guest lecture at Pathways to Stem Cell Science. Lab Launch. Monrovia, CA.

October 11, 2018 Lecture: Cardiovascular Research at HMRI: The Advantage of Well-Designed Research Space. Convergence. Research Communities of the Future: Creating Spaces for Creative Collisions Among Researchers. Symposium Sponsored by Perkins and Will. Huntington Medical Research Institutes, Pasadena, CA.

October 24, 2018 Brain Heart Connection (with Dr. Michael Harrington). Notable Speakers Dinner. The Valley Hunt Club. Pasadena, CA.

October 25, 2018 “Huntington Medical Research Institutes.” Pasadena: City of Learning. Science, Technology, and Innovation Symposium. Jet Propulsion Laboratory. Pasadena, CA.

October 25, 2018 Brain Heart Connection (with Dr. Michael Harrington). Innovate Pasadena. Huntington Medical Research Institutes, Pasadena, CA.

November 9, 2018 Lecture: Survival, differentiation, and contractility of immature cardiac cells implanted into the outer walls of aorta and vena cava of rats: A potential step in the development of an auxiliary circulatory pump. 3rd Annual Symposium. ACURE. Abstract Grader. Chicago, IL.

November 9, 2018 Panel discussion: Designing and executing a pivitol DTU clinical trial. 3rd Annual Symposium. ACURE. Poster Discussant. Chicago, IL.

November 11, 2018 Invited lecture: Testosterone therapy and CVD: Is it safe? Scientific Sessions of the American Heart Association. Chicago, IL.

January 11, 2019. Panel discussion: Cardiac risk factors and cardiovascular research at HMRI. MonteCedro, Altadena, CA.

January 23, 2019 “Introduction to ECG and Arrhythmias” Lecture at USC, as part of course AME 599 Cardiovascular and Biofluid Mechanics Course. Los Angeles, CA.

February 4, 2019 “The effects of electronic cigarettes on young versus old normal hearts and pathologic hearts.” Lecture at NIH as part of investigator’s meeting for Pulmonary and Cardiovascular Consequences of Inhaled Nicotine. Bethesda, MD.

March 11, 2019 “Reperfusion injury and its therapy. Update on cardioprotection.” Research Lecture, Huntington Medical Research Institutes, Pasadena, CA.

April 10, 2019 “The brain-heart connection. Stress as a trigger of cardiovascular events.” Lecture at USC, as part of course AME 599 Cardiovascular and Biofluid Mechanics Course. Los Angeles, CA.

May 16, 2019 “Is vaping safe? Don’t let E-cigarette smoke get in your eyes.” Community lecture at Huntington Medical Research Institutes: Food for Thought program. Pasadena, CA.

June 5, 2019 “The brain-heart connection. Stress as a trigger of cardiovascular events.” Lecture to USC Cardiology Division. Los Angeles, CA.

June 20, 2019 “Stunning and hibernation: Where are we 30 years later?” Lecture at Huntington Medical Research Institutes’ Investigator Meeting. Pasadena, CA.

June 24, 2019 Chair: Current perspectives in ACS Management: Part 1. Complex Cardiovascular Catheter Therapeutics, 2019. Orlando, FL.

Presentation: “Stunning and hibernation: Where are we 30 years later?” Complex Cardiovascular Catheter Therapeutics, 2019. Orlando, FL.

Moderator: C3Keynote Lecture. Complex Cardiovascular Catheter Therapeutics, 2019. Orlando, FL.

August 16, 2019 Biologic Left Ventricular Pump. Presentation to Pathways to Stem Cell Science. Monrovia, CA.

October 2, 2019 “The Brain-Heart Connection: Stress as a Trigger of Cardiovascular Events.” Cardiology Grand Rounds, Washington University in St. Louis, School of Medicine, Saint Louis, MO.

November 1, 2019 “Erectile Dysfunction: Harbinger of Your Cardiac Health.” Lecture to Medical Staff, Fountain Valley Regional Hospital, Fountain Valley, CA.

November 17, 2019 Moderator, “Ischemia-Reperfusion Injury: Novel Drugs Open a Window to the Future!” American Heart Association Scientific Sessions. Philadelphia, PA.

November 26, 2019 Medical Grand Rounds: “The Brain-Heart Connection: Stress as a Trigger of Cardiovascular Events.” University of California at Irvine, Irvine, CA.

January 30-31, 2020 Presentation: “The effect of electronic cigarettes on young versus old normal hearts and pathologic hearts.” NHLBI cardiopulmonary effects of inhaled nicotine and e-cigarettes annual PI meeting. Bethesda, MD.

February 12, 2020 “Risk Factors for Heart Disease and How to Manage them.; Women and Heart Disease.” Huntington Senior Care Network. Pasadena, CA.

March 12, 2020 “Update on Cardioprotection.” Lecture to USC Cardiology Staff and Fellows. Los Angeles, CA.

March 21, 2020 “Vaping and the Cardiovascular and Pulmonary Systems.” Huntington Medical Research Institutes, Bob Mackin Lecturer. Pasadena, CA (ZOOM).

April 30, 2020 “Stunned and hibernating myocardium.” Lecture to USC Cardiology Staff and Fellows. Los Angeles, CA (ZOOM).

May 18, 2020 “Alcohol and the cardiovascular system.” Virtual lecture for Huntington Medical Research Institutes. Pasadena, CA (ZOOM).

July 29, 2020 Lecture: “Stunning and hibernating myocardium: Where are we nearly 4 decades later?” American Heart Association, Basic Cardiovascular Sciences, 2020 Scientific Sessions, Virtual Event.

August 6, 2020 “Survival, differentiation, and contractility of immature cardiac cells implanted into the outer walls of aorta and vena cava of rats.” Pathways to stem cell science. Torrance, CA. Virtual lecture (ZOOM).

September 9, 2020 ECG. Lecture at USC to mechanical and biomedical engineering students. Los Angeles, CA (ZOOM).

October 1, 2020 Research Process. Lecture to USC Cardiology faculty and fellows. Los Angeles, CA (ZOOM).

October 27, 2020 Adverse Cardiovascular Effects of Marijuana Use. Research Roundtable, Huntington Medical Research Institutes, Pasadena, CA.

November 13, 2020 Adverse Cardiovascular Effects of Marijuana Use. Presentation at the Annual Scientific Sessions of the American Heart Association (Virtual).

November 18, 2020 Investigating treatment with therapeutic hypothermia for ischemia of the heart. Presentation at the ACURE virtual meeting.

January 21, 2021 The no reflow phenomenon. Lecture to USC Cardiology staff and fellows. Los Angeles, CA.

March 16, 2021 2021 Update on reducing heart attack size: New role for supersaturated oxygen. Bob Mackin Memorial Scientific Lecture at Huntington Medical Research Institutes, Pasadena, CA.

July 9, 2021 Responsible conduct of research. Lecture to HMRI postdoctoral fellows. HMRI, Pasadena, CA.

August 4, 2021 Cell therapy for Acute Myocardial Infarction. Lecture to Pathways to Stem Cell Science group, Torrance, CA.

August 19, 2021 Supersaturated oxygen therapy (SSO2): The next frontier in STEMI treatment. National Webinar, with Dr. Greg Stone.

November 12-14, 2021 Poster presentation: Kloner RA, Kostis JB, Qiu C, Gupta A, McGraw T. Clinical safety of tadalafil in patients receiving concomitant antihypertensive medication. Annual Scientific Sessions of the American Heart Association Meeting (Virtual).

November 16, 2021 Cell therapy for myocardial infarction. Bob Mackin Lecture at Huntington Medical Research Institute, Pasadena, CA.

March 1, 2022 Alzheimer’s and HMRI’s Brain Aging Study. Lunch and Learn. Huntington Medical Research Institutes, Pasadena, CA.

March 5, 2022 “The mystery of Long Covid.” Dr. Kim Shriner and Robert A. Kloner, presenters. Bob Mackin Lecture at Huntington Medical Research Institute, Pasadena, CA.

May 13, 2022 “The Effect of Phosphodiesterase-5 Inhibitors on Major Adverse Cardiovascular Events and Mortality in a Large Cohort of Men with Erectile Dysfunction from a Nationwide Insurance Database.” Presentation at American Heart Association Quality of Care and Outcomes Research annual meeting. Reston, VA.

July 19, 2022 “Erectile Dysfunction: Harbinger of your cardiovascular health; effects of PDE-5 inhibitors on cardiovascular outcomes.” Bob Mackin Lecture at Huntington Medical Research Institutes, Pasadena, CA.

August 31, 2022 “Electrocardiography.” Lecture to USC engineering students for Dr. Niema Pahlevan.

October 28, 2022 One acute exposure to e-cigarette smoke using various heating elements and power levels induces pulmonary inflammation. Lecture at NIH Webinar on EVALI Supplment.

December 3, 2022 Update on long COVID research, Kimberly Shriner and Robert A. Kloner. Huntington Medical Research Institutes. And Update on Vaping Research. Huntington Medical Research Institutes 70th Anniversary Holiday Open House. Pasadena, CA.

March 10-11, 2023 Princeton IV: PDE-5 inhibitors and cardiac health, symposium. Co-chair and organizer. At HMRI, Pasadena, CA. Introduction and Welcome; Meeting overview and purpose; Moderator: Section on ED. The Workup in 2023; Moderator Panel 1; Lecture: Potential cardiovascular benefites in general population of men with ED, in diabetics, in men with other risk factors. Are PDE-5 inhibitors cardioprotective? Panel 3; Closing remarks and summary.

March 16, 2023. Hometown Legends Series. Pasadena City College Foundation. Lecture: Be still my beating heart: A fascinating look at the brain-heart connection and why it matters. Pasadena, CA.

April 18, 2023 San Marino City Club at HMRI. “ Be still my beating heart.” Lecture. Pasadena, CA.

May 12, 2023 2023 Innaugural Krannert Biennial, “ Myocardial infarction and reperfusion injury: New evidence to shift paradigm.”. Lecture: “ Ischemia Reperfusion Injury-What is known?” U of Indiana Medical School, Indianapolis, IN.

May 16, 2023 Bob Mackin Lecture at HMRI. “ Ischemia reperfusion injury. What is known? Pasadena,CA

June 27, 2023 Inside HMRI. Lecture “ Stunning and hibernation: Where are we 30 years later?”

Oct 24, 2023 Bob Mackin Lecture. Kloner RA, Dai W, Shi J. The effect of e-cigarettes on heart and

 Lung. HMRI. Pasadena, CA

Nov 13, 2023 Presenter at the AHA Scientific Sessions, Philadelphia, PA. The effect of electronic

 Cigarette exposure with nicotine on expression of inflammatory genes and blood

 Parameters in a chronic myocardial infarction model. Shi J, Dia W, Carreno J, Kleinman

 MT, Herman DA, Arechavala RJ, Renusch S, Hasen I, Ting A, Kloner RA.

Dec 8, 2023 Presenter/Moderator at HMRI’s Brain Aging Retreat. Lecture: Heart-Brain Connection . and Stress. Pasadena, CA.

May 3. 2024 Lecture/Faculty: PDE-5 inhibitors could be cardioprotective. At the annual Sexual Medicine Society of North America/American Urological Association Meeting, San Antonio, Texas.

June 18, 2024. Bob Mackin Lecture at Huntington Medical Research Institute. Ischemia/reperfusion injury. What is known?

July 5, 2024. Lectures to STEM students at HMRI: Introduction to Cardiovascular Physiology

**STUDENTS, CLINICAL FELLOWS, POST DOCTORAL FELLOWS WHO TRAINED AND/OR COLLABORATED WITH KLONER GROUP**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **NAME** | **MD/PhD** | **YEARS TRAINED** | **CURRENT POSITION** |
| 1 | Rick F. Davis | MD | 1970s | Anesthesiology, Oregon Health and Science University. |
| 2  | L David Hillis | MD | 1970s | Professor and Chair, Dept of Medicine, University of Texas, Health Science Center, San Antonio, TX, Cardiologist, > 200 publications. |
| 3 | Markku Nieminen | MD | 1970s | Cardiologist. Professor and Head of Dept of Medicine at University of Helsinki Central Hospital, Finland. |
| 4 | Derek Maclean | MD | 1970s | Was in academic medicine in UK. Currently unknown.  |
| 5 | Robert E. Rude | MD | 1970s | Cardiologist, Electrophysiologist, Roanoke, VA. |
| 6 | Ruediger Lange | MD | 1970s-1980s | Professor and Director of the Dept of Cardiovascular Surgery at the German Heart Center, Munich, Germany, ~68 publications. |
| 7 | Huey-Ming Lo | MD | 1970s-1980s | Dept of Internal Medicine, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.  |
| 8 | Lance Briggs  | MD | 1970s-1980s  | Practicing cardiologist, Dover, NH. |
| 9 | Robert A. Wolf | MD | 1970s-1980s | Robert A. Wolf, Vice President of Bristol Meyers Squibb. |
| 10 | Tsunehiro Yasuda | MD | 1970s-1980s | Nuclear Medicine, Nuclear Cardiology, Massachusetts General Hospital, Boston, MA. |
| 11 | Laurence WV DeBoer | MD | 1970s-1980s | Cardiologist, Billings, MT. |
| 12 | Georg Ertl | MD | 1970s-1980s | Cardiologist, Professor and Chairman of Cardiology at University of Wurzburg, Germany. |
| 13 | J. Malcolm Arnold | MD | 1980s | Cardiologist, University Hospital, London, OntarioProfessor of Medicine, Physiology and Pharmacology, Western U, London, Ontario. |
| 14 | Nancy Barsamian |  | 1980s |  |
| 15 | Edward J. Brown, Jr. | MD | 1980s | Practicing cardiologist, Bronx Lebanon Hospital, Bronx, NY. |
| 16 | Colin A. Campbell | PhD | 1980s | Research, SmithKlineGlaxo, UK. |
| 17 | Daniel Eitzman | MD | 1980s | Professor of Internal Medicine, University of Michigan. |
| 18 | Steve G. Ellis | MD | 1980s | Interventional cardiologist, Cleveland Clinic. Head of Cardiac Cath lab at Cleveland Clinic. Prominent in clinical research (> 200 publications). |
| 19 | Dietmar Glogar | MD | 1980s | Cardiologist, University Professor, U of Vienna, Austria. |
| 20 | Prabodh Mehta | MD | 1980s | Cardiologist, Elizabethtown, KY. |
| 21 | James Kirshenbaum | MD | 1980s | Cardiologist, Brigham and Women’s Hospital, Associate Professor; Harvard Medical School, Boston, MA. |
| 22 | Bharat Patel  | MD | 1980s | Cardiologist, Webster, TX. |
| 23 | B. Ramesh Reddy  | MD | 1980s | Cardiologist, Internist, St Joseph Mercy Hospital, Port Huron, MI. |
| 24 | Shereif Rezkalla | MD | 1980s | Interventional Cardiologist, Marshfield Clinic, Clinical Professor of Medicine, University of Wisconsin, Madison, WI, ~ 30 publications. |
| 25 | Chuck S. Roberts  | MD | 1980s | Cardiac surgeon, Charleston, SC. |
| 26 | Maria T. Vivaldi  | MD | 1980s | Assistant Physician, Cardiology, Massachusetts General Hospital, Instructor in Medicine, Harvard Medical School, Boston, MA.  |
| 27 | Milagros Reyes | MD | 1980s-1990s | Professor of Medicine, Division of Infectious Disease, Wayne State U, Detroit, MI. |
| 28 | Karin Przyklenk | PhD | 1980s- 1990s | Director of the Cardiovascular Research Institute of Wayne State University and Professor of Physiology and Emergency Medicine, Wayne State University, Detroit, MI, > 150 publications. |
| 29 | Peter Whittaker | PhD | 1980s-1990s | Professor, Emergency Medicine, Cardiovascular Research Institute, Faculty Development Liaison, Wayne State University, Detroit, MI, > 40 publications. |
| 30 | Hiam Hammerman  | MD | 1980s, 1990s | Head of Dept of Cardiology at Rambam Health Care Campus and Associate Clinical Professor, Technion, Israel Institute of Technology, Medicine, Israel. > 60 publications. |
| 31 | Zehyani Bankwala | MD | 1990s | Practicing Cardiologist, Minneapolis, MN. |
| 32 | Barbara Bauer | PhD  | 1990s | Medical Device Work, Germany. |
| 33 | Yochai Birnbaum | MD | 1990s | Cardiologist, Professor of Medicine, Baylor College of Medicine, Houston, TX. |
| 34 | Richard A. Clugston | MD | 1990s | Interventional cardiology, Perth, Australia. |
| 35 | Rave H. Dave | MD | 1990s | Interventional cardiologist, Assoc Clin Professor of Medicine, UCLA. |
| 36  | JoAnn Giaconi  | MD | 1990s | Assistant Professor, Ophthalmology, UCLA, Los Angeles, CA. |
| 37 | Anne Gysembugh  | PhD | 1990s | Senior Industrial Contracts Officer at Assistance Publique Hosp de Paris, France. |
| 38 | James M. Hagar | MD | 1990s | Cardiologist, Glendale, CA. Former faculty at UC Irvine, and Long Beach VA Hospital. |
| 39 | Katsuya Hata | MD, PhD | 1990s | Cardiologist, Kobe University School of Medicine, Kobe, Japan. |
| 40  | Joanathan Leor  | MD | 1990s | Professor, Director of the Neufield Cardiac Research Institute, Tel-Aviv, University Institute, Sheba Medical Center, Israel, > 140 publications. |
| 41  | Yuwei Li  | PhD  | 1990s | Medical industry. |
| 42  | Michel Ovize  | MD | 1990s | Cardiologist, Professor University Lyon, Lyon, France, >160 publications. |
| 43  | Shi-ming Zheng  | BSc | 1990s | Consultant at Emblem Health, New York, NY. |
| 44 | Howard Prentice | PhD | 1990s | Associate Professor Biomedical Sciences, Florida Atlantic University, Boca Raton, FL. |
| 45  | Manuel Quinones | MD | 1990s | Endocrinologist, UCLA, Los Angeles, CA. |
| 46 | Ernst Schwarz | MD | 1990s | Clinical Cardiologist, Cedars Sinai Medical Center, Medical Director of Cardiac Support Program, Los Angeles, CA. |
| 47  | Guohu Li  | PhD | 1990s-2000s | Researcher at Crafoord Laboratory for Experimental Surgery, Karolinska Hospital, Stockholm, Sweden. |
| 48  | Coralie Poizat | PhD | 1990s-2000s | Became faculty at USC Institute of Genetics. Currently runs research facility in Saudi Arabia. |
| 49 | Hazim Al-Amari | MD | 2000s | Cardiologist / Electrophysiologist, Dearborn, MI. |
| 50  | Jason Chi | MD  | 2000s | Anesthesiologist, San Jose, CA. |
| 51  | Wangde Dai  | MD | 2000s | Assistant Prof of Medicine, USC, Senior scientist, Heart Inst Good Samaritan Hosp, Vascular Surgeon. |
| 52  | Jules Gardin | MD | 2000s | Cardiologist. Chairman of Dept of Internal Medicine at Hackensack University Medical Center; Former President American Society of Echocardiography. Hackensack, NJ. |
| 53  | Hyosook Hwang  | PhD  | 2000s | Research Staff, Chonbuook National University, Medical School and Hospital, Jeonju, Jeonbuk, Republic of Korea. |
| 54  | Johanna Landgraf  | MD | 2000s | Practicing in Germany. |
| 55 | Ankur Mehra | BS | 2000s | Was USC college student, currently in medical school.  |
| 56  | Jochen Muller-Ehmsen | MD | 2000s | Professor, Cardiologist, Universitat Zu Koln, Germany, ~100 publications. |
| 57 | Margaret Nordlie  | PhD | 2000s | Professor, Chair, Dept of Biology, Casey Center for Nursing Education, University of Mary, Bismark, ND. |
| 58 | Rohith Nayak  | BS | 2000s | College student, now medical student. |
| 59 | Casilde Sesti | PhD | 2000s | Medical Science Liaison at Providence Health and Services, Seattle, Washington. Previously Scientist, Preclinical Pharmacology at IKARIA and Research Scientist, Cardiovascular Medicine at University of Washington, Seattle, WA. |
| 60 | Mark T. Speakman | MD | 2000s | Cardiologist, Kaiser Permanente, Baldwin Park, CA. |
| 61 | Thorsten Reffelmann | MD | 2000s | Cardiologist, Dept of Cardiology, U Hospital Aachen, Aachen, Germany, ~ 70 publications. |
| 62  | Loren Wold | PhD | 2000s | Director of Biomedical Research and Associate Professor. The Ohio State University, College of Nursing. Editor of the journal “Life Sciences.”  |
| 63 | Mu Yao | PhD | 2000s | Central Clinical School and Bosch Institute, The University of Sydney and Dept of Endocrinology, Royal Prince Alfred Hospital, Sydney, Australia. |
| 64 | Justin Leeka | BS | 2000s- 2010s | USC College student, now in medical school. |
| 65 | Andrew Bland | …… | 2010s | College student. |
| 66  | Paul Gerczuk  | MD | 2010s | Cardiologist, Fellowship at Allegheny Medical Center, Pittsburgh, Currently in Electrophysiology Fellowship training.  |
| 67 | Roya Gheissari  | …….. | 2010s | College student (Columbia U, NYC). |
| 68  | Michael Herring  | BS | 2010s | College student, accepted to Rush Medical School, Chicago, 2014. |
| 69 | Peyman Mesbah Oskui | MD | 2010s | USC Trained internist, finishing clinical cardiology research fellowship at Heart Institute, Good Samaritan Hospital and Harbor UCLA.  |
| 70  | Jaspreet Sachdeva | PhD | 2010s | Finishing postdoctoral research fellowship at Heart Institute, Good Samaritan Hospital and University of Southern California. Entering postdoctoral position at Ohio State U, Columbus, OH, 2014. |
| 71  | Brian Schwartz | MD | 2010s | Cardiology Fellow, U of New Mexico, Albuquerque, NM. |
| 72 | Elissa Cheung | Student | 2015 | Undergraduate College Student at Occidental College. |
| 73 | Niema Pahlevan | PhD | 2015-16 | Boswell Fellow at Caltech; Currently an Assistant Professor in the Engineering Dept. at USC. |
| 74 | Rashid Alavi | PhD | 2019-Present | Student in USC’s Engineering Department with Niema Pahlevan. |
| 75 | Nicole Lin | PhD | Summer 2019 | HMRI Summer Student Program. Entering Junior Year at Emory University, Atlanta, GA. |
| 76 | Sidhant Umbrajkar | Student | Summer 2020 | HMRI Summer Student Program. Entering Junior Year at UCLA. |
| 77 | Anisha Karunananthan | Student | Summer 2022 | HMRI Summer Student Program. Entering Junior Year at Grove City College, PA. Pursuing BS in Biochemistry. |
| 78 | Jaspreet Sacheva | PhD | 2022-2023 | Senior postdoctoral fellow/instructor HMRI |

 79 Jaqueline A Enni Med Student Summer 2024 Third year med student Western U Health Sciences

 80 Jiajun Li PhD Student 2024 PhD student USC in Engineering Dept.

 81 Jason Lin PhD Student 2024 PhD student USC in Engineering Dept.